---
document_datetime: 2023-09-21 20:48:51
document_pages: 215
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xeljanz-h-c-004214-ii-0035-epar-assessment-report-variation_en.pdf
document_name: xeljanz-h-c-004214-ii-0035-epar-assessment-report-variation_en.pdf
version: success
processing_time: 340.6855102
conversion_datetime: 2025-12-17 08:18:22.745166
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
Send us a question

<!-- image -->

14 October 2021 EMA/CHMP/743175/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Xeljanz

International non-proprietary name: tofacitinib

Procedure No. EMEA/H/C/004214/II/0035

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

●

Go to www.ema.europa.eu/contact

●

+31 (0)88 781 6000

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 8                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................8 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................8                                                 |
| 2. Scientific discussion..............................................................................                     | 10                                                                                                        |
| 2.1. Introduction                                                                                                          | ...................................................................................................... 10 |
| 2.1.1. Problem statement                                                                                                   | .......................................................................................... 10             |
| 2.1.2. About the product                                                                                                   | ........................................................................................... 13            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 14                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................      | 14                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 14                                                                                                        |
| 2.2.2. Discussion on non-clinical aspects                                                                                  | ..................................................................... 16                                  |
| 2.2.3. Conclusion on the non-clinical aspect.................................................................              | 17                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 17     |
| 2.3.1. Introduction....................................................................................................    | 17                                                                                                        |
| 2.3.2. Pharmacokinetics ............................................................................................       | 18                                                                                                        |
| 2.3.3. Pharmacodynamics..........................................................................................          | 37                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 52                                                                                                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 55                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 55     |
| 2.4.1. Dose response study........................................................................................         | 55                                                                                                        |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 56  |
| 2.4.3. Discussion on clinical efficacy..........................................................................           | 121                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy ..................................................................             | 127                                                                                                       |
| 2.5. Clinical safety                                                                                                       | .................................................................................................. 127    |
| 2.5.1. Discussion on clinical safety............................................................................           | 186                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 189                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 190   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 190                 |
| 2.7. Update of the Product information......................................................................               | 206                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 206                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 206                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 206                                                                                                       |
| 3.1.1. Disease or condition ......................................................................................         | 206                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 207                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 207                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 208                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 209                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 210                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 211                                                               |
| 3.6. Effects Table....................................................................................................     | 212                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 213                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 213                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 214                            |

<div style=\"page-break-after: always\"></div>

3.8. Conclusions  ..................................................................................................... 214

4. Recommendations  ............................................................................... 214

5. EPAR changes ..................................................................................... 215

<div style=\"page-break-after: always\"></div>

## List of abbreviations

%CV % coefficient of variation

ACR American College of Rheumatology

AE(s) adverse event(s)

ALT alanine aminotransferase

ANCOVA analysis of covariance

ANOVA analysis of variance

AS ankylosing spondylitis

ASAS Assessment of SpondyloArthritis international Society

ASAS20 ≥20% increase from Baseline and ≥1 unit increase in at least 3 domains on a scale of 0 to 10, and no worsening of ≥20% and ≥1 unit in the remaining domain

ASAS40 ≥40% increase from Baseline and ≥2 units in at least 3 domains on a scale of 0 to 10 and no worsening at all in the remaining domain

ASAS 5/6 ASAS 5/6 assessed 6 domains: the domains as noted in the ASAS20 and 40, CRP and Spinal Mobility, specifically lateral spinal flexion (from the BASMI). Improvement was defined as ≥20% in at least 5 domains

ASDAS(CRP) Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein

ASQoL Ankylosing Spondylitis Quality of Life

ASspiMRI Ankylosing Spondylitis Spine Magnetic Resonance Imaging

AST aspartate aminotransferase

ATC Anatomical Therapeutic Chemical

ATE arterial thromboembolism

AUC area under the plasma concentration-time curve

AUC24 area under the plasma concentration-time curve from time 0-24 hours

BA bioavailability

BASDAI Bath Ankylosing Spondylitis Disease Activity Index

BASFI Bath Ankylosing Spondylitis Functional Index

BASMI Bath Ankylosing Spondylitis Metrology Index bDMARD biological disease-modifying antirheumatic drug

BE bioequivalence

BID twice-daily

BR benefit-risk

Cavg average plasma concentration

CI confidence interval

CK creatine kinase

Cmax maximum plasma concentration

<div style=\"page-break-after: always\"></div>

CMH Cochran-Mantel-Haenszel

CPK creatine phosphokinase

CO Clinical Overview

COVID-19 Corona Virus Disease (identified 2019)

COX-2 cyclo-oxygenase subtype 2

csDMARD conventional synthetic disease-modifying antirheumatic drug

CSR clinical study report

CYP cytochrome P450

DMARD disease-modifying antirheumatic drug

DILI drug-induced liver injury

DVT deep vein thrombosis

Emax maximum drug effect

EQ-5D-3L EuroQol 5-dimension scale- 3 Levels

EQ-VAS EuroQol-visual analogue scale

E-R exposure-response

EULAR European League Against Rheumatism

FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue

FAS full analysis set

GI gastrointestinal

HAQ-DI Health Assessment Questionnaire - Disability Index hsCRP high sensitivity C-reactive protein

HZ Herpes zoster

IBD Inflammatory Bowel Disease iAP Integrated Analysis Plan

ILD Interstitial Lung Disease

IL interleukin iPSP initial Pediatric Study Plan

IR immediate release

IV intravenous

JAK Janus kinase

JIA juvenile idiopathic arthritis

LOCF last observation carried forward

LSM least squares mean

LTE long-term extension

MA Marketing Application

<div style=\"page-break-after: always\"></div>

mAb monoclonal antibody

MACE major adverse cardiovascular events

MedDRA Medical Dictionary for Regulatory Activities

MMRM Mixed Model for Repeated Measures

MOA mechanism of action

MR modified release

MRI magnetic resonance imaging

MTX methotrexate

N , n number of subjects

NA not applicable

NDA New Drug Application

NMSC non-melanoma skin cancer

Non-IR non inadequate responder/response

NRI nonresponder imputation

NSAID nonsteroidal anti-inflammatory drug

NSAID-IR NSAID inadequate response

OC Oracle Clinical

OI(s) opportunistic infection(s)

OPC oral powder for constitution

OTIS Organisation of Teratology Information Services

PBRER Periodic Benefit Risk Evaluation Report

PCS Physical Component Summary

PE pulmonary embolism

PGA Patient Global Assessment of Disease

PK pharmacokinetic(s)

PMAR Population Modelling Analysis Report

PsA psoriatic arthritis

PsO psoriasis

PT Preferred Term

PV pharmacovigilance

PY patient-years

QD once daily

RA rheumatoid arthritis

RCT randomised controlled trial

RMM risk minimisation measures

<div style=\"page-break-after: always\"></div>

| RMP Risk Management Plan                                              |
|-----------------------------------------------------------------------|
| SAE(s) serious adverse event(s)                                       |
| SAP Statistical Analysis Plan                                         |
| SCE Summary of Clinical Efficacy                                      |
| SCP Summary of Clinical Pharmacology                                  |
| SCS Summary of Clinical Safety                                        |
| SD standard deviation                                                 |
| SF-36v2 Short Form - 36 Health Survey Version 2                       |
| SI sacroiliac                                                         |
| SJC Swollen Joint Count                                               |
| sNDA Supplemental New Drug Application                                |
| SpA spondyloarthritis                                                 |
| SPARCC Spondyloarthritis Research Consortium of Canada                |
| t½ half-life                                                          |
| TB tuberculosis                                                       |
| TEAE(s) treatment-emergent adverse event(s)                           |
| TNF tumor necrosis factor                                             |
| TNFi(s) tumor necrosis factor inhibitor(s)                            |
| TNFi-IR tumor necrosis factor inhibitor inadequate responder/response |
| Tofa tofacitinib                                                      |
| tsDMARD targeted synthetic DMARD                                      |
| UC ulcerative colitis                                                 |
| ULN upper limit of normal                                             |
| US United States                                                      |
| VTE venous thromboembolism                                            |
| WPAI Work Productivity and Activity                                   |
| XR extended release                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Pfizer Europe MA EEIG submitted to the European Medicines Agency on 2 February 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy for XELJANZ film-coated tablets; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 17.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0227/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0227/2020 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

Johann Lodewijk Hillege

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 2 February 2021   |
| Start of procedure:                                  | 20 February 2021  |
| CHMP Rapporteur Assessment Report                    | 19 April 2021     |
| CHMP Co-Rapporteur Assessment Report                 | 21 April 2021     |
| PRAC Rapporteur Assessment Report                    | 21 April 2021     |
| PRAC Outcome                                         | 6 May 2021        |
| CHMP members comments                                | 10 May 2021       |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 14 May 2021       |
| Request for supplementary information (RSI)          | 20 May 2021       |
| CHMP Rapporteur Assessment Report                    | 14 September 2021 |
| PRAC Rapporteur Assessment Report                    | 20 September 2021 |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 30 Sept 2021      |
| CHMP members comments                                | 04 Oct 2021       |
| Updated CHMP Rapporteur Assessment Report            | 07 Oct 2021       |
| Opinion                                              | 14 Oct 2021       |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

This Type II variation seeks approval for the treatment of active ankylosing spondylitis (AS) in adult patients. In total there are 2 studies in the Pfizer clinical development program for AS provided in this application: Study A3921119, a completed Phase 2, multicentre, randomized, double-blind, placebocontrolled dose-ranging, parallel group efficacy and safety study designed to characterize the doseresponse of tofacitinib in patients with active AS; and Study A3921120, a Phase 3 randomized, placebocontrolled, and double-blind study in adult patients with active AS.

## 2.1.1. Problem statement

## Disease or condition

AS is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine and is part of the family of related SpA disorders, which also includes PsA. AS or radiographic axial SpA is defined by the presence of definitive radiographic sacroiliitis based upon 1984 Modified New York classification criteria. AS causes chronic inflammation at the insertion of ligaments and tendons in the axial skeleton (entheses) and may progress from inflammation in the sacroiliac joints to sacroiliac and spine ankylosis over time. AS is also associated with peripheral arthritis, and enthesitis, and extraarticular manifestations such as anterior uveitis, psoriasis, and IBD. Osteoporosis is a common AS comorbidity. AS is often present for many years before it is diagnosed and typically presents in people between 20 and 40 years of age, with a higher prevalence in males, leading to back pain, stiffness, fatigue, progressive disability and adverse effects on health-related quality of life.

## State the claimed the therapeutic indication

The proposed indication for tofacitinib oral IR tablet 5 and 10 mg BID is for the treatment of active AS in adult patients who have responded inadequately to conventional therapy.

## Epidemiology and risk factors, screening tools/prevention

The incidence and prevalence of AS for a range of countries and geographical regions are provided in Table

1:

Table 1. Incidence andPrevalence of AnkylosingSpondylitisbyRegion

|                               | Incidenceper 100,000PY   | Prevalence(%)   | Reference(s)   |
|-------------------------------|--------------------------|-----------------|----------------|
| Region                        |                          |                 |                |
| Overall                       | 0.44-15                  | 0.01-1.8        | 16-37          |
| NorthernEuropeandNorthAmerica | 3-15                     | 0.1-1.8         | 16,19,21-28    |
| Iceland                       | 0.44                     |                 | 17,18          |
| Asia                          | 0.48                     | 0.01-0.54       | 16,17,20,29,30 |
| EasternEurope                 |                          | 0.07-0.12       | 31-33          |
| SouthenEurope                 |                          | 0.06-1.6        | 16,34,35       |
| MiddleEast                    |                          | 0.12-0.49       | 16             |
| Sub-SaharanAfrica             |                          | 0.02            | 36             |
| Mexico                        |                          | 0.1             | 37             |

<div style=\"page-break-after: always\"></div>

The highest incidence rates have been reported in Northern Europe and North America, while the lowest have been reported in Asia and Iceland ( Table 1 ). The reported prevalence across geographic regions follows a similar trend to the reported incidence. Mortality rates among patients with AS are 1.5 times higher than the general population, due to respiratory complications, and consequences from spinal fractures and other fractures.

Studies consistently report that AS occurs more frequently among men than women. One study in the United States reported a four-fold higher incidence in men than women and a similar difference in incidence rates between men and women was reported in the Czech Republic. the prevalence reported among men is also similarly higher than the prevalence reported among women. Studies report a male to female ratio ranging from 1.2-9 to 1.

AS usually starts in the second or third decade of life, with peak incidence occurring in the 20 to 34 age group. Studies report that the average age at onset of symptoms is between 20.9 and 32.5 years, while the average age of diagnosis is later, between 24.2 and 39.8 years.

## Biologic features, Aetiology and pathogenesis

Overall,  the  pathogenesis  of  AS  is  not  well  characterised  but  seems  to  include  both  genetic  and environmental components, which combine to elicit a chronic inflammatory response involving the innate and adaptive immune systems. A genetic link was noted in that 90 - 95% of white Western European people with  AS  are  positive  for  the  HLA-B27  allele,  and  risk  increases  with  HLA-B27-positive  relatives. Environmental factors, such as infections and mechanical stress at the entheses, have been postulated as being potential triggers of AS in genetically susceptible individuals. In AS, these entheseal stresses might activate downstream events that lead to inflammation, bone erosion and spur formation.

Key aspects of the pathology and pathogenesis of AS are listed below:

- In the earlier stages of the disease, AS primarily involves inflammation of the entheses (enthesitis) in the axial skeleton (mainly the sacroiliac joints) and bone erosion in the vertebral bodies;
- In the later stages of the disease, syndesmophyte (spur) formation and then fusion of adjacent vertebral  bodies  and  syndesmophytes  occur.  These  processes  appear  to  be  uncoupled  from inflammation;
- The development of AS is associated with specific genes; the most important is HLAB27; additional genes associated with AS include ERAP1, IL-23R, ANTXR2, and IL- R2;
- Key innate and adaptive immune cells involved in the initiation, progression, and modulation of inflammation in AS include dendritic cells, macrophages, NK cells, Th1 cells, Th2 cells, Th17 cells, Th22 cells, Treg cells, and T CD8+ cells. There may be a limited role for B cells.
- These innate and adaptive immune cells secrete a number of pro-inflammatory cytokines implicated in the pathogenesis of AS including IL-1, IL-6, IL-7, IL-12, IL-15, IL-17 IL- 22, IL-23, IFNγ and TNFalpha.

Confirmation that TNFaplha (secreted by Th1 and T CD8+ cells) and IL-17 (secreted by Th17 and T CD8+ cells) contribute to the pathogenesis of AS has been provided by the efficacy of interventions such as TNFi and anti-IL-17 mAb. These biologic therapies directly inhibit the effect of 1 cytokine pathway. Tofacitinib, a small molecule inhibitor of JAK, interferes directly (eg, IL-23) or indirectly (eg, TNFalpha, IL-17) with the signalling of multiple AS-associated cytokines.

<div style=\"page-break-after: always\"></div>

Tofacitinib therapy therefore has the potential to suppress the articular, as well as the extraarticular manifestations of AS, without the drug-induced immunogenicity and antidrug neutralising antibody formation seen with long-term monoclonal antibody use.

## Clinical presentation, diagnosis and stage/prognosis

There are no specific diagnostic tests or biomarkers for the diagnosis of AS. For the purpose of clinical trials, consistent with the EMA clinical guideline on Clinical Investigation of Medicinal Products for the Treatment of  Axial  Spondyloarthritis,  the  classification  criteria  based  on  the  1984  Modified  New  York  Criteria  for Ankylosing Spondylitis is used to define AS if the radiological criterion (pelvic radiograph) is associated with at least 1 clinical criterion. In the Phase 2 dose-ranging Study A3921119 and the Phase 3 pivotal Study A3921120, in addition to the above Modified New York criteria, a patient must have had active AS defined as a BASDAI score of ≥4 and a back pain score (BASDAI Question 2) of ≥4 at both screening and baseline in order to be included.

## Management

For many decades, the mainstay of treatment of AS has been NSAIDs and structured exercise programs including physical therapy with the aim of relieving clinical symptoms. However, gastrointestinal and other adverse effects limit the tolerability of NSAIDs including some COX-2 selective inhibitors. In addition, AS patients report insufficient control with NSAIDs alone. Treatment with csDMARDs that have shown efficacy in RA have not shown similar efficacy in AS. Sulfasalazine may provide some benefits for peripheral arthritis but does not impact axial disease. Locally administered parenteral glucocorticoids are also a treatment option for patients with active enthesitis, sacroiliitis or peripheral arthritis that have not responded fully to NSAID therapy. However, although local corticosteroid injections are widely used in clinical practice to good effect in AS patients, no clinical trials exist to support this use. TNFα antagonists or inhibitors, also known as TNFi, have demonstrated efficacy and are approved for the reduction of clinical signs and symptoms, in patients with AS. A recent ASAS recommendation stated that TNFi therapy is indicated for those patients with persistently high disease activity despite conventional treatment. Additional bDMARDs that inhibit IL-17, secukinumab and ixekizumab, have been subsequently approved in the US and EU. However, there is a substantial proportion of patients who have an inadequate response to each of these bDMARDs and as such therapy options are administered parenterally, this may act as an additional barrier to their use. Moreover, the long-term efficacy of some TNFi and IL-17i mAb may be limited by immunogenicity. Moreover, recently, also another JAK inhibitor (Upadacitinib) has been authorized in EU for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Current updates to the ASAS-EULAR axial SpA management recommendations provide initial therapy recommendations based upon an individual's disease activity the patient characteristics including comorbidities and psychosocial factors. Based on the current evidence and the considerations of ASAS and EULAR, NSAIDs and TNFi remain the primary classes of medications for the treatment of axial SpA (including AS). Sulfasalazine is considered only for the treatment of peripheral arthritis. IL-17i are recommended for patients with active disease in whom TNFi are contraindicated, and in primary nonresponders to TNFi. The use of IL-17i should be avoided in patients with active IBD, as TNFi monoclonal antibodies are better options.

Treatments are available to control and delay the progression of symptoms of AS. However, additional therapy options are still needed as up to 50% of patients with AS continue to have active disease despite treatment with NSAIDs or biological agents.

The use of NSAIDs is limited by gastrointestinal and other adverse events. Other effective agents for the

<div style=\"page-break-after: always\"></div>

treatment of active AS are bDMARDs, which require parenteral administration and may be limited by loss of efficacy, often due to immunogenicity. Of note, in a recent survey of patients receiving injectable bDMARDs to treat PsA, a condition related to AS, 54% found the therapy to be burdensome, with fear of injections and inconvenience amongst the most commonly reported reasons. Accordingly, there is a need for an oral tsDMARD with similar efficacy to bDMARDs for the treatment of AS.

As a number of genes and cytokines have been implicated in the pathogenesis of AS, it is likely that the etiology of AS is complex and has a plethora of underlying contributory factors. This implies that additional treatment options with mechanisms of action distinct from those currently available, such as tofacitinib, are needed as options for different AS patients.

In summary, despite the advances that have been made in the last decade in the treatment of AS, a significant number of patients with AS still have active disease and remain refractory to currently available pharmacotherapies. Unmet medical need therefore remains for a new effective oral DMARD with a new MOA that provides a favourable benefit-risk profile and broadens the treatment options for adult patients with AS to achieve and sustain clinical benefit.

## 2.1.2. About the product

## Mode of action.

Tofacitinib is a selective JAK inhibitor, with a high degree of selectivity against other kinases in the human genome. In kinase assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TYK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK3 and/or JAK1 with functional selectivity over receptors that signal via pairs of JAK2. Accordingly, tofacitinib may result in modulation of the adaptive and innate immune response in IBD and may, therefore, be effective in interrupting the chronic cycle of GI inflammation.

## Pharmacological classification.

Tofacitinib belongs to the therapeutic group of Immunosuppressants (L04) and its therapeutic subgroup is L04AA29

## Previously approved indications

Xeljanz® was approved in the EU at a dose of 5 mg BID (IR film-coated tablets approved on 22 Mar 2017; RA MAA (EMEA/H/C/004214/0000) as monotherapy or in combination with MTX in adult patients with moderate to severe active RA, who have had an inadequate response or intolerance to 1 or more DMARDs.

On 25 Jun 2018, tofacitinib was approved in the EU at a dose of 5 mg BID in combination with MTX, in adult patients with active PsA, who have had an inadequate response or intolerance to a previous DMARD treatment (EMEA/H/C/004214/II/0006). Furthermore, tofacitinib was approved in the EU at a dose of 5 mg and 10 mg IR BID (26 Jul 2018; EMEA/H/C/004214/X/0005/G) for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

An extension application to introduce a new pharmaceutical form (prolonged-release tablet) associated with a new strength (11 mg), was approved on 16/12/2019 (EMEA/H/C/004214/X/0012)

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The clinical development program plans for the treatment of AS generally reflects the CHMP Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1). However, in certain instances the guideline has not been strictly adhered. For example, regarding the choice of ASAS20 as primary endpont the guideline states that 'although the percentage of patients reaching an ASAS 20 response has been accepted as primary endpoint for a number of products, a higher magnitude of the clinical response are expected for biological medicinal products or products from a new therapeutic class. Thus, the ASAS 40 response criteria would be the preferred primary endpoint'. The MAH reports to have used ASA20 as primary endpoint, with the EMA preferred ASAS40 endpoint as a key secondary endpoint, also based on interactions occurred with the FDA that informed the design of the Phase 3 program and content of the AS sNDA submission (the MAH has not sought scientific advice from the EMA or national member states in relation to the development of Xeljanz for the treatment of ankylosing spondylitis but has sought advice from the US FDA).

Summary of Meeting Correspondence with FDA:

Key interactions between Pfizer and the FDA for the ankylosing spondylitis (AS) program under IND 70903 have been provided ( Table 2 ).

Table 2. FDA Interactions on Development of Tofacitinib for Ankylosing Spondylitis

| Interaction                                   | DateofMinutes/Correspondence   |
|-----------------------------------------------|--------------------------------|
| Type B End of Phase 2 Meeting                 | 21Feb2018                      |
| FDAcommentsonprotocolA3921120                 | 17May2018                      |
| Type C Meeting. ,Written Response Only        | 01Feb2019                      |
| FDA comments on analysis plans                | 11Feb2019                      |
| FDA comments on A3921120 protocol amendment 2 | 30 May 2019                    |
| Type C meeting gWritten Response Only         | 29 0ct2019                     |
| TypeBpre-sNDAMeeting                          | 06Feb2020                      |

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The Environmental Risk Assessment (ERA) has been submitted by the MAH as part of this application for seeking approval for a new indication (treatment of ankylosing spondylitis (AS) in adult patients).

For the treatment of AS, the maximum recommended dosage of Xeljanz is 5 mg twice daily (IR tablet) or 10 mg once daily (IR).

Tofacitinib  has  a  log  D  value  &lt;4.5  at  all  environmentally  relevant  pHs.  Screening  for  Persistence, Bioaccumulation and Toxicity (PBT) is not required.

Calculation of the Predicted Environmental Concentration in Surface Water (PECsw) Annual consumption of tofacitinib in the EU member states over the 12-month period from 1Q2019 through 4Q2019 was obtained from the IQVIA™ [formerly the Intercontinental Marketing Services (IMS)], the Health Management Integrity and Data Assessment System (MIDAS) database (Appendix 1). Based on these

<div style=\"page-break-after: always\"></div>

data, total annual consumption in the EU is 117.4 kg and includes patient use of tofacitinib for treatment of the approved indications, RA, PsA and UC. The highest consumption per inhabitant was found in Luxembourg, therefore the data from Luxembourg will be used to determine the most conservative consumption based Fpen. As per the ERA Guideline1 , the Fpen based on consumption is determined as follows:

<!-- formula-not-decoded -->

| Fpen                                       | Market penetration factor                  |                                            |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Consumption                                | mg per year (2019)                         | 545,900 mg:yr-1                            |
| DDD                                        | Defined daily dose*                        | 10 mg-inh-1-d-1                            |
| Inhabitants                                | Luxembourg population, 2019 (Worldbank)    | 619,896                                    |
| *Lowest recommended daily dose = 10 mg/day | *Lowest recommended daily dose = 10 mg/day | *Lowest recommended daily dose = 10 mg/day |

<!-- formula-not-decoded -->

Fpen = 0.00024

## Determination of PECsw, approved indications:

<!-- formula-not-decoded -->

| PECsw                                                       | Predicted environmental concentration in surface water      | -- mg/L                                                     |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| DOSEai                                                      | Maximum daily dose applied per inhabitant*                  | 22 mg-inh-1 ·d-1                                            |
| Fpen                                                        | Market penetration                                          | 0.00024 [Refined]                                           |
| WASTEWinhab                                                 | Amount of wastewater per inhabitant per day                 | 200 L·inh-1·d-1 [Default]                                   |
| DILUTION                                                    | Dilution factor                                             | 10 [Default]                                                |
| *Maximum recommended daily dose = 22 mg/day (UC indication) | *Maximum recommended daily dose = 22 mg/day (UC indication) | *Maximum recommended daily dose = 22 mg/day (UC indication) |

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

PECsw = 0.0026 pg/L based on consumption attributed to RA, PsA and UC.

Determination of PECsw, new indication (AS)

<!-- formula-not-decoded -->

| PECsw       | Predicted environmental concentration in surface water   | -- mg/L                  |
|-------------|----------------------------------------------------------|--------------------------|
| DOSEai      | Maximum daily dose applied per inhabitant                | 11 mg-inh-l·d-1          |
| Fpen        | Market penetration                                       | 0.01 [Default]           |
| WASTEWinhab | Amount of wastewater per inhabitant per day              | 200 L·inh-·d-1 [Default] |
| DILUTION    | Dilution factor                                          | 10 [Default]             |

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Total PECsw all indications (RA, PsA, UC, and AS):

<!-- formula-not-decoded -->

The PECsw value is greater than the 0.01  g/L action limit. Based on the PECsw value, a Phase II environmental fate and effects analysis for tofacitinib is required.

## PHASE II - TIER A: PHYSICAL-CHEMICAL PROPERTIES, ENVIRONMENTALFATE AND EFFECTS ANALYSIS

The PECsurfacewater was not refined for human metabolism and excretion, for removal during wastewater treatment or for biodegradation in the water-sediment environment. In this conservative estimate, the PEC is more than 4 orders of magnitude less than the lowest chronic NOEC obtained with fish. In addition, the PEC/PNEC values for surface water (2 x 10-4), groundwater (3.1 x 10-5), micro-organisms (5.8 x 10-6) and sediment dwelling  organisms  (1.9  x  10-2),  are  all  significantly  below  the  respective  action  limits, therefore it may be concluded that tofacitinib will not present an environmental risk following patient use. No environmental concerns are apparent.

## 2.2.2. Discussion on non-clinical aspects

PECsw calculation was made by the MAH by summing up the PECsw of all indications, Fpen refinement was made by taking into consideration the annual consumption for the already approved indications (RA, PsA and UC). This is made for renewal applications, as per ERA guideline.

In case of a type II variation, specifically the addition of a new indication, the Fpen should be refined by submitting European disease prevalence data for the sought indication. Such data should be published by a reliable and independent source, as per ERA Q&amp;A.

Moreover, a PECsw of all indications was made by summing up the already approved and the new one. Also, the PECsw of the sought indications only have to be summed to reach the PECsurface water that will be used in the ERA, as per ERA Q&amp;A.

In light of these considerations, as the present submission was dealing with a type II variation, the MAH was asked to recalculate the PECsw for the new indication (SA) only, and to refine the Fpen by submitting EU prevalence data, as per ERA Q&amp;A. For the new indication, AS, the default Fpen value of 0.01 was used

<div style=\"page-break-after: always\"></div>

to calculate the PECsw of 0.055 μg/L, as per ERA guideline and Q&amp;A documents. Fpen from Luxembourg was used for the previosly approved ones. Therefore, the Fpen from this member state was used for PECsw of 0.0026 μg/L. As this application is deali ng with extension of indication, a total PECsw can be calculated and the ERA based on the total PECsw of 0.058 μg/L, representing contributions from newly sought and from approved indications, as originally submitted by the MAH, is appropriate for this extension of indication application.

## 2.2.3. Conclusion on the non-clinical aspect

Considering the above data, tofacitinib is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 3 Tabular overview of clinical studies

Listing of All Studies

| Protocol No. (Countries)                                                                                                                       | StudyDesignandObjectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Treatment Groups                                                      | No. of Subjects (by Treatment Group)a   | Demographics (sex, age, race) (No. of Subjects)                                       | Duration of Treatment     | Study Status              | Study Synopsis              |
|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------|---------------------------|---------------------------|-----------------------------|
| Efficacy andSafetyStudies                                                                                                                      | Efficacy andSafetyStudies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Efficacy andSafetyStudies                                             | Efficacy andSafetyStudies               | Efficacy andSafetyStudies                                                             | Efficacy andSafetyStudies | Efficacy andSafetyStudies | Efficacy andSafetyStudies   |
| A3921119 (Canada, Czech Republic,Germanyb Hungary, Poland, Russia, Spain, Republic of Korea, Taiwan, United States)                            | A phase 2multicenter,randomized, DB, PC dose-ranging, parallel group efficacy andsafetystudy designed to characterize the dose-response of tofacitinibinsubjectswithactiveAS Study consisted of12weeks of tofacitinibtreatmentfollowedby4 weeks off treatment. Primary objective:To compare the efficacy oftofacitinib, at doses of2 mg BID,5 mg BID,10 mg BID versus placebo on theASAS20 response rate at Week 12 in subjects with active AS that had an inadequate response toprevious treatment.The primary analysis was by Emax modelling. | Tofacitinib 2 mg BID Tofacitinib 5 mgBID Tofacitinib 10 mgBID Placebo | 52 52 52 51                             | Sex:143M/64F Mean/Median Age (min/max): 41.6/39.0 (22/75) years Race: W/A/O: 168/39/0 | 12 weeks DB               | Completed                 | CSR Module 5.3.5.4 A3921119 |
| A3921120 (Australia, Bulgaria, Canada,China, Czech Republic, France, Hungary, Poland, Russia, Republic of Korea, Turkey, Ukraine,UnitedStates) | A phase 3,randomized,DB,PC, studyoftheefficacyandsafetyof tofacitinib in subjects with active AS. Eligible subjects were randomized in a1:1ratiototofacitinib5mgBIDor matching placebo BID for a total of 16weeksofblinded treatment.At the Week 16 visit all subjects were                                                                                                                                                                                                                                                                     | Tofacitinib5 mgBID Placebo (16 weeks) → Tofacitinib 5 mg BID (32      | 133 136                                 | Sex:224M/45F Mean/Median Age (min/max): 41.1/40.0 (20/70) years Race: W/A/O: 213/55/1 | 16 weeks DB 32 weeks OL   | Completed                 | CSR Module 5.3.5.1 A3921120 |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                           | assigned toreceive OLtofacitinib5 mgBID until Week48. Primaryobjective:To compare the efficacy of tofacitinib 5 mg BID versus placebo on the ASAS20 responserate at Week 16in subjects with activeAS that hadaninadequate responsetoprevioustreatment.                                                                           | weeks)                                                    |       |                                                                                              |                        |           |                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------|----------------------------------------------------------------------------------------------|------------------------|-----------|--------------------------------------|
| A3921092LTE (Australia, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Germany, Hungary, Mexico, Poland, Russia, Slovakia, Spain, Taiwan, United Kingdom, United                      | An OL,LTE Study oftofacitinib for thetreatmentofPsA. Primary objective: To evaluate the long-term safety and tolerability of treatment with tofacitinib (5 mg BID and 10 mg BID) in adult subjects with PsA.                                                                                                                     | Tofacitinib (5 or 10 mg BID)                              | 686   | Sex: 316M/370F Mean/Median Age (min/max): 48.8/50.0 (18/78) years Race: W/A/B/O: 646/21/2/17 | Approximately 3 yearsc | Completed | CSR Module 5.3.5.2 A3921092 LTE      |
| States) A3921092 Substudy (Australia, Belgium, Brazil, Bulgaria, Canada,Czech Republic, Germany, Hungary, Mexico, Poland, Russia, Slovakia, Spain, Taiwan, United Kingdom, United States) | A Randomized,DB Parallel GroupMTXwithdrawal A3921092sub-studyoftofacitinibfor the treatment of PsA. Primary objective:To assess the efficacyoftofacitinib5mgBID monotherapy as compared to tofacitinib5mgBIDwithbackground MTX in subjects fromStudy A3921092whohadreceivedprior treatment of tofacitinibin combination with MTX | Tofacitinib 5 mg BID + MTX Tofacitinib 5 mg BID + Placebo | 89 90 | Sex: 83M/96F Mean/Median Age (min/max): 52.4/54.0 (25/77) years Race: W/A/B/O: 170/3/0/6     | 12 monthsd             | Completed | CSR Module 5.3.5.2 A3921092 Substudy |

a. Numberofsubjectsrandomizedandtreated.

b. 4 active sites in Germany which terminated during the study; across the 4 sites there was 1 subject in the Screening phase

C. 36 standardized 4 week months; a month was defined as 4 weeks or 28 days.

d. 12standardized4-weekmonths;a monthwas defined as 4weeks or28days.

Note: A=Asian; AS = Ankylosing Spondylitis; ASDAS20= An improvement from Baseline ≥20% and ≥1 unit increase in at least 3 domains on a scale of 0 to 10, and no worsening of ≥20% and ≥1 unit in the remaining domain; B =Black; BID = Twice daily; CSR=Clinical Study Report; DB = Doubleblind; F = Female; LTE= Long-term extension; M = Male; MTX = methotrexate; No = Number; O = Other; OL = Open-label; PC = Placebo-controlled; PsA = Psoriatic Arthritis; W = White.

## 2.3.2. Pharmacokinetics

The previously submitted clinical pharmacology and in vitro studies provided within the initial tofacitinib RA MAA included 25 Phase 1 studies comprising of 20 clinical pharmacology and 5 biopharmaceutic studies and 19 in vitro studies using biomaterials relevant to PK processes.

In addition, population PK reports in RA (S0000 PMAR-00178), PsA (S0014 PMAR-EQDD-A392j-sNDA601) and PsO (S0002 PMAR-EQDD-A392g-DP3-112) were previously submitted.

Clinical pharmacology aspects that are included in this AS application are:

- Summary of population PK of tofacitinib in AS patients (PMAR-EQDD-A392k-sNDA-1064)
- E-R relationships for efficacy in AS patients
- Dose modifications based on PK data (ie, renal and hepatic impairment and DDIs)

No new Phase 1 clinical pharmacology studies or in vitro studies are included in this AS application.

Two studies are submitted within this application: Phase 2 dose-ranging Study A3921119 and Phase 3 Study A3921120. An overview of studies is presented in Table 4. Three tofacitinib doses of 2 mg, 5 mg and 10 mg BID were evaluated in both AS studies combined. Data from Studies A3921119 and A3921120 were pooled to characterise the PK of tofacitinib in adult patients with active AS and to identify intrinsic and extrinsic patient specific factors that may impact the PK of tofacitinib (pop PK: PMAR-EQDD-A392ksNDA-1064). Population PK analysis was conducted using the nonlinear mixed effects modelling approach. Exposure metrics derived from the population PK model were used for the further development of the E-R relationships.

<div style=\"page-break-after: always\"></div>

Table 4. Overview of Tofacitinib Studies in Patients With AS Included in the Population PK Analysis

| Study Identifier                      | Design Features                                                                                                                                                                                                                                                                                                                                                    | Treatment Groups                                                            | PK Sampling Schedule/Period                                                                                                                                                           |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A3921119 (Phase 2 Dose-Ranging Study) | Randomised, MC, DB, placebo-controlled, parallel group study to investigate the efficacy and safety of tofacitinib in patients with active AS in a bDMARD-naive population. Duration of blinded                                                                                                                                                                    | Tofacitinib 2 mg BID Tofacitinib 5 mg BID Tofacitinib 10 mg BID Placebo BID | Week 4 Predose a , 0.5, and 2 hours postdose Week 8 Predose a , 0.5, 2, and 3 hours post dose Early termination sample, if done Week 4 Predose a , 0.5 and 2 hours post dose Week 8 a |
| A3921120 (Phase 3 Study)              | treatment: 12 weeks. Phase 3, randomised, DB, placebo-controlled study to evaluate the efficacy and safety of tofacitinib in patients with active AS in a bDMARD-naive (~80%) and bDMARD- experienced (~20%) population. Duration of blinded treatment: 16 weeks. (at the Week 16 visit, all patients assigned to open-label tofacitinib 5 mg BID until Week 48) b | Tofacitinib 5 mg BID Placebo BID                                            | Predose , 0.5, 2, and 3 hours postdose                                                                                                                                                |

a. Predose sampling was planned to occur within 12 ± 2 hours of the previous dose of investigational product.

b. No PK samples were collected in the open-label portion of Study A3921120.

Source: Module 5.3.3.5 PMAR-EQDD-A392-k-sNDA-1064 Table 2.

Xeljanz immediate release (IR) formulation is currently approved in the EU as a BID treatment for RA, PsA and UC.

No new biopharmaceutic studies are included in this AS MAA IR dossier.

The biopharmaceutic data presented in that original submission for RA also support the use of tofacitinib in AS. Study A3921005 examined the BA of a tablet formulation used in the RA Phase 2A study relative to OPC, which was used in the single and multiple ascending dose studies (A3921002 and A3921003). Study A3921005 also estimated the effect of food on the pharmacokinetics of the tablet formulation. A pivotal BE study (A3921075) evaluated the BE between tofacitinib tablets used in Phase 2B and Phase 3 studies and commercial tablets. Study A3921076 estimated the effect of food on the commercial tablet. The absolute BA of tofacitinib was investigated in Study A3921077 using the commercial tablet versus an IV formulation. Study A3921135 was conducted to establish BE between tofacitinib 1 × 5 mg tablets and 5 × 1 mg tablets used in RA Phase 2B studies to support the registration in Japan for the treatment of RA.

Table 5 lists the formulations and dose strengths that were used in the AS studies. The commercial 5 mg tablet formulation was used in both AS trials, A3921119 and A3921120, while the 1 mg tablet formulation was used only in A3921119, a Phase 2 dose ranging study in AS patients.

<div style=\"page-break-after: always\"></div>

Table 5 Formulations Used in Phase 2 and Phase 3 Studies in AS Patients

| Dosage Form/Formulation                       | Strength   | Protocol           |
|-----------------------------------------------|------------|--------------------|
| Clinical Formulation a                        | 1 mg       | A3921119           |
| Commercial Formulation - Plain/Clinical Image | 5 mg       | A3921119, A3921120 |

a. IND 70,903; Module 3; Section P.1 Description and Composition of the Drug Product (CP-690,550, Tablet).

The specific and sensitive bioanalytical methods using solid-phase extraction followed by the HPLC-MS/MS detection that were developed and validated for the measurement of tofacitinib concentrations in human plasma from AS patients are briefly described below.

A  HPLC-MS/MS  method  (Pfizer  Validation  A3929023)  was  developed  and  validated  at  WuXi  AppTec (Shanghai, China), with a quantitative range of 0.100 to 350 ng/mL with quadratic regression. The method was transferred to PPD (Richmond, VA and Middleton, WI) and validated (Pfizer Validation A3929032) with a truncated quantitative range from 0.100 to 100 ng/mL with linear regression.

Details of the specific methods, validation assessments and results can be found in the validation reports listed in the Tables 6 as well as a summary of the bioanalytical assay performance during the sample analyses for clinical studies for the AS development program ( Table 7 ).

Table 6 Summary of the Validated Analytical Method for Tofacitinib in Human Plasma

| Pfizer/Vendor Validation No.    | Matrix                 | Assay Laboratory             |   LLOQ (ng/mL) | Inter-assay Precision %CVa   | Inter-assay Accuracy %REa   | Assay Range (ng/mL)   | Comments on Validation                                                   | Clinical Study Protocol No.   |
|---------------------------------|------------------------|------------------------------|----------------|------------------------------|-----------------------------|-----------------------|--------------------------------------------------------------------------|-------------------------------|
| A3929023 /11BAS0459             | Sodium Heparin Plasma  | WuXi AppTec, Shanghai. China |            0.1 | ≤13.1%b                      | 1.0% to 8.0%                | 0.100 to 350          | Full validation                                                          | A3921119                      |
| A3929023 Addendum 01 /12BAS0395 | Lithium Heparin Plasma | WuXi AppTec, Shanghai, China |            0.1 | ≤9.9%                        | -3.8% to 7.0%               | 0.100 to 350          | Partial (cross) validation using lithium heparin as afn anticoagulant    | A3921119                      |
| A3929023 Addendum 02 /11BAS0459 | Sodium Heparin Plasma  | WuXi AppTec, Shanghai, China |            0.1 | ≤15.0%                       | 1.0% to 3.0%                | 0.100 to 350          | Primary stock solution stability and frozen storage matrixstability      | A3921119                      |
| A3929023 Addendum 03 /11BAS0459 | Sodium Heparin Plasma  | WuXi AppTec, Shanghai. China |            0.1 | ≤9.3%                        | -0.5% to 5.3%               | 0.100 to 350          | Matrix effect and whole blood stability                                  | A3921119                      |
| A3929023 Addendum 04 /11BAS0459 | Sodium Heparin Plasma  | WuXi AppTec, Shanghai, China |            0.1 | ≤7.3%                        | 3.3% to 2.0%                | 0.100 to 350          | Ambient temperature matrix stability and frozen storage matrix stability | A3921119                      |
| A3929023 Addendum 05 /12BAS0395 | Lithium Heparin Plasma | WuXi AppTec, Shanghai, China |            0.1 | ≤10.0%                       | 2.3% to 12.0%               | 0.100 to 350          | Frozen storage matrix stability                                          | A3921119                      |
| A3929023 Addendum 06 /16BAS0584 | Sodium Heparin Plasma  | WuXi AppTec, Shanghai, China |            0.1 | ≤5.5%                        | 0.7% to 4.1%                | 0.100 to 350          | Cross validation between2 laboratories                                   | NA                            |
| A3929023 Amendment01 /11BAS0459 | Sodium Heparin Plasma  | WuXi AppTec, Shanghai, China |            0.1 | NAC                          | NAC                         | NA                    | Update the freezer                                                       | A3921119                      |

<div style=\"page-break-after: always\"></div>

| Pfizer/Vendor Validation No.   | Matrix                 | Assay Laboratory   |   LLOQ (ng/mL) | Inter-assay Precision %CVa   | Inter-assay Accuracy 0%REa   | Assay Range (ng/mL)   | Comments on Validation                                                                                       | Clinical Study Protocol No.   |
|--------------------------------|------------------------|--------------------|----------------|------------------------------|------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------|
| A3929032 /RGTF2                | Lithium Heparin Plasma | PPD, Richmond, VA  |            0.1 | ≤4.88%b                      | 2.04% to 1.31%b              | 0.100 to 100          | Full validation                                                                                              | A3921120                      |
| A3929032 Addendum 01 /AKEX2    | Lithium Heparin Plasma | PPD, Middleton, WI |            0.1 | NAC                          | NAC                          | 0.100 to 100          | Methodtransfer from PPD Richmond to PPD Middleton                                                            | A3921120                      |
| A3929032 Addendum02 /RGTF3     | Lithium Heparin Plasma | PPD, Richmond,VA   |            0.1 | ≤5.79%                       | 2.36% to -0.392%             | 0.100 to 100          | Interference assessment, frozen storage matrix stability and primary stock solution stability                | A3921120                      |
| A3929032 Addendum03 /AKEX2     | Lithium Heparin Plasma | PPD, Middleton, WI |            0.1 | NAC                          | NAC                          | 0.100 to 100          | Primary stock solution stability, IS stock and working solution stability and frozen storage matrixstability | A3921120                      |

a. criteria.

b. From accuracy andprecisionrums.

C. Inter-assayvalueswerenotavailable.

Table 7 Assay Performance of Tofacitinib in Human Plasma in Each Clinical Study

| Clinical Study   | Assay Laborat ory             | Pfizer Validati on No.   | Comp ound Analy sed   | Matrix   | Inter- run Precisi on %CV a   | Inter-run Accuracy %RE   | ISR   |
|------------------|-------------------------------|--------------------------|-----------------------|----------|-------------------------------|--------------------------|-------|
| A3921119         | Wuxi AppTec, Shangha i, China | A392902 3                | Tofaciti nib          | Plasma   | ≤ 5.7%                        | 0.0% to 1.4%             | Yes   |
| A3921120         | PPD, Middleto n, WI           | A392903 2                | Tofaciti nib          | Plasma   | ≤ 5.64%                       | - 1.56% to 8.59%         | Yes   |

a. Statistics (%RE and %CV) based on mean assay performance of low, mid-low, mid-high, and high dilution (if applicable) QC samples from all analytical batches meeting acceptance criteria.

Tofacitinib plasma concentrations were measured through HPLC-MS/MS method developed and validated at Wuxi AppTec (Shangai, China - A3929023) and then transferred at PPD (Richmond and Middleton).

Samples from Study A3921119 were analysed by Wuxi, whereas samples from Study A3921120 were analysed by PPD in Middleton. Furthermore, in study A3921119 sodium heparin plasma was used and in study A3921120 lithium heparin plasma. The table above reports the cross validation A3929023 addendum 6, however, as confirmed by the MAH and accepted by the CHMP this cross validation is not applicable to the current analysis since it is performed between Wuxi and PPD in Richmond

A method transfer was performed from PPD in Richmond to PPD in Middleton and an assay performance with respect to precision, accuracy, and specificity was conducted.

The Pfizer method A3929032 was transferred from PPD Richmond to PPD Middleton, and a method transfer was submitted as A3929032 addendum 1.

<div style=\"page-break-after: always\"></div>

No cross-validation was performed between PPD Middleton and Wuxi, however the MAH is the opinion that since the method used at Richmond and that used at Middleton remained exactly the same, the cross validation between Wuxi and PPD Richmond supports the comparability of data analysis also between Wuxi and PPD Middleton. This is not exactly in line with EMA guideline on Bioanalytical methods reports that states 'Where data are obtained from different methods within and across studies or when data are obtained within a study from different laboratories, applying the same method, comparison of those data is needed, and a cross validation of the applied analytical methods should be carried out'. However, since the method transfer to PPD Middleton showed that selectivity, carryover, linearity, sensitivity, accuracy, precision, recovery, dilution, and stability were met, the method is considered valid for the extraction and analysis of human lithium heparin plasma. This issue was not therefore further pursued by the CHMP.

The MAH didn't resubmit the Bioanalytical report for the determination of tofacitinib samples collected in Study A3921119, this was acceptable as the study was already submitted and assessed by the CHMP in the context of extension of indication in psoriatic arthritis. In this Study, a total of 1011 samples were analysed by Wuxi (method A3929023); the maximum storage time at -20±5°C in sodium heparin was 309 days (validated LTS at 1274 day at -20±5°C). The ISR was performed on 104 samples and fulfilled the acceptance criteria.

The MAH has provided the bioanalytical report for study A3921120 and declared that all samples were analysed during the stability period. The number of samples received is 1848, however the samples analysed were 922. In the Appendix 4 of the bioanalytical report, the note 8 denotes samples not assayed at Sponsor's request and was reported for several samples, all in the treatment B. The MAH was requested to clarify what treatment the letter B refers to and the reason why the Sponsor requested to not analyse these samples.

The MAH clarified that, Appendix 4 of the Bioanalytical Report for Study A3921120, titled, 'Concentration Data (ng/mL) for CP-690550 in Human Plasma Samples from Protocol A3921120' has a list of Comment Codes and Descriptions, of which samples with Code 8 or Note 8, identifies samples that were commented as, 'Sample not assayed at Sponsor's request'. The 'Sponsor Instructions and Bioanalytical Notes' section of the bioanalytical plan (Module 5.3.5.1 CSR A3921120 Analytical Reports Section 8.7 Appendix 2) in the bioanalytical report provides the following instructional text: 'Do not assay placebo samples'. As per this bioanalytical plan, samples that were designated as treatment B in Study A3921120 were not assayed as they were placebo samples. The clarification provided by the MAH is endorsed by the CHMP.

## Pharmacokinetic in target population

Study A3921120 - Week 16 Analysis - Tofacitinib plasma concentration data were summarized by time in the Table 8 :

<div style=\"page-break-after: always\"></div>

Table 8. Plasma Tofacitinib Concentration (ng/mL) versus Time Summary

<!-- image -->

Study A3921119 plasma tofacitinib concentration data are reported in the Table 9 , summarized by time and tofacitinib dose group, using the PK analysis set:

Table 9. Summary of PK concentration- safety Analysis Set

<!-- image -->

No statistical analysis has been performed in each study report for the two new studies because data have been included in the popPK, please refer to Population PK in AS patients section.

It is of note that a high variability is observed in PK parameters for all dosages and time points.

## Population PK in AS patients: PMAR-EQDD-A392k-sNDA-1064

The population PK of tofacitinib has been previously characterized in RA patients by pooling data from 5 Phase 2 studies (A3921019, A3921025, A3921035, A3921039 and A3921040), and a long-term extension study  A3921024,  in  PsO  patients  from  one  Phase  2  study(A3921047),  4  Phase  3  studies  (A3921078, A3921079, A3921080, A3921111), in patients with active PsA from 2 Phase 3 studies, and in patients with UC from one Phase 2 study (A3921063) and 3 Phase 3 studies (A3921094, A3921095, A3920196).

<div style=\"page-break-after: always\"></div>

A one compartment model parameterized in terms of apparent clearance (CL/F) and apparent volume of distribution  (V/F),  consistent  with  monophasic  elimination,  with  either  zero-order  absorption  or  first absorption were previously utilized to describe the PK of tofacitinib in these patient populations.

The current PopPK includes data from studies A3921119 and A3921120 ( Table 10 ). Study A3921229 was a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis with a duration of 12 weeks. Study A3921120 was Phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis; the duration was 16 weeks in double blind and 32 in open-label.

Table 10. PK Sampling Schedule in the Studies

PKSamplingScheduleintheStudies

| Study    | PK sampling schedule /Period                                                                                             | Treatment                   | Number of subjects in dataset   |
|----------|--------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------|
| A3921119 | Week 4 Pre-dose?, 0.5 and 2 hrs post-dose Week 8 Pre-dose?, 0.5, 2 and 3 hrs post-dose Early Termination sample, if done | 2 mg BID 5 mg BID 10 mg BID | 50 49 48                        |
| A3921120 | Week 4 Pre-dose?, 0.5 and 2 hrs post-dose Week 8 Pre-dosea, 0.5, 2 and 3 hrs post-dose                                   | 5 mg BID                    | 132                             |

Abbreviation: BID = twice daily

a Pre-dose sampling was planned to occur within 12±2 hours of previous dose of investigational product.

The objectives of this analysis were:

- To characterize the PK of tofacitinib in patients with ankylosing spondylitis (AS)
- To identify intrinsic and extrinsic factors (covariates) that impact the PK of tofacitinib in these patients.
-  To  obtain  individual  steady  state  exposures  and  PK  parameters  for  subsequent  exposure-response analyses.

The population PK analysis was conducted using the nonlinear mixed-effects modeling approach. The software packages NONMEM version 7.4.3 (ICON plc., Gaithersburg, MD) and Perl-speaks-NONMEM (PsN) version 4.9.0 as supporting software for the execution of NONMEM was used. R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for data handling, exploratory data analysis and creation of graphs for presentations and reports. The estimation method was the first-order conditional estimation method with interaction (FOCEI).

The study population consisted of 222 males and 57 females with ages ranging from 20 to 75 years and weights ranging from 42.3 to 143 kg. The median values of age and body weights at baseline were 40 years and 78 kg. The median value of the Cockroft-Gault calculated creatinine clearance at baseline (BCCL) was 126 mL/min ranging from 48.1 mL/min to 244 mL/min. The distributions of age and BCCL were similar across studies. Baseline CRP (BCRP) had a median value of 0.851 mg/dL and ranged from 0.019 to 8.71 mg/dL. Distribution of race was: 79.9% White, and 19.7% Asian. Hispanic/Latino patients were only 1.4% in the dataset population.

<div style=\"page-break-after: always\"></div>

Table 11. Number of Patients and Plasma Concentrations in the Analysis Dataset

## Number of Patients and Plasma Concentrations in the Analysis Dataset

| Study                                      | 2 mg BID   | 5 mg BID   | 10 mg BID   | Total     |
|--------------------------------------------|------------|------------|-------------|-----------|
| Number of subjects                         |            |            |             |           |
| A3921119                                   | 50         | 49         | 48          | 147       |
| A3921120                                   | 0          | 132        | 0           | 132       |
| All                                        | 50         | 181        | 48          | 279       |
| Numberof observedconcentrations(numberBLQ) |            |            |             |           |
| A3921119                                   | 338 (7)    | 338 (0)    | 320 (3)     | 996 (10)  |
| A3921120                                   | 0          | 921 (10)   | 0           | 921 (10)  |
| All                                        | 338 (7)    | 1259 (10)  | 320 (3)     | 1917 (20) |

Repository artifact IDFI-2108665.

Abbreviations:BLQ=below limit of quantification

Drug concentrations that were below the analytical lower limit of quantification, or any values that were otherwise missing, were labelled as such, and were excluded from the analyses. There were total of 20 (1.0%) data records below limit of quantification (BLQ) that were excluded. There were no missing observations in the final dataset, therefore no data imputations were performed. None of the covariates were missing data greater than 10%.

The analyses were conducted in the following steps: 1) Base Structural Model Development, 2) Random Effects Model Development, 3) Full Model Development, 4) Assessment of Model Adequacy and 5) Model Predictive Performance (Validation).

Base model. Given prior knowledge, a PK model based on the RA and PsA populations were used as a starting point for model development.

A one compartment disposition model parameterized in terms of apparent oral clearance (CL/F), apparent volume of distribution (V/F), and a first-order absorption rate constant (ka), was chosen as starting point.

Adding IIV to ka showed a decrease in OFV of 280. When an absorption lag time (tlag) was incorporated, the parameter value for ka was estimated to be very large (&gt; 9 hr-1; absorption t1/2&lt;5 minutes). According to the MAH, this may be due to the limited information describing the absorption in this sparsely sampled data set. Additionally, the distribution of the random effect on ka was still skewed in these models.

After evaluation of the different structural models, the one compartment model with first order absorption, IIV on CL/F and V/F with OMEGA block and no IIV on ka, different proportional residual error for observations with TAD&lt;9 or ≥9 hours on residual error were chosen as the base model ( Run 1, table 12 ).

<div style=\"page-break-after: always\"></div>

Table 12. List of Key Runs for Based Model

List of Key Runs for Based Model

| Run   | Description                                                                                             |     OFV | Comment                                                                          |
|-------|---------------------------------------------------------------------------------------------------------|---------|----------------------------------------------------------------------------------|
| #1    | 1-compartment model with 1st-order absorption (OMEGA BLOCK for CL/F & V/F), RUV was divided by TAD=9 hr | 619.251 | Base model                                                                       |
| #19   | #1 + IIV of ka (@ka)                                                                                    | 339.379 | θka=4.39, Oka=169%CV ($COV step was aborted, because o² became less than WcL-v.) |
| #72   | #19, replace 0y to ocL · 0(scaling factor) and remove covariance (@cL-v).                               | 339.378 | Oka=4.39 0ka=169%CV, (Distribution of individual ka estimate was skewed.)        |
| #73   | #72 + tlag (uug)                                                                                        | 263.083 | Oka=9.85,@k=202%CV, 0=0.247 (Distribution of individual ka estimate was skewed.  |

Repository tree ID: AT-4367271.

Abbreviations: CV = coefficient of variation; IIV = inter-individual variance; OFV = objective function value;

TAD = time after dose

The typical estimates of CL/F and V/F from the base model were 26.7 L/h and 124 L, respectively (Table 13 ) , with relative standard errors of &lt;3%. The ka was estimated to be 3.06 h-1 with an RSE of 10.1%. IIV estimates for CL/F and V/F were 30.5% and 39.2%, respectively. The correlation coefficient between CL/F and V/F was 0.735. Residual variability for observations with TAD &lt;9 hours and TAD ≥ 9 hours were 60.3% and 69.5%, respectively ( Table 13 ).  Shrinkage estimates from the base model were 21.5% for IIV of CL/F, 24.8% for IIV of V/F and 8.94% for IIV of residual error, respectively.

Table 13. Parameter Estimates for the Base Population Pharmacokinetic Model (Run 1)

## ParameterEstimatesfor theBasePopulationPharmacokinetic Model (Run 1)

| Parameter                        |   Estimate |   RSE (%) | IIV% (RSE%)   |
|----------------------------------|------------|-----------|---------------|
| CL/F (L/hr)                      |    26.7    |      2.17 | 30.5 (1.01)   |
| V/F (L)                          |   124      |      2.78 | 39.2 (2.01)   |
| ka (/hr)                         |     3.06   |     10.1  |               |
| Prop. Error CV for TAD < 9 hr(%) |    60.3    |      4.41 |               |
| Prop. Error CV for TAD ≥ 9 hr(%) |    69.5    |      6.71 |               |
| Covariance (CL/F &V/F)           |     0.0877 |     30.2  |               |

Source:FI-4390654

Abbreviations: ; CL/F = apparent clearance; CV = coefficient of variation; IIV = inter-individual variance;

ka =first-order absorption rate constant;RSE=relative standard error;TAD=time after dose;

Random Effects Model Development. Inter-individual variance (IIV) was included on the PK parameters using multiplicative exponential random effects. Inter-occasion variance (IOV) terms were investigated for F or CL/F. The individual parameter value ( θ i) is a function of the typical individual parameter value ( θ ) and an individual deviation represented by η i and an occasion-specific deviation represented by ki j, expressed as: θ i = θ · exp( η i+ki j).

Residual  variability  was  modeled  as  additive  on  log-transformed  scale  or  approximate  additive  + proportional on log-transformed scale error model: ln(Yijk) = ln(Fi jk)+ ε i jk where Yijk denotes the observed concentration for the ith individual at occasion jth, and time kth, Fijk denotes the corresponding predicted

<div style=\"page-break-after: always\"></div>

concentration based on the PK model, and ε ijk is the proportional error (additive in log scale) on the logtransformed domain assumed to have zero mean and variance σ 2.

ETA-shrinkage was monitored throughout model development.

Inclusion of Covariates and Full Model Development. The parameter-covariate combinations for included in the final full model are listed in Table 14 .

Table 14. Covariates to be evaluated during PK modeling

Covariates evaluated during PK modeling

| PKParameter   | Covariate                                                                                                                         |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------|
| CL/F          | Race [categorical], Sex [categorical], Ethnicity [categorical], Age, Body weight, Baseline renal function (CCL), and Baseline CRP |
| V/F           | Body Weight, Age                                                                                                                  |

Abbreviations: CL/F = apparent clearance, V/F = apparent volume of distribution,

CCL = creatinine clearance, CRP =C-reactive protein

Continuous covariates (eg. body weight) were included in the model as follows:

<!-- image -->

where θ i is the value of the parameter for the ith individual, θ TV is the typical value of the parameter in the population, covi is the value of the covariate for the individual, covmedian is the median value of the covariate in the study population and θ x is the effect of the covariate on the parameter.

Categorical covariates were introduced in the model as follows:

<!-- formula-not-decoded -->

where θ x,cov=Xy is the effect of the covariate belonging to category y, where y goes from 0 (reference category) to m (the number of categories-1).

Continuous covariates were incorporated as power functions, normalized to the reference (approximate median) values. Each category of categorical covariates (gender, and race) entered the model as one coefficient. The equations of the full model are listed below included for the final full model.

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

BWT and ethnicity (Hispanic or non-Hispanic) were also predefined as potential predictors of CL/F. However, for avoiding collinearity in predictors, BWT effect on CL/F was not employed in the final full model as BWT was correlated with BCCL (correlation coefficient&gt;0.5).

As BCCL was calculated using Cockcroft-Gault equation based on subjects' serum creatinine level as well as age, sex and body weight at baseline, the impact of including both BWT and BCCL on CL/F in the full model was investigated by testing the models including BCCL or BWT on CL/F. Compared to Run 65 (full model with BCCL only), the model with both BWT and BCCL (Run 2) or with BWT only (Run 90) on CL/F led to change slightly in OFV of -0.066 and +6.301, respectively, indicating that the impact of BWT on CL/F was negligible.

Also, as most patients in the dataset were non-Hispanic/Latino (97.8%), ethnicity was not included.

The parameter estimates for the final full model and bootstrap results are presented in the Tables 15, 16.

Table 15. Parameter Estimates for the Final Full Model (Run 65)

## ParameterEstimatesfor theFinal Full Model (Run 65)

| Parameter                        | Estimate (RSE%)   | IIV % (RSE%)   | Mediana (IIV%)   | 95% CIa (95% CI for IIV)   |
|----------------------------------|-------------------|----------------|------------------|----------------------------|
| CL/F (L/hr)                      | 27.1 (2.41)       | 28.2 (0.923)   | 27.1 (27.6)      | [25.8, 28.5] (21.4, 34.4)  |
| V/F (L)                          | 126 (2.81)        | 36.6 (1.90)    | 126 (36.0)       | [120, 134] (25.6, 47.0)    |
| ka (1/hr)                        | 3.07 (10.2)       |                | 3.08             | [2.56, 3.74]               |
| Prop. Error CV for TAD < 9 hr(%) | 60.2 (4.42)       |                | 60.1             | [54.8, 65.3]               |
| Prop. Error CV for TAD ≥ 9 hr(%) | 69.6 (6.73)       |                | 69.3             | [60.4, 78.3]               |
| Covariance (CL/F-V/F)            | 0.0760 (33.0)     |                | 0.0728           | [0.0348, 0.131]            |

Repository artifact ID FI-4399871

a: Calculated by bootstrap method (All 1000 runs minimized successfully).

Abbreviations: CI = confidence interval; CL/F = apparent clearance; CV = coefficient of variation;

IIV = inter-individual variance; ka = first-order absorption rate constant; RSE = relative standard error;

TAD = time after dose; V/F = apparent volume of distribution

The point estimates (95% bootstrap CI) of CL/F, V/F, and ka are 27.1 (25.8, 28.5) L/hr, 126 (120, 134) L and 3.07 (2.56, 3.74) hr-1, respectively, for the typical reference individual (white, male, 78 kg, 40 year old, BCCL 126 mL/min, and BCRP 0.851 mg/dL).

The 95% CIs for BCRP and SEX(Female) effects on CL/F contained the null value. The effects of Age, BCCL, and RACE(Asian) on CL/F were significant (CIs excluded null). Baseline body weight and age also impacted V/F (CIs excluding null).

<div style=\"page-break-after: always\"></div>

Table 16 . - Covariate Parameter Estimates for the Final Full Model (Run 65)

## Covariate Parameter Estimates for the Final Full Model (Run 65)

| Parameter   | Covariate    |   Estimate |   RSE% | 95% CIa           |
|-------------|--------------|------------|--------|-------------------|
| CL/F        | AGE          |    -0.244  |   33.7 | [-0.419, -0.0989] |
|             | BCCL         |     0.233  |   34.5 | [0.0688, 0.377]   |
|             | BCRP         |    -0.0185 |   75.7 | [-0.0447,0.00881] |
|             | SEX (Female) |     0.0237 |  177   | [-0.0598, 0.107]  |
|             | RACE (Asian) |    -0.103  |   31.7 | [-0.164, -0.0385] |
| V/F         | AGE          |    -0.23   |   42.3 | [-0.421, -0.0449] |
|             | BWT          |     0.574  |   23.1 | [0.306, 0.835]    |

Repository artifact ID FI-4399871

a: Calculated by bootstrap method (All 1000 runs minimized successfully).

Abbreviations: BCCL = creatinine clearance at baseline; BCRP = C-reactive protein at baseline;

BWT = body weight at baseline; CI = confidence interval; CL/F = apparent clearance;

RSE = relative standard error; V/F = apparent volume of distribution

Assessment of model adequacy. Goodness of fit (GOF) of different models to the data was evaluated using the following criteria: change in objective function value (OFV), visual inspection of various diagnostic plots ( Figure 1 ), precision of the parameter estimates.

Figure 1. Goodness-of-fit Plots for Final Full Model (Run 65)

<div style=\"page-break-after: always\"></div>

## Goodness-of-fit Plots for Final Full Model (Run 65)

<!-- image -->

Repository artifact ID FI-4369226.

Red line is the reference line of identity. Blue line is the threshold for identifying outliers.

Model Predictive Performance (Validation). Visual predictive check (VPC) Figure 2 were performed for the final base and full PK models.

VPCs of the full model demonstrated that the simulated distributions matched the observed concentrations except samples at 0.5 hours (immediately after dosing), which indicated the full model slightly underpredicted the absorption phase.

Figure 2. Visual Predictive Check for Final Full Model (Run 65)

<div style=\"page-break-after: always\"></div>

## Visual Predictive Check for Final Full Model (Run 65)

<!-- image -->

(b) FI-4400854

Repository artifact IDs are shown in subfigure labels.

For each panel, the red solid line (blue solid lines) represents 50 percentile (5 and 95 percentiles) of observed concentration versus time profile. The red dashed line (blue dashed lines) represents 5 and 95 percentiles for concentration versus time profile. The red area (blue areas) represents 95% CIs of 50 percentile (2.5 and 97.5 percentiles) for concentration versus time profile. The closed circles indicate individual observed concentration time data. Upper and lower VPCs were same data source. Lower is focus on up to 4 hours after dose with normal scale y-axis.

## Results

Some inferences could be made using the parameters from the full model:

- An elderly patient (64 years of age, 95th percentile of age) was estimated to have 10.9% lower CL/F compared to the CL/F a 40-year-old patient.
- Female patients were estimated to have 2.4% higher CL/F compared to males.
- Asian patients were estimated to have 10.3% lower CL/F compared to non-Asian patients.

<div style=\"page-break-after: always\"></div>

- A patient with a BCCL of 50 mL/min, CL/F was estimated have a 19.4% lower CL/F relative to a patient with BCCL 126 mL/min (median value in the analysis dataset).
- A patient with BCRP of 8 mg/dL was predicted to have a 4.1% lower CL/F compared to a patient with BCRP of 0.851 mg/dL.
- V/F estimates of an elderly patient (64 years of age, 95th percentile of age) was estimated to be 10.2% lower compared to the V/F of a 40-year-old patient.
-  V/F  estimates  for  patients  weighing  54  or  107  kg  (5th  and  95th  percentile  of  body  weight)  were approximately 19% lower or 20% higher compared to patients with body weight 78 kg, respectively.

Secondary exposure metrics for exposure-response analyses were calculated using the individual parameter estimates obtained from the full model ( Table 17 ).

Table 17. Summary of Secondary Pharmacokinetic Parameter Predictions Based on the Final Full Model (Run 65)

## Summary of SecondaryPharmacokineticParameterPredictionsBasedon the Final Full Model (Run 65)

|                |           | Geometric   | Geometric   | Geometric   |       |        |      |
|----------------|-----------|-------------|-------------|-------------|-------|--------|------|
| Parameter      | Dose      | Mean        | SD          | %CV         | Min   | Median | Max  |
| Cmax (ng/mL)   | 2 mg BID  | 14.0        | 1.27        | 24.7        | 7.83  | 14.1   | 24.3 |
|                | 5 mg BID  | 36.7        | 1.32        | 28.0        | 10    | 37.9   | 64   |
|                | 10 mg BID | 73.9        | 1.25        | 22.5        | 32.5  | 76.6   | 120  |
| Cavg (ng/mL)   | 2 mg BID  | 6.02        | 1.24        | 21.8        | 3.11  | 5.99   | 9.49 |
|                | 5 mg BID  | 15.9        | 1.28        | 25.4        | 5.38  | 15.8   | 33.1 |
|                | 10 mg BID | 31.0        | 1.28        | 24.7        | 16.8  | 32.2   | 62.8 |
| Cmin (ng/mL)   | 2 mg BID  | 1.28        | 1.51        | 43.4        | 0.4   | 1.29   | 3.17 |
|                | 5 mg BID  | 3.46        | 1.60        | 49.7        | 0.825 | 3.46   | 11.4 |
|                | 10 mg BID | 6.19        | 1.70        | 57.4        | 1.31  | 6.53   | 22.4 |
| AUC (ng.hr/mL) | 2 mg BID  | 72.2        | 1.24        | 21.8        | 37.3  | 71.9   | 114  |
|                | 5 mg BID  | 190.5       | 1.28        | 25.4        | 64.6  | 190    | 397  |
|                | 10 mg BID | 372.0       | 1.28        | 24.7        | 201   | 386    | 754  |

Repository artifact ID FI-4369223. Line 1 substituted. Columns [1 2 8 9 10 65 7] out of 10.

Abbreviations: AUC = area under the concentration-time curve over a dosing interval; BID = twice daily; Cavg = average steady-state tofacitinib concentration over the dosing interval; Cmax = maximum steady-state tofacitinib concentration over the dosing interval; Cmin = tofacitinib concentration at steady-state at the end of the nominal 12 hours dosing interval; CV = coefficient of variation; Max = maximum; Min = minimum; SD=standard deviation

The impact of covariate effects on tofacitinib secondary parameters (AUC and Cmax) is evaluated and demonstrated in Figure 3. With the exception of BCCL, point estimates of AUC and Cmax change relative to typical subject ranged between 98% and 112%, and between 89% and 115%, respectively. For a patient with a BCCL of 50 mL/min (lowest value in the analysis dataset was 48 mL/min), AUC was estimated to be 24% higher relative to a reference patient with baseline creatinine clearance of 126 mL/min. As subjects with baseline creatinine clearance values (estimated by Cockcroft-Gault equation) below 50 mL/min was very limited in the analysis dataset, the need for dose adjustment in renal impairment is primarily assessed using Phase 1 data from Studies A3921004 and A3921006. The point estimates of the AUC and Cmax ratios and the associated 90% CI indicated no major differences in tofacitinib exposure over the range of ages and body weights studied as well as race, and gender.

Figure 3. Impact of Covariates on the Pharmacokinetics of Tofacitinib in AS Patients

<div style=\"page-break-after: always\"></div>

## Impact of Covariates on the Exposure of Tofacitinib in AS Patients

<!-- image -->

## Repository artifact ID FI-11546118.

Abbreviations: AUC = area under the concentration-time curve over a dosing interval; BCCL = creatinine clearance at baseline; Cmax = maximum steady-state tofacitinib concentration over the dosing interval ; PK = pharmacokinetic; CI = confidence interval.

Dotted line represents limits of a range from 80% to 125%. A typical (reference) patient is represented as: White male with body weight 78 kg, C-reactive protein at baseline (BCRP) 0.851 mg/dL, creatinine clearance at baseline (BCCL) 126 mL/min, 40 year old. The impact of covariates were assessed at age of 64 year old (95th percentile) and body weights of 54 and 107 kg (5th and 95th percentiles, respectively), female, in Asian subjects with reference to the typical patient reported above. In addition. the impact of BCCL of 50 mL/min with respect to reference patient was also assessed. Dose adjustment recommendation for BCCL 50 mL/min is based on other data (Phase 1 renal impairment trials), as subjects with BCCL below 50 mL/min in this analysis dataset are limited (48.1 mL/min was the lowest BCCL in the analysis dataset). Magnitude of change is presented in reference to a typical patient. $: No dose adjustment for patients with mild or moderate renal impairment.

The population PK of tofacitinib in patients with active ankylosing spondylitis was adequately described by a one-compartment model with first order absorption.

Between-subject variability (%CV) in tofacitinib CL/F was estimated to be 28%.

Tofacitinib does not require dose modification or restrictions for age, body weight, gender, or race in the adult ankylosing spondylitis population based on the &lt;20% differences in AUC and Cmax ratios across these patient factors relative to a reference AS patient.

The relationship between tofacitinib CL/F and creatinine clearance is consistent with the known contribution of renal excretion to the total clearance of tofacitinib.

Population PK analysis results in AS indicated that tofacitinib exposure, as measured by the steady state AUC24 after 5 mg BID is similar (differences  between  geometric  means  within  25%)  among  AS  (382 ng·h/mL), PsA (419 ng·h/mL), RA (507 ng·h/mL) and PsO (404 ng·h/mL) patients.

Population PK analysis results indicated comparable inter-subject variability (%CV) in AUC across AS, RA, PsA and PsO patients (all ranged between 27% and 32%).

Change relative to the typical subject (%)

<div style=\"page-break-after: always\"></div>

Based on the demonstrated similarity in the tofacitinib PK profile between AS and RA (and PsA) patients, it is  proposed  that  dosing  modifications  derived  for  RA  patients,  primarily  based  on  Phase  1  clinical pharmacology studies, are also applicable for patients with AS.

Consistent  with  dose  adjustment  recommendations  in  the  current  SmPC  for  RA  and  PsA  patients,  the recommended total daily dose of tofacitinib will be reduced by half, from 5 mg BID to 5 mg QD (of the IR formulation) for AS patients with severe renal impairment, moderate hepatic impairment, patients receiving potent  inhibitors  of  CYP3A4  (for  example,  itraconazole),  patients  receiving  1  or  more  concomitant medications  that  result  in  both  moderate  inhibition  of  CYP3A4  and  potent  inhibition  of  CYP2C19  (for example,  fluconazole),  moreover  tofacitinib  is  not  recommended  in  AS  patients  with  severe  hepatic impairment and the coadministration of tofacitinib and potent inducers of CYP3A4, such as rifampin, to AS patients may result in loss of or reduced clinical response.

The  starting  point  for  the  popPk  in  AS  patients  was  based  on  models  previously  used  in  RA  and  PsA population. A one compartmental model with first order absorption and IIV on CL/F and V/F with OMEGA block was chosen. IIV on Ka reduced the OFV, moreover the inclusion of tlag determines an increase of Ka estimation with a very quickly absorption phase. The MAH justify this result, and then the exclusion of IIV on  Ka,  with  the  sparse  sampling  data  limiting  the  information  on  the  absorption  phase.  Although  this justification is sharable, the exclusion of IIV on ka did not permit to evaluate the variability in the absorption phase that, in general is of interest for the investigation of the PK profile, thus even for a PopPK model. The residual error for observations with TAD &lt;9 hours and TAD ≥ 9 hours was evaluated in the model.

The population (PK) analysis in AS patients was performed using pooled sparse samples collected in Studies A3921119 and A3921120, based on the PK sampling schema (i.e., pre-dose, 0.5, 2, and 3 hours after dose), as designated in the respective study protocols (S0113 Module 5.3.3.5 PMAR-EQDD-A392k-sNDA1064).

In this population PK analysis in AS patients, residual random effects were described with 2 proportional error models for non-trough samples defined as time after dose (TAD) &lt;9 hours, and trough samples (TAD ≥9 hours), respectively. Trough samples can be noisier than nontrough samples and tend to have a higher variability.

Figure 4 shows the distribution of observed tofacitinib plasma concentrations vs. time after dose by study. As mentioned above, the PK samples were collected based on a sparse sampling schema. It can be observed from Figure 4 that the trough samples (primarily from pre-dose sampling) were mostly collected beyond 9 hours post-dose, with very few to almost no samples between 5- and 9-hours TAD. Given this collection profile, 9 hours was used as the TAD cut-off value to differentially estimate residual errors for trough and non-trough plasma concentrations. Base on the provided justification, the choice of 9 hours as the TAD cutoff value is considered reasonable.

<div style=\"page-break-after: always\"></div>

Figure 4. Observed Tofacitinib Plasma Concentrations vs. Time after Dose by Study

## Observed Tofacitinib Plasma Concentrations vs. Time after Dose by Study

<!-- image -->

Abbreviations: BID = twice daily

Trough concentration was plotted as 12-hour observation instead of pre-dose.

In the initial MAA, the Applicant submitted a nonlinear mixed effects analysis of Cmax and AUC (derived using noncompartmental methods) from 16 Phase 1 studies concluding that Cmax is approximately dose proportional at least up to 10 times the proposed dose of 5 mg.

Study A3921002, a randomized, parallel-group, placebo-controlled, single-dose escalation study was also submitted in the initial MAA in which 95 subjects were randomized in different dose group to receive a single doses of 0.1 to 100 mg tofacitinib, (0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, 30 mg, 60 mg, 100 mg) administered as oral power for constitution (OPC). Systemic exposures (Cmax and AUC ∞ ) of tofacitinib increased  in  a  dose-proportional  manner,  indicating  linear  pharmacokinetics  across  the  dose  interval evaluated (0,1 and 100 mg dose, Table 18). There are only small changes from linearity mostly for Cmax values from 1 mg dose.

<div style=\"page-break-after: always\"></div>

Table 18. Mean (SD) PK Parameters Following Single Oral Doses in Healthy Subjects (A3921002 )

|   Dose group (mg) |   N | C max (ng/mL)   | AUC last (ng*hr/mL)   | AUC ∞ (ng*hr/mL)   | T max † (hr)    | t 1/2 (hr)   |
|-------------------|-----|-----------------|-----------------------|--------------------|-----------------|--------------|
|               0.1 |   5 | 1.27 (0.08)     | 0.16 (0.01)           | NC                 | 0.5 (0.5 - 0.5) | NC           |
|               0.3 |   8 | 2.65 (0.62)     | 3.91 (2.07)           | NC                 | 0.5 (0.5 - 1)   | NC           |
|               1   |   8 | 10.5 (2.28)     | 19.2 (6.54)           | NC                 | 0.5 (0.5 - 1)   | NC           |
|               3   |   8 | 21.8 (3.04)     | 69.5 (13.4)           | 75.5 (14)          | 0.5 (0.5 - 1)   | 2.31 (0.35)  |
|              10   |   8 | 88 (10.2)       | 283 (80.3)            | 289 (81.5)         | 0.5 (0.3 - 1)   | 2.61 (0.63)  |
|              30   |   9 | 240 (44.5)      | 933 (176)             | 938 (175)          | 0.5 (0.3 - 2)   | 2.72 (0.58)  |
|              60   |   8 | 408 (97.7)      | 1710 (435)            | 1720 (438)         | 1 (0.5 - 1)     | 2.68 (0.56)  |
|             100   |   7 | 638 (118)       | 2980 (709)            | 2990 (716)         | 0.5 (0.5 - 2)   | 3.07 (0.57)  |

†Median and Range are reported for Tmax N = Number of subjects; NC = Not Calculated Source: CSR A3921002, Tables 5.2.1 to 5.2.8

The MAH has provided the predicted PK parameters for 2 mg, 5 mg and 10 mg derived from PopPK in AS patients. Although, as previously highlighted, the results of the PopPK should be interpreted with caution, it seems that a dose proportionality exists between 2 mg and 5 mg.

The covariates included in the model are race, sex, ethnicity, age, BW, BCCL and BCRP on CL/F and BW and age on V/F. No stepwise testing was performed, whereas the full covariate approach was used. The correlation  between  covariates  was  assessed.  BW  was  not  included  in  the  final  model due  to  the  high correlation with BCLL and also ethnicity was not included due to high prevalence of non-Hispanic/Latino. The inclusion of covariates in the model improved the parameter estimation with decrease in IIV. The bootstrap confidence intervals (95% CI) for the parameters were generated from 1000 non-parametric bootstrap. The median value of CL/F and V/F calculated by the bootstrap was similar to that estimated in the  full  model.  Overall,  the  GoF  showed  that  the  model  adequately  fits  the  observed  concentrations, however it is noted that a greater number of observations are above the line of identity. Moreover, the CWRES vs time showed that, in particular at earlier time points, a number of observations are outside the -/+ 2 CWRES. This is in line with the fact that the model is not able to catch the variability in the absorption phase. Some outliers are also showed in the graphs of CWRES vs predicted concentrations.

The VPC showed that the concentrations in the early phase of absorption were underpredicted by the model, in particular the lower concentrations (5 th  percentile), whereas the concentrations in the 95 th  percentile were overpredicted. Y axis of VPC plot reports 'concentration.

The MAH was requested to better specify which PK parameter was reported and to provide the VPC plotting the  Cmin,  Cmax  and  Cavg  as  dependent  variable.  The  response  provided  by  the  MAH  is  considered sufficient. However, a certain degree of variability has been observed. Although a sparse sampling has been applied to PK parameters, the number of observed values appear to be sufficient to conclude that high variability  is  observed  after  the  administration  of  tofacitinib  and  that  the  model  predictions  (5  and  95 percentile) are even larger that observed concentrations. This reduce the reliability and the precision of the model. Therefore, all the analysis based on predicted plasma concentrations derived from the present model should be interpreted with caution.

<div style=\"page-break-after: always\"></div>

The PopPK model was also used to calculate the secondary exposure parameters Cmax, Cavg, Cmin, AUC over the dosing interval and to evaluate the impact of covariates on AUC and Cmax. Except for BCLL, impacted by the renal elimination of tofacitinib, all covariates have a marginal effect on PK parameters.

The tofacitinib  exposure  showed  in  the  PopPK  for  AS  is  superimposable  to  that  observed  in  the  other populations of patients (PsA, RA, PsO) in terms of AUC24 after 5 mg BID dose. The AUC24 considered were the following: AS (382 ng·h/mL), PsA (419 ng·h/mL), RA (507 ng·h/mL) and PsO (404 ng·h/mL).

In order to further compare the PK profile of tofacitinib throughout the different diseases, a summary of model-predicted exposure parameters based on the population PK analyses across indications is provided in the Table 19 . The results shows that tofacitinib exposure for AS is superimposable to that observed in the other populations of patients (PsA, RA, PsO) in terms of AUC24, as well as in terms of Cavg, Cmax and Cmin after 5 mg BID dose. However, the submission of observed exposure parameters would have been more correct in order to compare them and their variability among different indications. However, the AS effect on PK profile is not expected to be clinically relevant if any.

Table 19. Comparison of estimated Exposer parameters (for 5 mg BID) based on Population PK

## Comparison of estimated Exposure parameters (for 5 mg BID) based on Population PK analysis in AS, PsA, RA and UC Patients

|                 | Geometric Mean (%CV\")   | Geometric Mean (%CV\")   | Geometric Mean (%CV\")   | Geometric Mean (%CV\")   |
|-----------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Parameter       | AS                      | PsA                     | RAS                     | UC                      |
| Cavg (ng/mL)    | 15.9 (25.4)             | 17.5 (34.1)             | 21.1 (18.5)             | 17.6 (22.6)             |
| Cmax (ng/mL)    | 36.7 (28)               | 42.4 (31.6)             | 58 (29.3)               | 46.9 (19.4)             |
| Cmin (ng/mL)    | 3.46 (49.7)             | 4.23 (70.8)             | 4.37 (82.8)             | 3.59 (47.4)             |
| AUC24 (ng.h/mL) | 382 (25.4)              | 419 (34.1)              | 507 (22)                | 423 (22.6)              |

* %CV of Geometric mean; $Derived for 5 mg BID

Sources:S0113Module5.3.3.5PMAR-EQDD-A392k-sNDA-1064,S0014Module5.3.3.5PMAR-EQDD-A392j-sNDA601,S0000Module5.3.3.5PMAR-00178,S0012Module5.3.3.5PMAR-EQDD-A392i-sNDA-513

Abbreviations: AUC24 = area under the concentration-time curve over 24 hours; BID = twice daily; Cavg = average steady-state tofacitinib concentration over the dosing interval; Cmax = maximum steady-state tofacitinib concentration over the dosing interval; Cmin = tofacitinib concentration at steady-state at the end of the nominal 12 hours dosing interval; CV = coefficient of variation.

## 2.3.3. Pharmacodynamics

Exposure-Response Evaluation of Tofacitinib for Efficacy (ASAS20/40) in Patients with Ankylosing Spondylitis

The following studies were included in the analysis: A3921119 and A3921120. A brief overview of these studies is presented in Table 20 .

<div style=\"page-break-after: always\"></div>

Table 20. Tofacitinib Phase 2 and Phase 3 Studies in AS Population Included in the Analyses

| Study    | Design                                                                                                                                         | Duration andVisits                                                                                                         | Treatment Arm (Planned Number)                                                                             |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| A3921119 | Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and safety of tofacitinib in subjects with active AS | 12 weeks Visits on week 2, 4, 8 and 12                                                                                     | Placebo twice daily (BID) (n=50) 2 mg BID (n=50) 5 mg BID (n=50) 10 mg BID (n=50)                          |
| A3921120 | Phase 3, randomized, double-blind, placebo-controlled, study of theefficacyandsafetyof tofacitinib in subjects with active AS                  | 16 weeks double-blind phase followed by32weeks open-label phase Visits during double-blind phase on week 2,4, 8, 12 and 16 | 5 mg BID 0-48 weeks (n=120) Placebo for 16 weeks then transfer to tofacitinib 5 mg BID 16-48 weeks (n=120) |

Source: study protocols for A3921119 [5] and A3921120 [6]

The primary objectives are:

- To characterize the relationship between tofacitinib exposure and ASAS response levels of 20% and 40% (ASAS20  and  ASAS40,  respectively)  over  time,  in  subjects  with  active  AS  using  a  longitudinal exposure response model.
- To compare predicted PK measures, including of steady state Cavg, Cmin and Cmax, in an E-R analysis of ASAS20 and ASAS40 responses in subjects with active AS.

The secondary objectives are:

- Investigate the effects of specified covariates (prior biologic therapy) on the E-R relationship for ASAS20 and ASAS40

A dose-response analysis (with a Bayesian Emax model) was conducted, using ASAS20 responder rates at Week 12 from the Phase 2 dose-ranging study, Study A3921119. This study had evaluated placebo and 3 tofacitinib  doses  (2  mg,  5  mg  or  10  mg  BID)  for  12  weeks  in  bDMARD  naïve  patients  with  active  AS. Placebo-corrected  ASAS20  responder  rates,  along  with  95%,  60%  and  50%  credible  intervals  were estimated using this Bayesian model.

This primary endpoint analysis using an Emax model, estimated that ASAS20 response rates were higher than placebo for all tofacitinib dose groups. However, although the tofacitinib 2 mg BID and tofacitinib 5 mg BID treatment groups showed an estimated difference from placebo of 15.8% and 22.9%, respectively, they both did not meet the pre-specified statistical decision rules for the primary endpoint of the ASAS20 response rate at Week 12. Only the tofacitinib 10 mg BID treatment group met pre-specified rules for the primary endpoint of the ASAS20 response rate at Week 12 with an estimated response rate of 67.4%, an estimated difference from placebo of 27.3%, a 20.3% difference from placebo for the lower bound of the 2-sided 60% credible interval (ie, 1-sided 80% lower bound), and a 33.0% difference for the upper bound of the 2-sided 50% credible interval (ie, 1-sided 75% upper bound).

The  population  E-R  model  was  carried  out  using  the  nonlinear  mixed  effects  modeling  approach  as implemented in the software package NONMEMR version 7.4.1 (ICON Development Solutions, Hanover, MD). Perl-speaks-NONMEM (PsN),  version 4.8.0  was  used  as  supporting  software  for  the  execution  of NONMEM.

<div style=\"page-break-after: always\"></div>

The analysis was conducted based on the following strategy: Base Structural Model Development; Inclusion of  Covariates; Assessment of Model Adequacy (Goodness of Fit); Assessment of Final Model Predictive Performance.

Base Model Description. The ASAS20 and ASAS40 responses were modeled simultaneously as an ordered categorical variable Y(t) taking on possible responses with Y = 2 if achieving ASAS40, Y = 1 if achieving ASAS20 but not ASAS40 and Y = 0, if not achieving ASAS20 ,  at  time  t.  Hence the probability of achieving Y = k, with k = 1 or 2 to a predictor M(X;b) can be modeled using logistic regressions, such as:

<!-- formula-not-decoded -->

where α1 &gt; α2 represents the intercepts of each ASAS cutpoint, X a matrix of covariates, β a vector of regression coefficients, and h -1  the inverse link function that restricts the probability between 0 and 1. In a logistic  regression,  this  parameterization  where  M(X;β)  is  the  same  for  all  k  corresponding  to  the proportional odds assumption.

Note that prob[Y(t) ≥ 0] = 1, so that in the model it is only necessary to estimate the cumulative probability for  the  score  1  and  2.  The  probability  for  each  individual  score  can  thereafter  be  calculated  from  the estimated cumulative probability using following equations.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

For a logistic regression, the link function and its inverse function can be defined such as:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

For the E-R modeling, a general nonlinear mixed-effects model was constructed based on the combined ASAS20 and ASAS40 response:

<!-- formula-not-decoded -->

Where η is the inter -individual variance (IIV) which is assumed to be normally distributed with mean 0 and variance 1, fdrug(t) the drug effect function, and fplacebo(t) the placebo effect function. For the longitudinal analysis, the following exponential equation was used to investigate the time course and onset of drug effect and placebo effect:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

where Deffect and Peffect are the drug effect and placebo effect, respectively; DThalf and PThalf are the half-life of drug effect and placebo effect respectively; t stands for time with unit of week.

Drug effect was evaluated using individual Cavg values as the exposure metric, and investigated with linear, Emax, or exponential models (Equation 9).

<!-- formula-not-decoded -->

where Dslp is the slope for the exposure-response relationship with Cavg. Emax is the maximum drug effect. EC50 is the concentration to reach 50% of Emax. K is shape parameter.

Inclusion of Covariates. The primary covariate of interest in this analysis was previous bDMARD use. Approximately 20% of subjects in Study A3921120 were stratified to be biologic-experienced (either TNFinadequate  responders  or  bDMARD-experienced).  A  covariate  effect  for  previous  bDMARD  use  was evaluated. This effect was assessed on the most appropriate model parameter (i.e., Peffect of the placebo effect, or Deffect of the drug effect) or function.

## RESULTS

A total of 466 patients were included in the longitudinal analysis. Table 21

Table 21. Number of Subjects by Treatment Groups

| Dose      |   A3921119 |   A3921120 |   Total |
|-----------|------------|------------|---------|
| Placebo   |         51 |        136 |     187 |
| 2 mg BID  |         50 |          0 |      50 |
| 5 mg BID  |         49 |        132 |     181 |
| 10 mg BID |         48 |          0 |      48 |

Table 22 summarizes prior bDMARD experience for the patients in this analysis dataset.

Table 22. Summary of Prior bDMARD Experience

| PriorbDMARD   | A3921119   | A3921120    | Total       |
|---------------|------------|-------------|-------------|
| Naive         | 198(100%)  | 207 (77.2%) | 405 (86.9%) |
| Experienced   | (%0) 0     | 61 (22.8%)  | 61 (13.1%)  |

Repository artifact ID FI-4370388. Line 1 substituted.

bDMARD=biologic disease-modifying antirheumatic drug

Individual  exposure  metrics  from  a  post  processing  step  based  on  the  final  tofacitinib  population  PK modeling were used. The distribution of Cmax, Cmin and Cavg grouping by treatment groups is shown in Figure 5 and summary statistics are listed in Table 23 .

<div style=\"page-break-after: always\"></div>

Figure 5 . Tofacitinib Exposure Metrics by Study and Dose

<!-- image -->

RepositoryartifactIDFI-4118742.

Cmax=maximum concentration;Cmin=min ym concentration;Cavg=averageconcentration;BID=twice daily

Table 23 . Summary of Exposure Metrics

| Variable     | Study   | Treatment   |   Mean |   Median |   Min |   Max |
|--------------|---------|-------------|--------|----------|-------|-------|
| Cmin (ng/mL) | 1119    | 2 mg BID    |    1.4 |      1.3 |   0.4 |   3.2 |
|              |         | 5 mg BID    |    3.5 |      3.2 |   0.8 |   8.2 |
|              |         | 10 mg BID   |    7   |      6.5 |   1.3 |  22.4 |
|              | 1120    | 5 mg BID    |    4   |      3.6 |   0.9 |  11.4 |
| Cmar (ng/mL) | 1119    | 2 mg BID    |   14.5 |     14.1 |   7.8 |  24.3 |
|              |         | 5 mg BID    |   35.7 |     37.1 |  17.2 |  49.3 |
|              |         | 10 mg BID   |   75.6 |     76.6 |  32.5 | 119.7 |
|              | 1120    | 5 mg BID    |   38.7 |     40   |  10   |  64   |
| Cavg (ng/mL) | 1119    | 2 mg BID    |    6.2 |      6   |   3.1 |   9.5 |
|              |         | 5 mg BID    |   15.3 |     15   |   8.4 |  20.7 |
|              |         | 10 mg BID   |   31.9 |     32.2 |  16.8 |  62.8 |
|              | 1120    | 5 mg BID    |   16.7 |     16.3 |   5.4 |  33.1 |

Repository artifact ID FI-4118746.

Cavg=average concentration, Cmax=maximum concentration, Cmin=minimum concentration, BID=twice daily

A longitudinal ordered categorical model with exponential time-dependent onsets of placebo and drug effect was used to evaluate the relationship between tofacitinib exposure and ASAS20/40. Linear, exponential and Emax model forms using Cavg , an exposure metric that has been previously established as relevant for the efficacy of tofacitinib in diseases like RA and PsA, were evaluated to characterize the drug effect component. A summary of model evaluation metrics for the key runs are provided in Table 24.

<div style=\"page-break-after: always\"></div>

Table 24 . List of Key Model Runs

| Run   | ImproveID   | Model Deseription                                       |     OFV | Comments    |
|-------|-------------|---------------------------------------------------------|---------|-------------|
| 1     | ST-4099121  | Emax/EC50 model with Cavg                               | 3073.95 | Base model  |
|       | ST-4148540  | Linear model with Cavg                                  | 3111.64 |             |
| 3     | ST-4589958  | Exponential model with Cavg                             | 3073.57 |             |
| 4     | ST-4245150  | Runl + prior bDMARDs experience as covariate on Pedfeer | 3054.66 | Final model |
|       | ST-4245170  | Run4+Study effectonbaseline                             | 3051.99 |             |
|       | ST-4411916  | Run4 + Study effect on Pefect                           | 3054.66 |             |
| 7     |             | Run 1 with the same Drhaly and Prhalf                   | 3077.24 |             |
| 8     | ST-4157085  | Emax/ED50modelwithdose                                  | 3073.74 |             |

OFV= Objective Function Value; Cavg= average concentration at steady state.

Source: Improve analysis tree: AT-2109636

After careful evaluation of the various structural models, including a model that used tofacitinb BID dose, a model with exponential time-dependent onsets of placebo and drug effect, and the drug effect component described by an Emax model form (Run 1) was selected to describe the relationship between tofacitinib exposure and efficacy in AS.

Parameter estimates of the base model (Run 1) are presented in Table 25.

Table 25. Parameter Estimates of the Base Model

| Parameter     | Comment                                               |   Estimale | RSE (%)   | Bootstrap 90% CI   |
|---------------|-------------------------------------------------------|------------|-----------|--------------------|
| α1            | logit(prob[Y() ≥ 1]) without drug or placebo effect   |     -5     | 16.5      | (-6.52 to -3.99)   |
| α2            | logit(prob[Y(0) ≥ 1]) - logit(prob[Y() ≥2])           |     -2.06  | 88'5      | (-2.28 to -1.87)   |
| DThal (week)  | Half-life of drug effect                              |      1.16  | 29        | (0.735 to 2.02)    |
| Emr           | Maximum drug effect                                   |      3.13  | 40.5      | (2.63 to 4.48)     |
| EC50 (ng/mL)  | Concentration at which half of Emar was reached       |      0.831 | 09        | (0.2 to 6.24)      |
| Prhaly (week) | Half-life of placebo effect                           |      2.55  | 37.7      | (1.62 to 4.36)     |
| Peffea        | Maximum placebo effect                                |      3.31  | 22.7      | (2.45 to 4.64)     |
| IIV           | Inter-individual variability of logit(prob[Y(0) ≥ 1]) |      8.8   | 13.3      | (7.09 to 11.1)     |

Repository artifact ID FI-4319783.

Bootstrap 90% CI was based on 645 successful runs out of 1000.

RSE: relative standard error, Cl: confidence interval.

IIV was applied to the logit value of cumulative probability (h -1 prob[Y(t) ≥ k]). The standard errors for the parameter estimates were small (30%), except for estimate of EC50 (RSE = 604%). h-shrinkage was 21.5%. There was absence of extreme pairwise correlations (r&gt;0.95) of the parameters or high condition number of the correlation matrix of the parameter estimates (k&gt;1000). 1000 non-parametric bootstrap were performed to generate the 90%CI of parameter estimates using the base model. Of these, 29 runs with immunization terminated and 326 runs with estimates near a boundary (total 355) were excluded when calculating the bootstrap results.

Diagnostic plots for the base model are presented in Figure 6 and 7 .

<div style=\"page-break-after: always\"></div>

Figure 6 . Diagnostic Plots of the Base Model (1of 2)

<!-- image -->

Figure 7. Diagnostic Plots of the Base Model (2 of 2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

As  shown  in  the  ETA  (η)  histograms  and  quantile -quantile  plots,  there  is  lack  of  normality  in  the  η distribution. The sharp peak on the lower end of the distribution represents the inflat ed η values from non -responders (data not shown). The η values estimated for these patients were consistently low. However, this lack of normality in distribution did not impact the goodness of fit evaluated using simulation-based diagnostic plots, which are the primary diagnostic plots.

## Final Model Results

Prior bDMARD experience (PMED) and study effect (PROT) were tested on baseline (h -1 prob[Y(t) ≥ 1]), placebo effect (Peffect ), or drug effect (Deffect ) in order to evaluate their effect on ASAS20/40 response rates. PMED has 2 levels including 0 and 1, which represents bDMARD naive (0) or experienced (1). PMED was identified as significant covariate on Peffect (Run  4).  Patients  with  prior  bDMARD treatment experience showed a lower response to placebo in Study A3921120. However, study effect as a covariate did not provide a better fitting (Run 5 and 6), therefore, it was not included in the final model. Run 4 was considered the final model.

The parameter estimates for the final model are presented in Table 26 .

Table 26. Parameter Estimates of the Final Model (Run 4)

| Parameter        | Comment                                               |   Estimate |   RSE (%) | Bootstrap 90% CI   |
|------------------|-------------------------------------------------------|------------|-----------|--------------------|
| α1               | logit(prob[Y(0)≥1]) without drug or placebo effect    |      -4.93 |     14.9  | (-6.3 to -3.96)    |
| α2               | logit(prob[Y(t) ≥ 1]) logit(prob[Y(t) ≥ 2])           |      -2.07 |      5.73 | (-2.3 to -1.9)     |
| DThalg (week)    | Half-life of drug effect                              |       1.18 |     30.5  | (0.742 to 2.14)    |
| Emax             | Maximum drug effect                                   |       3.11 |     17.1  | (2.59 to 4.53)     |
| EC50 (ng/mL)     | Concentration at which half of Emar was reached       |       1.24 |    135    | (0.181 to 6.75)    |
| Prhaly (week)    | Half-life of placebo effect                           |       2.55 |     26.4  | (1.63 to 4.06)     |
| Peffed           | Placebo effect                                        |       3.6  |     18.7  | (2.64 to 4.79)     |
| PMED=1 on Peffec | Coefficient of PMED=on placebo effect                 |      -2.18 |     26.1  | (-3.16 to -1.24)   |
| IIV              | Inter-individual variability of logit(prob[Y(0) ≥ 1]) |       8.61 |     12.4  | (7.02 to 10.5)     |

Repository artifact ID FI-4312649.

Bootstrap 90% CI was based on 728 successful runs out of 1000.

RSE: relative standard error, CI: confidence interval, PMED: prior bDMARD experience

<div style=\"page-break-after: always\"></div>

The standard errors for the parameter estimates were small (30%), except for the EC50 estimate with RSE of 135%. h-shrinkage was 21.6%. There was absence of extreme pairwise correlations (r&gt;0.95) of the parameters or high condition number of the correlation matrix of the parameter estimates (k&gt;1000). Diagnostic plots for goodness of fit are presented in the Figure s 8 and 9.

Figure 8 . Diagnostic Plots of the Final Model (1of 2)

<!-- image -->

Figure 9 . Diagnostic Plots of the Final Model (2 of 2

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

As shown in the parameter estimates from both the base and final models, there is a high degree of uncertainty on the EC50 estimate (high RSE values), most likely due to the lack of data at the lower end of the  concentration  range  (Figure  10).  1000  non-parametric  bootstrap  were  performed  to  generate  the 90%CI of parameter estimates using the final model. Of these, 27 runs for which miminization terminated, and 245 runs with estimates near a boundary (total 272 runs) were excluded when calculating the bootstrap results. This may be due to the limited information in the data to precisely characterize the EC50. Placebo treatment reached half of the maximum effect in 2.55 weeks (90%CI [1.63, 4.06]). The half-life of drug onset was estimated to be 1.18 weeks for ASAS20/40 (90%CI [0.74, 2.14]).

Figure 10 . Overlay of EC50 Bootstrap 90% CI with Cavg Distribution

<!-- image -->

Repository artifact ID FI-4370385.

Shaded area represents the bootstrap 90% CI of EC50

## Final Model Predictive Performance

VPC plots for the final model are presented in Figures 11 , 12, 13, and 14 .

<div style=\"page-break-after: always\"></div>

Figure 11. Visual Predictive Check for ASAS20 and ASAS40 Response Rates Stratified by Dose (1 of 2)

<!-- image -->

Time (week)

Time (week)

Figure 12 . Visual Predictive Check for ASAS20 and ASAS40 Response Rates Stratified by Dose (2 of 2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13 . Visual Predictive Check for ASAS20 and ASAS40 Response Rates Stratified by Prior bDMARD Experience (1 of 2)

<!-- image -->

Time (week)

Time (week)

Figure 14. Visual Predictive Check for ASAS20 and ASAS40 Response Rates Stratified by Prior bDMARD Experience (2 of 2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Model Predicted ASAS20 and ASAS40 Responses based on Simulation

The model predicted ASAS20 and ASAS40 response rates based on simulation are listed in Table 27. Model-predicted ASAS20 response rates after tofacitinib 2 mg, 5 mg and 10 mg BID were 64%, 67% and 68%, respectively and ASAS40 response rates were 40%, 44%, and 45% respectively, in bDMARD-naive AS patients at Week 16.

Placebo-corrected estimates of ASAS20 and ASAS40 response rates at Week 16 were 32% and 28% after 5 mg BID in AS patients who were bDMARD-naive. In the bDMARD-experienced group, placebo-corrected ASAS20 and ASAS40 response rates at Week 16, after 5 mg BID were estimated to be 27% and 16%, respectively.

Table 27. Model- Predicted ASAS20 and ASAS40 Response Rates at Week 16 in bDMARD-Naïve Patients

| Endpoint   | Dose      | Response rate (95%C1)   | Placebo-corrected response rate (95%CI)   |
|------------|-----------|-------------------------|-------------------------------------------|
| ASAS20     | Placebo   | 0.34 (0.28 - 0.42)      |                                           |
| ASAS20     | 2 mg BID  | 0.64 (0.56 - 0.7)       | 0.29 (0.2 - 0.38)                         |
| ASAS20     | 5 mg BID  | 0.67 (0.6 - 0.74)       | 0.32 (0.24 - 0.41)                        |
| ASAS20     | 10 mg BID | 0.68 (0.62 - 0.75)      | 0.34 (0.25 - 0.43)                        |
| ASAS40     | Placebo   | 0.16 (0.11 - 0.21)      |                                           |
| ASAS40     | 2 mg BID  | 0.4 (0.33 - 0.46)       | 0.24 (0.15 - 0.32)                        |
| ASAS40     | 5 mg BID  | 0.44 (0.36 - 0.5)       | 0.28 (0.2 - 0.36)                         |
| ASAS40     | 10 mg BID | 0.45 (0.38 - 0.52)      | 0.29 (0.2 - 0.38)                         |

Repository artifact ID FI-4955677. Line 1 substituted.

Simulations to illustrate the exposure-response relationship were also performed and plotted with observed response rates at Week 12 ( Figure 15, Figure 16 ). Model predictions of placebo-corrected estimates after 2 mg BID (ASAS20 of 29% and ASAS40 of 24%) in bDMARD-naive AS patients at Week 16 were slightly lower compared to 5 mg BID.

Figure 15.  Exposure-Response Relationship in bDMARD-Naive Patients (Week 12)

<!-- image -->

Repository artifact ID FI-4320119.

bDMARD=biologic disease-modifying antirheumatic drug; Cavg=average concentration. The Cavg of the observation data points were the mean Cavg values for each dose group. Median predictions and CIs for ASAS20 and ASAS40 were based on 1000 simulations (at Cavg values ranging from 0 to 65 ng/ml) using the final model

<div style=\"page-break-after: always\"></div>

Figure 16.  Exposure-Response Relationship in bDMARD-Naive Patients Week 12 (PlaceboCorrected)

<!-- image -->

Repository artifact IDFI-4955670.

bDMARD=biologic disease-modifying antirheumatic drug; Cavg=average concentration. The Cavg Of the observation data points were the mean Cavg values for each dose group. Median predictions and CIs for ASAS20 and ASAS40 were based on 1000 simulations (at Cavg values ranging from 0 to 65 ng/ml) using the final model

## Comparison Between Tofacitinib Exposure Metrics

Table 28 summarizes the model evaluation for the different E-R models fitted using ASAS20 and ASAS40 response rates in AS patients. Models with Cavg, Cmin or Cmax as the predictor (univariate analysis) did not show differences in model diagnostics (OFV or AIC differences less than 3.84 units) that would support the conclusion of any one exposure parameter being more relevant to clinical efficacy compared to another. This was not unexpected since these PK parameters are highly correlated, particularly Cavg and Cmin (correlation coefficient=0.85) ( Figure 17 ); the exposure measures contain very similar information.

Table 28. Runs to Compare Between Tofacitinib Exposure Metrics

|   Run | Improve    | Model Description                     |     OFV |     AIC |
|-------|------------|---------------------------------------|---------|---------|
|     4 | ST-4245150 | Final model using Cavg                | 3054.66 | 3072.66 |
|     9 | ST-4616071 | Final model applied to Cmax           | 3054.16 | 3072.16 |
|    10 | ST-4616082 | Final model structure applied to Cmin | 3055.28 | 3073.28 |

OFV= Objective Function Value; AIC= Akaike information criterion; 1; Cmax= maximum concentration; ; Cmin=

<div style=\"page-break-after: always\"></div>

Figure 17. Frequency Distribution and Correlation Between Tofacitinib Exposure Metrics

<!-- image -->

Repository artifact IDFI-4370386.

Corr=correlation coefficient, CAVG=average concentration, CMAX=maximum concentration, CMIN=minimum concentration

Ten (10) mg ASAS20 and ASAS40 VPC final model plots showed a slight overprediction; for 2 mg and 5 mg ASAS 20 and ASAS 40 they seem to look better.

Placebo-corrected estimates of ASAS20 response rates in bDMARD-naive patients after the 5 mg BID dose, were 18% by Week 2, and reached 28% by Week 4. Placebo-corrected estimates of ASAS20 and ASAS40 response rates at Week 16 were 32% and 28% after 5 mg BID in AS patients who were bDMARD-naive. In the bDMARD-experienced group, placebo-corrected ASAS20 and ASAS40 response rates at Week 16, after 5 mg BID were estimated to be 27% and 16%, respectively.

For the base model the standard error was high, not only for the estimate of EC50 (RSE = 604%), but also for the estimate of Emax (RSE=40.5%); in the final model the standard error for the parameter estimates continues to be high for the EC50 estimate with RSE of 135%. The high degree of uncertainty on the EC50 estimate was imputed (most likely) to the lack of data at the lower end of the concentration range, in any case, for an E-R analysis, this represents a limitation.

In section Assessment of Model Adequacy (Goodness of Fit) it is reported that 'ETA (h) histograms and quantile-quantile plots were used assessing the assumption of normality and the appropriateness of the selected parameter variability.' Howbeit in both models, the base and the final ones, ETA (η) histograms and quantilequantile plots showed lack of normality in the η distribution. The MAH commented that this lack of normality in distribution did not impact the goodness of fit evaluated using simulation-based diagnostic plots, which are the primary diagnostic plots, however this represents another limitation.

<div style=\"page-break-after: always\"></div>

Models with Cavg, Cmin or Cmax as the predictor (univariate analysis) did not show differences in model diagnostics (OFV or AIC differences less than 3.84 units), this would support the conclusion that none exposure parameter is more relevant to clinical efficacy compared to another. However, Cavg has been chosen as exposure metric to select the model to describe the relationship between tofacitinib exposure and efficacy in AS, since it was previously established as the most relevant parameter for tofacitinib efficacy in RA. Although there are similarities between RA and AS diseases, the profiles of the two pathologies are not perfectly superimposable, therefore the MAH was requested to discuss, in general, the potential of disease effect affecting PK profile, and, more in details, that Cavg is the most suitable exposure metric, in terms of close association with efficacy, also for AS. which was provided by the MAH and the issue considered resolved by the CHMP.

According to the MAH, the half-life of drug onset was estimated to be 1.18 weeks for ASAS20/40 (90%CI [0.74, 2.14]), which is applicable across all dose groups.

The simulated exposure-response relationship appears to be flat, even flatter compared to observed data. In all the exposure-response plots, the 10 mg Cavg median values are always overpredicted; moreover, the 10 mg Cavg values are lower than the 5 mg, and, for the ASAS40 values (placebo-corrected), also lower than the 2 mg. Considering the above, it can be concluded that the exposure-response curve does not properly capture the shape of the relationship showed by the observed Cavg values, even if predicted values are within observed ICs values. Overall, the relationship between tofacitinib exposure (Cavg) and clinical response seems to be not well captured by the E-R model. In response the MAH clarified that the ASAS20 and ASAS40 response rates shown in the VPC plots as ' observed ' are observed proportions for each stratified group.

## 2.3.4. Discussion on clinical pharmacology

Two studies were submitted within this extension of indication in AS. The study A3921119 was a phase 2 study in which three doses (2 mg, 5 mg and 10 mg) were administered in bDMARD naïve population. The PK dataset included was 50, 49 and 48 patients for 2 mg, 5 mg and 10 mg dose cohort, respectively. The PK sampling was at pre-dose, 0.5 hr and 2 hours post dose at Week 4 and pre-dose, 0.5 hr and 3hr post dose at Week 8.  The Study A3921120 was a phase 3 study in which only 5 mg dose was administered. Patients enrolled were bDMARD naïve (77.2%) and bDMARD experienced (22.8%). The study consists of two parts, the first one was the blinded phase and lasted 16 weeks, the second one was the open label phase lasted until Week 48. The plasma samples were collected at pre-dose, 0.5 hr and 2 hours post dose at Week 4 and pre-dose, 0.5 hr and 3hr post dose at Week 8. The PK dataset included 132 patients.

Tofacitinib plasma concentrations were measured through HPLC-MS/MS method developed and validated at Wuxi AppTec (Shangai, China - A3929023) and then transferred at PPD (Richmond and Middleton). A method transfer was performed from PPD in Richmond to PPD in Middleton and an assay performance with respect to precision, accuracy, and specificity was conducted.

Samples from Study A3921119 were analysed by Wuxi, whereas samples from Study A3921120 were analysed by PPD in Middleton.

The cross validation A3929023 addendum 6 is not applicable to the current analysis since it is performed between Wuxi (method A3929023), Basi (A3929011) and PPD in Richmond (method A3929032). A further cross validation A3929023 Amendment 2 was performed between Wuxi and PPD Richmond.

No cross-validation was performed between PPD Middleton and Wuxi, however the MAH is of the opinion that since the method used at Richmond and Middleton remained exactly the same, the cross validation between Wuxi and PPD Richmond supports the comparability of data analysis also between Wuxi and PPD Middleton.

<div style=\"page-break-after: always\"></div>

This is not exactly in line with EMA guideline, however since the method transfer to PPD Middleton showed that selectivity, carryover, linearity, sensitivity, accuracy, precision, recovery, dilution, and stability were met, the method is considered valid for the extraction and analysis of human lithium heparin plasma.

The CSR A3921119 mentions a Section 16.2.5.10 containing the bioanalytical report; however, this section/appendix was initially missing. The MAH clarified that Study A3921119 was already submitted as supportive study in the contest of extension indication in psoriatic arthritis. The bioanalytical report was attached to that eCTD sequence and not re-submitted for the current variation. Which is considered acceptable by the CHMP.

A total of 1011 samples were analysed by Wuxi (method A3929023); the maximum storage time at 20±5°C in sodium heparin was 309 days (validated LTS at 1274 day at -20±5°C). The ISR was performed on 104 samples and fulfilled the acceptance criteria.

The MAH provided the bioanalytical report for study A3921120 and declared that all samples were analysed during the stability period. The number of samples received is 1848, however the samples analysed were 922. In the Appendix 4 of the bioanalytical report for study A3921120, the note 8 denotes samples not assayed at Sponsor's request and was reported for several samples, all in the treatment B. The MAH clarified that these samples were not assayed as they were placebo samples.

The PK data were analysed in the PopPK model in which both studies were included. A one compartment model with first order absorption, IIV on CL/F and V/F with OMEGA block and no IIV on ka, different proportional residual error for observations with TAD&lt;9 or ≥9 hours on residual error was chosen as the base model. The effect of covariates was evaluated through the full covariate approach.

IIV on Ka reduced the OFV, moreover the inclusion of tlag determines an increase of Ka estimation with a very quickly absorption phase. The MAH justify this result, and then the exclusion of IIV on Ka, with the sparse  sampling  data  limiting  the  information  on  the  absorption  phase.  Although  this  justification  is sharable, the exclusion of IIV on ka did not permit to evaluate the variability in the absorption that, in general, is a significant part of PopPK model. The residual error for observations with TAD &lt;9 hours and TAD ≥ 9 hours was evaluated in the model, since the trough samples (primarily from pre-dose sampling) were mostly collected beyond 9 hours post-dose, with very few to almost no samples between 5- and 9hours TAD. Given this collection profile, 9 hours was used as the TAD cut-off value to differentially estimate residual errors for trough and non-trough plasma concentrations.

In the initial MAA, dose proportionality was concluded over a dose range of 5 to 50 mg. The Applicant included plasma concentrations of patients with treated with 2 mg, 5 mg and 10 mg into the PopPK model. However, no information was provided on the dose-proportionately over the dose range of 2 to 5 mg in the current variation. In the initial MAA, the MAH submitted a nonlinear mixed effects analysis of Cmax and AUC  (derived  using  noncompartmental  methods)  from  16  Phase  1  studies  concluding  that  Cmax  is approximately dose proportional at least up to 10 times the proposed dose of 5 mg.

Study A3921002, a randomized, parallel-group, placebo-controlled, single-dose escalation study was also submitted in the initial MAA in which 95 subjects were randomized in different dose group to receive a single doses of 0.1 to 100 mg tofacitinib, (0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, 30 mg, 60 mg, 100 mg) administered as oral power for constitution (OPC). Systemic exposures (Cmax and AUC ∞ ) of tofacitinib increased  in  a  dose-proportional  manner,  indicating  linear  pharmacokinetics  across  the  dose  interval evaluated (0,1 and 100 mg dose). There are only small changes from linearity mostly for Cmax values from 1 mg dose.

In the contest of this response, the MAH also provided the predicted PK parameters for 2 mg, 5 mg and 10 mg derived from PopPK in AS patients. Although, the results of the PopPK should be interpreted with caution, it seems that a dose proportionality exists between 2 mg and 5 mg.

<div style=\"page-break-after: always\"></div>

The covariates included in the model are race, sex, ethnicity, age, BW, BCCL and BCRP on CL/F and BW and age on V/F. The correlation between covariates was assessed. BW was not included in the final model due to the high correlation with BCLL and also ethnicity was not included due to high prevalence of nonHispanic/Latino. The inclusion of covariates in the model improved the parameter estimation with decrease in IIV% (RSE%). The bootstrap confidence intervals (95% CI) for the parameters were generated from 1000 non-parametric bootstrap. The median value of CL/F and V/F calculated by the bootstrap was similar to that estimated in the full model.

Overall, the GoF showed that the model adequately fits the observed concentrations, however it is noted that a greater number of observations are above the line of identity. Moreover, the CWRES vs time showed that, in particular at earlier time points, a number of observations are outside the -/+ 2 CWRES. This is in line with the fact that the model is not able to catch the variability in the absorption phase. Some outliers are also showed in the graphs of CWRES vs predicted concentrations.

The VPC, describing tofacitinib plasma concentration over time, showed that the concentrations in the early phase  of  absorption  were  underpredicted  by  the  model,  in  particular  the  lower  concentrations  (5 th percentile),  whereas  the  concentrations  in  the  95 th   percentile  were  overpredicted.  A  certain  degree  of variability has been observed. Although a sparse sampling has been applied to PK parameters, the number of  observed  values  appear  to  be  sufficient  to  conclude  that  high  variability  is  observed  after  the administration  of  tofacitinib  and  that  the  model  prediction  (5  and  95  percentile)  are  even  larger  that observed concentrations. This reduces the reliability and the precision of the model. Therefore, all the analysis based on predicted plasma concentrations derived from the present model should be interpreted with caution.

The PopPK model was also used to calculate the secondary exposure parameters Cmax, Cavg, Cmin, AUC over the dosing interval and to evaluate the impact of covariates on AUC and Cmax. Except for BCLL, impacted by the renal elimination of tofacitinib, all covariates have a marginal effect on PK parameters.

The tofacitinib  exposure  showed  in  the  PopPK  for  AS  is  superimposable  to  that  observed  in  the  other populations of patients (PsA, RA, PsO) in terms of AUC24 after 5 mg BID dose. The AUC24 considered were the following: AS (382 ng·h/mL), PsA (419 ng·h/mL), RA (507 ng·h/mL) and PsO (404 ng·h/mL).

In order to further compare the PK profile of tofacitinib throughout the different diseases, the MAH was asked to provide a comparison of all the main exposure parameters, e.g. Cavg, Cmin, Cmax. The MAH submitted a summary of model-predicted exposure parameters based on PopPK analyses across indications for  Cavg,  Cmax,  Cmin  and  AUC24,  showing  that  tofacitinib  exposure  for  AS  is  superimposable  to  that observed in the other populations of patients (PsA, RA, PsO) after 5 mg BID dose. However, also giving the comment above on the model reliability in AS, the submission of observed exposure parameters would have been more correct to compare them and their variability among different indications. However, the AS effect on PK profile is not expected to be clinically relevant if any.

ASAS20 and ASAS40 responses from 2 studies in patients with active AS, A3921119 and A3921120 were pooled to support E-R analyses. A longitudinal ordered categorical model was developed to jointly model ASAS20  and  ASAS40  responses  to  describe  the  relationship  between  tofacitinib  exposure  and  clinical efficacy in patients with active AS after the administration of placebo or tofacitinib doses of 2 mg, 5 mg or 10 mg BID up to Week 16 (up to Week 12 for 2 mg and 10 mg BID dose groups). For the base model the standard error was high, not only estimate of EC50 (RSE = 604%), but also for the estimate of Emax (RSE=40.5%); in the final model the standard error for the parameter estimates continues to be high for the EC50 estimate with RSE of 13 5%. In both models, the base and the final ones, ETA (η) histograms and quantilequantile plots showed lack of normality in the η distribution. The MAH commented that this lack of normality in distribution did not impact the goodness of fit evaluated using simulation-based diagnostic plots, which are the primary diagnostic plots, even if the assumption of normality was not met.

<div style=\"page-break-after: always\"></div>

Cavg has been used as exposure metric to select the model to describe the relationship between tofacitinib exposure and efficacy in AS, since it was previously established as relevant for tofacitinib efficacy in RA.

Model evaluation with Cavg, Cmin or Cmax as the predictor (univariate analysis) for the different E-R models fitted using ASAS20 and ASAS40 response rates in AS patients, did not show differences in model diagnostics (OFV or AIC differences less than 3.84 units) that would support the conclusion of any one exposure parameter being more relevant to clinical efficacy compared to another. PK parameters are highly correlated, particularly Cavg and Cmin (correlation coefficient=0.85).

Overall, as in RA, Cavg can be considered as parameter for efficacy in AS.

The simulated exposure-response relationship appears to be flat, even flatter compared to observed data. In all the exposure-response plots, the 10 mg Cavg values are lower than the 5 mg, and, for the ASAS40 values (placebo-corrected), also lower than the 2 mg. Considering the above, it can be concluded that the predicted Cavg values do not properly capture the shape of the relationship showed by the observed Cavg values, even if predicted values are within observed ICs values. Overall, the relationship between tofacitinib exposure (Cavg) and clinical response seems to be not well captured by the E-R model. All the above considered, no reliable conclusion can be drown using the present analysis. In response the MAH clarified that the ASAS20 and ASAS40 response rates shown in the VPC plots as ' observed ' are observed proportions for each stratified group.

## 2.3.5. Conclusions on clinical pharmacology

The VPC in the PopPK model showed a high variability in the observed values and the model predictions (5 th   and  95 th   percentile)  are  even  larger  that  the  observed  concentrations,  reducing  the  reliability  and precision  of  the  model.  On  this  basis,  the  PK  comparison  between  the  different  indications  should  be interpreted with caution. However, the AS effect on PK profile is not expected to be clinically relevant if any.  Given  all  the  limitations  of  the  Exposure-Response  analysis,  any  conclusion  should  be  taken  with caution. However, the clinical pharmacology properties are still considered sufficiently characterised.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

A3921119 This was a Phase 2, multicenter, randomised, double-blind, placebo-controlled dose ranging, parallel group efficacy and safety study designed to characterise the dose response of tofacitinib in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs. This was a proof-of-concept as well as a dose-ranging study that evaluated the efficacy and safety of tofacitinib doses of 2 mg, 5 mg, and 10 mg IR BID versus placebo (randomised in 1:1:1:1 ratio) over a 12-week treatment period in adult patients with active AS who had an inadequate response to NSAIDs but were bDMARD-naïve. Given the results of Study A3921119, as well as taking into consideration the recommended BID posology for tofacitinib in other rheumatologic diseases, 5 mg IR BID of tofacitinib was selected to be evaluated in Study A3921120.

For complete study information please see section 'Supportive study'.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## A3921120

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy and safety study designed to compare tofacitinib 5mg dosed twice daily to placebo in subjects with active AS, who had experienced an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, TNFi-IR, or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]).

## Methods

The design of the pivotal A3921120 Study is presented in the Figure 18 :

Figure 18. Pivotal Study A3921120 Schematic of Study Design

<!-- image -->

The study design includes a screening period of approximately 30 days, a 16-week double-blind treatment period, a 32-week open-label treatment period and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

The primary efficacy analysis was at 16 weeks (data cutoff 19DEC2019, data snapshot 29JAN2020) and maintenance follow-up to 48 weeks.

In support of the sought indication the MAH is providing confirmatory evidence from one pivotal study only. As per the POINTS TO CONSIDER ON APPLICATION WITH 1. META-ANALYSES; 2. ONE PIVOTAL STUDY, CPMP/EWP/2330/99, this study will have to be exceptionally compelling, and in the regulatory evaluation special attention will be paid to key aspects including the internal/external validity; Clinical relevance, the estimated size of treatment benefit must be large enough to be clinically valuable; the degree of statistical significance, statistical evidence considerably stronger-internal consistency. Similar effects demonstrated in different pre-specified sub-populations. All-important endpoints showing similar findings.

The proposed study design is randomized, double-blind, placebo-controlled, parallel group comparing tofacitinib 5mg dosed twice daily to placebo in subjects with active AS, who had experienced an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, or TNFì-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]). As per the EMA guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) the design could be acceptable however

<div style=\"page-break-after: always\"></div>

since tofacitinib belongs to a new therapeutic class for the AS indication and the study includes biological naïve patients a three-arm trial (including an accepted active comparator) would have been recommended, particularly for assessing a relative B/R balance. The Applicant has performed a metaanalysis of approved treatments and also included the results of the tofacitinib trials (dose-finding and pivotal study) as supportive data. This is endorsed.

The time point for the primary analysis (DB phase) is within the time period indicated by the above guideline; the maintenance period is in line with the guideline although a longer Open-Label (OL) period would have been recommended for assessing structural changes. Moreover, evaluation of dose reduction/stop and/or increased dose interval for subjects obtaining resolution of inflammation could have been useful to guide prescribers for long term treatment to avoid unnecessary toxicity.

The MAH clarified that dose reduction/changing dose interval in AS patients after resolution of inflammation following tofacitinib treatment has not been evaluated and that there are no data supporting changing dose interval. The same apply for other tofacitinib indications such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). The MAH does not intend to seek therapeutic claims in this area and therefore any decision on modifying or stopping treatment should be at physician discretion. Moreover, the MAH has also specified that at present there is no plan to conduct a long-term extension study for tofacitinib in ankylosing spondylitis (AS) patients.

## Study participants

Key Inclusion criteria:

1. Adults' subjects with a diagnosis of AS based on the Modified New York Criteria for Ankylosing Spondylitis (1984).
2. The subject must have a radiograph of the SI joints (AP Pelvis) documenting diagnosis of AS. Previous radiographs (up to 2 years old) can be used if they are accepted by the central reader. Otherwise, a new radiograph will be obtained during the screening period.
3. Subject has active AS Screening and Baseline (Day 1) visits defined as:
- BASDAI score of ≥4; and
- Back pain score (BASDAI Question 2) of ≥4.
4. Subject has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or is intolerant to NSAIDs as defined by:

Subject must have had at least a total of 2 occurrences of an inadequate clinical response (minimum of 4 weeks trial) or intolerance to at least 2 different oral NSAIDs. An inadequate response to a previous NSAID or TNFi is defined as a lack of sufficient clinical response based on a clinical judgment or based on a related adverse event. Intolerance is defined as having discontinued NSAID treatment due to a related adverse event (e.g., allergic reaction, gastrointestinal symptoms or signs, hypertension, etc).

5. Subjects who are designated as TNFi-IR must have received at least 1, but not more than 2 approved TNFi that was administered in accordance with its labelling recommendations and was inadequately effective after the minimum treatment times listed below and/or not tolerated after one or more doses.
- At least 3 months of adalimumab treatment;
- At least 3 months of etanercept treatment;

<div style=\"page-break-after: always\"></div>

- At least 4 infusions of infliximab;
- At least 3 injections of golimumab;
- At least 3 months of certolizumab treatment.

Intolerance is defined as having experienced a treatment-related AE.  Subjects may be receiving the following csDMARDs at the time of the screening visit. These medications should be continued throughout the entire study and doses should remain unchanged. Any other Disease-Modifying Anti-Rheumatic Drugs (DMARDs) require discussion prior to enrolment with the sponsor for washout timeframe.

- Methotrexate (MTX): Maximum dose of 25 mg/week. Minimum duration of therapy 4 months and dose stable for 4 weeks prior to first dose of investigational product.
- Sulfasalazine (Azulfidine ® , Salazopyrin ® ): Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose stable for 4 weeks prior to first dose of investigational product.
6. Subjects who are already taking oral corticosteroids (not injectables) may participate in

the study:

- Oral corticosteroids: Subjects who are already receiving oral corticosteroids must be on a stable dose of ≤10 mg/day of prednisone or equivalent for 1 week prior to the first dose of investigational product.
- Injected (e.g., intraarticular, intramuscular, epidural or intravenous) corticosteroids must be discontinued 4 weeks prior to the first dose of investigational product.
- Topical and intra-rectal corticosteroids will be allowed during the study.
7. Subjects who are receiving any investigational or marketed treatment for AS, arthritis or back pain not mentioned elsewhere must have that treatment discontinued for 4 weeks or 5 half-lives, whichever is longer.
8. Subjects receiving non-prohibited concomitant medications for any reason must be willing to stay on a stable regimen (doses and frequency) as defined in the protocol.
9. No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by all of the following:
- A negative QuantiFERON ® -TB Gold (QFT G) In Tube test performed at or within 3 months prior to the Screening visit. Subjects with a history of Bacille Calmette Guérin (BCG) vaccination will be tested with the QFT G test.
- A chest radiograph taken at or within the 3 months prior to screening.
- •
- No history of either untreated or inadequately treated latent or active TB infection.

Women of childbearing potential must test negative for pregnancy prior to enrolment in this study.

Female subjects of non-childbearing potential only according to strict criteria.

## Key Exclusion criteria:

1. History of known or suspected complete ankylosis of the spine.

<div style=\"page-break-after: always\"></div>

2. Subjects that have been exposed to or are currently receiving targeted synthetic DMARDS (including JAK inhibitors) or those currently on biological DMARDS (i.e., washout from any current bDMARD required per Section 5.8.1), thalidomide (including previous use) and other prohibited concomitant medications noted in Appendix 4 of the bioanalytical report.
3. History of allergies, intolerance or hypersensitivity to lactose or tofacitinib (CP-690,550). This includes subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
4. Blood dyscrasias at screening or within 3 months prior to the first dose of investigational product including confirmed:
- Hemoglobin &lt;10 g/dL
- Absolute white blood cell count (WBC) &lt;3.0 x 10 9 /L (&lt;3000 mm 3 )
- Absolute neutrophil count (ANC) &lt;1.5 x 10 9 /L (&lt;1500 mm 3 )
- Absolute lymphocyte count &lt;1.0 x 10 9 /L (&lt;1000/mm 3 )
- Platelet count &lt;100 x 10 9 /L (&lt;100,000/mm 3 ).
5. Estimated Creatinine Clearance &lt;40 mL/min based on Cockcroft Gault equation at Screening visit.
6. Total bilirubin, AST or ALT more than 1.5 times the upper limit of normal (ULN) at screening visit.
7. History of any other autoimmune rheumatic disease.
8. History of an infected joint prosthesis at any time, with the prosthesis still in situ.
9. History of any lymphoproliferative disorder, such as Epstein Barr Virus related lymphoproliferative disease (EBV-LPD), history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
10. History of recurrent (more than one episode) herpes zoster or disseminated/multidermatomal (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
11. History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 3 months prior to the first dose of investigational product. History of infection requiring antimicrobial therapy within 2 weeks prior to the first dose of investigational product.
12. Any prior treatment with non-B cell specific lymphocyte depleting agents/therapies (e.g., alemtuzamab, efalizumab), alkylating agents (e.g., cyclophosphamide or chlorambucil), or total lymphoid irradiation.
13. Any subject who has been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of investigational product or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks after last dose of investigational product.
14. A subject with any condition possibly affecting oral drug absorption, e.g., gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. Procedures such as gastric banding, that simply divide the stomach into separate chambers, are NOT exclusionary.
15. A subject that is considered at risk for GI perforation by the investigator or Sponsor.

<div style=\"page-break-after: always\"></div>

16. Screening 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities which may affect subject safety (e.g., pattern of acute myocardial infarction, acute ischemia or serious arrhythmia) or interpretation of study results (e.g., continuously paced ventricular rhythm or complete left bundle branch block).
17. A subject with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.
18. A subject with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
19. Significant trauma or surgery procedure within 1 month prior to first dose of study medication, or any planned elective surgery during the study period.
20. A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus or any chronic infection.

## Treatments

During the first 16-week treatment period, patients were randomised in a double-blind 1:1 ratio to tofacitinib 5 mg BID or matching placebo BID. At the Week 16 visit, all patients, including those who were randomised to placebo, received open label tofacitinib 5 mg BID for the remaining 32 weeks of the study period.

## Prior and Concomitant Treatments

Patients continued their stable background AS therapy, which included NSAIDs including selective COX-2 inhibitors, MTX, sulfasalazine, and corticosteroids.

Methotrexate was allowed if it had been used for at least 4 months, on a stable dose ( ≤ 25mg/week) during the last 4 weeks. Sulfasalazine was allowed if used for at least 2 months, on a stable dose ( ≤ 3g/day) during the last 4 weeks. Patients who were already receiving oral corticosteroids must be on a stable dose of ≤ 10 mg/day of prednisone or equivalent for 1 week before baseline. Topical NSAIDs were allowed during the study.

Daily dosages of NSAIDs/COX-2 inhibitors, opioids, and paracetamol must be stable for 1 week prior to first study dose and must remain so during the study treatment period (Week 48) except if adjustment is needed to protect a subject's safety. The total daily dose of acetaminophen may not exceed 2.6 grams per day, and the total daily dose of opioid may not exceed the potency equivalent of 30 mg of orally administered morphine.

## Rescue medications

The maximum dose of acetaminophen/paracetamol was 2.6 g/day for no more than 10 consecutive days. The maximum dose of opioids was the maximum potency equivalent of 30 mg/day of orally -administered morphine (with or without acetaminophen/paracetamol) for no more than 10 consecutive days ( Table 29 ). Subjects who were not on stable, background opioid therapy, any of single opioid agents (e.g., hydrocodone, oxycodone or tramadol) could be given as rescue medication (with or without acetaminophen/paracetamol) for no more than 10 consecutive days. Subjects who required rescue medication for more than 10 consecutive days were discontinued from the investigational product. In addition, subjects were not dosed with rescue acetaminophen/paracetamol or opioids within 24 hours prior to a study visit.

<div style=\"page-break-after: always\"></div>

Table 29. Rescue therapy for Study A3921119 and A3921120

| Study    | Rescue therapy                                                                                                                                                                                          |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A3921119 | Increases of acetaminophen/paracetamol and opioids were allowed as rescue medication for no more than 10 consecutive days.                                                                              |
|          | Acetaminophen/paracetamol were added or increased to a maximum of 2.6 gm/day.                                                                                                                           |
|          | Opioids were added or increased to a maximum potency equivalent of 30 mg of orally-administered morphine.                                                                                               |
|          | Subjects who required rescue for more than 10 consecutive days were discontinued from the study.                                                                                                        |
|          | There was no limit to the duration of nonconsecutive use of rescue medications.                                                                                                                         |
|          | Subjects were not dosed with rescue medication during the 24 hours prior to a study visit.                                                                                                              |
|          | Baseline stable use acetaminophen/paracetamol or opioids were not discontinued in advance of study visits.                                                                                              |
|          | Subjects were not dosed with rescue acetaminophen/paracetamol or opioids within 24 hours prior to a study visit.                                                                                        |
|          | Baseline stable acetaminophen/paracetamol or opioids was not discontinued in advance of study visits.                                                                                                   |
| A3921120 | Increases of acetaminophen/paracetamol and opioids were allowed as rescue medication for no more than 10 consecutive days.                                                                              |
|          | Acetaminophen/paracetamol was added or increased to a maximum of 2.6 gm/day.                                                                                                                            |
|          | Combination products such as over-the-counter 'cold remedies' or pain medications were assessed for acetaminophen/paracetamol content so that the total dose will not exceed 2.6 gm/day.                |
|          | Opioids were added or increased to a maximum potency equivalent of 30 mg of orally-administered morphine.                                                                                               |
|          | Subjects who required rescue for more than 10 consecutive days were discontinued from the investigational product and designated as discontinued from the investigational product for lack of efficacy. |
|          | There was no limit to the duration of nonconsecutive use of rescue medications.                                                                                                                         |
|          | Subjects were not dosed with rescue medication during the 24 hours prior to a study visit.                                                                                                              |
|          | In the judgement of the investigator, if rescue therapy had any effect on efficacy data collected during a study visit, this constituted a protocol deviation.                                          |
|          | Baseline stable use of acetaminophen/paracetamol or opioids was not discontinued in advance of study visits.                                                                                            |

Source: S0113 Module 5.3.5.4 A3921119 Protocol Amendment 1 Section 5.6 and Appendix 6; S0113 Module 5.3.5.1 A3921120 Protocol Amendment 3 Section 5.8.3 and Appendix 6

## Treatment compliance

At the study visits, sufficient investigational product was dispensed to complete dosing until the next scheduled visit and all study medication had to be returned at each visit. Compliance was assessed by pill count at each visit. If compliance was &lt;80% the patient was offered counselling to improve compliance. If a patient was less than 80% compliant as assessed at two consecutive visits, the patient was withdrawn from investigational treatment.

## Discontinuation Criteria from the Investigational Product :

-  serious or significant opportunistic infections, other serious or severe AEs
-  defined alterations of neutrophils, lymphocytes, Hb, PLT, AST/ALT +/- hepatic injury, creatinine, CK,
-  pregnancy,
-  rescue medication &gt;10 consecutive days, interruption of IMP for more than 5 consecutive days (DB period) or 28 consecutive days (OL period) or &lt;80% compliance

## Objectives

Part I,  double-blind,  placebo-controlled (0-16 weeks): to evaluate the efficacy and safety of tofacitinib compared with placebo (superiority).

<div style=\"page-break-after: always\"></div>

Part II, open-label, tofacitinib 5mg (16-48 weeks): to evaluate the efficacy and safety of tofacitinib through up to 48 weeks of treatment in subjects who have completed Part I.

## Outcomes/endpoints

Improvement criteria based upon ASAS response have been developed for clinical trials in AS which include the ASAS20, ASAS40, ASAS 5/6 assessments and partial remission. 1,2  These composite scores are derived from several of the PRO measures or disease activity assessments. The composite score was calculated by the Sponsor.

A summary of the efficacy endpoints evaluated in Study A3921120 are presented Table 30 .

Table 30 . Summary of the efficacy endpoints

<!-- image -->

| Table l.        | Study Objectives and Endpoints                                                                                                                                                                                                                  | Study Objectives and Endpoints                                                                                                                                                                                                                              |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type            | Objective                                                                                                                                                                                                                                       | Endpoint                                                                                                                                                                                                                                                    |
| Primary         | Primary                                                                                                                                                                                                                                         | Primary                                                                                                                                                                                                                                                     |
| Efficacy        | To compare the efficacy of tofacitinib 5 mg BID versus placebo on the ASAS20' response rate at Week 16 in subjects with active AS that have had an inadequate response to previous treabment.                                                   | ASAS20 response* at Week 16.                                                                                                                                                                                                                                |
| Key Secondary   | Key Secondary                                                                                                                                                                                                                                   | Key Secondary                                                                                                                                                                                                                                               |
| Efficacy        | To compare the efficacy of tofacitimib 5 mg BID versus placebo on the ASAS40² response rate at Week 16 in subjects with active AS that have had an inadequate response to previous treabment.                                                   | ASAS40 response* at Week 16.                                                                                                                                                                                                                                |
| Other Secondary | Other Secondary                                                                                                                                                                                                                                 | Other Secondary                                                                                                                                                                                                                                             |
| Safety          | To compare the safety and toleability of tofacitinib5mg BD Versus placebo in subjects with active AS that have had an inadequate response to previous treatment.                                                                                | Incidence and severity of AEs. Clinical laboratory tests, vital sigus, physical examination snd 12-lead ECGparameters.                                                                                                                                      |
| Efficacy/HRQoL  | To compare the efficacy (including health-related quality of life, fimction, pain, and fatigue) of tofacitinib 5 mg BID versus placebo at all time points in subjects with active AS that have had an inadequate response to previous teatment. | ASAS20'response*atallother time points. ASAS40² response* at all other time points. Change from baseline in ASDAS(CRP)* at all time points. Change from baseline in hsCRp* at all time points. Change from baseline in ASQoL* at all time points collected. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Table l.   | Study Objectives and Endpoints   | Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type       | Objective                        | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |                                  | Change from baseline in SF-36v2* at all time points collected. Change from baseline in BASMI* including the 5 components (lateral spine flexion, tagus-to-wall distance, lumbar flexion, maximal intemmalleolar distance and cervical rotation) at all time points. Change from baseline in FACIT-F (3 endpoints: total score*, experience domain and impact domain scores) at all time points. Change fom baseline in PGA* at all time points collected. Change from baseline in Patient's Assessment of Spinal Pain (Iotal Back Pain**, Noctuual Spinal Pain) at all time points collected. Change from baseline in BASFI** at all time points. Change from baseline in inflammation**(mean of the answers to questions 5 and 6 of the BASDAI) at all time points collected. ASAS 5/6 response at all time points. ASAS partial remission criteria at all time points. Change from baseline in BASDAI at all time points. |

<div style=\"page-break-after: always\"></div>

| Table l.             | Study Objectives and Endpoints                                                           | Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type                 | Objective                                                                                | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                      |                                                                                          | BASDAI50 response at all time points. ASDAS clinically important improvement, ASDAS major improvement and ASDAS inactive disease at all time points. Change from baseline in MASES at all time points collected. Change from baseline in exba-articularInvolvement (Specific Medical History and peripheral articular involvement [as assessed by change from baseline in swollen joint coumt]) at all time points collected. Change from baseline in spinal mobility at all time points collected. Change from baseline in EQ-5D-3L amd EQ-VAS,at all time points collected. Change from baseline in WPAI Questionnaire: Spondyloarthritis at all time points collected. |
| Tertiary/Erploratory | Tertiary/Erploratory                                                                     | Tertiary/Erploratory                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PK.                  | To describe the PK of tofacitinib in subjects with active AS.                            | Oral clearance (CL/F) and other PK parameters calculated from plasma tofacitinib concentations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Safety               | To evaluate the effect of tofacitinib 5 mg BD on lymphocyte subsets using FACS analysis. | FACS analysis oflymphocyte subsets.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<!-- image -->

| Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                       | Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                       | Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type                                                                                                                                                                                                                                                                                                          | Objective                                                                                                                                                                                                                                                                                                     | Endpoint                                                                                                                                                                                                                                                                                                      |
| Medical Resource Utilization                                                                                                                                                                                                                                                                                  | To measuure the effect of tofacitinib 5mgBD onhealthcare resouwrce utilization at all collected time points.                                                                                                                                                                                                  | AS-HCRU at all time points collected.                                                                                                                                                                                                                                                                         |
| ASAS20 improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10and no Worsening of 220% and ≥1 unit in the remnining domain. 2ASAS40 improvement criteria are classified as ≥40% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. | ASAS20 improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10and no Worsening of 220% and ≥1 unit in the remnining domain. 2ASAS40 improvement criteria are classified as ≥40% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. | ASAS20 improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10and no Worsening of 220% and ≥1 unit in the remnining domain. 2ASAS40 improvement criteria are classified as ≥40% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. |

<div style=\"page-break-after: always\"></div>

The Table 31 summarises the description of the endpoints and the time points of the assessment.

Table 31. Summary and Description of all Efficacy Measures

| Assessment Endpoint                                                                                                    | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Measurement Timepoint(s) A3921120                                                                                      |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week           | Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week           |
| 16)                                                                                                                    | 16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16)                                                                                                                    |
| ASAS20 Response                                                                                                        | ASAS20 assesses 4 domains: the Patient Global Assessment of Disease, Spinal Pain (total back pain), Function (BASFI) and Inflammation (average of questions 5 and 6 of BASDAI). ASAS20 response is defined as an improvement from Baseline ≥20% and ≥1 unit in at least 3 domains on a scale of 0 to 10 and no worsening of ≥20% and ≥1 unit in the remaining domain.                                                                                                                                                                                                          | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 At Week 16 was the Primary Efficacy Endpoint                              |
| Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16) | Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16)                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16) |
| ASAS40 Response                                                                                                        | ASAS40 assesses the 4 domains as specified above. ASAS40 response is defined as an improvement from Baseline ≥40% and ≥2 units in at least 3 domains on a scale of 0 to 10 and no worsening at all in the remaining domain                                                                                                                                                                                                                                                                                                                                                     | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 At Week 16 was the Key Secondary Efficacy Endpoint                        |
| Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at             | Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at             |
| ∆ ASDAS(CRP) a                                                                                                         | The ASDAS(CRP) endpoint is derived from several patient-reported outcomes (Back Pain, Duration of Morning Stiffness, Patient Global Assessment, and Peripheral Pain/Swelling) and hsCRP and was calculated by the Sponsor. The following formula was used to calculate the ASDAS(CRP): ASDAS(CRP) = 0.121 × Back Pain + 0.058 × Duration of Morning Stiffness + 0.110 × Patient Global + 0.073 × Peripheral Pain/Swelling + 0.579×Ln (hsCRP mg/L+1)                                                                                                                            | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                           |
| ∆ hsCRP                                                                                                                | Blood samples were analysed by a central laboratory.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                           |
| ∆ ASQoL                                                                                                                | The ASQoL is an 18-item patient-completed questionnaire assessing the amount of restriction the patient is experiencing in daily activities, level of pain and fatigue, and the impact on the patient's emotional state. Each item is scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranges from 0 to 18, with higher values indicating more impaired health-related quality of life.                                                                                                                         | Weeks 16 and 48                                                                                                        |
| ∆ SF-36v2                                                                                                              | The SF-36 (Acute) is a 36-item patient-completed generic health status measure. It measures 8 general health domains (norm-based scores were used in analysis): physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. These domains are also summarised as physical and mental component summary scores (PCS and MCS, respectively). Higher scores indicate better health outcomes. PCS was a Type I error-controlled endpoint. | Weeks 16 and 48                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Assessment Endpoint                                                                                         | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Measurement Timepoint(s) A3921120                                                                           |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| ∆ BASMI Score - Linear Method                                                                               | The BASMI was used to assess the axial status and mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue). Five clinical measures comprise this scale and in this clinical study the linear function method was used. The combined index score was calculated by the Sponsor using the individual scores from the following measures: lateral spinal flexion, tragus to wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation.                                             | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ∆ FACIT-F                                                                                                   | The FACIT - Fatigue Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Instrument scoring yields a range from 0 to 52 for the total score, with higher scores representing better patient status (less fatigue). FACIT-F is also summarised as FACIT-F experience domain score (range 0-20) and FACIT-F impact domain (range 0-32) score. FACIT-F                                                                                                                                                           | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the | Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the                                                                                                                                                                                                                                                                                                                                                                                                                                     | Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the |
| ∆ PGA                                                                                                       | Patients assessed their overall disease activity over the last week using a NRS between 0 (Not Active) and 10 (Very Active) to the question, 'How active was your spondylitis on average during the last week?' PGA is 1 of the 4 ASAS20/ASAS40 components and the results of this assessment were used to calculate the ASAS improvement criteria.                                                                                                                                                                                             | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ∆ Spinal pain                                                                                               | Two NRS scales were used to assess the patient's spinal pain: level of nocturnal pain and total back pain on average during the last week. For each of these scales, patients marked their level of pain on a 0 to 10 NRS anchored by 0 for 'No Pain' to 10 'Most Severe Pain.' Results of total back pain were used to calculate the ASAS improvement criteria. The total back pain was a Type I error-controlled endpoint.                                                                                                                    | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ∆ Inflammation (morning stiffness)                                                                          | Inflammation is 1 of the 4 ASAS20/ASAS40 components, which is the average of the answers to questions 5 & 6 of BASDAI.                                                                                                                                                                                                                                                                                                                                                                                                                          | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ∆ BASFI                                                                                                     | The BASFI is a set of 10 questions designed to determine the degree of functional limitation in those with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the patients' ability to cope with everyday life. A 0-10 NRS is used to answer the questions with 0 being 'Easy' and 10 being 'Impossible.' BASFI is the average of these 10 scores and it ranges from 0 to 10, with higher scores indicating greater functional limitation. BASFI is 1 of the 4 ASAS20/ASAS40 components. | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| Secondary efficacy endpoints (not controlled for Type I error)                                              | Secondary efficacy endpoints (not controlled for Type I error)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Secondary efficacy endpoints (not controlled for Type I error)                                              |
| ASAS 5/6 response                                                                                           | ASAS 5/6 assesses 6 domains: the domains as noted in the ASAS20 and ASAS40, hsCRP and Spinal mobility, specifically lateral spinal flexion (from the BASMI). Response is defined as improvement ≥20% in at least 5 domains                                                                                                                                                                                                                                                                                                                      | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ASAS partial remission                                                                                      | ASAS partial remission is based on the same 4 ASAS domains noted above. Partial remission is defined as a response if a score of 2 or less (on a scale of 0 to 10) for each of the 4 domains                                                                                                                                                                                                                                                                                                                                                    | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |

<div style=\"page-break-after: always\"></div>

| Assessment Endpoint                                                              | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Measurement Timepoint(s) A3921120            |
|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| ∆ Spinal mobility (Chest expansion)                                              | The chest expansion (cm) was measured as the difference between maximal inspiration and expiration. Two attempts were performed and the better (ie, larger) of the 2 attempts was utilised for data analysis.                                                                                                                                                                                                                                                                                   | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
| ∆ BASDAI                                                                         | The BASDAI is a validated patient-completed questionnaire that consists of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a NRS from 0 (none) to 10 (very severe). The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then                  | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
| ASDAS Clinically Important Improvement, Major Improvement and Inactive Disease a | divided by 5. The ASDAS Clinically Important Improvement, Major Improvement and Inactive Disease were calculated from the ASDAS(CRP) data. Clinically important improvement and major improvement were defined as a decrease from Baseline in ASDAS(CRP) ≥1.1 units and ≥2.0 units, respectively. Inactive disease was defined as ASDAS(CRP) <1.3 unit.                                                                                                                                         | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
| ∆ MASES                                                                          | Enthesitis was evaluated by the qualified blinded assessor using the MASES. Thirteen sites (right and left) were assessed for tenderness: costochondral 1 (right and left), costochondral 7 (right and left), spina iliaca anterior superior (right and left), crista iliaca (right and left), spina iliaca posterior (right and left), processus spinosus at L5 and Achilles tendon proximal insertion (right and left). Scoring at each site will be 0 for no tenderness or 1 for tenderness. | At Weeks 4, 8, 12, 16, 24, 32, 40, and 48    |
| ∆ Swollen Joint Count                                                            | Forty-four (44) joints were assessed for swelling and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), knees, ankles, and metatarsophalangeals (MTP I, II, III, IV, V).                                                                                                                                                      | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
| ∆ EuroQoL EQ-5D- 3L and EQ-VAS                                                   | The EuroQol 3 Levels EQ-5D-3L Health State Profile is a patient completed instrument designed to assess impact on health-related quality of life in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with lower scores indicating better health outcomes. EQ-VAS (Your own health state today) records the patient's self-rated health, a score ranging from 0 to 100 mm is recorded, with higher scores representing better health state today        | Weeks 16 and 48                              |
| ∆ WPAI                                                                           | The WPAI: Spondyloarthritis is a 6-item patient- completed questionnaire that is specific for spondyloarthritis which yields 4 types of scores: percent work time missed due to health problem; percent impairment while working due to health problem; percent overall work impairment due to health problem; percent inactivity due to health problem. WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.         | Weeks 16 and 48                              |

<div style=\"page-break-after: always\"></div>

a. Per the method published by Machado et al3, for hsCRP values &lt; 2 mg/L, it is set to 2 mg/L in the formula to derive ASDAS(CRP) and endpoints based on ASDAS(CRP).

## Sample size

The primary efficacy analysis is to compare the ASAS20 response rate at week 16 of the tofacitinib 5 mg BID and placebo via the normal approximation for the  difference  in  binomial  proportions.  Assuming  a placebo response rate of 40% for ASAS20 response at week 16, a sample size of 120 per arm will yield about 89% power to detect a difference of at least 20% between tofacitinib 5 mg BID and placebo at a twosided significance level of 5%. In the Phase 2 proof of concept trial A3921119, ASAS20 response rates at week 12 were 63% and 40% for tofacitinib 5 mg BID and placebo, respectively.

Sample size calculation for pivotal phase III study A3921120 was based on the response rate found in phase 2 dose-ranging, proof of concept trial. It is recognized as appropriate, although the primary efficacy endpoint was then analysed by the Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata (prior treatment history).

## Randomisation

By use of an automatic Interactive web-based Response system. Subjects were randomized at the Baseline visit in a 1:1 ratio to one of the following two parallel blinded treatment sequences for a total of 16 weeks of treatment. Randomization was stratified by prior treatment history: (1) bDMARD-naive and (2) TNFi-IR or bDMARD use (non-IR) as shown in Table 32 . The clinical trial was designed to reflect the proportion of bDMARD-naïve and TNFi-IR or bDMARD use (non-IR) of approximately 80%/20%.

Table 32 . Safety Analysis Set (Final Analysis)

| Stratum                                    | Number of bDMARDs with InadequateResponse   | Tofacitinib 5 mgBID (N=133) (%)   | Placebo-> Tofacitinib 5 mg BID (N=136) n (%)   | Total (N=269) n (%)   |
|--------------------------------------------|---------------------------------------------|-----------------------------------|------------------------------------------------|-----------------------|
| bDMARD-naive                               |                                             | 102 (76.7)                        | 105 (77.2)                                     | 207 (77.0)            |
| TNFi-IR or bDMARD Use (Non-IR)             |                                             | 31 (23.3)                         | 31 (22.8)                                      | 62 (23.0)             |
| TNFi-IR                                    | 1 TNFi-IR                                   | 23 (79.3)                         | 20 (66.7)                                      | 43 (72.9)             |
|                                            | 2 TNFi-IR                                   | 6 (20.7)                          | 10 (33.3)                                      | 16 (27.1)             |
| bDMARD Use (Non- 1 bDMARD Use (Non-IR) IR) |                                             | 2 (100.0)                         | 1 (100.0)                                      | 3 (100.0)             |

WHODDEv202003 coding dictionary applied.

Prior drug treatment was defined as a drug taken on or before Day -1.

ie. If there was more than one record per drug for a subject, count as one medication.

Each subject was counted with the number of unique bDMARD-naive, TNFi-IR, or bDMARD Use (Non-IR) .

The strata of bDMARD-naive, TNFi-IR, and bDMARD Use (Non-IR) were derived from clinical database

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose of the investigational product.

Numbers of inadequate responses were summarized as number (%) of subjects in each category.

PFIZER CONFIDENTIAL SDTM Creation:11SEP2020(02:55)Source Data: adcm Table Generation:26SEP2020 (21:12)

OutputFile:./cdisc/A3921120\\_SCD/adcm\\_s005\\_i\\_a Table 14.1.4.4.4.2A is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

At the end of the 16 weeks double-blinded treatment period, all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48. The investigators, subjects and sponsor study team remained blinded to the first 16 weeks of treatment assignment through the entire duration of the trial until database release.

The randomisation scheme is considered adequate.

## Blinding (masking)

This study was subject-, investigator-, and sponsor-blinded. An IRT drug management system was used to dispense the bottles with medication at each visit from baseline to week 40, using unique container numbers. For the open-label treatment period, subjects, investigator and sponsor study team remained blinded to the double-blind treatment period study sequence. All subjects received tofacitinib 5 mg tablets supplied in containers labelled according to local regulatory requirements.

## Statistical methods

## Analysis of efficacy parameters

Full Analysis Set: The full analysis set (FAS) included all randomized subjects who received at least one dose of the randomized investigational product (i.e., tofacitinib or placebo).

Per  Protocol  Analysis  Set:  The  Per-Protocol  (PP)  analysis  set  excluded  all  subjects  who  had  a  protocol deviation The PP analysis set was used as a supportive analysis for the primary endpoint of ASAS20 and the key secondary endpoint of ASAS40.

There were 2 planned analyses: Week 16 Analysis (data cut-off 19DEC2019, data snapshot 29JAN2020) and Week 48 Analysis following the final database release.

The Week 16 Analysis included all placebo-controlled efficacy data through Week 16.  The Week 48 analysis results, which contained placebo-controlled results through Week 16 as well as open-label results postWeek 16, were secondary and supportive in nature.

All statistical tests were conducted on a 2 sided 5% significance level for comparing tofacitinib 5 mg BID to placebo. Type I error was controlled on a 2-sided 5%.

For the primary endpoint of ASAS20 response at Week 16, if the 2-sided p-value was ≤ 5%, the superiority of tofacitinib 5 mg BID to placebo was declared and the primary objective of the study was considered as being met.

## Estimands for ASAS20 and ASAS40 at Week 16

Only discontinuation of the investigational product was considered as an intercurrent event to define the estimands for this study. There are three estimands for the primary endpoint of ASAS20 at Week 16.

## Estimand 1:

The first  estimand  of  ASAS20  at  Week  16  is  a  composite  estimand  that  accounts  for  both  treatment adherence and response. A responder is defined  as  having  a  response  without  discontinuation  of  the investigational product prior to Week 16.

## Estimand 2:

The second estimand of ASAS20 at Week 16 is supportive to Estimand 1 and is a treatment policy estimand. It estimates the effect regardless of treatment adherence.

<div style=\"page-break-after: always\"></div>

## Estimand 3:

The third estimand of ASAS20 at Week 16 is supportive to Estimand 1 and is a hypothetical estimand. It estimates the treatment effect as if the intercurrent event of discontinuation of investigational product prior to Week 16 has not occurred.

The main difference between Estimand 1 and 3 is that Estimand 3 assumes the intercurrent event of discontinuation of investigational product prior to Week 16 has not occurred, while Estimand 1 considers the response after discontinuation of investigational product as non-response via the composite strategy. Also, the population-level summary in Estimand 3 is an odds ratio instead of difference in response rates as in Estimand 1.

Similarly, the same three estimand are also applicable to ASAS40 at Week 16. Specifically, Estimand 1 for ASAS40  at  Week  16  is  called  the  Key  Secondary  Estimand,  defined  according  to  the  key  secondary objective. Estimand 1 was also used for other binary secondary endpoints.

## Estimands for Continuous Secondary Endpoints

Only discontinuation of the investigational product was considered as an intercurrent event to define the estimands for this study. Estimand 4, a hypothetical estimand was used for other continuous secondary endpoints  thatestimates  the  treatment  effect as if the intercurrent event  of discontinuation of investigational product prior to Week 16 has not occurred

Estimand 5 was used only for the Type I error controlled continuous secondary endpoints as supportive analyses to Estimand 4 and is a treatment policy estimand.

## Estimand 4:

The difference between Estimand 5 and 4 is that Estimand 5 disregards treatment adherence and includes the additional data collected after the intercurrent event of discontinuation of the investigational product prior to Week 16, ie, On-Study data are used.

Primary  analysis: For  the  primary  analysis  of  the  ASAS20  response  at  Week  16,  the  normal approximation for the difference in binomial proportions adjusting for the stratification factor (ie, prior treatment history: \"bDMARD naïve\" versus \"TNFi IR or bDMARD Use [Non-IR]\") at randomisation via the CMH approach was used to test the superiority of tofacitinib 5 mg BID to placebo and to generate a 95% CI for the difference on the FAS.

. ASAS40 response at Week 16 was analysed using the same methods as those for the primary endpoint ASAS20 response, as well as other binary endpoints.

Continuous endpoints were analysed as change from baseline with a mixed model for repeated measures (MMRM).

When analysis included only a single post-baseline visit, these endpoints were analysed as change from baseline with an analysis of covariance (ANCOVA) model that included treatment group, stratification factor (i.e., prior treatment history), and baseline value.

For both MMRM and ANCOVA, if the Baseline was missing or if there were no post-baseline measurements, the patient was excluded from the analysis. In the final analysis, all data up to Week 48 were included in the analyses using another MMRM.

A tipping point analysis for the primary endpoint of ASAS20 and the key secondary endpoint of ASAS40 was conducted to address impact of missing values on the conclusions and to assess the robustness of the data; it was based on multiple imputation.

## Analysis at week 48

At week 16 all subjects have been assigned to open-label tofacitinib until week 48. Both primary and secondary endpoints have been analysed by the same models used until week 16 but extending visits until week 48. As the primary endpoint (ASAS20), the key secondary endpoint (ASAS40), and the other Type I error controlled secondary endpoints were at week 16, there was no additional adjustment made

<div style=\"page-break-after: always\"></div>

for Type I error rate at the final analysis at week 48. The week 48 contains results for earlier visits and serves as sensitivity analysis only to ensure there were no major changes to the definitive results for the primary and key secondary endpoints obtained at week 16.

Table 33. Numerical Characteristics of Select Continuous Efficacy Endpoints

| Endpoint                                                                                                                                         | Unit                                                                                                                                                                | Theoretical Range of Values                        | Direction of Improvement from Baseline                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient Global Assessment of Disease                                                                                                             | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| Patient Assessment of Spinal Pain (Total Back Pain, Nocturnal Spinal Pain)                                                                       | None                                                                                                                                                                | All: 0-10                                          | Decrease from Baseline                                                                                                                                                                    |
| BASFI                                                                                                                                            | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| BASDAI                                                                                                                                           | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| Inflammation Score (ie, Average of Q5 and Q6 of BASDAI)                                                                                          | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| hsCRP                                                                                                                                            | mg/L                                                                                                                                                                | ≥0                                                 | Decrease from Baseline                                                                                                                                                                    |
| BASMI score and its 5 component scores (A, S) (A is the unmapped component score, S is the mapped component score [range 0-10] via linear method | BASMI, 5 components (S): None Lateral flexion, Tragus-to-wall distance, lumbar flexion, and intermalleolar distance (A): cm Cervical rotation angle (A): degree (°) | BASMI, 5 components (S): 0-10 5 components (A): ≥0 | BASMI, 5 components (S), Tragus-to-wall distance (A): Decrease from Baseline Lateral flexion, lumbar flexion, intermalleolar distance, and cervical rotation (A): Increase from Baseline. |
| Spinal Mobility - Chest Expansion                                                                                                                | cm                                                                                                                                                                  | ≥0                                                 | Increase from Baseline (ie, higher score represents more spinal mobility)                                                                                                                 |
| ASDAS CRP                                                                                                                                        | None                                                                                                                                                                | ≥0                                                 | Decrease from Baseline                                                                                                                                                                    |
| MASES                                                                                                                                            | None                                                                                                                                                                | 0-13                                               | Decrease from Baseline                                                                                                                                                                    |
| Swollen Joint Count (44)                                                                                                                         | None                                                                                                                                                                | 0-44                                               | Decrease from Baseline                                                                                                                                                                    |
| SF-36v2, 8 domain scale (ie, norm- based), PCS, and MCS scores                                                                                   | None                                                                                                                                                                | All: Real values (Mean=50, SD=10)                  | Increase from Baseline                                                                                                                                                                    |
| EQ-5D-3L, 5 dimension scores                                                                                                                     | None                                                                                                                                                                | All: 1, 2, 3                                       | Decrease from Baseline                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| EQ-VAS                                                   | mm   | 0-100                                                   | Increase from Baseline                                            |
|----------------------------------------------------------|------|---------------------------------------------------------|-------------------------------------------------------------------|
| EQ-5D-3L, Utility Score (UK)                             | None | -0.594 - 1                                              | Increase from Baseline                                            |
| FACIT-F (Total, Impact domain, Experience domain scores) | None | Total: 0-52 Impact domain: 0-32 Experience domain: 0-20 | Increase from Baseline (ie, higher score represents less fatigue) |
| ASQoL                                                    | None | 0-18                                                    | Decrease from Baseline                                            |
| WPAI 4 subscale scores                                   | %    | All: 0-100                                              | Decrease from Baseline                                            |
| AS-HCRU Self-Rating of Job Performance                   | None | 0-10                                                    | Decrease from Baseline                                            |

Abbreviations: % = percent; ASDASCRP = Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein; AS-HCRU = Ankylosing Spondylitis - HealthCare Resource Utilization Questionnaire; ASQoL = Ankylosing Spondylitis Quality of Life; BASDAI = Bath Ankylosing Spondylitis Disease  Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; cm = centimeter; EQ-5D-3L = EuroQol Health State Profile - 5 Dimensions - 3 Levels; EQ-VAS = EuroQol Your own health state today-Visual Analog Scale; FACIT-F = Functional Assessment of Chronic Illness Therapy - Fatigue; hsCRP = high sensitivity C-Reactive Protein; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score;

MCS = mental component summary; mg/L = milligrams per liter; PCS = physical component summary; SD = standard deviation; SF-36v2 = 36-Item Short Form Survey Version 2 Acute; UK = United Kingdom; WPAI = Work Productivity &amp; Activity Impairment.

For the Phase III study, all statistical tests were conducted at the 2-sided 5% significance level for comparing tofacitinib 5 mg BID to placebo. The family-wise Type I error rate has been controlled at the 2sided 5% significance level using a step-down.

The method is not very rigorous, since the alpha level for each comparison is fixed at the 2-sided 5%.

In Study A3921120, 5 estimands were defined for the efficacy endpoints. The discontinuation of the investigational product was considered as an intercurrent event for the respective definitions.  There were 3 estimands for the primary endpoint of ASAS20 response at Week 16 and the key secondary endpoint of ASAS40 response at Week 16. Estimand 1 included only on-drug data and was the main estimand; Estimand 2 included on-study data; Estimand 3 assumed the intercurrent event had not occurred and included only on-drug data. Both Estimands 2 and 3 were supportive estimands. Two additional estimands, Estimand 4 (main) and Estimand 5 (supportive) were used for continuous secondary endpoints.

## Results

## Participant flow

Five hundred and fifty-six AS patients were screened globally. A total of 270 eligible patients were randomised in a 1:1 ratio to 1 of the following 2 parallel treatment groups

- Tofacitinib 5 mg BID (n = 134)
- Placebo (n = 136)

<div style=\"page-break-after: always\"></div>

Of the 270 randomised patients, 1 patient was randomised to tofacitinib 5 mg BID in error by the site but did not receive study drug, thus was excluded from all analyses. There were 269 patients included in the FAS. Overall, 9 (3.3%) patients discontinued from the study drug; 4 (3.0%) from tofacitinib 5 mg BID and 5 (3.7%) in the placebo treatment group up to Week 16. Subject disposition Up to Week 16 and 48 is presented in Figures 19 and 20 respectively.

Figure 19 . Subject Disposition Up to Week 16port

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 20 . Subject Disposition Up to Week 48

Table 34 summarises patient disposition for Study A3921120 up to Week 16 and Week 48, respectively.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 34. Patient Disposition

|                                                      | Up to Week 16        | Up to Week 16   | Up to Week 48        | Up to Week 48                  |
|------------------------------------------------------|----------------------|-----------------|----------------------|--------------------------------|
|                                                      | Tofacitinib 5 mg BID | Placebo         | Tofacitinib 5 mg BID | Placebo- >Tofacitinib 5 mg BID |
| Randomised                                           | 134                  | 136             | 134                  | 136                            |
| Treated                                              | 133 (99.3)           | 136 (100.0)     | 133 (99.3)           | 136 (100.0)                    |
| Not treated                                          | 1 (0.7)              | 0               | 1 (0.7)              | 0                              |
| Discontinued                                         | 4 (3.0)              | 5 (3.7)         | 15 (11.3)            | 14 (10.3)                      |
| Discontinuations due to AE                           | 3 (2.3)              | 1 (0.7)         | 8 (6.0)              | 3 (2.2)                        |
| Discontinuations due to                              | 1 (0.8)              | 2 (1.5)         | 6 (4.5)              | 4 (2.9)                        |
| Insufficient Clinical Response Analysed for Efficacy |                      |                 |                      |                                |
| Per-protocol analysis set                            | 130 (97.7)           | 134 (98.5)      | -                    | -                              |
| Full analysis set                                    | 133 (100.0)          | 136 (100.0)     | 133 (100.0)          | 136 (100.0)                    |

Percentages for the 'Not treated' and 'Treated' rows are calculated using the number of patients assigned to treatment (randomised) as the denominator. Other percentages are calculated using the number of 'Treated' patients as the denominator.

Discontinuations due to AE and discontinuations due to insufficient clinical response refer to discontinuation of study drug and not discontinuation of study participation.

Based on the Week 48 Analysis data.

A total of 269 patients in the A3921120 were treated and included in the FAS and 133 received tofacitinib 5 mg BID as shown in Table 34.

Five hundred and fifty-six AS patients were screened and a total of 270 eligible patients were randomised (Tofacitinib 5 mg BID n = 134 and Placebo n = 136).

Patient's disposition was balanced across the study. The great majority completed the DIB 16 weeks phase (only 4 and 5 subjects discontinued study drug in the Tofa and PLB arm, respectively). A higher but similar number of subjects discontinued study drug up to 48 weeks: 15 in the Tofa-Tofa and 14 in the PLB-Tofa arm; the main reasons of discontinuation being the same safety and lack of efficacy although a higher number is registered in the Tofa-Tofa (8 and 6, respectively) as compared to PLB-Tofa (3 and 4) group.

## Recruitment

Study Centers: A total of 57 sites randomized subjects from the following countries: Australia (3), Bulgaria (2), Canada (2), China (5), Czech Republic (3), France (1), Hungary (2), Republic of Korea (3), Poland (9), Russian Federation (6), Turkey (4), Ukraine (5), United States (12).

## Conduct of the study

## Amendments

Amendment 1, 06 September 2018 main changes:

1. Clarified the role of ASAS40 response at 16 weeks as a key secondary endpoint. Replaced ΔSF -36v2 Physical Functioning domain by ΔSF -36v2 PCS as a Type I error-controlled endpoint. Added ΔASQoL as an additional Type I error-controlled endpoint. Moved AS-HCRU from a secondary to tertiary endpoint.
2. Added Inflammation, Patients Assessment of Spinal Pain and PGA to the secondary endpoints. Clarified the BASMI secondary endpoint includes the 5 components. Realigned secondary endpoints to be consistent with the statistical testing (ie, Type I error control).

<div style=\"page-break-after: always\"></div>

3. Updated sections based upon FDA feedback for subject discontinuation of investigational product and withdrawal from study.
4. Inclusion criteria #7 updated the definition of inadequate response and clarified the definition of intolerance.
5. Updated inclusion criteria #9 (Subject must be on a stable dose of corticosteroids for 1 week prior to first dose of investigational product).
6. Updated exclusion criteria #5 to exclude targeted synthetic DMARDs (including tofacitinib) and subjects  that  have  been  previously  exposed  to  conventional  synthetic,  targeted  synthetic,  or biological DMARDs

Amendment 2 10 April 2019 main changes:

1. Changed to not exclude subjects with prior bDMARD use (non-IR) based on the available population to improve the recruitment in the study.
2. Moved the ASQol in sequence for global type 1 error control before the SF-36v2 PCS. Added the FACIT-F Total score to the global type I error control scheme.

## Amendment 3 03 April 2020 main changes:

This global amendment incorporates venous thromboembolism (VTE) risk factor checks. Pfizer has determined that  VTE  is  identified  as  an  important  identified  risk/dose  dependent  adverse  drug reaction for tofacitinib.

A summary of important protocol deviations is presented in Table 35 :

- There  was  a  similar  proportion  of  subjects  with  protocol  deviations  in  both  treatment groups.
- The majority of the protocol deviations occurred in the category of procedures/tests and concomitant medications with the most common being efficacy assessment/procedure not performed at appropriate visits.

<div style=\"page-break-after: always\"></div>

Table 35. Summary of important Protocol Deviations - Randomized Subjects (Final Analysis)

|                                                                                                                                                                                                               | Tofacitinib 5mgBID (N=134)   | Placebo-> Tofacitinib 5 mgBID (N=136)   | Total (N=270)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------|-----------------|
| Category for Protocol Deviation Subcategory for Protocol Deviation                                                                                                                                            | n(9)                         | (9）u                                    | n(%)            |
| Number (%) of Subjects With Any Important Protocol Deviation                                                                                                                                                  | 37 (27.6)                    | 32 (23.5)                               | 69 (25.6)       |
| CCMEDS                                                                                                                                                                                                        | 10 (7.5)                     | 12 (8.8)                                | 22 (8.1)        |
| Did not remain on stable dose of penmitted Concomitant                                                                                                                                                        | 4(3.0)                       | 7 (5.1)                                 | 11 (4.1)        |
| Medication as specified per Protocol Subject took moderate or potent CYP3A4 inhibitors and/or moderate orpotent CY3A4 inducerswithconcomitant use ofshudy                                                     | 0                            | 1 (0.7)                                 | 1(0.4)          |
| drug>7 days Took prohibited Concomitant Medication / Vaccine                                                                                                                                                  | 6(4.5)                       | 5 (3.7)                                 | 11 (4.1)        |
| INCLUSION/EXCLUSION                                                                                                                                                                                           | 6(4.5)                       | 4 (2.9)                                 | 10 (3.7)        |
| Did not meet inclusion criterion- Subject has active AS screening and baseline visits defined as-BAsDAI score of>=4 and Backpain score>=4                                                                     | 3 (2.2)                      | 1 (0.7)                                 | 4(1.5)          |
| Did not meet inclusion critenion-Subject has discontinued any investigatonal or marketed therapy for AS,back pain,arthntis,for 4                                                                              | 0                            | 1 (0.7)                                 | 1(0.4)          |
| weeks or 5 half-lives Did not meet inclusion critenion- Subject has inadequate clinical response of at least 2 NSAIDs (at least 4 weeks) or intolerance to at least 2 oral NSAIDs                             | 2 (1.5)                      | 2 (1.5)                                 | 4(1.5)          |
| Did not meet inclusion criterion- subject taking methotrexate or sulfasalazine should be taking it at appropriate dose and for minimum                                                                        | 1(0.7)                       | 0                                       | 1(0.4)          |
| duration with a stable dose 4 weeks prior to first dose of study drug Did not meet inclusion criterion- subjects designated as TNFi-IR must have an inadequate response or intolerance of lor not more than 2 | 2(1.5)                       | 1 (0.7)                                 | 3(1.1)          |
| TNFi agents Did not meet inclusion criterion- subjects taking injectable corticosteroid discontinued 4weeks prior to first dose                                                                               | 1 (0.7)                      | 0                                       | 1(0.4)          |
| INVESTIGATIONALPRODUCT                                                                                                                                                                                        | 3 (2.2)                      | 0                                       | 3 (1.1)         |
| Dosing/ Administration Error- Compliance with study drug less than S0%6 for 2 consecutive visits afier week 16 visit                                                                                          | 3 (2.2)                      | 0                                       | 3 (1.1)         |
| LAB                                                                                                                                                                                                           | 8(6.0)                       | 5 (3.7)                                 | 13 (4.8)        |
| Specimen could not be analyzed                                                                                                                                                                                | 7 (5.2)                      | 5 (3.7)                                 | 12 (4.4)        |
| Ss ueuaud pue eguaod Suueaqpugo uaom e si oafqns orFSH wasnot perfonned or negative test result was not documented                                                                                            | 1 (0.7)                      | 0                                       | 1(0.4)          |
| prior to dosing OTHER                                                                                                                                                                                         | 6(4.5)                       | 1 (0.7)                                 | 7(2.6)          |
| Study personnel exposed to unblinded sensitive clinical data                                                                                                                                                  | 6(4.5)                       | 1 (0.7)                                 | 7(2.6)          |
| PROCEDURES/TESTS                                                                                                                                                                                              | 13 (9.7)                     | 21 (15.4)                               | 34 (12.6)       |
| Efficacy assessments/procedures not performed at appropriate visits                                                                                                                                           | 11(8.2)                      | 16 (11.8)                               | 27 (10.0)       |
| Patient reported outcome questionnaries not performed at appropriate visits                                                                                                                                   | 2(1.5)                       | 2 (1.5)                                 | 4(1.5)          |
| Procedure not performed by a medically qualified individual or by incorrect personnel                                                                                                                         | 0                            | 1 (0.7)                                 | 1(0.4)          |
| Procedure/Test not performed as specified in the protocol                                                                                                                                                     | 0                            | 3 (2.2)                                 | 3 (1.1)         |
| RANDOMIZATION                                                                                                                                                                                                 | 2 (1.5)                      | 0                                       | 2 (0.7)         |
| Randonuized under wrong stratification (ie- TNFi naive vs TNFi- [R)                                                                                                                                           | 1(0.7)                       | 0                                       | 1(0.4)          |
| Subject was randomized in error (received a randomization mumber however didn't qualify)                                                                                                                      | 1(0.7)                       | 0                                       | 1(0.4)          |
| SAFETYREPORTING                                                                                                                                                                                               | 1 (0.7)                      | 0                                       | 1 (0.4)         |
| Matermal or Patemal exposure in utero was not reported or was not reported in the required timeframe specified in the protocol                                                                                | 1(0.7)                       | 0                                       | 1(0.4)          |

N: Number of randomized subjects; n (9%): Number of subjects in each analysis category (Percentages were based on N). PFIZERCONFIDENTIALSDTM Creation:13SEP2020 (09.0S) SourceData:dv Table Generaton:26SEP2020 (21:11) Output File:/edisc/A3921120 SCD/addv s001 ia

Table 14.1.5.1A is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

## Impact of COVID-19

In  response  to  the  COVID-19  pandemic,  a  PACL  was  approved  on  30  March  2020  that  outlined  the administrative changes that were implemented to clarify study procedures during the pandemic.

The COVID-19 pandemic impact of protocol changes due to the deviations on the data quality, data analysis or conclusion was minimal as the majority of patients had completed study participation prior to start of the COVID-19 pandemic.

Amendments have been done basically to refine the endpoints and their hierarchy; another important point was the inclusion of bDMARD non-IR subjects. No impact on study results is foreseen.

## Baseline data

Table 36 presents baseline demographic characteristics for the tofacitinib 5 mg BID and placebo groups for Study A3921120.

Table 16. Demographics and Baseline Characteristics by Treatment Group - Safety Analysis Set (Final Analysis)

|                    | Tofacitinib 5 mg BID (N = 133)   | Placebo->Tofacitinib 5 mg BID (N = 136)   | Total (N=269)   |
|--------------------|----------------------------------|-------------------------------------------|-----------------|
| Age years, n (%) a |                                  |                                           |                 |
| 18-44              | 83 (62.4%)                       | 86 (63.2%)                                | 169 (62.8%)     |
| 45-64              | 44 (33.1%)                       | 50 (36.8%)                                | 94 (34.9%)      |
| 65-74              | 6 (4.5)                          | 0                                         | 6 (2.2%)        |
| 75-84              | 0                                | 0                                         | 0               |
| ≥85                | 0                                | 0                                         | 0               |
| N1                 | 133                              | 136                                       | 269             |
| Mean (SD)          | 42.2 (11.85%)                    | 40.0 (11.06%)                             | 41.1 (11.49%)   |
| Range              | 20, 70                           | 20, 62                                    | 20, 70          |
| Gender, n (%)      |                                  |                                           |                 |
| Male               | 116 (87.2%)                      | 108 (79.4%)                               | 224 (83.3%)     |
| Female             | 17 (12.8%)                       | 28 (20.6%)                                | 45 (16.7%)      |
| Race, n (%)        |                                  |                                           |                 |
| White              | 107 (80.5%)                      | 106 (77.9%)                               | 213 (79.2%)     |
| Asian              | 25 (18.8%)                       | 30 (22.1%)                                | 55 (20.4%)      |
| Not reported       | 1 (0.8%)                         | 0                                         | 1 (0.4%)        |
| Ethnicity, n (%)   |                                  |                                           |                 |
| Hispanic/Latino    | 2 (1.5%)                         | 2 (1.5%)                                  | 4 (1.5%)        |

<div style=\"page-break-after: always\"></div>

|                             | Tofacitinib 5 mg BID (N = 133)   | Placebo->Tofacitinib 5 mg BID (N = 136)   | Total (N=269)   |
|-----------------------------|----------------------------------|-------------------------------------------|-----------------|
| Not Hispanic/Latino         | 129 (97.0%)                      | 133 (97.8%)                               | 262 (97.4%)     |
| Not reported                | 2 (1.5%)                         | 1 (0.7%)                                  | 3 (1.1%)        |
| BMI (kg/m 2 )               |                                  |                                           |                 |
| N1                          | 132                              | 136                                       | 268             |
| Mean (SD)                   | 26.7 (5.6)                       | 26.3 (5.77)                               | 26.5 (5.70)     |
| Range                       | 16.0, 50.6                       | 15.9, 48.9                                | 15.9, 50.6      |
| Weight (kg),n (%)           |                                  |                                           |                 |
| <60                         | 18 (13.5%)                       | 16 (11.8%)                                | 34 (12.6%)      |
| >=60 to <=100               | 97 (72.9%)                       | 110 (80.9%)                               | 207 (77.0%)     |
| >100                        | 18 (13.5%)                       | 10 (7.4%)                                 | 28 (10.4%)      |
| Geographic Region b , n (%) |                                  |                                           |                 |
| United States/Canada        | 16 (12.0%)                       | 11 (8.1%)                                 | 27 (10.0%)      |
| European Union              | 51 (38.3%)                       | 55 (40.4%)                                | 106 (39.4%)     |
| Asia b                      | 23 (17.3%)                       | 30 (22.1%)                                | 53 (19.7%)      |
| ROW c                       | 43 (32.3%)                       | 40 (29.4%)                                | 83 (30.9%)      |
| Smoking Status, n (%)       |                                  |                                           |                 |
| Never smoked                | 75 (56.4%)                       | 72 (52.9%)                                | 147 (54.6%)     |
| Current smoker              | 34 (25.6%)                       | 45 (33.1%)                                | 79 (29.4%)      |
| Ex-smoker                   | 24 (18.0%)                       | 19 (14.0%)                                | 43 (16.0%)      |

a. Age at screening.

N = number of patients included in the safety analysis set

N1 = number of patients included in the analysis

The data for Study A3921120 was based on the Week 48 Analysis data

<div style=\"page-break-after: always\"></div>

Table 37. Baseline Disease Characteristics by Treatment Group- Safety Analysis Set (Final Analysis)

<!-- image -->

|                                                                          |                              | Tofacidnib5 IgBID (N=113)   | Placebo Tofacitinib5mg BID (N=130)   | Total (N=269)   |
|--------------------------------------------------------------------------|------------------------------|-----------------------------|--------------------------------------|-----------------|
| Parameter                                                                | Summary Statities            |                             |                                      |                 |
| PriorTreatment History Derived from Clinieal Database,n (%6)             | bDMARD-naive                 | 102 (76.796)                | 105 (77.2%)                          | 207 (77.0%)     |
|                                                                          | INFi-IRcrbDMARD Use (Non-IR) | 31 (23.3%)                  | 31 (22.8%6)                          | 62 (23.096)     |
|                                                                          | TNFi-IR                      | 29 (21.86)                  | 30 (22.1%)                           | 59 (21.96)      |
|                                                                          | bDMARD Use (Non              | 2 (1.5%)                    | 1(0.7%)                              | 3 (1.1%)        |
| Anlylosing Spondylitis Diseave Symptom                                   |                              | 23 (17.3%6)                 | 35 (25.7%)                           | 58 (21.6%)      |
| Duation (Yean).n()                                                       | >5                           | 110 (82.7%)                 | 101(74.3%)                           | 211 (78.4%)     |
|                                                                          | IN                           | 133                         | 136                                  | 269             |
|                                                                          | Mean                         | 142                         | 12.9                                 | 13.5            |
|                                                                          | Std Dev.                     | 9.80                        | 9.47                                 | 9.64            |
|                                                                          | Medinn                       | 11.3                        | 10.3                                 | 10.7            |
|                                                                          | Range(min,mux)               | (0.3,46.8)                  | (0.7,49.4)                           | (03,49.4)       |
| Anlylosing Spondylitis Duration (Yean)                                   |                              | 63 (47.4%)                  | 74 (54.4%)                           | 137 (50.9%%)    |
| since Diagnosis, n (%6)                                                  | 5                            | 70 (52.6%)                  | 62 (45.6%)                           | 132 (49,1%)     |
|                                                                          | IN                           | 133                         | 136                                  | 269             |
|                                                                          | Mean                         | 8.9                         | 6.8                                  | 7.8             |
|                                                                          | StdDev.                      | 9.06                        | 6.94                                 | 8.11            |
|                                                                          | Median                       | 5.8                         | 4.8                                  | 4.9             |
|                                                                          | Range(minmax)                | (0.1,42.8)                  | (0.1,34.9)                           | (0.1,42.8)      |
| History of Uveitis, n (96)                                               | Yes                          | 22 (16.5%6)                 | 20 (14.7%6)                          | 42 (15.6%)      |
|                                                                          | No                           | 94(70.7%6)                  | 94 (69.1%)                           | 188 (69.9%)     |
|                                                                          | Missing                      | 17(12.8%6)                  | 22 (16.2%)                           | 39 (14.596)     |
| Cument Diagnosis ofUveitis for Subjects with History ofUveitis,n ()      |                              | 6 (27.36)                   | 5 (25.0%)                            | 11 (26.2%)      |
|                                                                          | No                           | 16 (72.7%)                  | 15 (75.0%)                           | 31 (73.8%)      |
| History ofPsoriasis,n(96)                                                |                              | 5(3.8%)                     | 3(22)                                | 8(3.0%6)        |
|                                                                          | No                           | 95 (71.4%)                  | 95 (69.9%6)                          | 190 (70.6%)     |
|                                                                          | Missing                      | 33 (24.8%6)                 | 38 (27.9%)                           | 71 (26.496)     |
| Cument Diagnosis ofPsoniasis for Subjects with History ofPsoriasis,n (9) |                              | 2 (40.0%)                   | 2 (66.7%)                            | 4(50.0%)        |
|                                                                          | No                           | 3(60.0%)                    | 1 (33.3%)                            | 4 (50.0%)       |
| History of Infinmmatory Bowel Disease (IBD).n(%)                         |                              | 1 (0.896)                   | 2(1.5%)                              | 3 (1.196)       |
|                                                                          | No                           | 95 (71.4%)                  | 94 (69.1%6)                          | 189 (70.3%)     |

<div style=\"page-break-after: always\"></div>

|                                                                                             |                    | Tofacidnib S BBID (N-115)   | Placrbo Tofacitinib5mg BID (-130   | Total (N-269)          |
|---------------------------------------------------------------------------------------------|--------------------|-----------------------------|------------------------------------|------------------------|
| Parameter                                                                                   | Summary Seatisties |                             |                                    |                        |
|                                                                                             | Missing            | 37(27.896)                  | 40 (29.4%)                         | 77 (28.6%)             |
| Cumeat Diagnois ofIBD for Subjects wnth Yes Hinstory ofIBD,n (%6)                           |                    | 1(100.0%)                   | 1(50.0)                            | 2(66.796)              |
|                                                                                             | No                 | 0                           | 1 (50.0%)                          | 1(033)                 |
| History of Peripheral Arthritis, n (%)                                                      |                    | 21 (15.8%)                  | 25 (18.4%)                         | 46 (17.1%)             |
|                                                                                             | No                 | 96(72.296)                  | 94 (69.1%6)                        | 190 (70.6%)            |
|                                                                                             | Mising             | 16 (12.096)                 | 17 (12.5%6)                        | 33 (12.3%)             |
| Ouneet Dinpnoss ofPenpbeal Arthnts for Subjects with History of Periphenal Arthritis, n (%) |                    | 18(85.796)                  | 22 (88.0%6)                        | 40 (87.0%6)            |
|                                                                                             | No                 | 3 (14.3%6)                  | 3 (12.0%)                          | 6(13.0%)               |
| HLA.B27,n (%)                                                                               | Negative           | 12 (9.0%6)                  | 14 (10.3%)                         | 26 (9.7%6)             |
|                                                                                             | Positive           | 117 (88.0%)                 | 118 (86.896)                       | 235 (87.4%6)           |
|                                                                                             | Missing            | 4 (3.096)                   | 4(2.9%)                            | 8 (3.0%)               |
| Baseline hsCRP (mg L). n (6)                                                                | 0=2.87 >2.87       | 23 (17.3%) 110 (82.7%)      | 20 (14.7%6) 116(85.396)            | 43 (16.0%) 226 (84.0%) |
|                                                                                             |                    | 41(0.8%)                    | 33 (24.3%6)                        | 74(27.5)               |
|                                                                                             | >5                 | 92 (69.29)                  | 103 (75.7%6)                       | 195 (72.59)            |
|                                                                                             | N1                 | 133                         | 136                                | 269                    |
|                                                                                             | Mean               | 16.36                       | 18.02                              | 17.20                  |
|                                                                                             | Sid. Dev.          | 17.255                      | 19.685                             | 18.508                 |
|                                                                                             | Medinn             | 9.12                        | 13.55                              | 11.60                  |
|                                                                                             | Range(min,mx)      | (0.23,87.10)                | (0.20,173.00)                      | (0.20,173.00)          |
| Baeline PGA (NRS)                                                                           | NI                 | 133                         | 136                                | 269                    |
|                                                                                             | Mesn               | 6.9                         | 7.0                                | 6.9                    |
|                                                                                             | Sd.Dev.            | 1.76                        | 1.66                               | 1.71                   |
|                                                                                             | Median             | 7.0                         | 7.0                                | 7.0                    |
| Baseline Patient Assessment ofPain-Total N1                                                 | Ranze(min mx)      | (1,10)                      | (2,10)                             | (1,10)                 |
| Back Pain (NRS)                                                                             |                    | 6.9                         | 6.9                                | 6.9                    |
|                                                                                             | Mean               |                             |                                    |                        |
|                                                                                             | Std Dev.           | 1.52                        | 1.61                               | 1.57                   |
|                                                                                             | Median             | 7.0                         | 7.0                                | 7.0                    |
|                                                                                             | Rnge(min mx)       | (1,10)                      | (2.10)                             | (1.10)                 |
| Baseline Patient Assessment of Pain-                                                        | IN                 | 133                         | 136                                | 269                    |
| Nochural Spinal Pain (NRS)                                                                  | Mesn               | 6.8                         | 6.8                                | 6.8                    |
|                                                                                             | Std.Dev.           | 1.92                        | 1.86                               | 1.89                   |
|                                                                                             | Medin              | 7.0                         | 7.0                                | 7.0                    |

<div style=\"page-break-after: always\"></div>

|                                              |                                              | Tofacitinib5 BID (N-139)   | Placrbo-> Tofacitinib 5mg 18 (N-136)   | Total (N-269)   |
|----------------------------------------------|----------------------------------------------|----------------------------|----------------------------------------|-----------------|
| Parameter                                    | Sunmary Seatisties                           |                            |                                        |                 |
|                                              | Range(minmx)                                 | (0,10)                     | (1,10)                                 | (0,10)          |
| Baseline BASFI                               | IN                                           | 133                        | 136                                    | 269             |
|                                              | Mean                                         | 5.8                        | 5.9                                    | 5.9             |
|                                              | Sd.Dev.                                      | 231                        | 2.07                                   | 219             |
|                                              | Medinn                                       | 6.3                        | 6.2                                    | 6.2             |
|                                              | Range(min,mmx)                               | (0.0,10.0)                 | (0.3,9.6)                              | (0.0,10.0)      |
| Baseline BASDAI Score                        | N1                                           | 133                        | 136                                    | 269             |
|                                              | Mean                                         | 6.4                        | 6.5                                    | 6.5             |
|                                              | Sid.Dev.                                     | 1.48                       | 1.44                                   | 1.46            |
|                                              | Median                                       | 65                         | 6.7                                    | 6.5             |
|                                              | Range(min,mx)                                | (1.5,10.0)                 | (3,10.0)                               | (15,10.0)       |
| Bavelne Infammation                          | N1                                           | 133                        | 136                                    | 269             |
|                                              | Mean                                         | 6.6                        | 6.8                                    | 6.7             |
|                                              | Sd.Dev.                                      | 1.86                       | 1.91                                   | 1.88            |
|                                              | Medinn                                       | 6.5                        | 6.5                                    | 6.5             |
|                                              | Range(min mx)                                | (0.0,10.0)                 | (1.5,10.0)                             | (0.0,10.0)      |
| Baseline BASM-Linear Method                  | IN                                           | 133                        | 136                                    | 269             |
|                                              | Mean                                         | 45                         | 4.4                                    | 4.4             |
|                                              | Std.Dev.                                     | 1.73                       | 1.78                                   | 1.75            |
|                                              | Median                                       | 4.6                        | 45                                     | 4.6             |
|                                              | Ranee(minmx)                                 | (L.1.7.8)                  | (0.6,8.4)                              | (0.6.8.4)       |
| Baseline Spinal Mobility -Chest Expansion N1 | Baseline Spinal Mobility -Chest Expansion N1 | 133                        | 136                                    | 269             |
|                                              | Mean                                         | 3.0                        | 33                                     | 3.2             |
|                                              | Sid.Dev.                                     | 1.63                       | 1.55                                   | 1.59            |
|                                              | Medinn                                       | 25                         | 3.0                                    | 3.0             |
|                                              | Range(min,mx)                                | (0.1.9.0)                  | (0.0,7.3)                              | (0.0,9.0)       |
| Baseline ASDAS(CRP),n(%)                     | <13[active dee]                              | 0                          | 0                                      | 0               |
|                                              | >=1.3to<2.1[ow disease activityl             | 2 (1.5%6)                  | 0                                      | 2 (0.796)       |
|                                              | >=21 to<=3.5[high disease activityl          | 48 (36.1%)                 | 40 (29.4%)                             | 88 (32.796)     |
|                                              | activity]                                    | 83 (62.4%)                 | 96(70.6%6)                             | 179 (66.5%)     |
|                                              | IN                                           | 133                        | 136                                    | 697             |
|                                              | Mean                                         | 3.8                        | 39                                     | 3.9             |
|                                              | Sd.Dev.                                      | 0.82                       | 0.79                                   | 0.81            |
|                                              | Medinn                                       | 3.7                        | 3.9                                    | 3.9             |
|                                              | Ranpe(min,max)                               | (1.4,5.6)                  | (2.1,5.9)                              | (1.4,5.9)       |

<div style=\"page-break-after: always\"></div>

|                                                      |                    | Tofacitinib S mgBID (N=133)   | Placebo> Tofacitinib5mg BID (N=136)   | Total (N=269)   |
|------------------------------------------------------|--------------------|-------------------------------|---------------------------------------|-----------------|
| Parameter                                            | Sunmary Statisties |                               |                                       |                 |
| Baseline Presence ofEnthesitis Based on MASES,n([a]  | Yes                | 71 (53.4%)                    | 81 (59.6%)                            | 152 (56.5%)     |
|                                                      | No                 | 62(46.6%)                     | 55（40.4%)                             | 117 (43.59)     |
| Baseline MASES for Subjects with Baseline MASES>O    | IN                 | 71                            | 81                                    | 152             |
|                                                      | Mean               | 3.7                           | 3.6                                   | 3.7             |
|                                                      | Std.Dev.           | 2.49                          | 2.40                                  | 244             |
|                                                      | Median             | 3.0                           | 3.0                                   | 3.0             |
|                                                      | Range(min.max)     | (1,11)                        | (1,13)                                | (1,13)          |
| Baseline Presence ofSwollenJoints,                   | Yes                | 33 (24.8%)                    | 38 (27.9%)                            | 71 (26.4%)      |
| [qk(%)                                               | No                 | 100 (75.2%)                   | 98 (72.19)                            | 198(73.6%)      |
| BaselineSJC(44) forSubjectswith Baseline SJC(44)>0   | IN                 | 33                            | 38                                    | 71              |
|                                                      | Mean               | 3.4                           | 4.1                                   | 3.8             |
|                                                      | Std.Dev.           | 2.97                          | 5.22                                  | 4.31            |
|                                                      | Median             | 2.0                           | 2.0                                   | 2.0             |
|                                                      | Range(min,max)     | (1,11)                        | (1,24)                                | (1,24)          |
| BaselineSF-36v2PlysicalComponent Summary (PCS) Score | IN                 | 133                           | 135                                   | 268             |
|                                                      | Mean               | 33.5                          | 33.1                                  | 33.3            |
|                                                      | Std.Dev.           | 7.25                          | 6.98                                  | 7.11            |
|                                                      | Median             | 33.6                          | SEE                                   | 33.6            |
|                                                      | Range(minmax)      | (17.9,57.3)                   | (14.7,53.7)                           | (14.7,57.3)     |
| Baseline SF-36v2Mental Componenf Summary (MCS)Score  | IN                 | 133                           | 135                                   | 268             |
|                                                      | Mean               | 39.4                          |                                       | 39.6            |
|                                                      | Std.Dev.           | 11.09                         | 12.69                                 | 11.90           |
|                                                      | Median             | 38.1                          | 40.8                                  | 39.1            |
|                                                      | Range(min,max)     | (14.1,65.3)                   | (8.0,64.7)                            | (8.0,65.3)      |
| BaselineFACTT-F Total Score                          | IN                 | 133                           | 136                                   | 269             |
|                                                      | Mean               | 27.2                          | 27.4                                  | 27.3            |
|                                                      | Std.Dev.           | 10.71                         | 9.32                                  | 10.01           |
|                                                      | Median             | 27.0                          | 27.0                                  | 27.0            |
|                                                      | Range(min,max)     | (4,52)                        | (1,46)                                | (1.52)          |
| Baseline ASQoL Total Score                           | N1                 | 133                           | 136                                   | 269             |
|                                                      | Mean               | 11.6                          | 11.3                                  | 11.5            |
|                                                      | Std.Dev.           | 4.67                          | 4.20                                  | 4.43            |
|                                                      | Median             | 12.0                          | 12.0                                  | 12.0            |
|                                                      | Range(min.max)     | (0,18)                        | (0,18)                                | (0,18)          |

Tofacitinib5 mgBID (N=133)

Placebo-&gt;

BID

Tofacitinib5mg

(N=136)

Total

Paraneter

SunnaryStatistics

N:Number of subjects included in the Safety Analysis Set;N1: Number of subjects included in the analysis;n(%):

based onN).Percentagesforcurrent symptomofUveitis,PsoriasisIBD,PeripheralArthritiswere basedonnumberof subjectswithhistoryofUveitis,Psoriasis,IBD,Peripheral

Numberofsubjects in each analysis category(Percentageswere

Arthritis,respectively.ForhsCRPvalues&lt;2mg/L,itissetto2mg/Lin theformula to derive ASDAS(CRP).

Inflammationbaselinewastheaverageofquestions5and6ofBASDAI.

Baselinewasdefined aslastnon-missing assessment onorbefore day1 and prior tofirstdose of investigational product.

[alYeswasdefinedforthosesubjectswithbaselineMaastrichtAnkylosingSpondylitisEnthesitisScore(MASES)&gt;0.

[b]YeswasdefinedforthosesubjectswithbaselineSwollenJointCount(44)&gt;0.

ForHLAB27,ifbaselineresultswerenot availableresultsafterbaselinewerealsoincludedin the summary.

SafetyAnalysisSet(SAFETY)-Allsubjectswhowererandomizedandreceivedatleastonedoseoftheinvestigational

(N=269)

<div style=\"page-break-after: always\"></div>

## Prior Treatments

## NSAIDS

Most (99.6%) subjects received prior NSAIDs such as diclofenac, celecoxib and meloxicam and a minor rate  of  patients  received  corticosteroids  (16%),  the  most  of  which  were  oral  corticosteroids  (13%). However, it was noted that a higher number of subjects was treated with corticosteroids in tofacitinib 5 mg (19.5%) compared to placebo group (12.5%) both with oral and intrarticular administration, suggesting possible  more  severe  manifestations.  Moreover,  this  imbalance  was  mainly  observed  in  highly  treated patients (TNFi-IR and bDMARD use), in which a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids and this is expected likely due to a more difficult to treat disease. No important differences were reported in previous csDMARDs use that was similar between tofacitinib and placebo group (57.1% vs 59.6%). The majority of patients were bDMARDs naïve (77%) with a similar distribution between the two groups. A minor number of patients (31 subjects  in  each  arm,  23%)  were  bDMARDs  experienced  (bDMARDs  use  or  TNFi-IR),  2  subjects  were bDMARDs use non-IR.; 1 subject did not take NSAIDs due to prior medical history.

Table 38. Prior Drug Treatments by Medication Type (Corticosteroids, NSAIDs, DMARDs) and Treatment Group - Safety Analysis Set (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

| MedicationType   | Route/Subcategory   | Tofacitinib5mg BID (N=133) n (%)   | Placebo->Tofacitinib5 mgBID (N=136) n (%)   | Total (N=269) n (%)   |
|------------------|---------------------|------------------------------------|---------------------------------------------|-----------------------|
| Corticosteroids  | Overall             | 26 (19.5)                          | 17 (12.5)                                   | 43 (16.0)             |
|                  | Intra-articular     | 4 (3.0)                            | 0                                           | 4 (1.5)               |
|                  | Oral                | 19 (14.3)                          | 16 (11.8)                                   | 35 (13.0)             |
|                  | Topical             | 5 (3.8)                            | 2 (1.5)                                     | 7 (2.6)               |
|                  | Missing             | 0                                  | 2 (1.5)                                     | 2 (0.7)               |
| DMARD            | CS-DMARD            | 76 (57.1)                          | 81 (59.6)                                   | 157 (58.4)            |
|                  | B-DMARD             | 31 (23.3)                          | 31 (22.8)                                   | 62 (23.0)             |
|                  | TNFiB-DMARD         | 31 (23.3)                          | 31 (22.8)                                   | 62 (23.0)             |
| NSAID            | Overall             | 133 (100.0)                        | 135 (99.3)                                  | 268 (99.6)            |

Tofacitinib 5 mg

BID

(N=133)

n (%)

Medication Type

Route/Subcategory

WHO DDE v201903 coding dictionary applied.

Prior dnug treatment was defined as a drug taken on or before Day -1.

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose of the investigational product.

PFIZER CONFIDENTIAL SDTM Creation: 31JAN2020 (23:27) Source Data: adcm Output File:

./umblind\\_1120/A3921120/adcm\\_s002\\_b\\_i Date of Generation: 17APR2020 (10:14)

Table 14.1.4.4.4.1 is for Pfizer internal use.

Placebo-&gt;Tofacitinib 5

mg BID

(N=136)

n (%)

Total

(N=269)

n (%)

<div style=\"page-break-after: always\"></div>

Table 39. Prior Treatment History of Stratification Factor (bDMARD-naive, TNFi-IR or bDMARD Use (NonIR)) by Treatment Group - Safety Analysis Set (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

| Stratum                                   | Number of Inadequate Responses   | BID (N=133) (%) uI   | Tofacitinib 5 mg Placebo->Tofacitinib 5 mg BID (N=136) n (%)   | Total (N=269) n (%)   |
|-------------------------------------------|----------------------------------|----------------------|----------------------------------------------------------------|-----------------------|
| bDMARD-naive                              |                                  | 102 (76.7)           | 105 (77.2)                                                     | 207 (77.0)            |
| TNFi-IR or bDMARD Use (Non-IR)            |                                  | 31 (23.3)            | 31 (22.8)                                                      | 62 (23.0)             |
| TNFi-IR                                   | 1 TNFi-IR                        | 23 (79.3)            | 20 (66.7)                                                      | 43 (72.9)             |
|                                           | 2 TNFi-IR                        | 6 (20.7)             | 10 (33.3)                                                      | 16 (27.1)             |
| bDMARD Use (Non-IR) 1 bDMARD Use (Non-IR) |                                  | 2 (100.0)            | 1 (100.0)                                                      | 3 (100.0)             |

WHO DDE v201903 coding dictionary applied.

Prior drug treatment was defined as a drug taken on or before Day -1.

Each subject was counted with the number of unique bDMARD-naive, TNFi-IR, or bDMARD Use (Non-IR).

ie. if there was more than one record per drug for a subject, count as one medication.

The strata ofbDMARD-naive, TNFi-IR, and bDMARD Use (Non-IR) were derived from clinical database.

Numbers of inadequate responses were summarized as number (%) of subjects in each category.

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose of the investigational product.

PFIZER CONFIDENTIAL SDTM Creation: 31JAN2020 (22:27) Source Data: adcm Output File:

/unblind\\_1120/A3921120/adcm\\_s005\\_i Date of Generation: 25FEB2020 (08:47)

Table 14.1.4.4.4.2 is for Pfizer internal use.

## Corticosteroid

- Prior corticosteroid use for the bDMARD naïve strata was similar, 12.7% in the tofacitinib 5 mg BID group compared with 13.3% in the placebo group. In the TNFi-IR and bDMARD

(non-IR) strata, a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids.

## DMARDs

A similar proportion of subjects received prior DMARDs in both treatment groups. The most frequently received prior csDMARD (approximately 50% in each treatment group) was sulfasalazine (Table 40).

Table 40 shows the most frequently received prior csDMARD (approximately 50% in each treatment group) was sulfasalazine.

<!-- image -->

|             |                                                  | Tofacitinib5mgBID (N=133)   | Placebo- Tofacitinib5mgBM (N=136)   | Total (N=269)   |
|-------------|--------------------------------------------------|-----------------------------|-------------------------------------|-----------------|
| Subcategory | Preferred Term                                   | n (%)                       | (%)                                 | n (9)           |
| CS-DMARD    | Number (%6) of Subjects with Any PriorMedication | 76 ( 57.1)                  | 81 ( 59.6)                          | 157 ( 58.4)     |
|             | LEFLUNOMDE                                       | 3（2.3)                      | 4 (2.9)                             | 7 (2.6)         |
|             | METHOTREXATE                                     | 22 ( 16.5)                  | 20 ( 14.7)                          | 42 ( 15.6)      |
|             | METHOTREXATESODIUM                               | 2 (1.5)                     | 1 (0.7)                             | 3 ( 1.1)        |
|             | SULFASALAZINE                                    | 66 ( 49.6)                  | 69 ( 50.7)                          | 135 ( 50.2)     |

<div style=\"page-break-after: always\"></div>

## bDMARDs

The percentage of bDMARD naïve or TNFi-IR or bDMARD use (non-IR) subjects were similar between treatment groups. The most frequently received prior bDMARDs (approximately 10% in each treatment group) were etanercept and adalimumab ( Table 41 ).

## Table 41.

<!-- image -->

- All  subjects  had  received  bDMARDs  included  in  the  category  of  TNFi.  There  were  43  (72.9%) subjects with 1 prior TNFi-IR and 16 (27.1%) subjects 2 prior TNFi-IR
- The most frequently received prior bDMARDs (approximately 10% in each treatment group) were etanercept  and  adalimumab.  The  most  common  reason  for  discontinuation  in  the  majority  of bDMARDs was lack of efficacy.
- There were 2 subjects in the tofacitinib 5 mg BID treatment group and 1 subject in the placebo group  with  prior  use  of  1  bDMARD  (non-IR).  These  subjects  had  bDMARD  use  with  the discontinuation reason of other, not due to either AE or lack of efficacy.

## Concomitant Rescue Medications

- -The most common rescue medication in either treatment group Day 1 up to Week 16 and Day 1 up to Week 48 was paracetamol (2.2% and 2.6% of subjects, respectively)
- -The most  common  NSAIDs  used  throughout  the  study were celecoxib and meloxicam, approximately 16% and 18% of all subjects, respectively
- -The most common concomitant corticosteroids taken at baseline (Day 1 only) and Day 1 up to Week 16 were methylprednisolone (3.7% of subjects for both) and prednisone (1.5% and 1.9% of subjects, respectively)
- -The most common concomitant corticosteroids taken Day 1 up to Week 48 were dexamethasone (2.2% of subjects), methylprednisolone (4.1% of subjects), and prednisone (1.9% of subjects)
- -The  most  common  concomitant  csDMARD  in  both  treatment  groups  (approximately  20%  of subjects) throughout the study was sulfasalazine

Concomitant rescue medications, NSAIDs, oral corticosteroids, intra-articular corticosteroids, and csDMARDs were taken by a similar proportion of subjects between treatment groups at baseline up to Week 48. A higher percentage of subjects with any csDMARDs was observed in placebo group than in tofacitinib group (33% vs 22%) probably reflecting a higher number of patients with a history of peripheral arthritis

<div style=\"page-break-after: always\"></div>

(18.4% vs 15.8%). (see related OC) The most common rescue medication in either treatment group Day 1 up to Week 16 and Day 1 up to Week 48 was paracetamol (2.2% and 2.6% of subjects, respectively).

Table 42. Concomitant Medications (Rescue, NSAIDs, Oral Corticosteroids, Intra-Articular Corticosteroids, csDMARD, and Pain Management/Analgesics) by Treatment Group - Safety Analysis Set (Week 16 Analysis) Date Cutoff 19 Dec 2019) Data snapshot 29 Jan 2020.

|                                                    | UptoWeek16                         | UptoWeek16   | UptoWeek16    | Up toWeek4S                | Up toWeek4S                          | Up toWeek4S   |
|----------------------------------------------------|------------------------------------|--------------|---------------|----------------------------|--------------------------------------|---------------|
| Medication Type                                    | Tofacitinib5 Placebo mgBID (N=133) | (N=130)      | Total (N=269) | Tofacitinib5 mgBID (N=133) | Placebo-> Tofacitinib5 mgBID (N=136) | Total (N=269) |
|                                                    | n(%)                               | n(%)         | n(9)          | n(%)                       | n(%)                                 | n(%)          |
| Number (%6)of Subjects with Any Rescue Concomitant | 3(2.3)                             | 5(3.7)       | 8(3.0)        | 5 (3.8)                    | 5 (3.7)                              | 10 (3.7)      |
| Number(oo)ofSubiectswith Any Concomitant NSAID     | 105 (78.9)                         | 109 (80.1)   | 214 (79.6)    | 107 (80.5)                 | 109 (80.1)                           | 216(80.3)     |

|                                                                 | UptoWeek16                          | UptoWeek16   | UptoWeek16    | UptoWeek48                 | UptoWeek48                           | UptoWeek48    |
|-----------------------------------------------------------------|-------------------------------------|--------------|---------------|----------------------------|--------------------------------------|---------------|
| Medication Type                                                 | Tofacitinib S Placebo mgBID (N=133) | (N=136)      | Total (N=269) | Tofacitinib5 mgBID (N=133) | Placebo- Tofacitinib 5 mgBID (N=136) | Total (N=269) |
|                                                                 | n(9)                                | n(%)         | n(%)          | n(90)                      | n(%)                                 | (%）           |
| Number (%)of Subjects with Any Oral Corticosteroid              | 13 (9.8)                            | 10(7.4)      | 23 (8.6)      | 13 (9.8)                   | 10(7.4)                              | 23 (8.6)      |
| Number (%6) of Subjects with Any Intra-Articular Corticosteroid | 1(0.8)                              | 0            | 1(0.4)        | 2(1.5)                     | 0                                    | 2(0.7)        |
| Number (9o)of Subjects with Any csDMARD                         | 29 (21.8)                           | 45 (33.1)    | 74 (27.5)     | 29 (21.8)                  | 45 (33.1)                            | 74 (27.5)     |
| Number(%)of Subjects with Any Pan Management/Analgesics         | 16(12.0)                            | 19 (14.0)    | 35 (13.0)     | 22 (16.5)                  | 20 (14.7)                            | 42 (15.6)     |

WHODDEv201903codingdichonaryapplied

Subjectswere only counted onceper treatment foreachrow.

Safety Analysis Set(SAFETY)-All subjects who wererandomized and received at least one dose of the investigatiomal product.

PFIZER CONFIDENTIAL SDTMCreation:31JAN2020(22:27) SouceDataradcm OutputFile:

/unblind 1120/A3921120/adcm s001\\_biDateofGeneration:19FEB2020(12:55)

Table 14.4.2.7.1l is forPfizer intemaluse.

## Numbers analysed

Full Analysis Set: subjects 133 in the Tofa and 136 in the PLB arm.

Per Protocol Analysis Set: which excluded 3 subjects in the tofacitinib 5 mg BID group and 2 subjects in the placebo group from the FAS.

## Outcomes and estimation

## Primary Endpoint Result - ASAS20 Response Rate at Week 16

<div style=\"page-break-after: always\"></div>

The study met the primary endpoint, tofacitinib 5 mg BID demonstrated superiority over placebo in ASAS20 response at Week 16 (p &lt;0.0001) (as shown in Table 43 ). ASAS20 response was a global Type I errorcontrolled endpoint.

|         |                            |          |                        |      | Treatment Comparison[a]   | Treatment Comparison[a]   | Treatment Comparison[a]   |
|---------|----------------------------|----------|------------------------|------|---------------------------|---------------------------|---------------------------|
| Visit   | Treatment                  |          | NN1n Response Rate (%) | SE   | Diff SE                   | 95%CI (Lower,Upper)       | p-Value                   |
| Week 16 | Tofacitinib5mg13312975 BID |          | 56.39                  | 4.30 | 27.085.71                 | (15.89,38.28)             | <.0001                    |
|         | Placebo                    | 13613140 | 29.41                  | 3.91 |                           |                           |                           |

Table 43. ASAS20 Response Rate at week 16, Treatment Comparison -Estimand 1, FAS, On-Drug Date, MR=NR- Primary Anslysis (Week 16 Analysis)

<!-- image -->

The results from pre-specified supportive analyses for ASAS20 response at Week 16 i.e. tipping analysis for different scenarios of missing responses in both arms were consistent with the primary analysis.

A summary of subjects was produced based on on-drug data for those who completed the Week 16 visit by their ASAS20 response status at Week 16 and those who discontinued from the investigational product prior to the Week 16 visit by their reason of discontinuation (estimand 1) are provided below ( Table 44 ). The summary for the on-study data (Estimand 2 as shown in Table 44 ) was consistent with the on-drug data.

Table 44. ASAS20 Response Rate at week 16, Treatment Comparison -Estimand 2,

| Status -n (%)                                                                            | Tofacitinib5mgBID (N=133) n (%)   | Placebo (N=136) n (%)   |
|------------------------------------------------------------------------------------------|-----------------------------------|-------------------------|
| ASAS20Responders                                                                         | 75 (56.39)                        | 40 (29.41)              |
| ASAS20Non-Responders                                                                     | 58 (43.61)                        | 96 (70.59)              |
| ASAS20Non-RespondersWhoCompletedtheWeek16Visitwith                                       | 54 (40.60)                        | 91 (66.91)              |
| ObservedOn-DrugData ASAS20Non-RespondersWhoCompleted theWeek16Visit withMissing          | 0                                 | 0                       |
| On-DrugData ASAS20Non-RespondersWhoDiscontinuedInvestigationalProductPrior toWeek16Visit | 4 (3.01)                          | 5(3.68)                 |
| ReasonsforDiscontinuationofInvestigationalProduct AdverseEvent                           | 3 (2.26)                          | 1(0.74)                 |
| Lack ofEfficacy                                                                          | 1(0.75)                           | 1 (0.74)                |
| Lost to Follow-Up                                                                        | 0                                 | 1 (0.74)                |
| PhysicianDecision                                                                        | 0                                 | 1(0.74)                 |
| WithdrawalbySubject                                                                      | 0                                 | 1(0.74)                 |

N:Number of subjectsin FAS.n (%):Number of subjects in each analysis category (Percentages were based on N). MR=NR:Missing response as non-response.

FullAnalysisSet(FAs)-All subjectswhowererandomizedtothestudyandreceived atleastonedoseof therandomized investigationalproduct.

ASAS20responsewasdefinedas&gt;=20%and&gt;=1unitimprovement in atleast3domainsonascaleof0-10andno worsening of&gt;=20% and&gt;=1 unit in the remaining domain.

PFIZERCONFIDENTIALSDTMCreation:31JAN2020(23:20)SourceData:adasOutputFile:

/unblind1120/A3921120/adass001DateofGeneration:16APR2020(22:48)

Table14.2.1.1.1 is forPfizer intermal use.

<div style=\"page-break-after: always\"></div>

## Subgroup Analysis for the Primary Endpoint

Subgroup comparisons for ASAS20 response at Week 16 were made on the FAS with missing values handled by MR=NR using the on-drug data corresponding to Estimand 1. Subgroup comparisons were not Type I error-controlled.

The efficacy of tofacitinib 5 mg BID versus placebo for ASAS20 responses at Week 16 was consistent across different subgroups examined with the exception of some which were smaller in size (Figure 21) .

- For the subgroup of prior treatment history (bDMARD naïve and TNFi-IR or bDMARD use [Non-IR]), ASAS20 response rate of tofacitinib 5 mg BID was greater than that of placebo at Week 16 in both categories ( Figure 21 .
- The efficacy of tofacitinib 5 mg BID versus placebo for ASAS20 responses at Week 16 was consistent for the subgroup of baseline AS disease activity defined by the categorization of baseline ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L.

Figure 21. Forest Plot of Subgroup Analysis of ASAS20 Response Rate at Week 16 (Estimand 1, FAS, OnDrug Data, MR=NR)

<!-- image -->

Full Analysis Set （PAs）-All subjeoto vho were randomiaed to the study and reoeived at least one dope of the randomized investigational produot.

[a] Nomal appronimation adjusting for the atratification factor (prior treatment history:bovaRD-naive vs DTi-IR or htmARD Use [Non-IRj）) derived from elinical database via Co approach gre dnoxbqsgoLobogeo yeesogpensekworaoddegemo[q]tqegrednosbqmsgoaobogeqpesogpesse

AsAs20repone was definedas&gt;=20tand&gt;alunit inprovement inatLeastJ domains onascaleof0-10 andno worseningof&gt;a20andoluit in thereainingdoain.

Ata subgroup eategory.hen one of the tvo treatment groups in comparison had 0subject,no formal conparison as made.Hhen reaponse rate of Otor 1oot was observed sn both treatnent groups in ooparison and in both strata,no fomal onparipon was performed,These inoluded“Otherfor Raoe,= 65 years′for Age at Baoeline,&gt;o0 leg/n2'andtiaoingfor

Baseline EMt,Inaetive Disease'andLov Disease Aetivstyfor Baseline AsDisease Aetivity.

PF12C0F1DENTALSDTCeation:31JA2020（23:20）SouroeData:aOuttFle:/1in\\_120/A3921120/ada\\_002DateoGenratom:01AFR2020(08:38）

<div style=\"page-break-after: always\"></div>

Table 45. Protocol A3921120 CMH Normal Approximation to ASAS20 Response Rate at Week 16 by Subgroup, Treatment Comparison - Estimand 1, FAS, On-Drug Data, MR=NR- Subgroup Analysis (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

<!-- image -->

|                                               |                             |     |     |    |                   |       | Treatment Comparison [a]   | Treatment Comparison [a]   | Treatment Comparison [a]   | Treatment Comparison [a]   |
|-----------------------------------------------|-----------------------------|-----|-----|----|-------------------|-------|----------------------------|----------------------------|----------------------------|----------------------------|
| Subgroup Category                             | Visit Treatment             | N   | N1  |    | Response Rate (%) | SE    | Diff                       | SE                         | 10 %56 (Lower, Upper)      |                            |
| High disease activity (2.1<=ASDAS (CRP)<=3.5) | Week16Tofacitinib5mgBID     | 48  | 45  | 23 | 47.92             | 7.21  | 12.61                      | 9.97                       | (-6.94,32.16)              |                            |
|                                               | Placebo                     | 41  | 41  | 15 | 36.59             | 7.52  |                            |                            |                            |                            |
| Very high disease activity (ASDAS (CRP)>3.5)  | Week 16Tofacitinib5mgBID    | 82  | 81  | 51 | 62.20             | 5.35  | 35.43                      |                            | 6.91( 21.88,48.98)         |                            |
|                                               | Placebo                     | 94  | 89  | 25 | 26.60             | 4.56  |                            |                            |                            |                            |
| Baseline hsCRP <=2.87 mg/L                    | Week 16Tofacitinib5 mg BID  | 23  | 22  | 11 | 47.83             | 10.42 | 17.02                      | 14.04                      | (-10.49,44.54)             |                            |
|                                               | Placebo                     | 20  | 20  | 6  | 30.00             | 10.25 |                            |                            |                            |                            |
| >2.87 mg/L                                    | Week 16Tofacitinib 5 mg BID | 110 | 107 | 64 | 58.18             | 4.70  | 28.95                      | 6.17                       | (16.86,41.05)              |                            |
|                                               | Placebo                     | 116 | 111 | 34 | 29.31             | 4.23  |                            |                            |                            |                            |

## Key Secondary Endpoint Result - ASAS40 Response Rate at Week 16

The study met the key secondary endpoint, tofacitinib 5 mg BID demonstrated superiority over placebo in ASAS40 response at Week 16 (p &lt;0.0001) ( Table  46 ).  ASAS40  response was  a  global  Type  I  errorcontrolled endpoint.

|         |                            |          |                         |      | TreatmentComparison[a]   | TreatmentComparison[a]   | TreatmentComparison[a]   |
|---------|----------------------------|----------|-------------------------|------|--------------------------|--------------------------|--------------------------|
| Visit   | Treatment                  |          | NN1 n Response Rate (%) | Diff | SE                       | 95% CI (Lower, Upper)    | p-Value                  |
| Week 16 | Tofacitinib5mg13312954 BID |          | 40.60                   |      | 28.175.06                | (18.26, 38.09)           | <.0001                   |
|         | Placebo                    | 13613117 | 12.50                   |      |                          |                          |                          |

Table 46. ASAS40 Response Rate at Week 16

<!-- image -->

Results from all the pre-specified supportive analyses for ASAS40 response at Week 16 ( Table 47 ) were consistent with the key secondary analysis.

A summary of subjects was produced based on on-drug data for those who completed the Week 16 visit by their ASAS40 response status at Week 16 and those who discontinued from the investigational product

<div style=\"page-break-after: always\"></div>

prior to the Week 16 visit by their reason of discontinuation ( Table 47 ). The summary for the on-study data (Estimand 2) was consistent with the on-drug data.

Table 47. ASAS40 Response at Week 16 and Reasons for Study Drug Discontinuation prior to Week 16 Estimand 1

| Status - n (%)                                                                           | Tofacitinib5mgBID (N=133) n (%)   | Placebo (N=136) n (%)   |
|------------------------------------------------------------------------------------------|-----------------------------------|-------------------------|
| ASAS40Responders                                                                         | 54 (40.60)                        | 17 (12.50)              |
| ASAS40Non-Responders                                                                     | 79 (59.40)                        | 119 (87.50)             |
| ASAS40Non-RespondersWhoCompletedtheWeek16Visitwith                                       | 75 (56.39)                        | 114 (83.82)             |
| Observed On-DrugData ASAS40Non-RespondersWhoCompleted theWeek16VisitwithMissing          | 0                                 | 0                       |
| On-DrugData ASAS40Non-RespondersWhoDiscontinuedInvestigationalProductPrior toWeek16Visit | 4 (3.01)                          | 5 (3.68)                |
| ReasonsforDiscontinuationofInvestigationalProduct                                        |                                   |                         |
| AdverseEvent                                                                             | 3 (2.26)                          | 1 (0.74)                |
| Lack of Efficacy                                                                         | 1 (0.75)                          | 1 (0.74)                |
| Lost toFollow-Up                                                                         | 0                                 | 1 (0.74)                |
| Physician Decision                                                                       | 0                                 | 1 (0.74)                |
| WithdrawalbySubject                                                                      | 0                                 | 1 (0.74)                |

N: Number of subjects in FAS. n (%): Number of subjects in each analysis category (Percentages were based on N). MR=NR:Missingresponse as non-response.

ASAS40responsewasdefinedas&gt;=40%and&gt;=2unitsimprovementin atleast3domainsonascaleof0-10andno worsening at all in theremaining domain.

FullAnalysisSet(FAS)-Allsubjectswhowererandomizedtothestudyandreceived atleastonedoseoftherandomized investigationalproduct.

PFIZERCONFIDENTIALSDTMCreation:31JAN2020(23:20)SourceData:adasOutputFile:

/unblind1120/A3921120/adass0013DateofGeneration:16APR2020(22:57)

Table14.2.2.1.1 isforPfizerinternaluse.

## Subgroup Analyses for the Key Secondary Endpoint

Subgroup comparisons for ASAS40 response at Week 16 were made on the FAS with missing values handled by MR=NR using the on-drug data corresponding to Estimand 1 ( Figure 22 ). Subgroup comparisons were not Type Ierror-controlled.

- The efficacy of tofacitinib 5 mg BID versus placebo for ASAS40 responses at Week 16 was consistent across different subgroups examined except for baseline weight in the category of &gt;100 kg, likely due  to  small  sample  size.  The  ASAS40  response  rates  for  tofacitinib  5  mg  BID  were  greater compared to placebo for the subgroups except for baseline weight in the category of &gt;100 kg.
- For the subgroup of prior treatment history (bDMARD naïve and TNFi-IR or bDMARD use [Non-IR]), ASAS40 response rate of tofacitinib 5 mg BID was greater than that of placebo at Week 16 in both categories.
- The efficacy of tofacitinib 5 mg BID versus placebo for ASAS40 responses at Week 16 was consistent for  the  subgroup  of  baseline  AS  disease  activity  defined  by  the  categorization  of  baseline ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L

<div style=\"page-break-after: always\"></div>

Figure 22 . Forest Plot of Subgroup Analysis of ASAS40 Response Rate at Week 16 (Estimand 1, FAS, OnDrug Data, MR=NR)

<!-- image -->

FullAnalyaie Set（FAs)-Allsabjocte who were randomised to the atudy and receivedatleant ome dose ottbe Tandominedinvestigational prodoct. [a]Nornal approxcimation adjusting for the stratificatiom factor （prlor treatnent hiatory: bcMAr-naive va mFi-IR or bcoRD Use [Non-Is]) derived from elinical database vla CMH approach vas uoed for each category of a subgroup variable.[b] Normal approximation wan used for each category ofa subgroup variable. AsAs40 reaponsewas definedas&gt;=40%and&gt;=2umitssaprovement snatleast3 donainsonascaleot0-ioand noworsening atall1n the remaiming domain. At4 subgroup category,when ose of the tuo treatment groups in couparioon hadosbject,no formal conparison was mede.hen reoponse rate ot ox or 1oox as observed in both troatment groups in comparison and in both strata,no formal couparison was pertorned.These includedOther'for Race,&gt;=65yearsfor Age at Baseline.&gt;=4o kg/a**2andMissingfor Baneline Bxt.Tnactive Dinoase'andLow Disease Activity' for Baseline As Dinease Activity.

Despite the limited sample size, the MAH was requested to include results according to bDMARDs naïve orTNF-IR subjects/bDMARD use subgroups in section 5.1 of the SmPC, in order to guide prescribers. The issue resolved and section 5.1 of the SmPC were updated accordingly.

## Secondary Endpoints Results

Table 48 presents the results of primary endpoints and selected secondary endpoints of the study. Primary and key secondary endpoints are reported above in the AR.

Secondary efficacy endpoints supported the primary findings:

- Tofacitinib 5 mg BID demonstrated superiority to placebo in signs and symptoms as well as health-related outcomes, based on the mean changes from baseline in ASDAS(CRP), hsCRP, ASQoL, SF36v2 PCS, BASMI Score (Linear Method), and FACIT-F Total Score at Week 16.
- Tofacitinib 5 mg BID demonstrated superiority to placebo in mean change from baseline in each of the 4 ASAS components: PGA, Total Back Pain, BASFI (physical function), and Inflammation at Week 16 (all p&lt;0.0001; Table 48 ).
- Tofacitinib 5 mg BID also demonstrated superiority to placebo at all timepoints through Week16 for ASAS20 response rates (Figure 5). In addition, tofacitinib 5 mg BID demonstrated superiority to placebo at all timepoints through Week 16 except Week 2 for ASAS40 response rates ( Figure 21 ).

<div style=\"page-break-after: always\"></div>

- For most of the secondary efficacy endpoints not controlled for Type I error , including SF36v2 Physical Functioning, Role-Physical, Bodily Pain, General Health, and Social Functioning domains, the tofacitinib 5 mg BID group showed greater numerical increases over placebo at Week 16 ( Table 48 ).
- Tofacitinib 5 mg BID demonstrated sustained efficacy in ASAS20 and ASAS40 response rates (Figure 5, Figure 6, and Table 7) and other secondary endpoints (ASDAS(CRP), hsCRP, ASQoL, SF-36v2 [PCS, Physical Functioning, Role-Physical, Bodily Pain, General Health, and Social Functioning domains], BASMI Score (Linear Method), FACIT-F Total Score, PGA, total back pain, BASFI, and inflammation) over time up to Week 48 (Table 7).

Table 48. Selected Efficacy Endpoints at Week 16 and Week 48 (FAS, On-Drug Data) - Study A3921120

|                                                                                                                                      | Week 16                                                                                                                              | Week 16                                                                                                                              | Week 16                                                                                                                              | Week 48                                                                                                                                   | Week 48                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                      | Tofacitinib 5 mgBID (N =133)                                                                                                         | Placebo (N =136)                                                                                                                     | Difference From Placebo                                                                                                              | Tofacitinib 5 mgBID (N = 133)                                                                                                             | Placebo->Tofacitinib 5 mgBID (N =136)                                                                                                |
| Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                          | Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                          | Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                          | Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                          | Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                               | Primary eficacy endpoint(subjecttohierarchicaltestingprocedureforglobal TypeIerror-control)                                          |
| ASAS20 response, n (%) [N1] or [95% C1]                                                                                              | 75 (56.39) [129]                                                                                                                     | 40 (29.41) [131]                                                                                                                     | 27.08*** [15.89, 38.28]                                                                                                              | 87 (65.41) [112]                                                                                                                          | 82 (60.29) [112]                                                                                                                     |
| Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                               | Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                               | Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                               | Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                               | Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                                    | Keysecondary eficacy endpoint (subject tohierarchical testingprocedure for global Type Ierror-control)                               |
| ASAS40 response, n (%) [N1] or [95% C1] a                                                                                            | 54 (40.60) [129]                                                                                                                     | 17 (12.50) [131]                                                                                                                     | 28.17*** [18.26, 38.09]                                                                                                              | 67 (50.38) [112]                                                                                                                          | 61 (44.85) [112]                                                                                                                     |
| △ASDAS(CRP), LSM (SE)                                                                                                                | -1.36 (0.073)                                                                                                                        |                                                                                                                                      | -0.98***                                                                                                                             | -1.70 (0.087) [100]                                                                                                                       | -1.50 (0.086) [103]                                                                                                                  |
| Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                     | Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                     | Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                     | Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                     | Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                          | Secondary efficacy endpoints(subject tohierarchicaltestingprocedureforglobal TypeIerror-control)                                     |
| [N1] or [95% C1] b                                                                                                                   | [129] -1.05 (0.096) [129] -4.03 (0.404) [129]                                                                                        | -0.39 (0.073) [131] -0.09 (0.096) [131] -2.01 (0.405) [130] 3.14 (0.590) [130] -0.11 (0.060) [131] 3.12 (0.794) [131]                | [-1.16, -0.79] -0.96*** [-1.20, -0.72] -2.02** [-3.03, -1.01] 3.55*** [2.09, 5.02]                                                   | -1.17 (0.081) [100] -5.97 (0.454) [112] 8.81 (0.720) [112] -0.69 (0.074) [100] 9.54 (0.897) [112] -3.47 (0.225) [112] -3.57 (0.220) [113] | -1.11 (0.080) [103]                                                                                                                  |
| △hsCRP (mg/dL), LSM (SE)                                                                                                             |                                                                                                                                      |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           |                                                                                                                                      |
| [N1] or [95% C1] b                                                                                                                   |                                                                                                                                      |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           |                                                                                                                                      |
| △ASQoL, LSM (SE)                                                                                                                     |                                                                                                                                      |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           | -4.70 (0.451) [112]                                                                                                                  |
| [N1] or [95% CI]“                                                                                                                    |                                                                                                                                      |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           |                                                                                                                                      |
| △SF-36v2 PCS, LSM (SE) [N1] or[95%CI]                                                                                                | 6.69 (0.588) [129]                                                                                                                   |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           | 7.39 (0.714) [111]                                                                                                                   |
| △BASMI Score (Linear Method), LSM (SE)                                                                                               | -0.63 (0.060)                                                                                                                        |                                                                                                                                      | -0.52***                                                                                                                             |                                                                                                                                           | -0.54 (0.073)                                                                                                                        |
| [N1] or [95% CI] b                                                                                                                   | [129]                                                                                                                                |                                                                                                                                      | [-0.67, -0.37]                                                                                                                       |                                                                                                                                           | [103]                                                                                                                                |
| △FACIT-F Totalscore,LSM (SE)                                                                                                         | 6.54 (0.795)                                                                                                                         |                                                                                                                                      |                                                                                                                                      |                                                                                                                                           | 7.35 (0.891)                                                                                                                         |
|                                                                                                                                      |                                                                                                                                      |                                                                                                                                      | 3.43**                                                                                                                               |                                                                                                                                           |                                                                                                                                      |
| [N1] or [95% C1] b                                                                                                                   | [129]                                                                                                                                |                                                                                                                                      | [1.44, 5.42]                                                                                                                         |                                                                                                                                           | [111]                                                                                                                                |
| Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses) | Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses) | Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses) | Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses) | Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses)      | Secondary effcacy endpoints (subject to hierarchical testing procedure for Type I error-control within the family of ASAS responses) |
| PGA, LSM (SE)                                                                                                                        | -2.47 (0.204)                                                                                                                        | -0.91 (0.204)                                                                                                                        | -1.56***                                                                                                                             |                                                                                                                                           | -2.94 (0.223)                                                                                                                        |
| [N1] or [95% C1] b                                                                                                                   | [129]                                                                                                                                | [131]                                                                                                                                | [-2.07, -1.05]                                                                                                                       |                                                                                                                                           | [112]                                                                                                                                |
| △Total back Pain, LSM (SE)                                                                                                           | -2.57 (0.191)                                                                                                                        | -0.96 (0.191)                                                                                                                        | -1.62***                                                                                                                             |                                                                                                                                           | -2.87 (0.218)                                                                                                                        |
| [N1] or[95% C1]                                                                                                                      | [129]                                                                                                                                | [131]                                                                                                                                | [-2.10, -1.14]                                                                                                                       |                                                                                                                                           | [112]                                                                                                                                |
| △BASFI, LSM (SE)                                                                                                                     | -2.05 (0.170)                                                                                                                        | -0.82 (0.169)                                                                                                                        | -1.23***                                                                                                                             | -2.61 (0.196)                                                                                                                             | -2.32 (0.195)                                                                                                                        |
| [N1] or [95% C1]                                                                                                                     | [129]                                                                                                                                | [131]                                                                                                                                | [-1.66, -0.80]                                                                                                                       | [113]                                                                                                                                     | [113]                                                                                                                                |
| Inflammation, LSM (SE)                                                                                                               | -2.69 (0.185)                                                                                                                        | -0.97 (0.185)                                                                                                                        | -1.72***                                                                                                                             | -3.46 (0.214)                                                                                                                             | -2.90 (0.213)                                                                                                                        |
| [N1] or [95% C1] b                                                                                                                   | [129]                                                                                                                                | [131]                                                                                                                                | [-2.18, -1.25]                                                                                                                       | [113]                                                                                                                                     | [113]                                                                                                                                |

|                                                                                                                                                  | Week 16                                                                                                                                          | Week 16                                                                                                                                          | Week 16                                                                                                                                          | Week48                                                                                                                                           | Week48                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                  | Tofacitinib 5 mgBID (N =133)                                                                                                                     | Placebo (N =136)                                                                                                                                 | Difference From Placebo                                                                                                                          | Tofacitinib 5 mgBID (N =133)                                                                                                                     | Placebo->Tofacitinib 5 mgBID (N =136)                                                                                                            |
| ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate TimePoints (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) |
| Week 12, n (%) [N1] or[95% C】]                                                                                                                   | 85 (63.91) [132]                                                                                                                                 | 40 (29.41) [132]                                                                                                                                 | 34.61*** [23.63, 45.58]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| Week 8, n (%) [N1] or [95% C】]                                                                                                                   | 76 (57.14) [132]                                                                                                                                 | 34 (25.00) [133]                                                                                                                                 | 32.24*** [21.32, 43.17]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| Week 4, n (%) [N1] or [95% CI]                                                                                                                   | 68 (51.13) [132]                                                                                                                                 | 27 (19.85) [132]                                                                                                                                 | 31.35*** [20.64, 42.06]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| Week 2, n (%) [N1] or [95% C1]                                                                                                                   | 38 (28.57) [132]                                                                                                                                 | 14 (10.29) [133]                                                                                                                                 | 18.28** [9.06, 27.50]                                                                                                                            | NA                                                                                                                                               | NA                                                                                                                                               |
| ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              | ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              | ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              | ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              | ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              | ASAS40ResponseRatesTimePoints (subjecttohierarchicaltestingprocedurefor TypeIerror-control within theASAS40responserate timecourse)              |
| Week 12, n (%) [N1] or [95% CI]                                                                                                                  | 57 (42.86) [132]                                                                                                                                 | 16 (11.76) [132]                                                                                                                                 | 31.18*** [21.34, 41.02]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| Week 8, n (%)                                                                                                                                    | 46 (34.59) [132]                                                                                                                                 | 8 (5.88) [133]                                                                                                                                   | 28.56*** [19.66, 37.47]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| [N1] or[95% CI] Week 4, n (%) [N1] or [95% C]a                                                                                                   | 36 (27.07) [132]                                                                                                                                 | 5 (3.68) [132]                                                                                                                                   | 23.43*** [15.30, 31.56]                                                                                                                          | NA                                                                                                                                               | NA                                                                                                                                               |
| Week 2, n (%)                                                                                                                                    | 14 (10.53)                                                                                                                                       | 6 (4.41)                                                                                                                                         | 6.12                                                                                                                                             | NA                                                                                                                                               |                                                                                                                                                  |
| [N1] or [95% C1]                                                                                                                                 | [132]                                                                                                                                            | [133]                                                                                                                                            | [-0.13, 12.37]                                                                                                                                   |                                                                                                                                                  | NA                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                              | Week 16                                                                                                  | Week 16                                                                                                     | Week 16                                                                                                             | Week 48                                                                                                                              | Week 48                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                              | Tofacitinib 5 mg BID (N = 133)                                                                           | Placebo (N = 136)                                                                                           | Difference From Placebo                                                                                             | Tofacitinib 5 mg BID (N = 133)                                                                                                       | Placebo->Tofacitinib 5 mg BID (N = 136)                                                         |
| ASAS 5/6, n (%) [N1] or[95%CI] ASAS Partial Remission, n (%) [N1] or [95% C】]a Spinal mobility (Chest expansion), LSM (SE) [N1] or [95% C1]  △BASDAI, LSM (SE) [N1] or [95% C1]  ASDAS Clinically Important Improvement, n (%) [N1] or[95%C1] ASDAS Major Improvement, n (%) | 58 (43.61) [129]                                                                                         | 10 (7.35) [131] 4 (2.94) [131] [131] [131] [131] 6 (4.65) [124] 0 (0.00) [131] [76] [36] 3.29 (0.665) [130] | 36.34*** [27.05, 45.63] 12.05** [5.29, 18.80] 0.21 [-0.11, 0.53] -1.44*** 42.30*** 25.28*** 6.69* -0.53 -0.57 2.22* | 58 (43.61) [100] 31 (23.31) [112] 0.50 (0.127) [100] -3.30 (0.199) [113] 77 (58.33) [100] 41 (33.33) [94] 20 (15.04) [100] [60] [23] | 61 (44.85) [103] 24 (17.65)                                                                     |
| Secondary eficacy endpoints(not controlledfor TypeI error)                                                                                                                                                                                                                   | Secondary eficacy endpoints(not controlledfor TypeI error)                                               |                                                                                                             |                                                                                                                     |                                                                                                                                      |                                                                                                 |
|                                                                                                                                                                                                                                                                              | 20 (15.04) [129] 0.59 (0.128) [129] -2.55 (0.175) [129] 81 (61.36) [128] 37 (30.08) [119] 9 (6.77) [129] | 0.38 (0.127) -1.11 (0.174) 26 (19.12)                                                                       | [-1.88, -1.00] [31.73, 52.88] [16.47, 34.10] [2.05, 11.33] [-1.22, 0.16]                                            | 7.80 (0.775) [112]                                                                                                                   | [112] 0.47 (0.125) [103] -2.80 (0.197) [113] 72 (52.94) [103] 37 (28.68) [100] 18 (13.24) [103] |
| [N1] or [95% C】] ASDAS Inactive Disease, n (%) [N1] or [95% C1] △MASES, LSM (SE)                                                                                                                                                                                             |                                                                                                          |                                                                                                             |                                                                                                                     |                                                                                                                                      |                                                                                                 |
|                                                                                                                                                                                                                                                                              |                                                                                                          |                                                                                                             |                                                                                                                     | -2.87 (0.225)                                                                                                                        | -2.56 (0.222)                                                                                   |
|                                                                                                                                                                                                                                                                              | -1.94 (0.288)                                                                                            | -1.41 (0.272)                                                                                               |                                                                                                                     |                                                                                                                                      |                                                                                                 |
| [N1] or [95% C1] b Swollen Joint Count, LSM (SE)                                                                                                                                                                                                                             | -3.35 (0.475)                                                                                            | -2.79 (0.465)                                                                                               |                                                                                                                     | -3.31 (0.176)                                                                                                                        | [59] -3.82 (0.174)                                                                              |
|                                                                                                                                                                                                                                                                              | [70]                                                                                                     |                                                                                                             | [-1.78, 0.65]                                                                                                       |                                                                                                                                      |                                                                                                 |
| [N1] or [95% C1] b                                                                                                                                                                                                                                                           | [33]                                                                                                     |                                                                                                             |                                                                                                                     |                                                                                                                                      | [27]                                                                                            |
| △SF-36v2, LSM (SE) [N1] or [95% C1]“ Physical Functioning                                                                                                                                                                                                                    | [129] 6.13 (0.744)                                                                                       | 3.13 (0.745)                                                                                                | [0.56, 3.88] 3.00* 4.46*** [2.69, 6.23] 3.24***                                                                     | 11.67 (0.920) [112]                                                                                                                  | 6.94 (0.766) [111] 7.29 (0.862)                                                                 |
| Role Physical                                                                                                                                                                                                                                                                | [129] 7.93 (0.710)                                                                                       | [130]                                                                                                       | [1.15, 4.85]                                                                                                        |                                                                                                                                      | [111]                                                                                           |
| Bodily Pain                                                                                                                                                                                                                                                                  | 5.52 (0.665)                                                                                             | 1.76 (0.618)                                                                                                |                                                                                                                     |                                                                                                                                      |                                                                                                 |
|                                                                                                                                                                                                                                                                              | 5.00 (0.617)                                                                                             |                                                                                                             |                                                                                                                     |                                                                                                                                      | 9.55 (0.912) [111]                                                                              |
|                                                                                                                                                                                                                                                                              | [129]                                                                                                    | 3.47 (0.713) [130]                                                                                          |                                                                                                                     | 8.66 (0.870) [112]                                                                                                                   |                                                                                                 |
| General Health                                                                                                                                                                                                                                                               |                                                                                                          |                                                                                                             |                                                                                                                     |                                                                                                                                      |                                                                                                 |
|                                                                                                                                                                                                                                                                              |                                                                                                          |                                                                                                             |                                                                                                                     | 6.31 (0.777)                                                                                                                         | 5.10 (0.770)                                                                                    |
|                                                                                                                                                                                                                                                                              | [129]                                                                                                    | [130]                                                                                                       | [1.70, 4.78]                                                                                                        | [112]                                                                                                                                | [111]                                                                                           |

|                                                        | Week16                       | Week16              | Week16                   | Week 48                     | Week 48                               |
|--------------------------------------------------------|------------------------------|---------------------|--------------------------|-----------------------------|---------------------------------------|
|                                                        | Tofacitinib 5 mgBID (N =133) | Placebo (N =136)    | Difference From Placebo  | Tofacitinib 5 mgBID (N=133) | Placebo->Tofacitinib 5 mgBID (N =136) |
| Vitality                                               | 5.34 (0.864) [129]           | 3.56 (0.869) [130]  | 1.78 [-0.38, 3.94]       | 9.83 (0.997) [112]          | 9.28 (0.992) [111]                    |
| Social Functioning                                     | 5.45 (0.835) [129]           | 2.49 (0.837) [130]  | 2.96* [0.88, 5.05]       | 8.16 (0.923) [112]          | 6.77 (0.915) [111]                    |
| Role-Emotional                                         | 4.13 (1.020) [129]           | 2.05 (1.017) [130]  | 2.08 [-0.46, 4.61]       | 7.17 (1.004) [112]          | 6.32 (0.989) [111]                    |
| Mental Health                                          | 3.57 (0.886) [129]           | 2.49 (0.888) [130]  | 1.08 [-1.13, 3.29]       | 7.10 (0.960) [112]          | 6.45 (0.954) [111]                    |
| Mental Component Summary                               | 3.45 (0.914) [129]           | 2.13 (0.915) [130]  | 1.33 [-0.95, 3.61]       | 7.07 (0.926) [112]          | 6.35 (0.920) [111]                    |
| △EQ-VAS (mm), LSM (SE) [N1] or [95% C1]                | 13.00 (1.840) [128]          | 2.89 (1.840) [130]  | 10.11*** [5.52, 14.70]   | 20.64 (1.879) [112]         | 18.00 (1.862) [111]                   |
| △EuroQoL EQ-5D-3L,LSM (SE)                             |                              |                     |                          |                             |                                       |
| [N1]'                                                  |                              |                     |                          |                             |                                       |
| Mobility                                               | -0.23 (0.044) [129]          | -0.06 (0.044) [131] | -0.17* [-0.28, -0.06]    | -0.32 (0.051) [112]         | -0.26 (0.050) [112]                   |
| Self-care                                              | -0.21 (0.043) [129]          | -0.20 (0.043) [131] | -0.01 [-0.11, 0.10]      | -0.33 (0.048) [112]         | -0.33 (0.047) [112]                   |
| Usual activities                                       | -0.18 (0.046) [129]          | -0.09 (0.046) [131] | -0.09 [-0.20, 0.03]      | -0.32 (0.053) [112]         | -0.34 (0.053) [112]                   |
| Pain/discomfort                                        | -0.30 (0.036) [129]          | -0.12 (0.036) [131] | -0.18*** [-0.27, -0.09]  | -0.37 (0.047) [112]         | -0.36 (0.047) [112]                   |
| Anxiety/depression                                     | -0.11 (0.048) [129]          | -0.10 (0.048) [131] | -0.01 [-0.13, 0.11]      | -0.17 (0.054) [112]         | -0.21 (0.053) [112]                   |
| WPAI, LSM (SE)                                         |                              |                     |                          |                             |                                       |
| [N1] or [95% CI] “                                     |                              |                     |                          |                             |                                       |
| Percentworktimemissedduetohealth problem               | -3.65 (2.659) [74]           | 0.88 (2.622) [81]   | -4.53 [-11.15, 2.09]     | -8.10 (2.136) [61]          | -5.79 (2.047) [70]                    |
| Percent impairment while working due to health problem | -19.83 (2.274) [71]          | -6.94 (2.303) [77]  | -12.89*** [-18.59,-7.19] | -25.35 (2.769) [58]         | -23.00 (2.656) [70]                   |
| Percentoverallworkimpairment duetohealth               | -21.49 (2.508)               | -7.64 (2.559)       | -13.85***                | -27.63 (3.005)              | -23.22 (2.890)                        |
| problem                                                | [71]                         | [76]                | [-20.18, -7.52]          | [58]                        | [69]                                  |

<div style=\"page-break-after: always\"></div>

|                                           | Week16                       | Week16           | Week16                  | Week48                        | Week48                                  |
|-------------------------------------------|------------------------------|------------------|-------------------------|-------------------------------|-----------------------------------------|
|                                           | Tofacitinib 5 mgBID (N =133) | Placebo (N =136) | Difference From Placebo | Tofacitinib 5 mg BID (N =133) | Placebo->Tofacitinib 5 mg BID (N = 136) |
| Percent activity impairment due to health | -19.03 (1.969)               | -5.63 (1.968)    | -13.40***               | -27.37 (2.339)                | -19.77 (2.310)                          |
| problem                                   | [129]                        | [131]            | [-18.30, -8.50]         | [112]                         | [112]                                   |

Nominal *p≤0.05; **p&lt;0.001; ***p&lt;0.0001

a. Nommal approximation adjusting for the stratification factor (prior treatment history:bDMARD-naive versus TNFi-IR or bDMARD Use[Non-IR]) derived from clinical database via CMH approach was used. Missing response was considered as non-response.

c.ANCOVA model that includedfixed effects of treatment group, stratification factor derived from clinical database, and baseline value,was fitted using data at Week 16for the 2 treatments: tofacitinib 5 mg BID and placebo for Week 16 Analysis only. Missing value was not imputed. Results at Week 16 were from this ANCOVA model. Results at Week 48were from another MMRM modelfitted using data up toWeek 48for the 2 treatments:tofacitinib5 mg BID andplacebo-&gt;tofacitinib5 mgBID(Week 48Final Analysis).

b. MMRM included fixed effect of treatment group, visit, and treatment-group by visit interaction, stratification factor derived from clinical database, stratification-factor by visit interaction,baselinevalue,andbaseline-valuebyvisitinteraction;anunstructuredcovariancematrixwasused.Missingvaluewasnotimputed.Results atWeek16were from 1 MMRM model fitted using data up to Week 16 for the 2 treatments: tofacitinib 5 mg BID and placebo (Week 16 Analysis). Results at Week 48 were from another MMRM modelfitted using data up toWeek 48for the 2 treatments:tofacitinib5mg BDandplacebo-&gt;tofacitinib5mgBID(Week 48FinalAnalysis).

Results at Week 16 were based on the Week 16 Analysis data: data cutoff 19DEC2019, data snapshot 29JAN2020. Results at Week 48 were based on Week 48 Final Analysis.

Source: Module 5.3.5.1 A3921120 Week 16 Amended Study Report Tab1e 14.2.1.2.1.1;Table 14.2.2.2.1.1; Table 394a.14.2.6.1.3; Table 14.2.7.1.3; Table 14.2.12.1.3;Table 14.2.11.1.3;Table 14.2.12.1.3.1;Table 14.2.10.1.3;Table14.2.3.1.3;Table 14.2.4.2;Table 14.2.5.2;Table14.2.19.3;Table 14.2.8.3.1;Table14.2.3.1.3;Table 394a.14.2.6.3.2;394a.Table 14.2.6.4.2;Table 394a.14.2.6.5.2;Table 14.2.17.4;Table 14.2.18.4; Table 14.2.12.1.6;Table 14.2.13.1.3; Table 14.2.14.1.3. Module 5.3.5.1 A3921120 Week 48Study Report Table 14.2.1.2.1.1A; Table 14.2.2.2.1.1A;Table 14.2.6.1.3A;Table14.2.7.1.3A;Table 14.2.11.1.3A;Table 14.2.12.1.3A; Table 14.2.6.5.2A;Table 14.2.17.4A;Tab1e 14.2.18.4A;Table 14.2.13.1.3A;Table 14.2.14.1.3A.

The efficacy for the ASAS20 and ASAS40 response rates were increased at Week 24 (first post-placebo assessment) for tofacitinib 5 mg BID in patients who started placebo and advanced to tofacitinib at Week 16 ( Figure 23 and Figure 24 ). This was maintained over time up to Week 48 in these patients ( Figure 23 and Figure 24 ).

Figure 23. Line Graph of ASAS20 Response Rate (± SE) by Visit up to Week 48 -Estimand 1, FAS, OnDrug Data, MR=NR, Study A3921120

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 24. Line Graph of ASAS40 Response Rate (± SE) by Visit up to Week 48 - Estimand 1, FAS, OnDrug Data, MR=NR, Study A3921120

<!-- image -->

## Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein Change from Baseline

Change from baseline in ASDAS(CRP) at Week 16 was a global Type I error-controlled endpoint.

- The LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (p &lt;0.0001) based on the MMRM analysis (Estimand 4)
- The LS means decrease from baseline in ASDAS(CRP) for tofacitinib 5 mg BID were greater than those of placebo at all other time points (2-sided 95% CI excluded 0).
- Results of the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data
- Results were consistent for ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L

## High Sensitivity C-Reactive Protein (hsCRP) Change from Baseline

Change from baseline in hsCRP at Week 16 was a global Type I error-controlled endpoint.

- The LS mean change from baseline in hsCRP showed statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (p &lt;0.0001) based on the MMRM analysis (Estimand 4)
- The LS means decrease from baseline in hsCRP for tofacitinib 5 mg BID were greater than those of placebo at all other time points (2-sided 95% CI excluded 0).
- Results of the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data.

Many secondary endpoints (21, 1 key) controlled for multiplicity (step-down testing procedure with a fixed alpha level for each comparison at the 2-sided 5%) were selected by the MAH.

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint

Ankylosing Spondylitis Disease Activity Score (ASDAS)(CRP):  The ASDAS is a composite index that combines the following 5 disease activity variables:  spinal pain (BASDAI Question 2 NRS score 0 - 10), peripheral joint pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity C-reactive protein (hsCRP).  Higher scores indicate more active disease.

ASDAS (CRP) the LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the PLB arm at week 16, delta of -0.98, p &lt;0.0001, FAS on drug data estimand 4), the achieved difference was clinically relevant. Consistent results were shown by the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data.

At week 48 improvement of ASDAS(CRP) from baseline is still seen in both arms similarly -1.70 and -1.50 for the TOFA-TOFA and PLB-TOFA, respectively.

## Secondary endpoints type I controlled:

In the hierarchical order as second endpoint the MAH selected the Change from baseline of an inflammatory marker i.e., hsCRP at Week 16 showing statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.05 versus -0.09, p &lt;0.0001) based on the MMRM analysis (Estimand 4). Importantly this endpoint is not considered key for demonstration of tofacitinib clinical benefit but only regarded as supportive for effect on inflammation since no data support this biomarker as useful surrogate to assess efficacy in axial SpA.

## Secondary endpoints but not controlled for type I error:

-ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3) ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16 overall showing a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoint measuring improvement. Low disease activity or partial remission endpoints: ASDAS inactive disease (6.7 versus 0 delta 6.7, p 0 ˂ 0.05) at week 16 and ASAS partial remission (a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001) showing very/limited effect size.

-ASAS 5/6 results are consistent with those of the primary and key secondary endpoint showing a statistical and clinical relevant improvement (44% responders, delta of 36 at week 16 and maintained at week 48).

As measure of improvement of enthesitis the MAH had included the change in MASES index (total score ranging 0 - 13) at week 16 as not controlled secondary endpoint showing an improvement of -2 versus 1.41, delta of -0.53 slightly increasing at week 48.

Other measures of symptoms and physical function recommended which has been included within secondary endpoints not controlled for multiplicity is the change of BASDAI at week 16 (showing an improvement of -2.55 at week 16 delta of -1.44), however i) this is a widely used measure of disease activity and its changes with treatment should be assessed as secondary endpoint; ii) the percentage of patients with clinical response as measured by an improvement of at least a 50% from the baseline score in BASDAI is considered useful to judge the clinical benefit of a treatment and was not included by the MAH.

## Ancillary analyses

## Combination With csDMARDs Versus Monotherapy

In Study A3921120, the efficacy of tofacitinib 5 mg BID versus placebo for ASAS20 response rate at Week 16 was consistent between patients who were receiving tofacitinib 5 mg BID as monotherapy and those receiving  tofacitinib  5  mg  BID  with  concomitant  csDMARDs  However,  the  magnitude  of  the  ASAS20

<div style=\"page-break-after: always\"></div>

response rate was greater with concomitant csDMARD use. The efficacy of tofacitinib 5 mg BID versus placebo  for  ASAS40  response  rate  at  Week  16  was  consistent  between  patients  who  were  receiving tofacitinib 5 mg BID as monotherapy and those receiving tofacitinib 5 mg BID with concomitant csDMARDs and again the magnitude of the response rate was greater with Day 1 concomitant csDMARD use ( Table 49).

Table 49. CMH Normal Approximation to ASAS20 Response Rate at Week 16 by Subgroup, Treatment Comparison - Estimand 1, FAS, On-Drug Data, MR=NR -Subgroup Analysis (Week 16 Analysis)

-

<!-- image -->

Table 50 CMH Normal Approximation to ASAS40 Response Rate at Week 16 by Subgroup, Treatment Comparison Estimand 1, FAS, On-Drug Data, MR=NR- Subgroup Analysis (Week 16 Analysis)

<!-- image -->

The ASAS20 and ASAS40 respones are higher in tofacitinib 5 mg BID compared to placebo group both in patients with concomitant csDMARDs use that in those with not (as shown in Tables 49 and 50 ). It is noted that the magnitude of the effect of tofacitnib is slightly greater when using concomitant csDMARDs compared to monotherapy (diff. of 30.88 vs 26.76 for ASAS20 and 31.41 vs 27.56 for ASAS 40 response), even though the number of patients with concomitant csDMARDs treatment (tofa: 29, PLB: 44) is limited compared to that of patients in monotherapy (tofa: 104, PLB: 92).

## Efficacy in the Pivotal Study A3921120 Beyond Week 16

The efficacy of the tofacitinib IR for AS is based on the Week 16 data analysis and supplemented by the Week 48 data analysis from Study A3921120. As previously described, all patients in this study received active treatment of tofacitinib 5 mg BID after Week 16. Therefore, no placebo data are available after this time point.

The efficacy of tofacitinib 5 mg BID as measured by ASAS20 and ASAS40 responses are shown over the full  48-week  treatment  period  in  the  study  (Figure  5  and  Figure  6  above).  The  ASAS20  and  ASAS40 response rates were sustained for tofacitinib 5 mg BID after Week 16 to the end of the study (Week 48). In addition, as measured by type-I error-controlled secondary endpoints (ASDAS(CRP), hsCRP, ASQoL, SF36v2  PCS,  BASMI  Score  (Linear  Method),  FACIT-F  Total  Score,  PGA,  total  back  pain,  BASFI,  and

<div style=\"page-break-after: always\"></div>

inflammation) efficacy was sustained or improved for tofacitinib 5 mg BID after Week 16 to the end of the study.

## Summary of main study

Table 51 summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment.

Table 51. Summary of Efficacy

| Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                     | A3921120                                                                                                                                             | A3921120                                                                                                                                             | A3921120                                                                                                                                                                                 |
| Design                                                                                                                                               | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                      | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                      | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                          |
| Design                                                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                       | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                       | 16 weeks not applicable 32 weeks                                                                                                                                                         |
| Hypothesis                                                                                                                                           | Superiority to placebo                                                                                                                               | Superiority to placebo                                                                                                                               | Superiority to placebo                                                                                                                                                                   |
| Treatments groups                                                                                                                                    | tofacitinib 5 mg                                                                                                                                     | tofacitinib 5 mg                                                                                                                                     | tofacitinib 5 mg po BID, N=134                                                                                                                                                           |
| Treatments groups                                                                                                                                    | Placebo                                                                                                                                              | Placebo                                                                                                                                              | Placebo po BID, N=136                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                            | Primary endpoint                                                                                                                                     | ASAS20 response at week 16                                                                                                                           | Improvement of ≥ 20% and ≥ 1 unit on a scale of 0 to 10 in at least three of the four ASAS scale main domains and no worsening of ≥ 20% and ≥ 1 unit in the remaining domain, at week 16 |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | ASAS40 response at week 16                                                                                                                           | Improvement of ≥ 40% and ≥ 2 units on a scale of 0 to 10 in at least three of the four ASAS scale main domains and no worsening at all in the remaining domain, at week 16               |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in ASDAS-CRP at week 16                                                                                                         | Change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) based on CRP at week 16                                                                                    |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in hsCRP at week 16                                                                                                             | Change from baseline in high-sensitivity C- Reactive protein at week 16                                                                                                                  |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in ASQoL at week 16                                                                                                             | Change from baseline in ankylosing spondylitis quality of life (ASQoL) at week 16                                                                                                        |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in SF-36v2 PCS at week 16                                                                                                       | Change from baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary (PCS) score at week 16                                                                |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in BASMIlin at week 16                                                                                                          | Change from baseline in linear Bath Ankylosing Spondylitis Metrology Index - linear method (BASMIlin) at week 16                                                                         |

<div style=\"page-break-after: always\"></div>

|                                                                  | Secondary endpoint                                                               | Change from baseline in FACIT-F at week 16                                       | Change from baseline in FACIT-F at week 16                                       | Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale at week 16   | Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale at week 16   |
|------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020 | Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                 | Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                 | Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                 | Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                                              | Database lock Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                                              |
| Results and Analysis                                             | Results and Analysis                                                             | Results and Analysis                                                             | Results and Analysis                                                             | Results and Analysis                                                                                          | Results and Analysis                                                                                          |
| Analysis description                                             | Primary Analysis                                                                 | Primary Analysis                                                                 | Primary Analysis                                                                 | Primary Analysis                                                                                              | Primary Analysis                                                                                              |
| Analysis population and time point                               | Full Analysis set (randomised, received at least one dose of study drug) Week 16 | Full Analysis set (randomised, received at least one dose of study drug) Week 16 | Full Analysis set (randomised, received at least one dose of study drug) Week 16 | Full Analysis set (randomised, received at least one dose of study drug) Week 16                              | Full Analysis set (randomised, received at least one dose of study drug) Week 16                              |
| description Descriptive statistics and estimate variability      | Treatment group                                                                  | Treatment group                                                                  | tofacitinib BID 5 mg                                                             | tofacitinib BID 5 mg                                                                                          | Placebo                                                                                                       |
| description Descriptive statistics and estimate variability      | Number of subjects                                                               | Number of subjects                                                               | 133                                                                              | 133                                                                                                           | 136                                                                                                           |
| description Descriptive statistics and estimate variability      | ASAS20 response%                                                                 | ASAS20 response%                                                                 | 56.39%                                                                           | 56.39%                                                                                                        | 29.41%                                                                                                        |
| description Descriptive statistics and estimate variability      | Number of subjects                                                               | Number of subjects                                                               | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| description Descriptive statistics and estimate variability      | ASAS40 response%                                                                 | ASAS40 response%                                                                 | 40.60%                                                                           | 40.60%                                                                                                        | 12.50%                                                                                                        |
| description Descriptive statistics and estimate variability      | Number of subjects                                                               | Number of subjects                                                               | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from baseline in ASDAS-                                                   | Change from baseline in ASDAS-                                                   | -1.36                                                                            | -1.36                                                                                                         | -0.39                                                                                                         |
| description Descriptive statistics and estimate variability      | CRP Number of subjects                                                           | CRP Number of subjects                                                           | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from                                                                      | Change from                                                                      | -1.05                                                                            | -1.05                                                                                                         | -0.09                                                                                                         |
| description Descriptive statistics and estimate variability      | baseline in hsCRP Number of subjects                                             | baseline in hsCRP Number of subjects                                             | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from baseline in ASQoL                                                    | Change from baseline in ASQoL                                                    | -4.03                                                                            | -4.03                                                                                                         | -2.01                                                                                                         |
| description Descriptive statistics and estimate variability      | units Number of subjects                                                         | units Number of subjects                                                         | 129                                                                              | 129                                                                                                           | 130                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from baseline in SF-36v2                                                  | Change from baseline in SF-36v2                                                  | 6.69                                                                             | 6.69                                                                                                          | 3.14                                                                                                          |
| description Descriptive statistics and estimate variability      | PCS Number of subjects                                                           | PCS Number of subjects                                                           | 129                                                                              | 129                                                                                                           | 130                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from baseline in BASMIlin units                                           | Change from baseline in BASMIlin units                                           | -0.63                                                                            | -0.63                                                                                                         | -0.11                                                                                                         |
| description Descriptive statistics and estimate variability      | Number of subjects                                                               | Number of subjects                                                               | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| description Descriptive statistics and estimate variability      | Change from baseline in FACIT-F                                                  | Change from baseline in FACIT-F                                                  | 6.54                                                                             | 6.54                                                                                                          | 3.12                                                                                                          |
| description Descriptive statistics and estimate variability      | Number of subjects                                                               | Number of subjects                                                               | 129                                                                              | 129                                                                                                           | 131                                                                                                           |
| Effect estimates per comparison                                  | Primary endpoint ASAS20 response                                                 | Primary endpoint ASAS20 response                                                 | Comparison groups                                                                | Comparison groups                                                                                             | tofacitinib BID 5 mg vs Placebo                                                                               |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | %difference in response                                                          | %difference in response                                                                                       | 27.08                                                                                                         |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | rate 95% CI                                                                      | rate 95% CI                                                                                                   | 15.89, 38.28                                                                                                  |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | P-value                                                                          | P-value                                                                                                       | <0.0001                                                                                                       |
| Effect estimates per comparison                                  | Secondary endpoint ASAS40 response                                               | Secondary endpoint ASAS40 response                                               | Comparison groups                                                                | Comparison groups                                                                                             | tofacitinib BID 5 mg vs Placebo                                                                               |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | %difference in response rate                                                     | %difference in response rate                                                                                  | 28.17                                                                                                         |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | 95% CI                                                                           | 95% CI                                                                                                        | 18.26, 38.09                                                                                                  |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  | P-value                                                                          | P-value                                                                                                       | <0.0001                                                                                                       |
| Effect estimates per comparison                                  | Secondary endpoint Change from                                                   | Secondary endpoint Change from                                                   | Comparison groups                                                                | Comparison groups                                                                                             | tofacitinib BID 5 mg vs Placebo                                                                               |
| Effect estimates per comparison                                  | baseline in ASDAS- CRP                                                           | baseline in ASDAS- CRP                                                           | Mean Diff                                                                        | Mean Diff                                                                                                     | -0.98                                                                                                         |
| Effect estimates per comparison                                  | LS                                                                               | LS                                                                               | 95% CI                                                                           | 95% CI                                                                                                        | -1.16, -0.79                                                                                                  |
| Effect estimates per comparison                                  |                                                                                  |                                                                                  |                                                                                  |                                                                                                               |                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                           | P-value           | <0.0001                         |
|-----------------------------------------------------------|-------------------|---------------------------------|
| Secondary endpoint Change from baseline in hsCRP          | Comparison groups | tofacitinib BID 5 mg vs Placebo |
| Secondary endpoint Change from baseline in hsCRP          | LS Mean Diff      | -0.96                           |
| Secondary endpoint Change from baseline in hsCRP          | 95% CI            | -1.20, -0.72                    |
| Secondary endpoint Change from baseline in hsCRP          | P-value           | <0.0001                         |
| Secondary endpoint Change from baseline in ASQoL          | Comparison groups | tofacitinib BID 5 mg vs Placebo |
| Secondary endpoint Change from baseline in ASQoL          | LS Mean Diff      | -2.02                           |
| Secondary endpoint Change from baseline in ASQoL          | 95% CI            | -3.03, -1.01                    |
| Secondary endpoint Change from baseline in ASQoL          | P-value           | <0.001                          |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | Comparison groups | tofacitinib BID 5 mg vs Placebo |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | LS Mean Diff      | 3.55                            |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | 95% CI            | 2.09, 5.02                      |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | P-value           | <0.0001                         |
| Secondary endpoint Change from baseline in BASMIlin units | Comparison groups | tofacitinib BID 5 mg vs Placebo |
| Secondary endpoint Change from baseline in BASMIlin units | LS Mean Diff      | -0.52                           |
| Secondary endpoint Change from baseline in BASMIlin units | 95% CI            | -0.67, -0.37                    |
| Secondary endpoint Change from baseline in BASMIlin units | P-value           | <0.0001                         |
| Secondary endpoint Change from baseline in FACIT-F        | Comparison groups | tofacitinib BID 5 mg vs Placebo |
| Secondary endpoint Change from baseline in FACIT-F        | LS Mean Diff      | 3.43                            |
| Secondary endpoint Change from baseline in FACIT-F        | 95% CI            | 1.44, 5.42                      |
| Secondary endpoint Change from baseline in FACIT-F        | P-value           | <0.001                          |

## Analysis performed across trials (pooled analyses and meta-analysis)

The Applicant has submitted a report concerning a systematic review and meta-analysis of placebocontrolled trials of EMA-approved biological DMARDs, including ASAS20/40 at week 12-16, in patients with AS with or without previous experience with biological DMARDs.

Placebo-controlled RCTs of biological DMARDs approved for AS by the EMA were included if they reported ASAS20 or ASAS40 at 12-16 weeks and included patients with prior nonsteroidal anti-inflammatory drug (NSAID) failure. Only multicenter studies were included and studies conducted in single countries were excluded. The initial search was conducted up to August 2019 and was recently refreshed up to August 2020. The studies concerning tofacitinib were studies A3921119 and A3921120 discussed in this report.

ASAS20 and ASAS40 response rates were extracted from the study reports, and from the AS subgroup in trials conducted in the SpA population. The mean differences and 95% confidence intervals (CI) for ASAS20 and ASAS40 responses between intervention arms and placebo were calculated, using ITT data. The results were depicted using forest plots, for all trials separately.

According to the results, ASAS20 and ASAS40 responses ( Figure25 ) for tofacitinib 5 mg BID across Studies A3921119 and A3921120, were similar compared with adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab and secukinumab. The treatment effects on ASAS40 were 26% and 28% in the two tofacitinib trials ( Figure 25 ), while the majority of treatment effects of the other biological DMARDs ranged from 17% (adalimumab, COAST V) to 37% (infliximab, ASSERT). One of the secukinumab trials with a loading and a non-loading treatment arm versus placebo, had lower treatment effects (MEASURE 4).

<div style=\"page-break-after: always\"></div>

Figure 25 ASAS40 Responses in placebo-controlled clinical trials: tofacitinib and approved AS therapies

<!-- image -->

Key: L = loading dose; NL = no loading dose.

a. Results from the RAPID-axSpA study were taken from the subgroup of patients with AS. The full analysis set included both patients with AS and non-radiographic axial spondyloarthritis.

b. The sulfasalazine arm of the ASCEND study was treated as placebo in this analysis.

c. The COAST-V study included ixekizumab 80 mg Q2W and Q4W. Results from ixekizumab Q4W are shown here.

Source: Module 5.3.5.3 Contextualization of Efficacy Endpoints for Tofacitinib Versus Currently Approved Treatments for AS Figure 3.

## Clinical studies in special populations

No data are available on special populations. No specific data on elderly are reported for axSA subjects. In the SmPC dose adjustments are included for renal and hepatic impairment based on initial submission.

## Supportive studies

## A3921119

This was Phase 2, multicenter, randomised, double-blind, placebo-controlled dose-ranging, parallel group efficacy and safety study designed to characterise the dose-response of tofacitinib in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs ( Figure 26 )for design schematic).

Figure 26.  Study A3921119 Schematic of Study Design

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

The clinical programme was designed to evaluate the efficacy of tofacitinib in adult patients with active AS who had experienced an inadequate clinical response or were intolerant to NSAID therapy. A diagnosis of AS was based on the Modified New York Criteria for AS (1984). Active disease was also defined as: BASDAI score of ≥ 4 and back pain score (BASDAI Question 2) of ≥ 4 despite treatment with NSAIDs at both screening and baseline. Patients met the definition of NSAID-IR if they had either an inadequate clinical response, intolerance to at least 2 different oral NSAIDs, or ongoing NSAID treatment but with active AS.

Patients continued their stable background AS therapy, which included NSAIDs including selective COX-2 inhibitors, MTX, sulfasalazine, and corticosteroids ( ≤ 10 mg/day of prednisone or equivalent). In Study A3921119, background therapies were to be stable for 4 weeks except NSAIDs (1 week) prior to the first dose of investigational product.

Selected key enrolment criteria for Study A3921119 are the same of the pivotal phase study with the exception of exclusion of subjects exposed to bDMARDs.

## Treatments

A twice daily dosing regimen (3 doses of tofacitinib 2 mg, 5 mg, 10 mg, or placebo) was evaluated in the dose-ranging Phase 2 Study A3921119. During the 12-week treatment period, patients were randomised in a 1:1:1:1 ratio to receive 1 of the 4 blinded treatments. The assignment occurred according to a randomisation schedule and to which the patient, site personnel, and the Sponsor's personnel directly involved in the study conduct were blinded through the entire duration of the study.

The duration of participation for eligible patients was approximately 150 days. This included a screening period of approximately 28 days, a 12-week double-blind treatment period, and a 28-day follow-up period.

Of 445 subjects screened for entry into the study, 208 subjects were randomized in a 1:1:1:1 ratio to double-blind treatment; 52 subjects to each treatment group (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo).

The efficacy of Tofacitinib 5 mg BID dose was supported by the outcomes of the Phase 2 dose-ranging Study A3921119. The study design is considered appropriate and in line with the EMA guideline (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) recommendation for placebo controlled parallel group studies. Similar eligibility criteria were applied across the two key studies. Inclusion and exclusion criteria are overall appropriate reflecting subjects with AS who have responded inadequately to conventional therapy. However, differently to Study A3921120, only patients naïve to previous bDMARDs were allowed to be included in Study A3921119, excluding patients bDMARDs experienced. Therefore, the phase 2 study could be of support of tofacitinib treatment only in a bDMARD naïve patient population. The activity of disease required for entry into this study was defined as for the pivotal on: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4 and back pain score (BASDAI Question 2) of ≥4 despite treatment with NSAIDs (or intolerance to NSAIDs). Regarding the different doses, the MAH states that similar to the RA and psoriasis Phase 2 studies, where inclusion of doses &lt;5 mg BID provided lower efficacy thereby allowing a complete characterization of the dose-response curve, a 2 mg BID dose was included in the study.

<div style=\"page-break-after: always\"></div>

## Objectives

1. To compare the efficacy of tofacitinib, in doses of 2 mg twice daily (BID), 5 mg BID, 10 mg BID versus placebo  on  the  ASAS20  response  rate  at  Week  12  in  subjects  with  active  AS  that  had  an  inadequate response to previous treatment.

2. To estimate the placebo-corrected dose-response for the ASAS20 at Week 12 in subjects with active AS that had an inadequate response to previous treatment.

3. To compare the safety of tofacitinib at all doses versus placebo in all study subjects.

## Outcomes/endpoints

The primary efficacy endpoint was ASAS20 response rate at 12 weeks of treatment.

The secondary efficacy endpoints were:

- A validated endpoint such as Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index of disease activity score and/or modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging (ASspiMRI) Activity Score of the SI joints and spine at Week 12.
- ASAS20 response at all other time points (2,4 and 8 weeks).
- ASAS40 response at all time points (2,4,8 and 12 weeks).
- ASAS 5/6 response at all time points (2,4,8 and 12 weeks).
- ASAS partial remission criteria at all time points (2,4,8 and 12 weeks).
- Ankylosing Spondylitis Disease Activity Score (ASDAS) using C-Reactive Protein (ASDASCRP) at all time points (2,4,8 and 12 weeks).
- ASDAS clinically important improvement, ASDAS major improvement and ASDAS inactive disease at all time points (2,4,8 and 12 weeks).
- BASDAI at all time points (2,4,8 and 12 weeks).
- 50% improvement from Baseline in the BASDAI (BASDAI50) response at all time points (2,4,8 and 12 weeks).
- BASFI at all time points (2,4,8 and 12 weeks).
- BASMI at all time points (2,4,8 and 12 weeks).
- Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at all time points collected (4,8 and 12 weeks)
- Extra-articular involvement (specific medical history and peripheral articular involvement [as assessed by swollen joint count]) at all time points collected (2,4,8 and 12 weeks).

Other evaluations included QoL endpoints: Ankylosing Spondylitis Quality of Life (ASQoL), Short-Form-36 Health Survey (SF-36) Version 2, EuroQol Health State Profile - 5 Domains (EQ-5D), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Impairment (WPAI) Questionnaire: Spondyloarthritis, AS HealthCare Resource Utilization Questionnaire (AS-HCRU).

The efficacy of tofacitinib in active AS in phase 2 Study was evaluated using a core set of validated measures similar to those used in the pivotal Study and this is agreed. However, the primary endpoint (ASAS20) was assessed at week 12 instead of at week 16 as in Study A3921120 not allowing for a pooling of efficacy results. As reported in the above comment for Study A3921120, ASAS 20 is not the preferred primary endpoint according to EMA guideline (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) that

<div style=\"page-break-after: always\"></div>

recommends to use the more stringent endpoint ASAS40 as primary. However, due to the reasons explained above and considering this as a supportive study, ASAS20 is deemed an acceptable endpoint. Moreover, ASAS40 response is one of the secondary end-point together with other validated endpoints such as ASAS 5/6, ASAS partial remission, ASDAS (CRP), BASDAI improvement, BASDAI 50. It is also noted that a radiological endpoint is also included (SPARCC) and this is agreed according to EMA GL.

Eligible subjects were randomized in a 1:1:1:1 ratio to one of the 4 blinded treatments (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, or placebo BID as shown in Table 52 ). Tofacitinib was provided as 1 mg or 5 mg tablets with corresponding matching placebo. A total of 8 tablets per day encompassed the total daily dose taken by the subject:

Table 52. Treatment Allocation

| Sequence   | Treatmeat Description                                                                   |   Planned Numberof Randomized Subjects |
|------------|-----------------------------------------------------------------------------------------|----------------------------------------|
| 1          | Tofacitinib2mgBID Two Img tabletsandhwo5mgmatchingplacebo tablets Bn AMand PM           |                                     50 |
|            | Tofacitinib SmgBiD andwo Img matchingplacebo tablets in AMand PM                        |                                     50 |
| 3          | Tofacitinib 1o mgBiD Two 5mglablets and hwoImgmatchingplacebo fablets in AMand PM       |                                     50 |
|            | Placebo BID Two Img matchingplacebo tablets andho 5mg matchingplacebo tablets inAMandPM |                                     50 |

SoureesFinal ProtocoL Amendmeut L.Section Io.I.l

Abbreviations:AMI=ante menidiem.BID=rwice daily.PM=post menidiem

## Selection of Doses in the Study

The 5 and 10 mg BID doses were demonstrated to be efficacious in RA subjects and in subjects with psoriasis. Since 10 mg BID provided increased efficacy over 5 mg BID in RA and psoriasis while maintaining an acceptable safety profile, and doses &gt;10 mg BID did not provide substantially improved efficacy, 10 mg BID was selected as the highest dose for the current study. Similar to the RA and psoriasis Phase 2 studies, where inclusion of doses &lt;5 mg BID provided lower efficacy thereby allowing a complete characterization of the dose-response curve, a 2 mg BID dose was included in the study.

## Rescue medications:

The maximum dose of acetaminophen/paracetamol was 2.6 g/day for no more than 10 consecutive days. The maximum dose of opioids was the maximum potency equivalent of 30 mg/day of orally -administered morphine.

## Sample size

Sample size was assessed using clinical trial simulations in which a dose-response model (the 3parameter maximal effect [Emax] model) determined the true percentage of ASAS20 responders at week 12. Simulations under several plausible truths were conducted assuming 50 subjects per treatment group to evaluate the operational characteristics of this same model when used for the analysis. If the true placebo-corrected ASAS20 response in the range of 1 to 10 mg BID was between 20 to 40%, then it was projected based on simulations that the estimated placebo-corrected effect for that dose ±10%, would capture the true placebo-corrected response at least 83% of the time. Under the same assumption about the true effect, it was projected that the estimated placebo-controlled effect ±5% would capture the true value at least approximately 50% of the time.

Emax model to the primary endpoint was used for the dose-response study A3921119. It is recognised to find the optimal dose and investigate the relationship between dose and efficacy relative to control.

<div style=\"page-break-after: always\"></div>

## Randomisation

A total of 208 patients were randomised in a 1:1:1:1 ratio to receive tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, or placebo.

## Blinding (masking)

The Study was conducted in a double-blind, placebo-controlled manner. The randomization scheme is considered adequate.

## Statistical methods:

A 3-parameter Emax model to estimate the ASAS20 dose-response at Week 12, the primary efficacy endpoint, with missing response considered as non-response. As a supportive analysis, the normal approximation for estimating the difference in binomial proportions was used to compare each of the dose groups of tofacitinib to placebo at Week 12 with missing response considered as non-response. All analyses of the efficacy endpoints were based on the FAS. Evaluation of secondary efficacy endpoints was either by:

The normal approximation for the difference in binomial proportions (both testing and confidence interval) was applied to the following endpoints:

- ASAS20 response at all other time points.
- ASAS40 response at all time points.
- ASAS 5/6 response at all time points.
- ASAS partial remission criteria at all time points.
- ASDAS clinically important improvement, ASDAS major improvement and ASDAS inactive disease at all time points.
- BASDAI50 response at all time points.

Missing values due to dropout were set to non-responsive and mixed LOCF was used for missing data that may have existed in components of the above endpoints.

A repeated measures model was used to analyze change from Baseline for the endpoints listed below. The marginal repeated measure model included fixed effects of treatment group, visit, and treatment-group by visit  interaction,  and  Baseline  value.  An  unstructured  variance  covariance  matrix  was  used.  Pairwise comparisons of  each  tofacitinib  dose  to  placebo  (providing  both  2-sided  p-values  and  95%  confidence interval) at each post-Baseline time point was generated from contrast statements using this model.

- ASDASCRP at all time points.
- BASDAI at all time points.
- BASFI at all time points.
- BASMI (linear method) at all time points.
- MASES at all time points collected.
- Extra-articular  involvement  (specific  medical  history  and  peripheral  articular  involvement  [as assessed by swollen joint count]) at all time points collected.
- Spinal mobility at all time points collected
- Total score on the FACIT-F at all time points.

<div style=\"page-break-after: always\"></div>

An analysis of covariance (ANCOVA) model was used to analyze change from Baseline for the endpoints listed  below.  The  ANCOVA  model  included  a  fixed  effect  for  treatment  group  and  Baseline  value  as  a covariate. Pairwise comparisons of each tofacitinib dose to placebo (providing both 2-sided p-values and 95% confidence interval) were generated from contrast statements using this model.

- Total score on the ASQoL at Week 12.
- Summary components and domains of the SF-36 Version 2, Acute at Week 12.
- Domains and utility index from the EQ-5D at Week 12.
- WPAI Questionnaire: spondyloarthritis at Week 12.
- A validated endpoint such as SPARCC MRI index of disease activity score and/or modified Berlin ASspiMRI Activity Score of the SI joints and spine at Week 12.

The Early Termination visit value was used as the Week 12 value if the Week 12 value for a subject was missing.

The use of the Emax model as primary analysis to estimate the ASAS20 dose-response at Week 12, and the  use  of  the  normal  approximation  as  supportive  analysis  for  estimating  the  difference  in  binomial proportions to compare each of the dose groups of tofacitinib to placebo at Week 12 are acknowledged.

## Participant flow

The duration of participation for eligible patients was approximately 150 days. This included a screening period of approximately 28 days, a 12-week double-blind treatment period, and a 28-day follow-up period. Table 53 summaries patient dispositions for Studies A3921119 up to week 12.

Of 445 subjects screened for entry into the study, 208 subjects were randomized in a 1:1:1:1 ratio to double-blind treatment; 52 subjects to each treatment group (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo).

Table 53. Patient Disposition - Studies A3921119 (up to Week 12)

|                                                   | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   |
|---------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                   | Tofacitinib 2 mg BID     | Tofacitinib 5 mg BID     | Tofacitinib 10 mg BID    | Placebo                  |
| Study A3921119                                    |                          |                          |                          |                          |
| Randomised                                        | 52                       | 52                       | 52                       | 52                       |
| Treated                                           | 52                       | 52                       | 52                       | 51                       |
| Completed                                         | 51 (98.1)                | 51 (98.1)                | 47 (90.4)                | 47 (90.4)                |
| Discontinued                                      | 1 (1.9)                  | 1 (1.9)                  | 5 (9.6)                  | 4 (7.7)                  |
| Discontinuations due to treatment related Adverse | 0                        | 1 (1.9)                  | 1 (1.9)                  | 2 (3.9)                  |
| Analysed for Efficacy                             |                          |                          |                          |                          |
| Per-protocol analysis set                         | 49 (94.2)                | 49 (94.2)                | 50 (96.2)                | 49 (94.2)                |
| Full analysis set                                 | 52 (100.0)               | 52 (100.0)               | 52 (100.0)               | 51 (98.1)                |

Percentages  for  the  'Not  treated'  and  'Treated'  rows  are  calculated  using  the  number  of  patients assigned to treatment (randomised) as the denominator. Other percentages are calculated using the number of 'Treated' patients as the denominator.

Of the 208 randomised patients, 1 patient was randomised to placebo but did not receive study drug thus was excluded from analyses. There were 207 patients included in the FAS; all 207 patients in the FAS were analysed for AEs and 205 patients were analysed for laboratory data. Overall, 196 patients

<div style=\"page-break-after: always\"></div>

completed the study; approximately 98% of patients in the lower dose treatment groups (tofacitinib 2 mg and 5 mg BID) compared to approximately 90% in the tofacitinib 10 mg BID and placebo treatment groups.

## Recruitment

Study A3921119

Study initiation date: 17 April 2013

Completion date: 18 March 2015

Conduct of the study: One amendment to the study A3921119 protocol was planned; the implemented changes seem do not impact study results, and no significant concern has been identified.

## Baseline data

Patient baseline demographics and disease characteristics were similar across all treatment groups. The overall mean age was 41.6 years. The majority (82.7%) of patients in the study were White and 3.8% of patients were of Hispanic/Latino ethnicity. Patients were from the EU (61.8%), Asia (18.8%), North America (13.5%), and the ROW (5.8%). Patients were balanced across treatment groups in their corticosteroid (3.8% to 17.3%) and DMARD (34.6% to 55.8%) use at baseline. The mean (median) duration since diagnosis of AS for the 5 mg BID treatment group was 6.3 (3.5 [range: 0.0-24.4]) years and was similar across treatment groups.

## Medical history

Table 54. Medical History Related to Primary Diagnosis - Safety Analysis Set

Table 10.Medical History Related to Primary Diagnosis -Safety Analysis Set

|                                                                       | Tofacitinib 2 mg BID   | Tofacitinib 2 mg BID   | Tofacitinib 2 mg BID   | Tofacitinib5mgBID   | Tofacitinib5mgBID   | Tofacitinib5mgBID   |
|-----------------------------------------------------------------------|------------------------|------------------------|------------------------|---------------------|---------------------|---------------------|
| Nunber of subjects No significant history related toprimary diagnosis | Yes                    | 52 32 No               | Unknown n (%)          | Yes n (%)           | 52 34 No n (%)      | Unknown n (%)       |
| Eye disorders                                                         | n (%) 13 (25.0)        | n (%) 12 (23.1)        | 0                      | 12 (23.1)           | 14 (26.9)           | 0                   |
| Uveitis                                                               | 13 (25.0)              | 12 (23.1)              | 0                      | 12 (23.1)           | 14 (26.9)           | 0                   |
| Gastrointestinal disorders                                            | 0                      | 25 (48.1)              | 0                      | 3 (5.8)             | 23 (44.2)           | 0                   |
| Inflammatorybowel disease                                             | 0                      | 25 (48.1)              | 0                      | 3 (5.8)             | 23 (44.2)           | 0                   |
| Skin and subcutaneoustissue disorders                                 | 1 (1.9)                | 24 (46.2)              | 0                      | 2 (3.8)             | 24 (46.2)           | 0                   |
| Psoriasis                                                             | 1 (1.9)                | 24 (46.2)              | 0                      | 2 (3.8)             | 24 (46.2)           | 0                   |
| Uncoded                                                               | 11 (21.2)              | 14 (26.9)              | 0                      | 6 (11.5)            | 20 (38.5)           | 0                   |
| Peripheral articularinvolvement                                       | 11 (21.2)              | 14 (26.9)              | 0                      | 6 (11.5)            | 20 (38.5)           | 0                   |
|                                                                       | Tofacitinib 10 mg BID  | Tofacitinib 10 mg BID  | Tofacitinib 10 mg BID  | Placebo             | Placebo             | Placebo             |
| Number of subjects Nosignificanthistoryrelatedtoprimarydiagnosis      |                        | 52 36 No               | Unknown n (%)          | Yes                 | 51 36 No            | Unknown n (%)       |
|                                                                       | Yes n (%)              | n (%)                  |                        | n (%)               | n (%)               |                     |
| Eye disorders                                                         | 6 (11.5)               | 14 (26.9)              | 0                      | 7 (13.7)            | 14 (27.5)           | 0                   |
| Uveitis                                                               | 6 (11.5)               | 14 (26.9)              | 0                      | 7 (13.7)            | 14 (27.5)           | 0                   |
| Gastrointestinal disorders                                            | 0                      | 20 (38.5)              | 0                      | 1 (2.0)             | 20 (39.2)           | 0                   |
| Inflammatorybowel disease                                             | 0                      | 20 (38.5)              | 0                      | 1 (2.0)             | 20 (39.2)           | 0                   |
| Skin andsubcutaneoustissuedisorders                                   | 1 (1.9)                | 19 (36.5)              | 0                      | 2 (3.9)             | 19 (37.3)           | 0                   |
| Psoriasis                                                             | 1 (1.9)                | 19 (36.5)              | 0                      | 2 (3.9)             | 19 (37.3)           | 0                   |
| Uncoded                                                               | 9 (17.3)               | 10 (19.2)              | 1 (1.9)                | 6 (11.8)            | 15 (29.4)           | 0                   |
| Peripheral articular involvement                                      | 9 (17.3)               | 10 (19.2)              | 1 (1.9)                | 6 (11.8)            | 15 (29.4)           | 0                   |

Source: Table 14.1.3.2

Subjects are counted only once for specific disease/syndrome in the table body.

MedDRA (v18.0) coding dictionary applied.

Abbreviations: BID = twice daily, MedDRA = Medical Dictionary for Regulatory Activities, n = number of subjects with data.

Few patients (7 treated and 4 placebo) discontinued the Study A3921119, of which the majority in tofacitinib 10 mg BID arm, and 94-96% of subjects were included in the Per-protocol analysis set.

Overall, demographic characteristics were quite balanced across groups and similar to those of phase 3 study. The majority of subjects in all treatment groups were white males HLA-B27 positive; the

<div style=\"page-break-after: always\"></div>

proportion of subjects positive for HLA-B27 was greatest in the tofacitinib 10 mg BID treatment group. The baseline disease characteristics were compatible with the diagnosis of active AS disease indicated by a median value of 6.2 in tofa 5 mg BID and 6.6 in placebo group for BASDAI and of 3.7 and 3.5, respectively in ASDAS (CRP). A slightly higher median baseline hsPCR value was observed in tofa 5 mg BID group (8.74) compared to placebo group (6.91). A higher number of patients in tofa 5 mg BID group compared to placebo group had a history of IBD, psoriasis and peripheral articular involvement.

## Results

Results of the primary and secondary efficacy endpoints at Week 12 were as follows:

- The primary analysis of the ASAS20 response rate at Week 12 was conducted on the FAS using an Emax model with MR=NR (as shown in Table 55 ). The estimated response rates were 40.1% for placebo and 56.0%, 63.0%, 67.4% for tofacitinib 2, 5, and 10 mg BID, respectively, demonstrating that the response rates for tofacitinib were higher than for placebo.

Table 55 . Analysis of ASAS20 Response Rate at Week 12 Using Emax Model, Comparison to Placebo Full Analysis Set.

|                      |    | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   |
|----------------------|----|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                      |    |                                          |                                          | 95%C                                     | 95%C                                     | 60%C1                                    | 60%C1                                    | 50%CT                                    | 50%CT                                    |
|                      | N  | Estimated                                | Estimate                                 | Lower                                    | U'pper                                   | Lower                                    | U'pper                                   | Lower                                    | U'pper                                   |
| Treatmknt            |    | Responve Rate                            |                                          |                                          |                                          |                                          |                                          |                                          |                                          |
| Tofacinb2 mg BID     | 52 | 56.0                                     | 15.8                                     | 5.0                                      | 30.3                                     | 10.2                                     |                                          | I11                                      | 19.9                                     |
| Tofacitimib 5mgBID   | 52 | 63.0                                     | 22.9                                     | 8.4                                      | 37.7                                     | 16.5                                     | 29.3                                     | 17.8                                     | 28.0                                     |
| Tofscitinib I0 mzBID | 52 | 67.4                                     | 27.3                                     | 10.7                                     | 43.4                                     | 20.3                                     | 34.4                                     | 21.8                                     | 33.0                                     |
| Placebo              | 51 | 40.1                                     |                                          |                                          |                                          |                                          |                                          |                                          |                                          |

Souce:Table1421l1

Missing values dse lo a subjeet dopping from tbe study for amy reason (eg. lack of effcacy or advere event) are hawdled by setting the ASAS20 valse lo non-responsive.Ifcomponents of the ASAS20 are missing atWeek 12. LoCF mixed compoweuts are applied

ASAS20 reponse is defined as ≥20 and ≥1 uit in at least 3 dois on a scale of 0-10 and no worening of &gt;20 and ≥1 mit in the reining doin The 4 ASAS domains are the Patieat Global Aswessment ofDiuease'(from the CRF Labeled NUMERlCAL RATING SCALE -Patiest Global Assesument of Inflammmation (from the BASDAI ie.the average ofquestion5 and 6from the BASDAI CRF)

Abbeviations: AS = ankylosing spondylitis, ASAS =Asesument of SpoodyloAuthritis inlermational Society.ASAS20 =≥2oincrease from Baweline and ≥l mit imcrease in at least 3 domins on a scale of 0 to 10, and no worsening of ≥2o and ≥1 umit in the remaining domnin, BASDAI = Bath Anlylosing Spondyltis Diseae Activity Index.BASFI -Bath Anlylosing Spondylitis Functiomal Index,BID- rwice a day.CI=credible inlerval CRF = Cae Report Forn LOCF = last observation camied forward, N = ntumber of sabjects with available data or data imputed using the non-responderLOCF method

The ASAS20 response rate at Week 12 with missing response as non-response was 41.2% for placebo and 51.9%, 80.8%, 55.8% for tofacitinib 2 mg, 5 mg, and 10 mg BID, respectively (as shown in Table 56 ); the difference in response rates by normal approximation method between tofacitinib 5 mg BID and placebo was statistically significant (p&lt;0.001, without multiple comparison adjustment).

<div style=\"page-break-after: always\"></div>

Table 56 . Normal Approximation to ASAS20 Response at Week 12, Comparison to Placebo - Full Analysis Set NRL/LOCF.

|                     |    |    |                   |      | Differencefrom Placebo\" (Active-Placebo)   | Differencefrom Placebo\" (Active-Placebo)   | Differencefrom Placebo\" (Active-Placebo)   | Differencefrom Placebo\" (Active-Placebo)   | Differencefrom Placebo\" (Active-Placebo)   |
|---------------------|----|----|-------------------|------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Treatment           | N  |    | Responve Rate (%) | SE   | Diff                                       | SE                                         | Lower                                      | Upper                                      | p-Value                                    |
| Tofacitnb2mgBID     | 52 | 27 | 51.92             | 6.93 | 10.75                                      | 9.77                                       | -8.41                                      | 066                                        | 0.271                                      |
| Tofscitinib 5mg BID | 52 | 42 | 80.77             | 5.47 | 39.59                                      | 8.80                                       | 22.35                                      | 56.83                                      | .001                                       |
| Tofcitinb 10 maBID  | 52 | 29 | 55.77             | 6.89 | 14.59                                      | 9.74                                       | -4.50                                      | 33.69                                      | 0.134                                      |
| Placebo             | 51 | 21 | 41.18             | 6.89 |                                            |                                            |                                            |                                            |                                            |

SouceTable14.2.1.2.1

ASAS20 response is defimed as ≥20% and ≥1 umit in at least 3 domwims on a scale of 0-10 and no worsening of ≥20 and ≥1 umit in te remaining domxin The 4 ASAS doumaims are tbePatient Glcbal Assessment of Disease(from the CRF Labeled:NUMfERiCAL RATING SCALE-Patient Global Assessment of AS'). Spinal Pain (from the'NUMERICAL RATING SCALE- Total Back Pain'). Function (avenage of te 10 questions fiom the BASFI CRF) and Lnflammnation (from the BASDAl ie.the average of qoestion 5 and 6 firom the BASDAl CRF)

Abbreviations: ASAS =Assessneul of SponloArthritis intematiomal Society. ASAS20 =≥2oes increase from Baseline and ≥l umit increase in at least 3 domnins on a scale of0 to 10, and no wocsening of ≥20% and ≥1 umit in the remaining domain. BASDAI - Bath Ankylosing Spondylitis Disease Activity Index, BASFI =Bath Ankylosing Spondylitis Functional Index,BID = twice daily. CI = confidence interval. CRF = Case Report Fomm,Diff= difference, LOCF =last observation carried forwand N = munber of subjects with avalable data or data imputed uing the non-esponder/LOCF method n = mmaber of respondens,NRI =noe-responderimputation,SE=standarderor.

Normalapproximation

The ASAS20 response rate in tofacitinib 5 mg BID was higher than placebo at Week 4 (55.8% versus 33.3%; p ≤ 0.05 without multiple comparison adjustment).

- At Week 12, there was a statistically significant higher ASAS40 response rate for tofacitinib 5 mg BID compared with placebo: 21.6% for placebo and 42.3% (p=0.020), 46.2% (p=0.006), and 38.5% (p=0.057) for tofacitinib 2, 5, and 10 mg BID, respectively (without multiple comparison adjustment).
- At Week 12, all ASAS family components showed greater mean reductions from baseline for tofacitinib 5 mg BID versus placebo (2-sided 95% CI for the difference between tofacitinib 5 mg BID and placebo excluded 0).
- At Week 12, there was a statistically significant greater improvement from Baseline for the LS mean SPARCC MRI index of disease activity score of the SI joints and the spine and for the LS mean modified Berlin ASspiMRI Activity Score compared to placebo for the tofacitinib 5 mg BID ( Table 57 ).

| Table 27. Selected Efficacy                                | Endpoints at Week 12 (FAS) Tofacitinib 5 mg BID   | - Study A3921119 Placebo (N = 51)   |
|------------------------------------------------------------|---------------------------------------------------|-------------------------------------|
| Primary efficacy endpoint                                  | Primary efficacy endpoint                         | Primary efficacy endpoint           |
| ASAS20 response rate (Emax model) (%) a                    | 63.0                                              | 40.1                                |
| Normal approximation to ASAS20 response rate, n (%) [N1] a | 42 (80.8)** [52]                                  | 21 (41.2) [51]                      |
| Secondary efficacy endpoints                               | Secondary efficacy endpoints                      | Secondary efficacy endpoints        |
| Normal approximation to ASAS40 response rate, n (%) [N1] a | 24 (46.2)* [52]                                   | 11 (21.6) [51]                      |
| ∆ ASDAS(CRP), LSM (SE) [N1]                                | -1.41 (0.119)** [50]                              | -0.68 (0.123) [45]                  |
| ∆ hsCRP (mg/L), LSM (SE) [N1]                              | -7.00 (1.174)** [50]                              | -1.00 (1.221) [45]                  |
| ∆ ASQoL, LSM (SE) [N1] b                                   | -4.79 (0.615)* [52]                               | -2.53 (0.627) [51]                  |

<div style=\"page-break-after: always\"></div>

Table 27. Selected Efficacy Endpoints at Week 12 (FAS) - Study A3921119

|                                                          | Tofacitinib 5 mg BID (N = 52)   | Placebo (N = 51)   |
|----------------------------------------------------------|---------------------------------|--------------------|
| ∆ SF-36v2, LSM (SE) [N1] b                               |                                 |                    |
| PCS                                                      | 6.49 (0.914)** [52]             | 2.69 (0.932) [51]  |
| MCS                                                      | 4.15 (1.294) [52]               | 2.41 (1.318) [51]  |
| ∆ BASMI Score (Linear Method), LSM (SE) [N1] c           | -0.39 (0.108) [50]              | -0.15 (0.111) [46] |
| ∆ FACIT-F Total Score, LSM (SE) [N1] c                   | 7.03 (1.145)* [50]              | 3.08 (1.178) [46]  |
|  PGA, mean (SD) [N1]                                    | -2.8 (2.18) [50]                | -1.7 (2.54) [46]   |
| ∆ Total Back Pain, mean (SD) [N1]                        | -3.2 (2.19) [49]                | -2.0 (2.40) [46]   |
| ∆ Inflammation, mean (SD) [N1]                           | -3.17 (2.147) [50]              | -1.78 (2.260) [46] |
| ∆ BASFI, LSM (SE) [N1] c                                 | -2.39 (0.260)* [50]             | -1.43 (0.266) [46] |
| ASAS 5/6, n (%) [N1] a                                   | 36 (69.23)** [52]               | 12 (23.53) [51]    |
| ASAS Partial Remission, n (%) [N1] a                     | 10 (19.23) [52]                 | 6 (11.76) [51]     |
| ∆ Spinal mobility (Chest expansion, cm), LSM (SE) [N1] c | 0.49 (0.187) [50]               | 0.31 (0.193) [46]  |
| BASDAI, LSM (SE) [N1] c                                  | -2.88 (0.276)* [50]             | -1.85 (0.283) [46] |
| ASDAS Clinically Important Improvement, n (%) [N1] a,d   | 33 (63.46)** [52]               | 14 (27.45) [51]    |
| ASDAS Major Improvement, n (%) [N1] a,e                  | 12 (23.08) [52]                 | 6 (11.76) [51]     |
| ASDAS Inactive Disease, n (%) [N1] a,f                   | 7 (13.46) [52]                  | 4 (7.84) [51]      |
| ∆ MASES, LSM (SE) [N1] c                                 | -1.37 (0.259)* [50]             | -0.34 (0.265) [46] |
| ∆ Swollen Joint Count, LSM (SE) [N1] c                   | -0.79 (0.362) [50]              | -0.99 (0.373) [46] |
| ∆ EuroQoL EQ-5D-3L, LSM (SE) [N1] b                      |                                 |                    |
| Mobility                                                 | -0.29 (0.063) [52]              | -0.11 (0.064) [51] |
| Self-care                                                | -0.14 (0.055) [52]              | -0.19 (0.056) [51] |
| Usual activities                                         | -0.29 (0.071) [52]              | -0.15 (0.073) [51] |
| Pain/discomfort                                          | -0.30 (0.067) [52]              | -0.22 (0.068) [51] |
| Anxiety/depression                                       | -0.17 (0.070) [52]              | -0.03 (0.071) [51] |

<div style=\"page-break-after: always\"></div>

Table 27. Selected Efficacy Endpoints at Week 12 (FAS) - Study A3921119

|                                                        | Tofacitinib 5 mg BID (N = 52)   | Placebo (N = 51)    |
|--------------------------------------------------------|---------------------------------|---------------------|
| ∆ WPAI, LSM (SE) [N1] b                                |                                 |                     |
| Percent work time missed due to health problem         | -5.19 (1.488) [35]              | -1.40 (1.642) [29]  |
| Percent impairment while working due to health problem | -20.91 (3.394)* [36]            | -6.09 (3.780) [29]  |
| Percent overall work impairment due to health problem  | -21.67 (3.570)* [35]            | -5.39 (3.916) [29]  |
| Percent inactivity due to health problem               | -19.46 (3.131)** [50]           | -11.22 (3.270) [46] |
| ∆ SPARCC MRI spine, LSM (SE) [N1] b,g                  | -5.51 (1.063)** [52]            | -0.09 (1.085) [51]  |
| ∆ SPARCC MRI SI Joint, LSM (SE) [N1] b                 | -3.15 (0.788)* [52]             | -0.81 (0.806) [51]  |
| ∆ ASspiMRI, LSM (SE) [N1] b                            | -2.22 (0.364)** [52]            | -0.41 (0.372) [51]  |

Nominal *p≤0.05; **p&lt;0.001 tofacitinib 5 mg BID versus placebo at Week 12

N1 = number of patients evaluable at Week 12

a. NRI/LOCF Mixed Components

b. ANCOVA model includes fixed effects for treatment group and baseline value as a covariate with LOCF for imputing missing values.

- c. The fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value were included, an unstructured covariance matrix was used.
- d. ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units.
- e. ASDAS major improvement is define d as change (decrease) from baseline of ≥2.0 units.
- f. ASDAS inactive disease is defined as ASDAS &lt;1.3 units
- g. Index of disease activity score of the spine at Week 12

Figure 17. Line Graph of ASAS20 Response Rate (+/- SE) (Normal Approximation) by Visit Up to Week 12 - FAS, NRI/LOCF Mixed Components - Study A3921119

Figure 28. Line Graph of ASAS40 Response Rate (+/- SE) (Normal Approximation) by Visit Up to Week 12 - FAS, NRI/LOCF Mixed Components - Study A3921119

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

In the Phase 2 dose-ranging Study A3921119, at Week 12 patients with active AS receiving tofacitinib 2 mg, 5 mg, or 10 mg IR BID had a respective estimated ASAS20 response rate of 56.0%, 63.0%, or 67.4% compared to an estimated placebo response rate of 40.1% (primary analysis using an Emax model). Therefore, only the tofacitinib 10 mg BID treatment group met pre-specified statistical decision rules for the primary endpoint of the ASAS20, with an estimated difference from placebo of 27.3%, a 20.3% difference for the lower bound of the 2-sided 60% credible interval, and a 33.0% difference for the upper bound of the 2-sided 50% credible interval. Results from supportive analysis using the normal approximation method showed the ASAS20 response rate of 51.9%, 80.8%, 55.8% for tofacitinib 2 mg, 5 mg, and 10 mg BID, respectively, and 41.2% for placebo. Only the difference between tofacitinib 5 mg BID and placebo was statistically significant (p&lt;0.001). Across most of the secondary endpoint pertaining to disease activity and physical functions, health related outcomes and radiological progression, tofacitinib 5 mg showed to be more effective than placebo, supporting results from phase 3 pivotal study. Regarding spinal mobility , which is an important efficacy parameter to support ASAS as primary endpoint (see also comment above on pivotal study), a major change in Linear BASMI Score at week 12 was observed in tofacitinib 5 mg BID group (-0.39) compared to placebo group (-0.15) which however did not reach the statistical significance, as well as the other spinal mobility score used to evaluate chest expansion (0.49 vs 0.31). Moreover, for other more stringent endpoint at week 12 such as ASAS partial remission, ASDAS major improvement and ASDAS inactive disease for tofacitinib 5 mg BID there were no statistically significant differences from placebo, although a slightly greater response rate was observed.

## Additional supportive studies

The Applicant has submitted a report summarising the existing scientific evidence on the development and psychometric properties of three patient reported outcomes: ASQoL, SF-36v2, FACIT-F ( Table 55 ). These three outcomes were included in the set of secondary outcomes subjected to the hierarchical testing procedure for control of global type-I error in the pivotal study A 391120 (Table 58) The concept and psychometric properties of the ASQoL and of the FACIT-F for use in AS is presented below. Similar results supporting the reliability, validity and sensitivity to change of the SF-36 in AS were also prepared by the MAH but are not reproduced in this section.

<div style=\"page-break-after: always\"></div>

## Table 58 Patient reported efficacy outcomes in study A3921120.

| Concept/Outcome          | Measurement Tool   | Endpoint                                                                                                                                                   |
|--------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Disease-specific HRQoL   | ASQoL              | △ in ASQoL at Week 16 and Week 48                                                                                                                          |
| Functional Health Status | SF-36v2            | in SF-36v2 Acute (10 endpoints: eight norm-based domain scores [PF, RP, BP, GH, VT, SF, RE, and MH] as well as PCS and MCS scores) at Week 16 and Week 48. |
| Fatigue                  | FACIT-F            | in FACIT-F (three endpoints: total score, experience domain, and impact domain scores) at all timepoints collected up toWeek 48                            |

Abbreviations: A = change from baseline; ASQoL = Ankylosing Spondylitis Quality of Life; BP = bodily pain; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; GH = General Health; HRQoL =Health-related Quality of Life; MCS = Mental Component Summary; MH = Mental Health; PCS = Physical Component Summary, PF = Physical Functioning: RE = Role-Emotional; RP = Role-Physical; SF-36v2 = Short Form 36 Version 2; SF = Social Functioning: VT = Vitality

## ASQoL

The ASQoL is an 18-item PRO questionnaire to assess QoL impacts specific to AS ( Figure 29 ).  It  was originally developed in the United Kingdom through qualitative, unstructured interviews and focus groups with patients to ensure that the content was relevant and covered issues of importance to AS patients.

## Figure 29 Overview of the ASQoL items

<!-- image -->

The ASQoL leads to a single total score. Each ASQoL statement is given a score of 1 = Yes or 0 = No, with an answer of 'Yes' indicating adverse QoL. All item scores are summed to give a total score ranging from 0 (good QoL) to 18 (poor QoL). For respondents with one to three missing responses (no more than 20% missing), a total score can still be calculated, based on the nonmissing items. The ASQoLhas been fitted to the Rasch Measurement Model to allow for parametric statistical analyses (the

<div style=\"page-break-after: always\"></div>

Rasch model was not applied in the analyses for study A3921120). The ASQoL is completed previous to the clinical visit, on paper with a pen/pencil, and generally takes less than 10 minutes for respondent to complete.

The internal consistency or item-scale correlation of the ASQoL is good with high values for Cronbach's α in several studies (Table 59 ).

Table 59 Internal consistency of the ASQoL

| Reference                               | Instrument                       | Population         | Timepoint/ Instrument Version   | Internal Consistency   |
|-----------------------------------------|----------------------------------|--------------------|---------------------------------|------------------------|
| ASQoL User Manual- Galen Research 20194 | ASQoL                            | N/A                | N/A                             | α=0.94                 |
| Doward et al. 20035                     | ASQoL                            | 129 AS patients    | UK time 1                       | α=0.91                 |
| Doward et al. 20035                     | ASQoL                            | 129 AS patients    | UK time 2                       | α=0.92                 |
| Doward et al. 20035                     | ASQoL                            | 119 AS patients    | NL time 1                       | α=0.89                 |
| Doward et al. 20035                     | ASQoL                            | 119 AS patients    | NL time 2                       | α=0.90                 |
| Duruoz et al. 20136                     | ASQoL (Turkish version)          | 277 AS patients    |                                 | Q=0.89                 |
| Fallahi et al. 2014?                    | ASQoL (Iranian version)          | 163 AS patients    |                                 | α=0.91                 |
| Graham et al. 2015s                     | ASQoL (Greek version)            | 92 AS patients     |                                 | 0=0.92                 |
| Leung et al. 20179                      | ASQoL(Singapore Chinese version) | 183 axSpA patients | English version                 | α=0.86                 |
| Leung et al. 20179                      | ASQoL(Singapore Chinese version) | 183 axSpA patients | Singapore Chinese version       | α=0.93                 |

Abbreviations: AS = ankylosing spondylitis; ASQoL = Ankylosing Spondylitis Quality of Life; axSpA = axial spondyloarthritis; UK = United Kingdom; N/A =Not Available; NL =Netherlands; α= Cronbach's alpha coefficient

The test-retest reliability , preferably analysed using intraclass correlation coefficients (ICC) is high in several studies-and-languages/cultures ( Table 60 ).

Table 60 Test-retest reliability of the ASQoL

| Reference                                | Instrument                        | Population        | Timepoint/Instrument Version                                                                          | Correlation Coefficient   |
|------------------------------------------|-----------------------------------|-------------------|-------------------------------------------------------------------------------------------------------|---------------------------|
| ASQoL User Manual - Galen Research 20194 | ASQoL                             | N/A               | N/A                                                                                                   | 0.94                      |
| Doward etal. 2003                        | ASQoL                             | 129 AS patients   | UK two weeks apart                                                                                    | p=0.92*                   |
| Doward etal. 2003                        | ASQoL                             | 119 AS patients   | NL two weeks apart                                                                                    | p=0.91*                   |
| Duruoz et al. 20136                      | ASQoL (Turkish version)           | 277 AS patients   | One week apart                                                                                        | ICC=0.96                  |
| Fallahi et al. 20147                     | ASQoL (Iranian version)           | 163 AS patients   | Two visits for 54 patients within a 48-hour interval                                                  | ICC=0.97**                |
| Graham et al. 20158                      | ASQoL (Greek version)             | 92 AS patients    | 87 patients at two timepoints                                                                         | p=0.98                    |
| Leung et al. 20179                       | ASQoL (Singapore Chinese version) | 42 axSpA patients | 19 completed the Singapore Chinese, and 23 completed the English version at timepoints twoweeks apart | p=0.81                    |

Abbreviations: AS = ankylosing spondylitis; ASQoL = Ankylosing spondylitis Quality of Life; axSpA = axial spondyloarthritis; ICC = intraclass correlation coefficient; UK = Umited Kingdomr; N/A = Not Available; NL = Netherlands; p = Spearman's rank

correlation coefficient

*Spearman rank correlation coefficient and ICCs were identical; **p &lt; 0.001; fcorrelation coefficient used not specified

The construct validity of the ASQoL ( Table 61 ) was assessed by relating scores to the Nottingham Health Profile (NHP) and self-perceived severity of illness. Moderately high Spearman rank correlation coefficients were  seen  between  the  ASQoL  and  NHP  section  scores:  energy  levels  (0.80),  pain  (0.77),  emotional reactions (0.66), sleep disturbance (0.59), social isolation (0.62), and physical mobility (0.87).

<div style=\"page-break-after: always\"></div>

Table 61 Construct validity of the ASQoL

| Reference             | Trial Description                                                                                                                                                                                                   | Sample Size (treatment)            | Domain                        | Criterion Measure             | Correlation   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------|-------------------------------|---------------|
| Deodhar et al. 201926 | A five-year, Phase III randomised control trial in Austria, Canada, Czech Republic, Finland, Germany. Italy, Netherlands, Russia, Singapore, Spain, Switzerland UK, and US                                          | 72 (secukinumab 150 mg) 74 placebo | ASQoL Item 5 Response (sleep) | VAS spinal pain at Week 16    | 1= -0.46*     |
| Deodhar et al. 201926 | A five-year, Phase III randomised control trial in Austria, Canada, Czech Republic, Finland, Germany. Italy, Netherlands, Russia, Singapore, Spain, Switzerland UK, and US                                          | 72 (secukinumab 150 mg) 74 placebo | ASQoL Item 5 Response (sleep) | VAS nocturnal pain at Week 16 | f=-0.43*      |
| Deodhar et al. 201926 | A five-year, Phase III randomised control trial in Austria, Canada, Czech Republic, Finland, Germany. Italy, Netherlands, Russia, Singapore, Spain, Switzerland UK, and US                                          | 72 (secukinumab 150 mg) 74 placebo | ASQoL Item 5 Response (sleep) | VAS spinal pain at Week 52    | f=-0.31*      |
| Deodhar et al. 201926 | A five-year, Phase III randomised control trial in Austria, Canada, Czech Republic, Finland, Germany. Italy, Netherlands, Russia, Singapore, Spain, Switzerland UK, and US                                          | 72 (secukinumab 150 mg) 74 placebo | ASQoL Item 5 Response (sleep) | VAS nocturnal pain at Week52  | I=-0.34*      |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 129 UK AS patients                 | ASQoL                         | NHP physical mobility         | p=0.78        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 129 UK AS patients                 | ASQoL                         | NHP energy                    | p=0.74        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 129 UK AS patients                 | ASQoL                         | NHP pain                      | p=0.81        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 129 UK AS patients                 | ASQoL                         | NHP emotional reactions       | p=0.72        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 129 UK AS patients                 | ASQoL                         | BASFI                         | p=0.72        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 119 NL AS patients                 | ASQoL                         | NHP physical mobility         | p=0.79        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 119 NL AS patients                 | ASQoL                         | NHP energy                    | p=0.73        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 119 NL AS patients                 | ASQoL                         | NHP pain                      | p=0.79        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 119 NL AS patients                 | ASQoL                         | NHP emotional reactions       | p=0.73        |
| Doward et al. 20035   | Development of the ASQoL in parallel in the UK and NL involving patient interviews, field testing. and postal surveys                                                                                               | 119 NL AS patients                 | ASQoL                         | BASFI                         | p=0.75        |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | FACIT-F at Week 12            | f=-0.81**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 PF at Week 12           | f=-0.70**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 PF at Week 12           | f=-0.73**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 RP at Week 12           | f=-0.73**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 BP at Week 12           | f=-0.76**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 VT at Week 12           | f=-0.72**     |
| Revicki et al. 201110 | Psychometric analyses of PRO data collected from two Phase III, randomised, double-blind, placebo-controlled clinical trials that assessed the safety and clinical efficacy of adalimumab in Canada. Europe, and US | 397 AS patients (adalimumab 40 mg) | ASQoL                         | SF-36 SF at Week 12           | f=-0.77**     |

Abbreviations: AS = ankylosing spondylitis; ASQoL = ankylosing spondylitis quality of life; ASAS = Assessment of Spondyloarthritis Intermational Society; BASFI =Bath Ankylosing Spondylitis Functional Index; BP = bodily pain; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; GH = general health; NL = Netherlands; NHP = Nottingham Health =g r p =  e = d  p =   p g = Form 36; UK = United Kingdom; US = United States; VAS = visual analogue scale; VT = vitality; r = Pearson correlation coefficient; p = Spearman's rank correlation coefficient

*p&lt;0.05; **p&lt;0.0001

Evidence of sensitivity to change is found in several clinical trials. In a clinical trial for adalimumab (van der Heijde 2015) the MID was defined as a decrease of ≥ 1.8 points on the ASQoL. This definition was also used in a clinical trial for certolizumab pegol (Sieper 2015). The ASQoL has since been used in Food and Drug Administration (FDA) and EMA labelling claims for adalimumab and certolizumab pegol. Thus, although the MID has not been explicitly mentioned in the labels, this change provides a precedent, a threshold, which should be expected for an efficacious drug endpoint, and can support interpretation of the ASQoL instrument in a clinical trial for AS.

Additional data on the ability of the ASQoL to detect change between groups in placebo-controlled trials with FDA and EMA-approved drugs are: secukinumab (Deodhar 2016), certolizumab pegol (Sieper 2015), tofacitinib and adalimumab (Strand 2019).

## FACIT-F

The FACIT-F is a 13-item questionnaire to asses self-reported fatigue and its impact upon daily activities and function. It is a subset of items from the larger 47-item Functional Assessment of Cancer Therapy Anaemia (FACT-An) that is comprised of the 27-item Functional Assessment of Cancer Therapy General (FACT-G) and a 20-item anaemia subscale. The FACT-An, from which the FACIT-F is derived, was developed in  1994  to  1995  for  cancer-related  anaemia  over  a  series  of  four  phases:  item  generation  involving

<div style=\"page-break-after: always\"></div>

interviews with patients and medical experts; item review and selection, involving additional interviews with medical experts; scale construction; and psychometric evaluation (Cella 2012; FACIT.org).

The FACIT-F uses a five-point Likert scale for all items (where 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, and 4=Very Much) and has a recall period of 'the past 7 days.' Thus, each FACIT-F item is scored from 0 to 4; higher scores indicate lower fatigue.

Three endpoints can be derived from the FACIT-F: the FACIT-F total score, the FACIT-F experience domain score, and the FACIT-F impact domain score ( Figure 30 ). The FACIT-F total score is calculated by summing the 13 items and ranges from 0 to 52. If there are missing items and more than 50% of the items were answered (i.e., at least seven of 13 for the FACIT-F total score, at least three of five for FACIT-F experience domain score, and at least five of eight for the FACIT-F impact domain score), then the score can be considered valid.

Figure 30 FACIT-F overview of items, subscales and total score

<!-- image -->

The FACIT-F was originally developed to assess fatigue in cancer patients that resulted from chemotherapy regimens or a corresponding anaemia. Regarding content validity , the development process ensured that the fatigue subscale items covered concepts relevant to fatigue in general. The development process included item generation with patients and medical experts, item selection, psychometric testing and item reduction and validation.

Up to now, the FACIT-F was used in one EMA labelling claim for secukinumab in AS. In the initial study for FACIT-F development, convergent and divergent validity of the FACIT-F in testing to differentiate patients by haemoglobin level and patient-rated performance status was demonstrated (Cella 2012; FACIT.org). Data regarding the psychometric properties of the FACIT-F in AS is found in several studies (tables below).

The internal consistency , or item-scale correlation, of the FACIT-F, as shown in the tofacitinib studies in this application and three other studies in patients with Psoriatic Arthritis is good, with high levels of Cronbach's α ( Table 62 ).

<div style=\"page-break-after: always\"></div>

Table 62 Internal consistency of the FACIT-F

| Reference                          | Instrument   | Population          | Domain/ Timepoint                     | Internal Consistency   |
|------------------------------------|--------------|---------------------|---------------------------------------|------------------------|
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 204 AS patients     | Study 1119 total score baseline       | α=0.94                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 194 AS patients     | Study 1119 total score Week 12        | α=0.95                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 204 AS patients     | Study 1119 experience domain baseline | α=0.89                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 194 AS patients     | Study 1119 experience domain Week 12  | α=0.93                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 204 AS patients     | Study 1119 impact domain baseline     | α=0.90                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 194 AS patients     | Study 1119 impact domain Week 12      | α=0.92                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 268 AS patients     | Study 1120 total score baseline       | α=0.93                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 264 AS patients     | Study 1120 total score Week 16        | α=0.94                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 268 AS patients     | Study 1120 experience domain baseline | α=0.88                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 265 AS patients     | Study 1120 experience domain week 16  | α=0.92                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 269 AS patients     | Study 1120 impact domain baseline     | α=0.88                 |
| Appendix5.FACIT- FValidation in AS | FACIT-F      | 264 AS patients     | Study 1120 impact domain Week 16      | α=0.90                 |
| Cella 201336 Yellen et al. 199711  | FACIT-F      | 49 anaemic patients | Initial                               | α=0.93                 |
| Cella 201336 Yellen et al. 199711  | FACIT-F      | 49 anaemic patients | Retest                                | α=0.95                 |
| Cella et al. 201912                | FACIT-F      | 760 PsA patients    | Total score                           | α=0.95                 |
| Cella et al. 201912                | FACIT-F      | 763 PsA patients    | Experience domain                     | α=0.93                 |
| Cella et al. 201912                | FACIT-F      | 762 PsA patients    | Impact domain                         | α=0.91                 |
| Cella et al. 201912                | FACIT-F      | 766 PsA patients    | Total score                           | α=0.94                 |
| Cella et al. 201912                | FACIT-F      | 768 PsA patients    | Experience domain                     | α=0.91                 |
| Cella et al. 201912                | FACIT-F      | 768 PsA patients    | Impact domain                         | α=0.90                 |
| Revicki et al. 201110              | FACIT-F      | 82 AS patients      | Baseline                              | α=0.82                 |
| Revicki et al. 201110              | FACIT-F      | 82 AS patients      | Week 12                               | α=0.86                 |

Abbreviations: AS = ankylosing spondylitis; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; PsA = psoriatic arthritis, α = Cronbach's alpha coefficient

The test-retest reliability of the FACIT-F was assessed in the current tofactitinib trials using the baseline and week 2 data, and in some other trials in patients with anaemia and in patients with Psoriatic Arthritis. The intraclass correlation coefficients point to good test-retest reliability (Table 63).

Table 63 Test-retest reliability of the FACIT-F

| Reference                         | Instrument   | Population          | Domain            | Correlation Coefficient   |
|-----------------------------------|--------------|---------------------|-------------------|---------------------------|
| Appendix5.FACiT-F Validation inAS | FACIT-F      | AS patients         | Total score       | ICC-0.86-0.89             |
| Appendix5.FACiT-F Validation inAS | FACIT-F      | AS patients         | Experience domain | ICC-0.75-0.86             |
| Appendix5.FACiT-F Validation inAS | FACIT-F      | AS patients         | Impact domain     | ICC-0.84-0.87             |
| Cella 201336                      | FACIT-F      | 49 anaemic patients |                   | F0.90                     |
| Yellen et al. 1997l1              | FACIT-F      | 49 anaemic patients |                   |                           |
| Cella et al. 2019l                | FACIT-F      | 760 PsA patients    | Total score       | ICC-0.79                  |
| Cella et al. 2019l                | FACIT-F      | 760 PsA patients    | Experience domain | ICC=0.78                  |
| Cella et al. 2019l                | FACIT-F      | 760 PsA patients    | Impact domain     | ICC=0.78                  |
| Cella et al. 2019l                | FACIT-F      | 766 PsA patients    | Total score       | ICC=0.87                  |
| Cella et al. 2019l                | FACIT-F      | 766 PsA patients    | Experience domain | ICC=0.81                  |
| Cella et al. 2019l                | FACIT-F      | 766 PsA patients    | Impact domain     | ICC-0.87                  |

Abbreviations: AS = ankylosing spondylitis; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; ICC = intraclass corelation coefficient; PsA = psoriatic arthrilis; P = Pearson correlation coefficient

The construct validity in patients with AS has been assessed in the two current trials with tofacitinib and in two other trials in AS. Medium to high-sized correlation coefficients were found for relations with other patient assessed questionnaires assessing related outcomes: ASQoL, SF-36, ASAS20, VAS pain, PGA (Table 64 ).

<div style=\"page-break-after: always\"></div>

## Table 64. Construct validity of the FACIT-F

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Reference       | Trial Deseription                                                  | Sample Size     | Domain            | Criterion Mfeasure                                   | Correlation/ Effect Size   |
|-----------------|--------------------------------------------------------------------|-----------------|-------------------|------------------------------------------------------|----------------------------|
|                 |                                                                    | (Ireatment)     |                   | SF-36v2 VT at Week 16                                | r=0.80                     |
|                 |                                                                    |                 |                   | SF-36v2 SF at Week 16                                | r=0.76                     |
|                 |                                                                    |                 |                   | SF-36v2 RE at Week 16                                | r=0.69                     |
|                 |                                                                    |                 |                   | SF-36v2 MH at Week 16                                | r=0.74                     |
|                 |                                                                    |                 |                   | SF-36v2 PCS at Week 16                               | r=0.65                     |
|                 |                                                                    |                 |                   | SF-36v2 MCS at Week 16                               | r=0.77                     |
|                 |                                                                    | Study 1120      | Experience        | ASQoL at Week 16                                     | r=-0.74                    |
|                 |                                                                    |                 | domain            | SF-36v2 PF at Week 16                                | r=0.60                     |
|                 |                                                                    |                 |                   | SF-36v2 RP at Week 16                                | r=0.70                     |
|                 |                                                                    |                 |                   | SF-36v2 BP at Week 16                                | r=0.69                     |
|                 |                                                                    |                 |                   | SF-36v2 GH at Week 16                                | r=0.63                     |
|                 |                                                                    |                 |                   | SF-36v2 VT at Week 16                                | r=0.85                     |
|                 |                                                                    |                 |                   | SF-36v2 SF at Week 16                                | r=0.72                     |
|                 |                                                                    |                 |                   | SF-36v2 RE at Week 16                                | r=0.66                     |
|                 |                                                                    |                 |                   | SF-36v2 MH at Week 16                                | r=0.72                     |
|                 |                                                                    |                 |                   | SF-36v2 PCS at Week 16                               | r=0.62                     |
|                 |                                                                    |                 |                   | SF-36v2 MCS at Week 16                               | r=0.76                     |
|                 |                                                                    | Study 1120      | Impact domain     | ASQoL at Week 16                                     | r= -0.78                   |
|                 |                                                                    |                 |                   | SF-36v2PF at Week 16                                 | r=0.64                     |
|                 |                                                                    |                 |                   | SF-36v2 RP at Week 16                                | r=0.71                     |
|                 |                                                                    |                 |                   | SF-36v2 BP at Week 16                                | r=0.68                     |
|                 |                                                                    |                 |                   | SF-36v2 GH at Week 16                                | r=0.53                     |
|                 |                                                                    |                 |                   | SF-36v2 VT at Week 16                                | r=0.71                     |
|                 |                                                                    |                 |                   | SF-36v2 SF at Week 16                                | r=0.74                     |
|                 |                                                                    |                 |                   | SF-36v2 RE at Week 16                                | r=0.66                     |
|                 |                                                                    |                 |                   | SF-36v2 MH at Week 16                                | r=0.70                     |
|                 |                                                                    |                 |                   | SF-36v2 PCS at Week 16                               | r=0.61                     |
|                 |                                                                    |                 |                   | SF-36v2 MCS at Week 16                               | r=0.72                     |
|                 |                                                                    | Study 1119      | Total score       | PGA at Week 12                                       | r=-0.39**                  |
|                 |                                                                    | Study 1120      | Total score       | PGA at Week 12                                       | r=-0.53**                  |
|                 |                                                                    | Study 1120      | Total score       | PGA at Week 16                                       | r=-0.46**                  |
|                 |                                                                    | Study 1119      | Experience domain | PGA at Week 12                                       | r=-0.34**                  |
|                 |                                                                    | Study 1120      | Experience domain | PGA at Week 12                                       | r=-0.50**                  |
|                 |                                                                    | Study 1120      | Experience domain | PGA at Week 16                                       | r=-0.45**                  |
|                 |                                                                    | Study 1119      | Impact domain     | PGA at Week 12                                       | r=-0.38**                  |
|                 |                                                                    | Study 1120      | Impact domain     | PGA at Week 12                                       | r=-0.49**                  |
|                 |                                                                    | Study 1120      | Impact domain     | PGA at Week 16                                       | r=-0.42**                  |
|                 |                                                                    | Study 1119      | Total score       | PGA \"not active disease\"                             | ES=1.38**                  |
|                 |                                                                    |                 | Experience domain | and \"very achive disease\" at post-baseline visits up | ES=1.63**                  |
|                 |                                                                    |                 | Impact domain     | to Week 12                                           | ES=1.17**                  |
|                 |                                                                    | Study 1120      | Total score       | PGA \"not active disease\"                             | ES=1.40**                  |
|                 |                                                                    |                 | Experience domain | and \"very active disease\" at post-baseline visits up | ES=1.61**                  |
|                 |                                                                    |                 | Impact domain     | to Week 16                                           | ES=1.23**                  |
| Deodhar, 201926 | A five-year, phase III, randomised control tial in Aushia, Canada, | 72 (secukinumab | FACIT-F score     | VAS spinal pain at Week                              | r=-0.49*                   |
| Deodhar, 201926 | A five-year, phase III, randomised control tial in Aushia, Canada, | 150 mg)         | FACIT-F score     | 16                                                   |                            |
| Deodhar, 201926 | Czech Republie,                                                    | 74 (placebo)    | FACIT-F score     | VAS noctunal pain at Week 16                         | r=-0.48*                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Reference       | Trial Description                                                                                                                                                                 | Sample Size (Treatment)            | Domain              | Criterion Mfeasure            | Correlation/ Effect Size   |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------|-------------------------------|----------------------------|
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | FACIT-F             | VAS spinal pain at Week 104   | r=-0.58*                   |
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | FACIT-F             | VAS nochunal pain at Week 104 | =-0.50*                    |
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | response            | VAS spinal pain at Week 16    | r=-0.48*                   |
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | response            | VAS noctunal pain at Week 16  | r=-0.51*                   |
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | response            | VAS spinal pain at Week 104   | r=-0.68*                   |
|                 | Finland, Germany, Italy. Netherlands, Russia, Singapore, Spain, Switzerland, UK, and US                                                                                           |                                    | response            | VAS nochunal pain at Week 104 | r=-0.58*                   |
| Revicki, 201110 | Psychometric analyses of PR.O data collected from two phase IIl, randomised, double- blind, placebo- conhrolled clinical trials that assessed the safety and clinical efficacy of | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | ASQoL at Week 12              | r=-0.81**                  |
| Revicki, 201110 | Psychometric analyses of PR.O data collected from two phase IIl, randomised, double- blind, placebo- conhrolled clinical trials that assessed the safety and clinical efficacy of | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | SF-36 MCS at Week 12          | r=0.71**                   |
| Revicki, 201110 | Psychometric analyses of PR.O data collected from two phase IIl, randomised, double- blind, placebo- conhrolled clinical trials that assessed the safety and clinical efficacy of | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | SF-36BP at Week 12            | r=0.75**                   |
| Revicki, 201110 | Psychometric analyses of PR.O data collected from two phase IIl, randomised, double- blind, placebo- conhrolled clinical trials that assessed the safety and clinical efficacy of | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | SF-36 VT at Week 12           | r=0.82**                   |
| Revicki, 201110 | Psychometric analyses of PR.O data collected from two phase IIl, randomised, double- blind, placebo- conhrolled clinical trials that assessed the safety and clinical efficacy of | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | SF-36SF at Week 12            | r=0.73**                   |
| Revicki, 201110 | adalimumab in Canada Europe, and US                                                                                                                                               | 397 AS patients (adalimumab 40 mg) | FACIT-F total score | ASAS20                        | ES=0.92t (n=12)            |

Abbreviatious: AS = ankylosing spondylitis; ASAS = Assessment of Spondyloarthritis Intermational Society; ASQoL = ankylosing spondylitis quality of life; BP = bodily pain; ES = effect size; FACIT-F = Functional Assessment of Chromic Illness Therapy-Fatigue; GH = general health; MCS = mental component siwmmary; MH =mental health; PCS =physical component summary; PGA = Patient Global Assessment of Disease; PF = physical fimctioning; RE =role emotional; RP = role physical; SF = social functioning; SF-36 = Short Fonm 36; VAS =visual amalogue scale; VT = vitality; r=Pearson comelation coefficient p &lt; 0.05; **p &lt; 0.0001; ↑Effect sizes reported for≥ 0.70, p &lt; 0.0001

The sensitivity to change of the FACIT-F was confirmed in several recent placebo-controlled trials in AS (secukinumab, Deodhar 2016), and in PsA (tofacitinib, Strand 2019a, Strand 2019b, Gladman 2017; golimumab, Krüger 2018).

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

With this submission, the MAH seeks a new indication for Tofacitinib for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. The recommended dose of tofacitinib is 5 mg administered twice daily.

In support of the sought indication the MAH is providing i) supportive data from Study A3921119 a phase 2, multicenter, randomised, double-blind, placebo-controlled dose ranging, parallel group efficacy and safety study designed to characterize the dose response of tofacitinib 2 mg BID, 5 mg BID and 10 mg BID in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs; dose of 5mg BID was selected; ii) confirmatory evidence from one pivotal study A3921120, a phase 3, randomized, double-blind, placebo-controlled, parallel group comparing tofacitinib 5mg dosed twice daily to placebo in subjects with active AS, who had experienced an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, or TNFi-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]).  The study design included a 16-week double-blind treatment period, a 32-week open-label treatment period (all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48) and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

<div style=\"page-break-after: always\"></div>

The design of the pivotal study could be acceptable, however since tofacitinib belongs to a new therapeutic class for the AS indication and the study includes biological naïve patients a three-arm trial (including an accepted active comparator) would have been recommended as per the EMA guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis

(EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) , particularly for assessing a relative B/R balance. However, the MAH has performed a meta-analysis of approved treatments and also included the results of the tofacitinib trials (dose-finding and pivotal study) as supportive data.

The duration of the maintenance period is in line with the guideline although a longer OL period would have been recommended for assessing structural changes. Dose reduction/changing dose interval in ankylosing spondylitis (AS) patients after resolution of inflammation following tofacitinib treatment has not been evaluated and that there are no data supporting changing dose interval, which has been acceptable.

The study included subjects with active AS defined as: Modified New York Criteria for Ankylosing Spondylitis (1984), BASDAI score of ≥4 and back pain score (BASDAI Question 2) of ≥4 at both screening and baseline and that have had an inadequate response to at least 2 different NSAIDs. Additionally, bDMARD naïve, TNFi-IR, or bDMARD (non-IR) exposed were enrolled in this study. Overall inclusion and exclusion criteria are adequate for selecting an active AS population and also for taking into account the safety profile of the drug.

The proportion of bDMARD-naïve and TNFi-IR or bDMARD use (non-IR i.e., discontinued the bDMARD due to other reasons than lack of efficacy or intolerance) was of approximately 80%/20%. Randomization was stratified by prior treatment history: (1) bDMARD-naive and (2) TNFi-IR or bDMARD use (non-IR). Overall inclusion and exclusion criteria were adequate for selecting an active AS population and also for taking into account the safety profile of the drug. From the Clinical Overview and from what can be derived from clinicaltrials.gov, it appears that no studies with tofacitinib in patients with non-radiographic axial spondyloarthritis are being performed.  Upon request the MAH specified that at present there are no plans to conduct tofacitinib studies for patients with non-radiographic axial spondyloarthritis and therefore will not be applying for this sub-indication/therapeutic claim. Moreover, criteria for defining previous or concomitant allowed, or prohibited therapies and stable doses are considered acceptable. The MAH specified the criteria for using rescue therapy in both studies. The agents allowed

(acetaminophen/paracetamol, opioid agents) were used primarily to relieve pain conditions and it seems to be unlikely that they could have affected the clinical course or the outcome of the disease, also considering that subjects were not dosed with rescue medication during the 24 hours prior to a study visit and that a small number of subjects used rescue therapy.

The study evaluates 1 primary endpoint, 1 key secondary endpoint, and other 20 secondary endpoints;

moreover, the statistical analysis includes 3 estimands for binary endpoint, and 2 estimands for continuous secondary endpoints. This choice is considered suboptimal. A statistical planning more focussed on the relevant estimations by using more robust approaches would have been preferable.

The primary endpoint of the study was ASAS20 response at week 16. This is not in line with the current Guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) stating that the ASAS 40 response is preferred primary endpoint for biological medicinal products or products from a new therapeutic class, as a higher magnitude of the clinical response are expected. It is disappointing that the MAH did not seek advice to EMA on this choice nor  considered  a  separate  statistical  analysis  plans  (SAPs),  each  using  the  endpoint  preferred  by  the approving regulatory agency.  ASAS40 was therefore defined as key secondary endpoint.

The use of the Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata (bDMARD-naïve, TNFi-IR or bDMARD use) for the analysis of the primary efficacy endpoint (ASAS20) is acknowledged.

Numerous secondary endpoints have been proposed. However, the established hierarchy and the absence of some important endpoint   assessing the clinical benefit of the drug as also clearly recommended in the

<div style=\"page-break-after: always\"></div>

EMA GL is not completely understood. Analyses of key secondary endpoints using MMRM or ANCOVA models are recognized as adequate.

It should be noted that no endpoint that could monitor structural changes, as highly recommended in the EMA GL was included. The MAH justified the lack of endpoints monitoring structural changes in Study A3921120 stating that the study design for Study A3921120 was not considered of sufficient duration to provide evidence of structural changes relative to placebo using radiography (modified Stoke Ankylosing Spondylitis Spinal Score [mSASS]) given that the placebo period was only of 16 weeks duration and the entire treatment duration was 48 weeks. Sample size calculation for pivotal phase III study A3921120 was based on the response rate found in phase 2 dose-ranging, proof of concept trial. It is recognized as appropriate, although the primary efficacy endpoint was then analysed by the Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata (prior treatment history). A total of 269 patients in the A3921120 were treated and included in the FAS and 133 received tofacitinib 5 mg bid. Patient's disposition was balanced across the study.  The great majority completed the DB 16 weeks phase. A higher but similar number of subjects discontinued study drug up to 48 weeks: 15 in the Tofa-Tofa and 14 in the PLB-Tofa arm; the main reasons of discontinuation being the same safety and lack of efficacy although a higher number is registered in the Tofa-Tofa (8 and 6, respectively) as compared to PLB-Tofa (3 and 4) group. Demographic and baseline characteristics were quite balanced between the two arms and representative of the target population i.e., active AS.  The majority of patients were white males with a mean age of 41 years. Patients from Europe were adequately represented being about 40% although enrolment was exclusively done in few countries. Enrolled subjects had an active disease status as well indicated by a median value of 6.5 in BASDAI, of 3.9 in ASDAS (CRP) and a Patient's Assessment of Total Back Pain (NRS) and nocturnal spinal pain of 7. An involvement of the spine as shown by the spinal mobility index BASMI (mean 4.5, range 0-10) and chest expansion (mean 3, range 0-12, enthesis involvement in roughly 50% of subjects and swollen joints in slightly less than 30% and impaired quality of life i.e., ASQoL (mean 11-11.5, range 0-18). Considering ASDAS (CRP) score, the majority of patients (66.5%) had a very high disease activity [ASDAS (CRP) &gt;3.5] with an imbalance between tofacitinib and placebo group with a slightly higher number of patients (70.6%) with very high disease activity as compared to tofacitinib group (62.4%). According to the more recent EULAR management recommendations for axial spondyloarthritis (2016), ASDAS is considered a relevant measure to assess disease activity (it correlates far better with both patients' and physicians' level of disease activity) and an elevated ASDAS index is considered more predictive of a good response than an elevated BASDAI. Therefore, the higher representativeness of subjects with very high disease activity according to ASDAS(CRP) in the placebo arm could impact the response. 99.3%) use at baseline. The majority of patients were positive for HLA-B27 (87.4% of subjects) and the

Patients were generally balanced across treatment groups in their csDMARD (57.1% for tofacitinib 5 mg BID group to 60.3% for placebo group), oral corticosteroid (14.3% to 11.0%), and NSAID (100.0% to median AS diagnosis duration was of 4.9 years (range: 0.1, 42.8).

A minority of patients had extra-articular manifestations at baseline. Regarding peripheral arthritis, the number of patients with current symptoms in tofacitinib and placebo groups were respectively 19 and 26 corresponding to 86.4% and 89.7% of subjects with history of peripheral arthritis. Moreover, a higher percentage of subjects with any csDMARDs was observed in placebo group than in tofacitinib group (33% vs 22%) probably reflecting a higher number of patients with a history of peripheral arthritis (18.4% vs 15.8%).   However, no meaningful differences were noted between patients with and without concomitant csDMARDs with regard to ASAS40 and ASDAS(CRP) endpoints as well as with and without swollen joints. A slightly higher response in ASAS20 endpoint, a less stringent endpoint, was observed in tofacitinib

<div style=\"page-break-after: always\"></div>

group with concomitant csDMARDs (diff from plb: 30.88) compared to those without concomitant csDMARDs (diff from plb: 26.76), with the trend in favour of tofacitinib. Almost all patients (99.6%) received prior NSAIDs, and a minor rate of patients received corticosteroids (16%). However, it was noted that a higher number of subjects was treated with corticosteroids in tofacitinib 5 mg (19.5%) compared to placebo group (12.5%) both with oral and intrarticular administration, suggesting possible more severe manifestations. Moreover, this imbalance was mainly observed in highly treated patients (TNFi-IR and bDMARD use [non-IR]), in which a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids and this is expected likely due to a more difficult to treat disease. No important differences were reported in previous csDMARDs use. The majority of patients were bDMARDs naïve (77%) with a similar distribution between the two groups. A minor number of patients (31 subjects in each arm, 23%) were bDMARDs experienced (bDMARDs use or TNFi-IR), 2 subjects were bDMARDs use non-IR. Concomitant rescue medications, NSAIDs, oral corticosteroids, intra-articular corticosteroids, and csDMARDs were taken by a similar proportion of subjects between treatment groups at baseline up to Week 48.

## Efficacy data and additional analyses

Primary endpoint: a statistically significant higher proportion of patients in the tofacitinib 5 mg BID group reached ASAS20 at week 16 in comparison to the placebo group (56.4% vs 29.4%, p&lt;0.0001), with a treatment difference of 27.08 (95% CI: 15.89, 38.28), which is in line with the 20% difference expected in the sample size calculation. Moreover, the primary analysis is supported by results from all the pre-specified supportive analyses.

ASAS20 is a weaker endpoint compared to the more stringent ASAS40, which is preferred by the EMA guidelines. The choice of ASAS20 has been discussed and agreed with FDA and not with EMA. ASAS40 has been used as the key secondary endpoint and this was also met from a statistical perspective with a higher response rate of subjects in tofacitinib 5 mg BID group (40.6%) compared to placebo group (12.5%) at week 16 (difference of 28.17, 95% CI: 18.26, 38.09 p&lt; 0.0001). The effect size being very similar to that observed for ASAS20. A post-hoc analysis for ASAS20 at week 16 has been provided for the main subgroups showing no important differences except for geographic region of North America in which a smaller difference between tofacitinib 5 mg and placebo is seen (however, the small sample size of this subgroup hampers any firm conclusion) and body weight. In the subgroup with a body weight &gt;100 kg the estimate of the treatment effect based on ASAS40 was -13% in favour of placebo. The MAH considers that the trend of ASAS40 at Week 16 in the Study A3921120 participants with a body weight &gt;100 kg is most likely explained by the small sample size (10 and 18 patients, respectively in placebo and tofacitinib groups). This was not seen in the subgroup analysis of body weight and ASAS20, where the treatment effect was 20% in patients &gt;100kg, 27% in patients 60-100kg and 38% in patients &lt;60kg. The treatment effect in the highest BMI classes was in line with the other results, for ASAS20 as well as ASAS40.

Moreover, no major differences in tofacitinib exposure over the range of body weights studied were reported and no clinically significant decrease in efficacy of tofacitinib has been observed in &gt;100 kg RA patients and according to SmPC section 5.2, systemic exposure (AUC) of tofacitinib in the extremes of body weight (40 kg, 140 kg) were similar (within 5%) to that of a 70 kg patient. Therefore, changes in the SmPC are not warranted at present.

A higher efficacy of tofacitinib 5 mg compared to placebo was observed in the subgroups with very high disease activity (ASDAS (CRP)&gt;3.5) (∆ 35.43 vs 12.61 of patients with high disease activity) and high er baseline hsCRP (&gt;2.87 mg/L) (∆ 28.95 vs 17.02 of patients with lower baseline hsCRP), suggesting that tofacitinib could perform better in this target population. The same figure was also observed for ASAS40 endpoint.

<div style=\"page-break-after: always\"></div>

For both ASAS20 and ASAS40 a better response rate between study drug and placebo is reported in bDMARDs naïve compared to TNF-IR subjects or bDMARD use [non-IR] (difference form placebo 28 versus 22.5 and 28.4 versus 23 for ASAS20 and 40, respectively; in the TNF-IR or bDMARD use due to the limited sample size wide CI are seen); the better performance of the active drug is clinically expected in bDMARD naïve patients. Results according to bDMARDs naïve or TNF-IR subjects/bDMARD use [non-IR] subgroups have been included in 5.1 section of the SmPC, in order to guide prescribers.

Many secondary endpoints (21, 1 key) controlled for multiplicity (step-down testing procedure with a fixed alpha level for each comparison at the 2-sided 5%) were selected by the MAH. Secondary endpoint: ASDAS (CRP) is a validated and accepted method to assess disease activity and physical function considered a very important disease activity score a clinically important improvement of ≥1.1 is required to define a response. The LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the PLB arm at week 16, delta of -0.98, p &lt;0.0001, FAS on drug data estimand 4), the achieved difference was clinically relevant. Consistent results were shown by the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data. At week 48 improvement of ASDAS(CRP) from baseline is still seen in both arms similarly -1.70 and -1.50 for the TOFA-TOFA and PLB-TOFA, respectively. However, as per EMA GL, to facilitate interpretation of the clinical relevance of the observed effect, responder analyses are preferable over mean absolute changes. The MAH has provided these analyses for secondary endpoints not controlled for type I error so results are only descriptive/supportive including ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3), ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16 overall showing a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoint measuring improvement. In view of available treatments for ax SpA, disease remission is increasingly regarded as an appropriate therapeutic goal, no validate definition still exists. Therefore, endpoints aimed at assessing low disease activity or partial remission are considered of key importance for establishing the clinical benefit of a drug meant for axial SpA treatment as highlighted by EMA GL. ASDAS inactive disease (6.7 versus 0 delta 6.7, p 0 ˂ 0.05) at week 16  and ASAS partial remission (a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001) were assessed only as part of secondary not controlled endpoints showing very/limited effect size when inactive disease/partial remission was the goal, of interest is an increase of responders at week 48 (roughly 13-15% for ASDAS inactive and 18-23% for ASAS partial remission. In the hierarchical order as second endpoint the MAH selected the Change from baseline of an inflammatory marker i.e., hsCRP at Week 16 showing statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.05 versus -0.09, p &lt;0.0001) based on the MMRM analysis (Estimand 4). Importantly this endpoint is not considered key for demonstration of tofacitinib clinical benefit but only regarded as supportive for effect on inflammation since no data support this biomarker as useful surrogate to assess efficacy in axial SpA. Patient reported outcomes of 6 of type I controlled endpoints) over other endpoints. To support the validity of these three outcomes,

Descending in the established order there is the change in Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire (total scores range from 0 to 18, with higher scores representing worse QoL) at week 16 showing an improvement at week 16 (tofa -4 versus PLB -2 and increasing at -6 and -5 at week 48). The ASQoL is an AS specific QoL measure and improvement of this disease domain is within treatment objectives and as such patient reported outcomes and quality of life evaluation may also be considered as secondary endpoints as per EMA GL. The MAH gave priority to these QOL endpoints (3 out the MAH has provided a study report summarising the psychometric properties of these QoL measures. These are used in SA and considered useful for the assessment of QoL, and overall results support clinically meaningful changes.

<div style=\"page-break-after: always\"></div>

The inclusion among secondary endpoints (type I controlled) of a measure of spinal mobility i.e., BASMI: Linear BASMI (BASMI lin) composite score change at week 16, is supported being a relevant efficacy parameter in axial SpA. In particular, when ASAS is used as primary endpoint, as in this case, since this index does not include the assessment of the spine mobility should be supplemented with the assessment of spinal mobility as a secondary endpoint. Results showed a change at week 16 of -0.63 versus -0.11 for Tofa and PLB, respectively; similar change (-0.6-0.7) at week 48 in both arms showing a statistical significance p 0.001 but not a clinically relevant difference for which improvement of &gt; 1 point is expected. Another endpoint assessing spinal mobility i.e., change of spinal mobility (chest expansion, score 0-12) at week 16 was included with secondary endpoints not controlled for type I error showing a change of 0.59 versus 0.21 in the Tofa and PLB arm, not significant. Overall results on spinal mobility, which is an important domain of axSpA are not robust as those evaluating tofacitinib efficacy on sign and symptoms/inflammation of the disease.

The individual components of the ASAS responses have been included within secondary endpoints (type I controlled) in general showing a consistent and similar (delta of -1.5-1.7 at week 16) improvement slightly higher at week 48 for all the components.

ASAS20 and 40 responses over time: the onset of efficacy for tofacitinib 5 mg BID was seen early in the ASAS20 and ASAS40 response rates. Tofacitinib 5 mg BID become superior to placebo at Week 2 for ASAS20 response rate and at Week 4 for ASAS40 response rate and was sustained after Week 16 to the end of the study (Week 48). However, a slightly decrease was noted at week 16 as compared to week 12, -7.5% for ASAS20 (from 63.91% at week 12 to 56.39 at week 16) and -2.3% for ASAS40, although subsequently increased again at week 24 reaching a plateau thereafter. The reduction observed at week 16 has been clarified by the MAH by given a plausible response assuming that the observed trend was due to a random variability, since ASAS20 comprises subjective (patient-reported) components. However, it should be noted that a \"real\" decrease may have occurred. Moreover, considering the ASAS20 response rate, the same trend was observed with both Estimand 1 (on-drug data) and Estimand 2 (on-study data), with only 4/133 (3%) subjects discontinuing the investigational product; therefore, the intercurrent event of discontinuation which classifies the subject as non-responder for the visit of interest shouldn't have impacted the response rate at week 16. The issue was not further pursued.

According to the ASAS40 and all other secondary outcomes over time, the effect was maintained. In the group that was originally allocated to tofacitinib, the ASAS40 response at week 16 was 41%, which increased to 50% at week 48. In the patient group that was on placebo at week 16 and switched to tofacitinib, the proportion of patients with an ASAS40 response increased over time to 45% at week 48. Nevertheless, the increasing response after week 16, the Applicant was asked to analyse the new occurrences of response over time, and to discuss the inclusion of a statement in the SmPC about when to stop tofacitinib if no response occurred. An update of the 4.2 section of the SmPC suggesting to carefully reconsidering to continue therapy in patients exhibiting no clinical improvement within 16 weeks was added.

The EMA GL recommends using as secondary endpoints if not selected as primary endpoints, measures of disease activity such as the ASAS 5/6 as well as the peripheral tender joints and swollen joint count which were included by the MAH only as secondary (not controlled type I error) endpoints. ASAS 5/6 results are consistent with those of the primary and key secondary endpoint showing a statistical and clinically relevant improvement (44% responders, delta of 36 at week 16 and maintained at week 48). As measure of improvement of enthesitis the MAH had included the change in MASES index (total score ranging 0 - 13) at week 16 as not controlled secondary endpoint showing an improvement of -2 versus 1.41, delta of -0.53 slightly increasing at week 48. Therefore, no significant statistical difference has been shown for this domain of the disease.

Other measures of symptoms and physical function recommended which has been included within secondary endpoints not controlled for multiplicity is the change of BASDAI at week 16 (showing an improvement of -2.55 at week 16 delta of -1.44). However, this is a widely used measure of disease

<div style=\"page-break-after: always\"></div>

activity and its changes with treatment should be assessed as secondary endpoint. Moreover, the percentage of patients with clinical response as measured by an improvement of at least a 50% from the baseline score in BASDAI is considered useful to judge the clinical benefit of a treatment but was not included by the MAH.

Overall, results from Study A3921119 were supportive of the phase 3 study with regard to different endpoints pertaining to disease activity and physical functions, health related outcomes, spinal mobility.

## Indirect comparison with active treatments

The placebo-controlled trial did not include an active comparator. To indirectly compare the treatment effects of tofacitinib 5 mg BID with other treatments for AS, the MAH performed a systematic review and meta-analysis of placebo-controlled trials of EMA-approved biological DMARDs, including ASAS20/40 at week 12-16, in patients with AS with or without previous experience with biological DMARDs.

According to the results, ASAS20 and ASAS40 responses for tofacitinib 5 mg BID across Studies A3921119 and A3921120, were similar compared with adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab and secukinumab. The treatment effects on ASAS40 were 26% and 28% in the two tofacitinib trials, while the majority of treatment effects of the other biological DMARDs ranged from 17% (adalimumab, COAST V) to 37% (infliximab, ASSERT). The MEASURE 4 trial in secukinumab showed lower treatment effects than the other trials including MEASURE 2. MEASURE 1 and 3 were not included in the meta-analysis, because of the iv loading dose that was used in those trials, which is not in the approved posology of secukinumab.

## 2.4.4. Conclusions on the clinical efficacy

A clinically relevant effect as measured by ASAS20/ASA40 has been demonstrated for tofacitinib 5 mg BD in the target population of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.  Most of the secondary endpoints measuring mainly signs and symptoms, inflammation and QoL endpoints provide supportive results. For other disease domains such as spinal mobility and enthesitis only limited or only a trend in effect was seen.

## 2.5. Clinical safety

## Introduction

## Tofacitinib Clinical Programmes in RA and PsA

Tofacitinib has previously been evaluated in other clinical programmes such as RA and PsA.

The RA and PsA programmes comprise a larger number of patients over a longer duration compared to the current AS programme. Safety data from these non-AS indications have been included for contextualisation of the safety data observed in the AS clinical programme.

The RA and PsA databases integrated within each programme enable the following evaluations:

- To compare the incidence rates for AEs of special interest to determine whether there are similarities.
- To compare the rates of certain AEs, especially those with long latency periods (e.g., malignancies), to determine whether there is an increase following exposures to tofacitinib for longer periods than in AS studies.

<div style=\"page-break-after: always\"></div>

The integrated datasets from the 23 RA studies and the 3 PsA studies were used to compare key safety endpoints to further contextualise the safety profile in AS. Details on the safety populations from the RA and PsA studies used for contextualisation are shown in Table 65.

Table 35. RA and PsA Safety Populations and Completed Studies Contributing to Safety Assessment for the AS Programme

| Analysis Set                                   | Brief Description                                                                                                                                                                                                                                                                       | Safety Analysis                                                                                                                            | Phase / Studies                                                                                                                                                               |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RA Safety Populations (for contextualisation)  | RA Safety Populations (for contextualisation)                                                                                                                                                                                                                                           | RA Safety Populations (for contextualisation)                                                                                              | RA Safety Populations (for contextualisation)                                                                                                                                 |
| RA P2P3                                        | All patients randomised to tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 2 and 3 studies in the RA clinical programme.                                                                                                                              | The Tofa 5 mg BID group of the RA P2P3 Cohort will provide RA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort. | Phase 3 A3921045; A3921046; A3921064; A3921032, A3921044; A3921069; A3921187; A3921237 Phase 2 A3921019; A3921025; A3921035; A3921039; A3921040; A3921073; A3921129; A3921068 |
| RA P123LTE                                     | All patients exposed to at least 1 dose of tofacitinib from the completed Phase 1, 2, 3 and LTE studies                                                                                                                                                                                 | The All Tofa group of the Cohort RA P123LTE will provide RA contextualisation for the All Tofa group of the AS All Tofa Cohort.            | P2P3 Studies listed above Phase 1 A3921130; A3921152 Phase 2 A3921109 Phase 3 A3921192; A3921215 (Japan specific); LTE A3921024; A3921041 (Japan                              |
| PsA Safety Populations (for contextualisation) | PsA Safety Populations (for contextualisation)                                                                                                                                                                                                                                          | PsA Safety Populations (for contextualisation)                                                                                             | PsA Safety Populations (for contextualisation)                                                                                                                                |
| Cohort 2a                                      | All patients randomised to tofacitinib 5 mg IR BID or placebo → tofacitinib 5 mg IR BID sequences and received at least 1 dose of tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 3 Studies A3921125 (up to 6 months) and A3921091 (up to 12 months). | The All Tofa 5 mg BID group of PsA Cohort 2a will provide PsA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort  | Phase 3 A3921125; A3921091                                                                                                                                                    |
| Cohort 3                                       | All patients who received at least 1 dose of tofacitinib (tofacitinib 5 or 10 mg BID) from the completed Phase 3 Studies A3921091, A3921125 and the long-term extension (LTE) Study A3921092.                                                                                           | The All Tofa group of the PsA Cohort 3 will provide PsA contextualisation for the All Tofa group of the AS All Tofa Cohort                 | Phase 3 and LTE A3921125; A3921091; A3921092                                                                                                                                  |

## Known Safety Profile

Tofacitinib, in the already approved indications, has shown a safety profile mainly characterised by the following considerations (from the current SmPC section 4.4):

<div style=\"page-break-after: always\"></div>

- -Serious VTE events including pulmonary embolism (PE), some of which were fatal, and deep vein thrombosis (DVT), have been observed in patients taking tofacitinib. A dose dependent increased risk for VTE was observed in a clinical study with tofacitinib compared to TNF inhibitors.
- -Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib. The risk of opportunistic infections is higher in Asian geographic regions.
- -Viral reactivation and cases of herpes virus reactivation (e.g., herpes zoster) were observed in clinical studies with tofacitinib. In patients treated with tofacitinib, the incidence of herpes zoster appears to be increased in: Japanese or Korean patients, Patients with an ALC less than 1,000 cells/mm3, Patients with long standing RA who have previously received two or more biological disease- modifying antirheumatic drugs (DMARDs), Patients treated with 10 mg twice daily.
- -Lymphomas have been observed in patients treated with tofacitinib. Other malignancies were observed in clinical studies and the post-marketing setting, including, but not limited to, lung cancer, breast cancer, melanoma, prostate cancer, and pancreatic cancer. The effect of tofacitinib on the development and course of malignancies is not known.
- -NMSCs have been reported in patients treated with tofacitinib.
- -Events of interstitial lung disease (some of which had a fatal outcome) have been reported in patients treated with tofacitinib in RA clinical trials and in the post-marketing setting although the role of Janus kinase (JAK) inhibition in these events is not known.
- -Events of gastrointestinal perforation have been reported in clinical trials although the role of JAK inhibition in these events is not known.
- -Treatment with tofacitinib was associated with an increased incidence of liver enzyme elevation in some patients.

Furthermore, on 18 January 2021 the MAH informed the EMA about an Emerging Safety Issue (ESI) notification for tofacitinib pertaining to two signals identified from review of the final study data for the co-primary endpoints in Study A3921133, specifically including the increased incidence of adjudicated MACE and adjudicated malignancies (excluding NMSC). Interim results of the study have been assessed as part of a signal procedure (EPITT ref. No. 19382). Consequently, sections 4.4, 4.8 and 5.1 of the SmPC and correspondent sections of the Package Leaflet were updated to appropriately reflect the information. The RMP was also updated with additional risk minimisation measures and a DHPC for tofacitinib was also endorsed. The final study report of Study A3921133 is currently under evaluation (EMEA/H/C/004212/II/0044) and the assessment will follow.

## Source of Safety Data

The studies included in the present analysis are:

- 1 completed Phase 2 , 12-week long randomised double-blind, placebo-controlled, dose-ranging Study A3921 119 in patients with AS. Tofacitinib IR was evaluated at doses of 2, 5 and 10 mg BID.
- 1 completed pivotal Study A3921 120 in patients with AS. This was a 48-week long phase 3, randomised, double-blind, placebo-controlled (first 16 weeks) study of the efficacy and safety of tofacitinib in patients with active AS. Tofacitinib IR was evaluated at a dose of 5 mg BID.

Note that for Study A3921120 , the treatment duration was 48 weeks which comprised an initial placebo-controlled treatment period of 16 weeks duration followed by an open-label treatment period of 32 weeks duration. All patients, investigators, and the study team remained blinded to the double-blinded treatment until Week 48 when the final database was released.

<div style=\"page-break-after: always\"></div>

The studies in the AS development programme are described in Table 66 .

Table 66. Completed Studies in the Tofacitinib Clinical Programme for AS

| Protocol                   | Title/Study Population                                                                                                                                                                                                                                                                                                                       | Treatment                                                                                                                                                                                                                                                                             | Safety Population                           |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Phase 3 Study              | Phase 3 Study                                                                                                                                                                                                                                                                                                                                | Phase 3 Study                                                                                                                                                                                                                                                                         | Phase 3 Study                               |
| A3921120                   | A phase 3, randomised, double- blind, placebo-controlled, study of the efficacy and safety of tofacitinib in patients with active AS. The study enrolled patients with an inadequate response to NSAIDs who were either: bDMARD naïve (~80%) or TNFi inadequate responders or had prior bDMARD use (non- inadequate responder) (~20%).       | Double-blind Placebo → Tofacitinib 5 mg IR BID Double-blind: Placebo 0-16 weeks Open-label b : Tofacitinib 5 mg IR BID 16-48 weeks Tofacitinib 5 mg IR BID → Tofacitinib 5 mg IR BID Double-blind: Tofacitinib 5 mg IR BID 0-16 weeks Open-label: Tofacitinib 5 mg IR BID 16-48 weeks | Total = 269 a n = 136 n = 133 c             |
| Phase 2 Dose-ranging Study | Phase 2 Dose-ranging Study                                                                                                                                                                                                                                                                                                                   | Phase 2 Dose-ranging Study                                                                                                                                                                                                                                                            | Phase 2 Dose-ranging Study                  |
| A3921119                   | A phase 2 multicenter, randomised, double-blind, placebo-controlled dose-ranging, parallel group efficacy and safety study designed to characterize the dose-response of tofacitinib in patients with active AS. Duration of blinded treatment was 12 Weeks. The study enrolled bDMARD naïve patients with an inadequate response to NSAIDs. | Double-blind Tofacitinib 2 mg BID 0-12 weeks Tofacitinib 5 mg IR BID 0-12 weeks Tofacitinib 10 mg BID 0-12 weeks Placebo 0-12 weeks                                                                                                                                                   | Total d = 207 n = 52 n = 52 n = 52 n = 51 e |

Source: Module 5.3.5.1 A3921120 Week 48 Study Report Table 14.1.1.1.1A; Module 5.3.5.4 A3921119 Amended Study Report Table 14.1.1.1

- a. 270 patients were randomised but 269 patients received study treatment and were included in the analysis.
- b. Patients switched to open-label treatment at Week 16 visit until Week 48.
- c. 134 patients were randomised to Tofacitinib 5 mg IR BID→Tofacitinib 5 mg IR BID but 133 patients received study treatment and were included in the analysis.
- d. 208 patients were randomised, but 207 patients received study treatment and were included in the analysis.
- e. 52 patients were randomised to Placebo, but 51 patients received study treatment and were included in the analysis.

The integrated analysis of safety included pooling of Studies A3921119 and A3921120 ( Table 67 ) to assess:

- Short-term (0-16 weeks) safety of tofacitinib 5 mg IR BID in comparison to placebo in the combined trials (the 'Placebo-controlled Cohort'; table below).
- Longer-term (0-48 weeks) safety of tofacitinib in the combined trials' exposure to the study drug (the 'All Tofa Cohort'; next table). The All Tofa Cohort has 2 analysis groups: All Tofa 5 mg BID

<div style=\"page-break-after: always\"></div>

(tofacitinib 5 mg IR BID in the combined trials) and All Tofa (tofacitinib 2 mg, 5 mg, and 10 mg BID in the combined trials).

Table 67. Safety Populations in Integrated Analysis

| Integrated Study Cohorts          | Studies Included and Pooling Strategies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16 Week Placebo-controlled Cohort | • A3921119 (0 - 12 Weeks), A3921120 (0 - 16 Weeks) • This cohort includes patients who were randomised and received tofacitinib 5 mg IR BID or placebo from the double-blinded placebo-controlled periods of the studies. • Analysis groups of the cohort: (1) Tofa 5 mg BID, (2) Placebo. • Comparison: Tofa 5 mg BID versus Placebo.                                                                                                                                                                                                                                                                                                                                                                                               |
| 48 Week All Tofa Cohort           | • A3921119 (0 - 12 Weeks), A3921120 (0 - 48 Weeks) • This cohort includes all randomised patients and treated with at least 1 dose of tofacitinib (2 mg, 5 mg, and 10 mg BID) from the tofacitinib- exposed periods, therefore excluding placebo-exposed period for patients randomised to placebo → tofacitinib 5 mg IR BID group a in Study A3921120. • Analysis groups of the cohort: (1) All Tofa 5 mg BID, (2) All Tofa. The All Tofa 5 mg BID group differs from All Tofa analysis group because the All Tofa 5 mg BID group includes only the patients who received 5 mg BID, while the All Tofa analysis group includes additional data from the Tofa 2 mg BID and 10 mg BID groups from Study A3921119. • Comparison: None. |

Source: Module 5.3.5.3 SCS iAP Table 3

a. In Study A3921120, patients randomised to the placebo → tofacitinib 5 mg IR BID group received placebo during the doubleblind period (0 - 16 Weeks) and switched to open-label tofacitinib 5 mg IR BID at Week 16 in a blinded fashion. All patients, investigators, and the Pfizer study team remained blinded to the double-blinded treatment until Week 48 when the final database was released.

Safety data come from 2 studies, one Phase 2 (A3921 119 ) and one pivotal Phase 3 (A3921 120 ). The Study 119 was double-blind and different tofacitinib doses were tested (2, 5, and 10 mg BID) and included a placebo arm, for a duration of 12 weeks. The Study 120 (phase 3) was double-blind placebocontrolled for the first 16 weeks and after that continued as open-label with all subjects receiving tofacitinib, until 32 weeks (total 48 weeks).

## Patient exposure

The number of patients included in the Placebo-controlled Cohort and the All Tofa Cohort, including those exposed to tofacitinib 5 mg IR BID, are presented in Table 68.

Table 68. Tofacitinib summary of Clinical Safety (Ankylosing Spondylitis) Number of Subjects and Tofacitinib Exposure- AS Placebo-Controlled Cohort and All Tofa Cohort

<div style=\"page-break-after: always\"></div>

|                                                     | ASPlacebo-ControlledCohort   | ASPlacebo-ControlledCohort   | ASPlacebo-ControlledCohort   | ASPlacebo-ControlledCohort   | AllTofaCohort    | AllTofaCohort    | AllTofaCohort   | AllTofaCohort   |
|-----------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------|------------------|-----------------|-----------------|
|                                                     | Tofa 5 mg BID                | Tofa 5 mg BID                | Placebo                      | Placebo                      | All Tofa5 mg BID | All Tofa5 mg BID | AllTofa         | AllTofa         |
| Exposure Duration (StandardizationExposureDuration) | N                            | PY                           | N                            | PY                           | N                | PY               | N               | PY              |
| At least one dose (>0.00 subject-year)              | 185                          | 52.77                        | 187                          | 53.07                        | 316              | 208.90           | 420             | 232.98          |
| >=1 month (>=0.08 subject-year)                     | 183                          | 52.71                        | 186                          | 53.01                        | 314              | 208.84           | 416             | 232.91          |
| >=3 months (>=0.23 subject-year)                    | 170                          | 49.81                        | 169                          | 49.74                        | 297              | 205.22           | 375             | 224.24          |
| >=6 months (>=0.46 subject-year)                    | NA                           | NA                           | NA                           | NA                           | 253              | 193.83           | 253             | 193.83          |
| >=12 months (>=0.92subject-year)                    | NA                           | NA                           | NA                           | NA                           | 108              | 100.46           | 108             | 100.46          |

N: Number of subjects included in the analysis.NA: Not Applicable. One month is equivalent to 28 days.

Both N and PY are cumulative.

The durations of exposure are standardized to subject-years by dividing the sum of exposure times in days by 365.25. For subjects randomized to Placebo-&gt;Tofa5 mg BID in All Tofa cohort, the date of first dose refers to the date of first dose of tofacitinib treatment.

Exposure duration in days = date of last dose - date of first dose +1.Any missed doses between subject's first dose and last dose are counted as dosed.

IncludedProtocols:A3921119,A3921120(FinalData).

PFIZERCONFIDENTIALSourceData:adslTableGeneration:24NOV2020(07:35)

(FinalData:10Sep2020)OutputFile:./unblind\\_1120/A392\\_SCSPC\\_EU/adsl\\_s102

Table C12.4.2-E is for Pfizer internal use.

In the Placebo-controlled Cohort, the mean age was 41.9 years in the Tofa 5 mg BID group and 40.5 years in the Placebo group, &lt;5% (n=13 in All Tofa) of patients were ≥ 65, there was a predominance of males (83.8% in the Tofa 5 mg BID group and 74.9% in the Placebo group) and the majority of patients were White (81.1% in the Tofa 5 mg BID group and 79.7% in the Placebo group). Geographic distribution in the Tofa 5 mg BID group was as follows: North America (14.6%), European Union (43.8%), Asia (17.3%) and Rest of World (24.3%).

## Prior Medication Use

Prior medication use in the AS programme is summarised below:

- 96.5% of patients had an inadequate response to 2 or more NSAIDs
- 83.3% of the patients were bDMARD naïve
- 11.0% of patients had prior use of oral CS

## Concomitant Medication Use

Concomitant medications to treat AS on Day 1 are summarised below:

- 27.7% of patients were on csDMARDs on Day 1. There were more patients in the Placebo arm (31.0%) on concomitant csDMARDs than the Tofa 5 mg BID arm (24.3%).
- 83.3% of patients were on concomitant NSAIDs and 9.7% were on other pain management/analgesics.
- 8.1% of patients were on CS on Day 1. There were more patients in the Tofa 5 mg BID arm (9.7%) on concomitant CS than the Placebo arm (6.4%).

For the All Tofa Cohort, demographic and baseline characteristics are presented in Table 69. The characteristics in the All Tofa 5 mg BID were comparable to those in the Tofa 5 mg BID group in the Placebo-controlled Cohort, according to the MAH.

<div style=\"page-break-after: always\"></div>

Table 69. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Demographic and Baseline Characteristics - AS Placebo-Controlled Cohort and All Tofa Cohort

|                        | Placebo-Controlled Cohort   | Placebo-Controlled Cohort   | All Tofa Cohort           | All Tofa Cohort   |
|------------------------|-----------------------------|-----------------------------|---------------------------|-------------------|
|                        | Tofa 5 mg BID (N=185)       | Placebo (N=187)             | All Tofa 5 mg BID (N=316) | All Tofa (N=420)  |
| Age (Years), n (%)     |                             |                             |                           |                   |
| <18                    | 0                           | 0                           | 0                         | 0                 |
| >=18 to <=44           | 115 (62.2%)                 | 120 (64.2%)                 | 199 (63.0%)               | 263 (62.6%)       |
| >=45 to <=64           | 63 (34.1%)                  | 63 (33.7%)                  | 110 (34.8%)               | 144 (34.3%)       |
| >=45 to <=49           | 23 (12.4%)                  | 25 (13.4%)                  | 42 (13.3%)                | 55 (13.1%)        |
| >=50 to <=59           | 28 (15.1%)                  | 28 (15.0%)                  | 50 (15.8%)                | 66 (15.7%)        |
| >=60 to <=64           | 12 (6.5%)                   | 10 (5.3%)                   | 18 (5.7%)                 | 23 (5.5%)         |
| >=65                   | 7 (3.8%)                    | 4 (2.1%)                    | 7 (2.2%)                  | 13 (3.1%)         |
| >=65 to <=74           | 7 (3.8%)                    | 4 (2.1%)                    | 7 (2.2%)                  | 12 (2.9%)         |
| >=75 to <=84           | 0                           | 0                           | 0                         | 1 (0.2%)          |
| >=85                   | 0                           | 0                           | 0                         | 0                 |
| <50                    | 138 (74.6%)                 | 145 (77.5%)                 | 241 (76.3%)               | 318 (75.7%)       |
| >=50                   | 47 (25.4%)                  | 42 (22.5%)                  | 75 (23.7%)                | 102 (24.3%)       |
| <60                    | 166 (89.7%)                 | 173 (92.5%)                 | 291 (92.1%)               | 384 (91.4%)       |
| >=60                   | 19 (10.3%)                  | 14 (7.5%)                   | 25 (7.9%)                 | 36 (8.6%)         |
| N1                     | 185                         | 187                         | 316                       | 420               |
| Mean (Std.Dev.)        | 41.9 (11.43)                | 40.5 (11.60)                | 41.0 (11.29)              | 41.1 (11.51)      |
| Median (Min, Max)      | 41.0 (20, 70)               | 39.0 (20, 70)               | 40.0 (20, 70)             | 40.0 (20, 75)     |
| Q1, Q3                 | 33.0, 50.0                  | 32.0, 48.0                  | 33.0, 49.0                | 33.0, 49.0        |
| Gender, n (%)          |                             |                             |                           |                   |
| Male                   | 155 (83.8%)                 | 140 (74.9%)                 | 261 (82.6%)               | 333 (79.3%)       |
| Female                 | 30 (16.2%)                  | 47 (25.1%)                  | 55 (17.4%)                | 87 (20.7%)        |
| Race, n (%) [a]        |                             |                             |                           |                   |
| White                  | 150 (81.1%)                 | 149 (79.7%)                 | 252 (79.7%)               | 334 (79.5%)       |
| Asian                  | 34 (18.4%)                  | 38 (20.3%)                  | 63 (19.9%)                | 85 (20.2%)        |
| Black                  | 0                           | 0                           | 0                         | 0                 |
| Other                  | 1 (0.5%)                    | 0                           | 1 (0.3%)                  | 1 (0.2%)          |
| Ethnicity, n (%)       |                             |                             |                           |                   |
| Hispanic or Latino     | 4 (2.2%)                    | 2 (1.1%)                    | 6 (1.9%)                  | 6 (1.4%)          |
| Not Hispanic or Latino | 179 (96.8%)                 | 184 (98.4%)                 | 308 (97.5%)               | 412 (98.1%)       |
| Not Reported           | 2 (1.1%)                    | 1 (0.5%)                    | 2 (0.6%)                  | 2 (0.5%)          |
| Height (cm)            |                             |                             |                           |                   |
| N1                     | 184                         | 186                         | 315                       | 419               |

<div style=\"page-break-after: always\"></div>

Table 69. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Demographic and Baseline Characteristics - AS Placebo-Controlled Cohort and All Tofa Cohort

|                                  | Placebo-Controlled Cohort   | Placebo-Controlled Cohort   | All Tofa Cohort           | All Tofa Cohort      |
|----------------------------------|-----------------------------|-----------------------------|---------------------------|----------------------|
|                                  | Tofa 5 mg BID (N=185)       | Placebo (N=187)             | All Tofa 5 mg BID (N=316) | All Tofa (N=420)     |
| Mean (Std.Dev.)                  | 172.8 (9.09)                | 171.2 (9.02)                | 172.4 (8.82)              | 171.9 (8.86)         |
| Median (Min, Max)                | 173.0 (146.0, 194.9)        | 171.3 (140.0, 196.0)        | 172.0 (145.5, 196.0)      | 172.0 (145.5, 196.0) |
| Q1, Q3                           | 167.8, 179.0                | 165.0, 177.0                | 167.0, 178.0              | 166.8, 178.0         |
| Weight (kg), n (%)               |                             |                             |                           |                      |
| <60                              | 26 (14.1%)                  | 25 (13.4%)                  | 42 (13.3%)                | 63 (15.0%)           |
| >=60 to <=100                    | 136 (73.5%)                 | 146 (78.1%)                 | 242 (76.6%)               | 318 (75.7%)          |
| >100                             | 23 (12.4%)                  | 16 (8.6%)                   | 32 (10.1%)                | 39 (9.3%)            |
| N1                               | 185                         | 187                         | 316                       | 420                  |
| Mean (Std.Dev.)                  | 79.3 (18.15)                | 78.0 (18.03)                | 78.5 (17.76)              | 78.0 (17.41)         |
| Median (Min, Max)                | 78.2 (45.0, 142.9)          | 77.9 (34.5, 148.0)          | 78.0 (34.5, 148.0)        | 78.0 (34.5, 148.0)   |
| Q1, Q3                           | 65.2, 88.0                  | 65.5, 88.5                  | 65.1, 88.0                | 65.0, 88.0           |
| Body Mass Index (kg/m**2), n (%) |                             |                             |                           |                      |
| <18.5                            | 5 (2.7%)                    | 12 (6.4%)                   | 15 (4.7%)                 | 19 (4.5%)            |
| >=18.5 to <25                    | 69 (37.3%)                  | 67 (35.8%)                  | 117 (37.0%)               | 157 (37.4%)          |
| >=25 to <30                      | 69 (37.3%)                  | 62 (33.2%)                  | 112 (35.4%)               | 148 (35.2%)          |
| >=30 to <40                      | 37 (20.0%)                  | 41 (21.9%)                  | 65 (20.6%)                | 88 (21.0%)           |
| >=40                             | 4 (2.2%)                    | 4 (2.1%)                    | 6 (1.9%)                  | 7 (1.7%)             |
| Missing                          | 1 (0.5%)                    | 1 (0.5%)                    | 1 (0.3%)                  | 1 (0.2%)             |
| <30                              | 143 (77.3%)                 | 141 (75.4%)                 | 244 (77.2%)               | 324 (77.1%)          |
| >=30                             | 41 (22.2%)                  | 45 (24.1%)                  | 71 (22.5%)                | 95 (22.6%)           |
| Missing                          | 1 (0.5%)                    | 1 (0.5%)                    | 1 (0.3%)                  | 1 (0.2%)             |
| <35                              | 174 (94.1%)                 | 173 (92.5%)                 | 299 (94.6%)               | 398 (94.8%)          |
| >=35                             | 10 (5.4%)                   | 13 (7.0%)                   | 16 (5.1%)                 | 21 (5.0%)            |
| Missing                          | 1 (0.5%)                    | 1 (0.5%)                    | 1 (0.3%)                  | 1 (0.2%)             |
| N1                               | 184                         | 186                         | 315                       | 419                  |
| Mean (Std.Dev.)                  | 26.6 (5.45)                 | 26.5 (5.82)                 | 26.4 (5.42)               | 26.4 (5.28)          |
| Median (Min, Max)                | 26.1 (16.0, 50.6)           | 26.2 (15.9, 48.9)           | 26.0 (15.9, 50.6)         | 26.1 (15.9, 50.6)    |
| Q1, Q3                           | 22.7, 29.5                  | 22.0, 29.9                  | 22.4, 29.6                | 22.6, 29.7           |
| Geographic Region, n (%) [b]     |                             |                             |                           |                      |
| North America (US and Canada)    | 27 (14.6%)                  | 15 (8.0%)                   | 38 (12.0%)                | 51 (12.1%)           |
| European Union                   | 81 (43.8%)                  | 89 (47.6%)                  | 136 (43.0%)               | 200 (47.6%)          |

<div style=\"page-break-after: always\"></div>

Table 69. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Demographic and Baseline Characteristics - AS Placebo-Controlled Cohort and All Tofa Cohort

|                                                                         | Placebo-Controlled Cohort   | Placebo-Controlled Cohort   | All Tofa Cohort           | All Tofa Cohort   |
|-------------------------------------------------------------------------|-----------------------------|-----------------------------|---------------------------|-------------------|
|                                                                         | Tofa 5 mg BID (N=185)       | Placebo (N=187)             | All Tofa 5 mg BID (N=316) | All Tofa (N=420)  |
| Asia                                                                    | 32 (17.3%)                  | 38 (20.3%)                  | 61 (19.3%)                | 83 (19.8%)        |
| Rest of World                                                           | 45 (24.3%)                  | 45 (24.1%)                  | 81 (25.6%)                | 86 (20.5%)        |
| Smoking Status, n (%)                                                   |                             |                             |                           |                   |
| Never Smoked                                                            | 95 (51.4%)                  | 99 (52.9%)                  | 165 (52.2%)               | 217 (51.7%)       |
| Former Smoker                                                           | 32 (17.3%)                  | 24 (12.8%)                  | 51 (16.1%)                | 67 (16.0%)        |
| Current Smoker                                                          | 58 (31.4%)                  | 64 (34.2%)                  | 100 (31.6%)               | 136 (32.4%)       |
| Duration of Smoking Started (Years) for Current Smoker or Former Smoker |                             |                             |                           |                   |
| N1                                                                      | 88                          | 87                          | 149                       | 200               |
| Mean (Std.Dev.)                                                         | 21.9 (12.11)                | 22.4 (11.65)                | 22.0 (11.72)              | 21.6 (11.67)      |
| Median (Min, Max)                                                       | 20.1 (1.3, 49.8)            | 19.8 (2.7, 55.0)            | 20.0 (1.3, 50.0)          | 19.8 (1.3, 50.0)  |
| Q1, Q3                                                                  | 12.9, 30.0                  | 14.4, 30.0                  | 13.7, 30.0                | 12.8, 30.0        |
| Duration of Smoking Stopped (Years) for Former Smoker                   |                             |                             |                           |                   |
| N1                                                                      | 32                          | 24                          | 51                        | 67                |
| Mean (Std.Dev.)                                                         | 10.9 (9.72)                 | 10.2 (9.91)                 | 10.2 (8.63)               | 10.1 (8.44)       |
| Median (Min, Max)                                                       | 7.8 (0.3, 37.0)             | 8.1 (0.8, 46.0)             | 7.8 (0.3, 37.0)           | 7.7 (0.3, 37.0)   |
| Q1, Q3                                                                  | 3.5, 16.1                   | 3.4, 13.8                   | 3.7, 13.8                 | 4.0, 13.8         |
| Current Alcohol Use, n (%) [c]                                          |                             |                             |                           |                   |
| Yes                                                                     | 68 (36.8%)                  | 70 (37.4%)                  | 115 (36.4%)               | 152 (36.2%)       |
| No                                                                      | 117 (63.2%)                 | 117 (62.6%)                 | 201 (63.6%)               | 268 (63.8%)       |
| Amount of Alcohol Use (Units/Week) for Current Alcohol User             |                             |                             |                           |                   |
| N1                                                                      | 67                          | 70                          | 114                       | 151               |
| Mean (Std.Dev.)                                                         | 3.7 (4.84)                  | 3.1 (3.25)                  | 3.4 (4.26)                | 3.0 (3.88)        |
| Median (Min, Max)                                                       | 2.0 (0.3, 35.0)             | 2.0 (0.5, 15.0)             | 2.0 (0.3, 35.0)           | 2.0 (0.3, 35.0)   |
| Q1, Q3                                                                  | 1.0, 5.0                    | 1.0, 4.0                    | 1.0, 4.0                  | 1.0, 4.0          |

<div style=\"page-break-after: always\"></div>

Table 69. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Demographic and Baseline Characteristics - AS Placebo-Controlled Cohort and All Tofa Cohort

| Placebo-Controlled Cohort   | Placebo-Controlled Cohort   | All Tofa Cohort           | All Tofa Cohort   |
|-----------------------------|-----------------------------|---------------------------|-------------------|
| Tofa 5 mg BID (N=185)       | Placebo (N=187)             | All Tofa 5 mg BID (N=316) | All Tofa (N=420)  |

N: Number of subjects included in the Safety Analysis Set; N1: Number of subjects included in the analysis; n (%): Number of subjects in each analysis category (Percentages are based on N).

[a] Race used for subgroup analysis, 'Other' here stands for other than White, Asian and Black. [b] North America (US and Canada) includes United States and Canada. European Union includes Bulgaria,

Czech Republic, France, Hungary, Poland and Spain. Asia includes China, South Korea and Taiwan. Rest of World includes Ukraine, Russia, Australia and Turkey. [c] Yes is defined for subjects who have current alcohol use at baseline, else No.

Body Mass Index (kg/m**2) = weight (kg) / [height (cm)*0.01]**2. Height is at Screening and weight is at baseline for both studies.

For Placebo-Controlled Cohort: Baseline is defined as last non-missing assessment prior to first dose of investigational product (including Placebo).

For All Tofa Cohort: Baseline is defined as last non-missing assessment prior to first dose of the study.

Included Protocols: A3921119, A3921120 (Final Data).

PFIZER CONFIDENTIAL Source Data: adsl and adsc Table Generation: 12NOV2020 (01:46)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adsl\\_s001\\_pboat

Table C12.1.2.1-E is for Pfizer internal use.

## Exposure in the RA and PsA Integrated Dataset

Exposure to tofacitinib 5 mg IR BID in the RA and PsA databases is larger than the exposure to tofacitinib in the AS integrated safety dataset (All Tofa Cohort).

The Tofacitinib 5 mg IR BID RA P2P3 and All Tofa 5 mg BID PsA Cohort 2a have been compared to the AS All Tofa 5 mg BID group. The maximum exposure for these groups is as follows:

- Tofacitinib 5 mg IR BID RA P2P3: 2664 patients representing 2476.66 PY of exposure
- All Tofa 5 mg BID PsA Cohort 2a: 347 patients representing 196.2 PY of exposure.

The RA P123LTE All Tofa group and PsA Cohort 3 All Tofa group have been compared to the AS All Tofa group. Exposure data are provided in Table 70

Table 70. Number of Patients and Tofacitinib Exposure in the RA P123LTE and PsA Cohort 3 Integrated Datasets

|                 | All Tofa RA P123LTE   | All Tofa RA P123LTE   | All Tofa PsA Cohort 3   | All Tofa PsA Cohort 3   |
|-----------------|-----------------------|-----------------------|-------------------------|-------------------------|
| Duration        | N                     | PY                    | N                       | PY                      |
| At least 1 dose | 7964                  | 23496.73              | 783                     | 2037.97                 |
| ≥ 1 month       | 7792                  | 23489.51              | 771                     | 2037.47                 |
| ≥3 months       | 7115                  | 23370.21              | 748                     | 2034.41                 |
| ≥6 months       | 6622                  | 23178.14              | 713                     | 2023.62                 |
| ≥12 months      | 5028                  | 21821.56              | 636                     | 1973.80                 |
| ≥18 months      | 4504                  | 21215.76              | 579                     | 1910.80                 |
| ≥24 months      | 4168                  | 20636.96              | 538                     | 1845.47                 |
| ≥30 months      | 3816                  | 19880.70              | 508                     | 1784.31                 |

Source: RA IR Module 5.3.5.3 RA P123LTE Table 1582.10.4 Final data date for RA dataset 18 Jan 2019; PsA IR Module 5.3.5.3 PsA Cohort 3 Table 00118.C3.3.13.3 Final data date for PsA dataset 31 Jul 2019

<div style=\"page-break-after: always\"></div>

## Adverse events

An overall summary of Treatment-Emergent Adverse Events (All Causalities) in the AS PlaceboControlled Cohort is shown in Table 71.

Table 71. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number (%) of Subjects                                                        | Tofa 5 mg BID n (%)   | Placebo n (%)   |
|-------------------------------------------------------------------------------|-----------------------|-----------------|
| Subjects evaluable for adverse events                                         | 185                   | 187             |
| Number of adverse events                                                      | 205                   | 205             |
| Subjects with adverse events                                                  | 101 (54.6)            | 92 (49.2)       |
| Subjects with serious adverse events                                          | 3 (1.6)               | 2 (1.1)         |
| Subjects with severe adverse events                                           | 3 (1.6)               | 3 (1.6)         |
| Subjects discontinued from study due to adverse events (a)                    | 1 (0.5)               | 3 (1.6)         |
| Subjects discontinued study drug due to adverse events (b)                    | 4 (2.2)               | 4 (2.1)         |
| Subjects with dose reduced or temporary discontinuation due to adverse events | 12 (6.5)              | 6 (3.2)         |

The table is based on the data from OC AE only.

Except for the Number of Adverse Events subjects are counted only once per analysis group in each row.

(a) Subjects who have an AE record that indicates that the AE causes the subject to be discontinued from the study.

(b) Subjects who have an AE record that indicates that Action Taken with Study Treatment is Drug Withdrawn.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

Percentages are calculated using number of subjects evaluable for adverse events as the denominator.

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 11NOV2020 (23:37)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s010

Table C1.3.1.2.1-E is for Pfizer internal use.

Table 72 shows an overall summary in the AS All Tofa Cohort.

Table 72. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS All Tofa Cohort

| Number (%) of Subjects                | All Tofa 5 mg BID n (%)   | All Tofa n (%)   |
|---------------------------------------|---------------------------|------------------|
| Subjects evaluable for adverse events | 316                       | 420              |
| Number of adverse events              | 507                       | 617              |
| Subjects with adverse events          | 201 (63.6)                | 251 (59.8)       |
| Subjects with serious adverse events  | 10 (3.2)                  | 11 (2.6)         |

<div style=\"page-break-after: always\"></div>

Table 72. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS All Tofa Cohort

| Number (%) of Subjects                                                        | All Tofa 5 mg BID n (%)   | All Tofa n (%)   |
|-------------------------------------------------------------------------------|---------------------------|------------------|
| Subjects with severe adverse events                                           | 7 (2.2)                   | 8 (1.9)          |
| Subjects discontinued from study due to adverse events (a)                    | 2 (0.6)                   | 3 (0.7)          |
| Subjects discontinued study drug due to adverse events (b)                    | 11 (3.5)                  | 12 (2.9)         |
| Subjects with dose reduced or temporary discontinuation due to adverse events | 30 (9.5)                  | 32 (7.6)         |

The table is based on the data from OC AE only.

Except for the Number of Adverse Events subjects are counted only once per analysis group in each row.

(a) Subjects who have an AE record that indicates that the AE causes the subject to be discontinued from the study.

(b) Subjects who have an AE record that indicates that Action Taken with Study Treatment is Drug Withdrawn.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

Percentages are calculated using number of subjects evaluable for adverse events as the denominator.

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 12NOV2020 (02:05)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s010

Table C2.3.1.2.1-E is for Pfizer internal use.

## Most Common AEs

The most frequently reported TEAEs in the Placebo-controlled cohort, by SOC and PT ( ≥ 2% of patients), are documented in Table 73 (all causalities).

Table 73. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                                         | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   |
|------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%)              | Mod. n (%)              | Sev. n (%)              | Total n (%)             | Mild n (%)        | Mod. n (%)        | Sev. n (%)        | Total n (%)       |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                         | 2 (1.1)                 | 0                       | 0                       | 2 (1.1)                 | 4 (2.1)           | 0                 | 0                 | 4 (2.1)           |
| EYE DISORDERS                                                                | 3 (1.6)                 | 0                       | 1 (0.5)                 | 4 (2.2)                 | 4 (2.1)           | 0                 | 0                 | 4 (2.1)           |
| GASTROINTESTINAL DISORDERS                                                   | 20 (10.8)               | 4 (2.2)                 | 0                       | 24 (13.0)               | 25 (13.4)         | 3 (1.6)           | 0                 | 28 (15.0)         |
| Abdominal pain upper                                                         | 0                       | 0                       | 0                       | 0                       | 5 (2.7)           | 0                 | 0                 | 5 (2.7)           |
| Diarrhoea                                                                    | 7 (3.8)                 | 0                       | 0                       | 7 (3.8)                 | 4 (2.1)           | 2 (1.1)           | 0                 | 6 (3.2)           |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                         | 8 (4.3)                 | 2 (1.1)                 | 0                       | 10 (5.4)                | 6 (3.2)           | 1 (0.5)           | 0                 | 7 (3.7)           |
| Fatigue                                                                      | 3 (1.6)                 | 1 (0.5)                 | 0                       | 4 (2.2)                 | 1 (0.5)           | 0                 | 0                 | 1 (0.5)           |

<div style=\"page-break-after: always\"></div>

Table 73. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                                         |            | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   |            | Placebo (N=187)   | Placebo (N=187)   |             |
|------------------------------------------------------------------------------|------------|-------------------------|-------------------------|-------------------------|------------|-------------------|-------------------|-------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%) | Mod. n (%)              | Sev. n (%)              | Total n (%)             | Mild n (%) | Mod. n (%)        | Sev. n (%)        | Total n (%) |
| INFECTIONS AND INFESTATIONS                                                  | 38 (20.5)  | 13 (7.0)                | 0                       | 51 (27.6)               | 33 (17.6)  | 10 (5.3)          | 0                 | 43 (23.0)   |
| Influenza                                                                    | 5 (2.7)    | 1 (0.5)                 | 0                       | 6 (3.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)     |
| Nasopharyngitis                                                              | 12 (6.5)   | 1 (0.5)                 | 0                       | 13 (7.0)                | 12 (6.4)   | 1 (0.5)           | 0                 | 13 (7.0)    |
| Respiratory tract infection viral                                            | 3 (1.6)    | 1 (0.5)                 | 0                       | 4 (2.2)                 | 0          | 0                 | 0                 | 0           |
| Upper respiratory tract infection                                            | 13 (7.0)   | 1 (0.5)                 | 0                       | 14 (7.6)                | 9 (4.8)    | 2 (1.1)           | 0                 | 11 (5.9)    |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                | 4 (2.2)    | 1 (0.5)                 | 0                       | 5 (2.7)                 | 6 (3.2)    | 2 (1.1)           | 0                 | 8 (4.3)     |
| INVESTIGATIONS                                                               | 17 (9.2)   | 3 (1.6)                 | 1 (0.5)                 | 21 (11.4)               | 8 (4.3)    | 0                 | 0                 | 8 (4.3)     |
| Alanine aminotransferase increased                                           | 5 (2.7)    | 0                       | 1 (0.5)                 | 6 (3.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)     |
| Aspartate aminotransferase increased                                         | 3 (1.6)    | 0                       | 1 (0.5)                 | 4 (2.2)                 | 0          | 0                 | 0                 | 0           |
| Protein urine present                                                        | 4 (2.2)    | 1 (0.5)                 | 0                       | 5 (2.7)                 | 2 (1.1)    | 0                 | 0                 | 2 (1.1)     |
| METABOLISM AND NUTRITION DISORDERS                                           | 4 (2.2)    | 0                       | 0                       | 4 (2.2)                 | 6 (3.2)    | 0                 | 0                 | 6 (3.2)     |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                              | 7 (3.8)    | 8 (4.3)                 | 0                       | 15 (8.1)                | 13 (7.0)   | 7 (3.7)           | 1 (0.5)           | 21 (11.2)   |
| Arthralgia                                                                   | 1 (0.5)    | 2 (1.1)                 | 0                       | 3 (1.6)                 | 5 (2.7)    | 3 (1.6)           | 0                 | 8 (4.3)     |
| Arthritis                                                                    | 2 (1.1)    | 2 (1.1)                 | 0                       | 4 (2.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)     |
| Spinal pain                                                                  | 0          | 1 (0.5)                 | 0                       | 1 (0.5)                 | 2 (1.1)    | 1 (0.5)           | 1 (0.5)           | 4 (2.1)     |
| NERVOUS SYSTEM DISORDERS                                                     | 7 (3.8)    | 1 (0.5)                 | 0                       | 8 (4.3)                 | 9 (4.8)    | 1 (0.5)           | 0                 | 10 (5.3)    |
| Dizziness                                                                    | 1 (0.5)    | 0                       | 0                       | 1 (0.5)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)     |
| Headache                                                                     | 3 (1.6)    | 1 (0.5)                 | 0                       | 4 (2.2)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)     |
| PSYCHIATRIC DISORDERS                                                        | 1 (0.5)    | 0                       | 0                       | 1 (0.5)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)     |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                              | 9 (4.9)    | 1 (0.5)                 | 0                       | 10 (5.4)                | 9 (4.8)    | 1 (0.5)           | 0                 | 10 (5.3)    |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                       | 5 (2.7)    | 0                       | 0                       | 5 (2.7)                 | 6 (3.2)    | 1 (0.5)           | 0                 | 7 (3.7)     |

<div style=\"page-break-after: always\"></div>

## Table 73. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                             | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   |
|------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a)                                                      | Mild                    | Mod.                    | Sev.                    | Total                   | Mild              | Mod.              | Sev.              | Total             |
| Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | n (%)                   | n (%)                   | n (%)                   | n (%)                   | n (%)             | n (%)             | n (%)             | n (%)             |

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurrence is counted.

Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column). PFIZER CONFIDENTIAL Source Data: adae Table Generation: 17NOV2020 (10:41)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s160

Table C1.3.1.2.3.2-E is for Pfizer internal use.

The most frequent TEAEs by SOC in the Placebo-controlled Cohort were as follows:

- Infections and infestations (Tofa 5 mg BID: 27.6%, Placebo: 23.0%)
- GI disorders (Tofa 5 mg BID: 13.0%, Placebo: 15.0%)
- Investigations (Tofa 5 mg BID: 11.4%, Placebo: 4.3%)
- Musculoskeletal and connective tissue disorders (Tofa 5 mg BID: 8.1%, Placebo: 11.2%)

TEAE frequencies by PT that were higher (&gt;1% difference between treatment groups) in the Tofa 5 mg BID group compared to the Placebo group included:

- Fatigue, influenza, respiratory tract infection viral, upper respiratory tract infection, ALT increased, AST increased, protein urine present, and arthritis.

In contrast, the following PTs were higher (&gt;1% difference between treatment groups) for the Placebo group compared to the Tofa 5 mg BID group:

- Abdominal pain upper, arthralgia, spinal pain, and dizziness.

The most frequently reported TEAEs in the All Tofa cohort, by SOC and PT ( ≥ 2% of patients), are documented in Table 74 .

<div style=\"page-break-after: always\"></div>

Table 74 Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                         |            | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   |            |            | All Tofa (N=420)   |             |
|------------------------------------------------------------------------------|------------|-----------------------------|-----------------------------|-----------------------------|------------|------------|--------------------|-------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%) | Mod. n (%)                  | Sev. n (%)                  | Total n (%)                 | Mild n (%) | Mod. n (%) | Sev. n (%)         | Total n (%) |
| EYE DISORDERS                                                                | 6 (1.9)    | 4 (1.3)                     | 1 (0.3)                     | 11 (3.5)                    | 7 (1.7)    | 5 (1.2)    | 2 (0.5)            | 14 (3.3)    |
| GASTROINTESTINAL DISORDERS                                                   | 41 (13.0)  | 11 (3.5)                    | 0                           | 52 (16.5)                   | 53 (12.6)  | 15 (3.6)   | 0                  | 68 (16.2)   |
| Abdominal pain upper                                                         | 5 (1.6)    | 0                           | 0                           | 5 (1.6)                     | 9 (2.1)    | 1 (0.2)    | 0                  | 10 (2.4)    |
| Diarrhoea                                                                    | 14 (4.4)   | 0                           | 0                           | 14 (4.4)                    | 15 (3.6)   | 1 (0.2)    | 0                  | 16 (3.8)    |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                         | 14 (4.4)   | 3 (0.9)                     | 0                           | 17 (5.4)                    | 17 (4.0)   | 3 (0.7)    | 0                  | 20 (4.8)    |
| Fatigue                                                                      | 7 (2.2)    | 2 (0.6)                     | 0                           | 9 (2.8)                     | 8 (1.9)    | 2 (0.5)    | 0                  | 10 (2.4)    |
| HEPATOBILIARY DISORDERS                                                      | 10 (3.2)   | 4 (1.3)                     | 0                           | 14 (4.4)                    | 13 (3.1)   | 4 (1.0)    | 0                  | 17 (4.0)    |
| Hepatic function abnormal                                                    | 6 (1.9)    | 2 (0.6)                     | 0                           | 8 (2.5)                     | 7 (1.7)    | 2 (0.5)    | 0                  | 9 (2.1)     |
| INFECTIONS AND INFESTATIONS                                                  | 79 (25.0)  | 35 (11.1)                   | 0                           | 114 (36.1)                  | 93 (22.1)  | 42 (10.0)  | 0                  | 135 (32.1)  |
| Influenza                                                                    | 7 (2.2)    | 2 (0.6)                     | 0                           | 9 (2.8)                     | 7 (1.7)    | 2 (0.5)    | 0                  | 9 (2.1)     |
| Nasopharyngitis                                                              | 23 (7.3)   | 2 (0.6)                     | 0                           | 25 (7.9)                    | 28 (6.7)   | 3 (0.7)    | 0                  | 31 (7.4)    |
| Upper respiratory tract infection                                            | 27 (8.5)   | 5 (1.6)                     | 0                           | 32 (10.1)                   | 33 (7.9)   | 6 (1.4)    | 0                  | 39 (9.3)    |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                | 7 (2.2)    | 5 (1.6)                     | 0                           | 12 (3.8)                    | 13 (3.1)   | 6 (1.4)    | 0                  | 19 (4.5)    |
| INVESTIGATIONS                                                               | 45 (14.2)  | 7 (2.2)                     | 1 (0.3)                     | 53 (16.8)                   | 50 (11.9)  | 8 (1.9)    | 1 (0.2)            | 59 (14.0)   |
| Alanine aminotransferase increased                                           | 7 (2.2)    | 3 (0.9)                     | 1 (0.3)                     | 11 (3.5)                    | 8 (1.9)    | 3 (0.7)    | 1 (0.2)            | 12 (2.9)    |
| Aspartate aminotransferase increased                                         | 3 (0.9)    | 3 (0.9)                     | 1 (0.3)                     | 7 (2.2)                     | 3 (0.7)    | 3 (0.7)    | 1 (0.2)            | 7 (1.7)     |
| Blood creatine phosphokinase increased                                       | 7 (2.2)    | 1 (0.3)                     | 0                           | 8 (2.5)                     | 8 (1.9)    | 1 (0.2)    | 0                  | 9 (2.1)     |
| Protein urine present                                                        | 10 (3.2)   | 1 (0.3)                     | 0                           | 11 (3.5)                    | 10 (2.4)   | 1 (0.2)    | 0                  | 11 (2.6)    |
| Weight increased                                                             | 9 (2.8)    | 1 (0.3)                     | 0                           | 10 (3.2)                    | 9 (2.1)    | 1 (0.2)    | 0                  | 10 (2.4)    |
| METABOLISM AND NUTRITION DISORDERS                                           | 8 (2.5)    | 1 (0.3)                     | 0                           | 9 (2.8)                     | 11 (2.6)   | 1 (0.2)    | 0                  | 12 (2.9)    |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                              | 18 (5.7)   | 15 (4.7)                    | 3 (0.9)                     | 36 (11.4)                   | 23 (5.5)   | 18 (4.3)   | 3 (0.7)            | 44 (10.5)   |
| Arthralgia                                                                   | 4 (1.3)    | 3 (0.9)                     | 0                           | 7 (2.2)                     | 4 (1.0)    | 4 (1.0)    | 0                  | 8 (1.9)     |
| NERVOUS SYSTEM DISORDERS                                                     | 14 (4.4)   | 3 (0.9)                     | 0                           | 17 (5.4)                    | 21 (5.0)   | 3 (0.7)    | 0                  | 24 (5.7)    |
| Headache                                                                     | 9 (2.8)    | 2 (0.6)                     | 0                           | 11 (3.5)                    | 13 (3.1)   | 2 (0.5)    | 0                  | 15 (3.6)    |

<div style=\"page-break-after: always\"></div>

Table 74 Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                         |            | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   |            |            | All Tofa (N=420)   |             |
|------------------------------------------------------------------------------|------------|-----------------------------|-----------------------------|-----------------------------|------------|------------|--------------------|-------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%) | Mod. n (%)                  | Sev. n (%)                  | Total n (%)                 | Mild n (%) | Mod. n (%) | Sev. n (%)         | Total n (%) |
| RENAL AND URINARY DISORDERS                                                  | 7 (2.2)    | 1 (0.3)                     | 0                           | 8 (2.5)                     | 10 (2.4)   | 1 (0.2)    | 0                  | 11 (2.6)    |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                              | 18 (5.7)   | 4 (1.3)                     | 1 (0.3)                     | 23 (7.3)                    | 23 (5.5)   | 4 (1.0)    | 1 (0.2)            | 28 (6.7)    |
| Cough                                                                        | 4 (1.3)    | 3 (0.9)                     | 0                           | 7 (2.2)                     | 6 (1.4)    | 3 (0.7)    | 0                  | 9 (2.1)     |
| Oropharyngeal pain                                                           | 8 (2.5)    | 0                           | 0                           | 8 (2.5)                     | 9 (2.1)    | 0          | 0                  | 9 (2.1)     |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                       | 9 (2.8)    | 2 (0.6)                     | 0                           | 11 (3.5)                    | 10 (2.4)   | 2 (0.5)    | 0                  | 12 (2.9)    |

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurrence is counted.

Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column). Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 17NOV2020 (10:52)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s161

Table C2.3.1.2.3.2-E is for Pfizer internal use.

Table 75 shows incidence and severity of Treatment Related TEAEs in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term - Treatment Policy Estimand, AS PlaceboControlled Cohort.

Table 75 . Incidence and Severity of Treatment Related TEAEs

<div style=\"page-break-after: always\"></div>

Table C1.3.1.3.3.2-E Page 1 of 1 Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent AdverseEvents in &gt;=2% of Subjects in AnyAnalysis Group by System Organ Class and Preferred Term

(TreatmentRelated)-TreatmentPolicyEstimand,ASPlacebo-ControlledCohort

| NumberofSubjectsEvaluableforAEs                              | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   |
|--------------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a)                                                  | Mild                 | Mod.                 | Sev.                 | Total                | Mild              | Mod.              | Sev.              | Total             |
| Number(%) of Subjects: bySYSTEM ORGAN CLASS andPreferredTerm | (%)                  | (%)                  | n (%)                | (%)                  | (%)               | (%)               | n (%)             | (%)               |
| GASTROINTESTINAL DISORDERS                                   | 4 (2.2)              | 1 (0.5)              | 0                    | 5 (2.7)              | 12（ 6.4)          | 0                 | 0                 | 12 ( 6.4)         |
| INFECTIONSANDINFESTATIONS                                    | 10 (5.4)             | 3 ( 1.6)             | 0                    | 13 ( 7.0)            | 11 ( 5.9)         | 2 ( 1.1)          | 0                 | 13( 7.0)          |
| Upper respiratory tract infection                            | 7 (3.8)              | 1( 0.5)              | 0                    | 8（ 4.3)              | 5( 2.7)           | 0                 | 0                 | 5( 2.7)           |
| INVESTIGATIONS                                               | 10 ( 5.4)            | 1( 0.5)              | 1 ( 0.5)             | 12（ 6.5)             | 5( 2.7)           | 0                 | 0                 | 5( 2.7)           |
| NERVOUSSYSTEMDISORDERS                                       | 3 ( 1.6)             | 1( 0.5)              | 0                    | 4( 2.2)              | 2( 1.1)           | 0                 | 0                 | 2( 1.1)           |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS                 | 4（ 2.2)              | 1( 0.5)              | 0                    | 5( 2.7)              | 4( 2.1)           | 0                 | 0                 | 4( 2.1)           |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS                          | 1 ( 0.5)             | 0                    | 0                    | 1( 0.5)              | 4 (2.1)           | 1( 0.5)           | 0                 | 5 (2.7)           |

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurence is counted. Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occuurence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1. TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL

(Final Data: 10Sep2020)

## AEs of special interest

Summaries on selected signals of interest for tofacitinib are presented below from the AS pooled safety analysis. These signals of interest were derived from clinical experience with tofacitinib in RA and PsA patients and were as follows:

- Infection including serious infections, adjudicated OIs, all HZ, and TB.
- Malignancy excluding NMSC.
- NMSC.
- Cardiovascular safety including adjudicated CV events and events of DVT, PE, ATE and VTE.
- GI perforation.
- EBV-related events.
- ILD.
- Hepatic function.
- Renal function.
- Rhabdomyolysis.
- Lipids.
- Hematological.
- Vital signs.

Incidence rates, incidence proportion and hazard ratio for selected adverse events in the Tofa 5 mg BID and Placebo groups of the Placebo-controlled Cohort are summarised in Table 76 .

Source Data: adae Table Generation: 21NOV2020 (07:54) Output File:./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s183\\_1

<div style=\"page-break-after: always\"></div>

Table 76. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Numbers of Subjects with Events, Incidence Proportions, Incidence Rates (Number of Subjects with Event per 100 PY) by Analysis Group, Hazard Ratio and Incidence Proportions (Estimand 4) for Selected Adverse Events - While on Treatment Estimand, AS Placebo-Controlled Cohort

|                                    | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Placebo N = 187 = 53.07 Patient-Years   | Exposure   | Placebo N = 187 = 53.07 Patient-Years   | Placebo N = 187 = 53.07 Patient-Years   | Comparison (Tofa 5 mg BID - Placebo)   |
|------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------|------------|-----------------------------------------|-----------------------------------------|----------------------------------------|
| Adverse Events                     | n (%)                                                  | n1 (%)                                                 | PY                                                     | IR (95% CI) per 100 PY                                 | n (%)                                   | n1 (%)     | PY                                      | IR (95% CI) per 100 PY                  | HR (95% CI)                            |
| General                            |                                                        |                                                        |                                                        |                                                        |                                         |            |                                         |                                         |                                        |
| TEAEs                              | 101 ( 54.59)                                           | 0                                                      | 37.74                                                  | 267.61 (215.42, 319.81)                                | 91 ( 48.66)                             | 1 ( 0.53)  | 38.41                                   | 237.37 (188.59, 286.14)                 | 1.12 (0.85, 1.49)                      |
| Serious AEs                        | 3 ( 1.62)                                              | 0                                                      | 56.76                                                  | 5.28 (0.00, 11.25)                                     | 2 ( 1.07)                               | 1 ( 0.53)  | 56.59                                   | 3.56 (0.00, 8.49)                       | 1.47 (0.25, 8.80)                      |
| Severe AEs                         | 3 ( 1.62)                                              | 0                                                      | 56.82                                                  | 5.27 (0.00, 11.24)                                     | 3 ( 1.60)                               | 0          | 56.68                                   | 5.41 (0.00, 11.98)                      | 0.96 (0.19, 4.78)                      |
| Discontinuation of study           | 2 ( 1.08)                                              | 0                                                      | 57.06                                                  | 3.49 (0.00, 8.33)                                      | 7 ( 3.74)                               | 0          | 57.02                                   | 12.35 (3.20, 21.50)                     | 0.28 (0.06, 1.36)                      |
| Discontinuation of study treatment | 5 ( 2.70)                                              | 0                                                      | 56.79                                                  | 8.82 (1.09, 16.55)                                     | 9 ( 4.81)                               | 0          | 56.80                                   | 15.90 (5.51, 26.29)                     | 0.55 (0.18, 1.65)                      |
| Discontinuation due to AEs         | 4 ( 2.16)                                              | 0                                                      | 56.85                                                  | 7.04 (0.14, 13.94)                                     | 4 ( 2.14)                               | 0          | 56.95                                   | 7.10 (0.14, 14.05)                      | 0.97 (0.24, 3.90)                      |
| Death (Mortality)                  | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Infections                         |                                                        |                                                        |                                                        |                                                        |                                         |            |                                         |                                         |                                        |
| Serious Infections                 | 1 ( 0.54)                                              | 0                                                      | 56.98                                                  | 1.77 (0.00, 5.89)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NC (0.00, Inf.)                        |
| Opportunistic Infections*          | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Pneumonia                          | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Serious Pneumonia                  | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Herpes Zoster                      | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Serious Herpes Zoster              | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Urinary Tract Infection            | 2 ( 1.08)                                              | 0                                                      | 56.96                                                  | 3.53 (0.00, 8.92)                                      | 2 ( 1.07)                               | 0          | 56.86                                   | 3.50 (0.00, 8.87)                       | 1.00 (0.14, 7.07)                      |
| Cellulitis                         | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Tuberculosis*                      | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Candidiasis*                       | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Pneumocystis Jirovecii Pneumonia*  | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Malignancy                         |                                                        |                                                        |                                                        |                                                        |                                         |            |                                         |                                         |                                        |
| Malignancy excluding NMSC*         | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |

<div style=\"page-break-after: always\"></div>

| NMSC*                                   | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
|-----------------------------------------|-----------|-----|---------|---------------------|-----------|-----|---------|---------------------|--------------------|
| GI                                      |           |     |         |                     |           |     |         |                     |                    |
| GI Perforation*                         | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Cardiovascular Events                   |           |     |         |                     |           |     |         |                     |                    |
| Total MACE*                             | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Deep vein thrombosis*                   | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Pulmonary embolism*                     | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Arterial thromboembolism*               | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Venous thromboembolism a *              | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Thromboembolism b *                     | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Additional Adverse Events               |           |     |         |                     |           |     |         |                     |                    |
| Epstein-Barr Virus (EBV)-Related Events | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Interstitial Lung Disease (ILD)*        | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Rhabdomyolysis                          |           |     |         |                     |           |     |         |                     |                    |
| Rhabdomyolysis                          | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Creatine Kinase (CK) Elevation          | 3 ( 1.62) | 0   | 56.64   | 5.26 (0.00, 11.20)  | 2 ( 1.07) | 0   | 56.65   | 3.55 (0.00, 8.46)   | 1.50 (0.25, 9.00)  |
| Renal                                   |           |     |         |                     |           |     |         |                     |                    |
| Acute Renal Failure                     | 5 ( 2.70) | 0   | 56.50   | 8.92 (0.78, 17.05)  | 2 ( 1.07) | 0   | 56.93   | 3.49 (0.00, 8.85)   | 2.57 (0.50, 13.27) |
| Serum Creatinine Elevations             | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Hepatic                                 |           |     |         |                     |           |     |         |                     |                    |
| Hepatic Steatosis                       | 2 ( 1.08) | 0   | 56.84   | 3.54 (0.00, 8.94)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NC (0.00, Inf.)    |
| Transaminase Elevations                 | 8 ( 4.32) | 0   | 56.11   | 14.27 (4.38, 24.16) | 2 ( 1.07) | 0   | 56.73   | 3.55 (0.00, 8.47)   | 4.03 (0.86, 18.97) |
| Hematologic                             |           |     |         |                     |           |     |         |                     |                    |
| Lymphopenia                             | 1 ( 0.54) | 0   | 56.98   | 1.73 (0.00, 5.88)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NC (0.00, Inf.)    |
| Neutropenia                             | 0         | 0   | 57.06   | 0.00 (0.00, 3.28)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NE (-, -)          |
| Thrombocytopenia                        | 1 ( 0.54) | 0   | 56.83   | 1.77 (0.00, 5.91)   | 0         | 0   | 57.02   | 0.00 (0.00, 3.31)   | NC (0.00, Inf.)    |
| Anemia                                  | 1 ( 0.54) | 0   | 56.98   | 1.76 (0.00, 5.89)   | 2 ( 1.07) | 0   | 56.88   | 3.50 (0.00, 8.87)   | 0.51 (0.05, 5.57)  |
| Vital Signs                             |           |     |         |                     |           |     |         |                     |                    |
| Hypertension                            | 4 ( 2.16) | 0   | 56.35   | 7.14 (0.00, 14.51)  | 2 ( 1.07) | 0   | 56.51   | 3.52 (0.00, 8.92)   | 2.05 (0.37, 11.17) |
| Weight Increase                         | 2 ( 1.08) | 0   | 56.75   | 3.55 (0.00, 8.97)   | 1 ( 0.53) | 0   | 56.90   | 1.79 (0.00, 6.03)   | 2.00 (0.18, 22.10) |
| Lipids                                  |           |     |         |                     |           |     |         |                     |                    |
| Hyperlipidemia                          | 4 ( 2.16) | 0   | 56.29   | 7.11 (0.14, 14.08)  | 2 ( 1.07) | 0   | 56.51   | 3.56 (0.00, 8.50)   | 2.01 (0.37, 10.95) |

<div style=\"page-break-after: always\"></div>

Exposure is the sum of treatment exposures of all the subjects in the group. * Adjudicated events in all studies. a. Venous thromboembolism includes deep vein thrombosis and/or pulmonary embolism. b. Thromboembolism includes deep vein thrombosis, pulmonary embolism and/or arterial thromboembolism.

The Ankylosing Spondylitis Placebo-Controlled Cohort includes safety data from the double-blind placebo-controlled periods of the two studies, completed A3921119

(Up to Week 12) and completed A3921120 (Up to Week 16). Under While on Treatment Estimand, PY (ie, denominator for IR) is the sum of the times to the first event for subjects with an event or the risk periods for subjects without an event within the 28-Day While on Treatment Risk Period. n is the number of subjects with an event within the 28-Day While on Treatment Risk Period. n1 is the number of subjects with an event beyond the 28-Day While on

Treatment Risk Period which are not included in the IR estimation. Incidence proportions, PYs, IRs, and HRs are estimated based on n under this estimand/risk period.

IRs (95% CI) by analysis group are estimated using Cochran-Mantel-Haenszel weighting method adjusting to study. HR and its associated CI are estimated from a Cox regression model including fixed effects of treatment and study. MedDRA v23.0 coding dictionary applied.

NC: not calculated, 0 events in one analysis group of the comparison. NE: not estimable, 0 events in both analysis groups of the comparison.

PFIZER CONFIDENTIAL Source Data: adae &amp; adsaec &amp; adaj &amp; adds Table Generation: 24NOV2020 (05:07) (Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_ir\\_combine\\_3 Table C1.5.15.2.3-E is for Pfizer internal use.

## Safety of Tofacitinib in the RA and PsA development programmes

The safety databases from the RA and PsA programmes provide insight on the incidence rates and range of AEs reported with tofacitinib treatment in the AS programme, whilst recognising the differences regarding the design of the RA (separate monotherapy and background csDMARD) and PsA (background csDMARD only) programmes.

A description of the RA P2P3, RA P123LTE, PsA Cohort 2a, and PsA Cohort 3 safety populations is Table 77.

Table77. RA and PsA Safety Populations and Completed Studies Contributing to Safety Assessment for the AS Programme

| Analysis Set                                  | Brief Description                                                                                                                                          | Safety Analysis                                                                                                                            | Phase / Studies                                                                                                                                                               |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RA Safety Populations (for contextualisation) | RA Safety Populations (for contextualisation)                                                                                                              | RA Safety Populations (for contextualisation)                                                                                              | RA Safety Populations (for contextualisation)                                                                                                                                 |
| RA P2P3                                       | All patients randomised to tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 2 and 3 studies in the RA clinical programme. | The Tofa 5 mg BID group of the RA P2P3 Cohort will provide RA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort. | Phase 3 A3921045; A3921046; A3921064; A3921032, A3921044; A3921069; A3921187; A3921237 Phase 2 A3921019; A3921025; A3921035; A3921039; A3921040; A3921073; A3921129; A3921068 |

<div style=\"page-break-after: always\"></div>

Table77. RA and PsA Safety Populations and Completed Studies Contributing to Safety Assessment for the AS Programme

| Analysis Set                                   | Brief Description                                                                                                                                                                                                                                                                       | Safety Analysis                                                                                                                           | Phase / Studies                                                                                                                                  |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| RA P123LTE                                     | All patients exposed to at least 1 dose of tofacitinib from the completed Phase 1, 2, 3 and LTE studies                                                                                                                                                                                 | The All Tofa group of the Cohort RA P123LTE will provide RA contextualisation for the All Tofa group of the AS All Tofa Cohort.           | P2P3 Studies listed above Phase 1 A3921130; A3921152 Phase 2 A3921109 Phase 3 A3921192; A3921215 (Japan specific); LTE A3921024; A3921041 (Japan |
| PsA Safety Populations (for contextualisation) | PsA Safety Populations (for contextualisation)                                                                                                                                                                                                                                          | PsA Safety Populations (for contextualisation)                                                                                            | PsA Safety Populations (for contextualisation)                                                                                                   |
| Cohort 2a                                      | All patients randomised to tofacitinib 5 mg IR BID or placebo → tofacitinib 5 mg IR BID sequences and received at least 1 dose of tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 3 Studies A3921125 (up to 6 months) and A3921091 (up to 12 months). | The All Tofa 5 mg BID group of PsA Cohort 2a will provide PsA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort | Phase 3 A3921125; A3921091                                                                                                                       |
| 3 Cohort                                       | All patients who received at least 1 dose of tofacitinib (tofacitinib 5 or 10 mg BID) from the completed Phase 3 Studies A3921091, A3921125 and the long-term extension (LTE) Study A3921092.                                                                                           | The All Tofa group of the PsA Cohort 3 will provide PsA contextualisation for the All Tofa group of the AS All Tofa Cohort                | Phase 3 and LTE A3921125; A3921091; A3921092                                                                                                     |

Table 78 summarises the incidence rate (While on Treatment Estimand) per 100 PY (with 95% CIs) for the AEs of special interest in all patients treated with tofacitinib 5 mg IR BID comparing the AS All Tofa 5 mg BID group in the All Tofa Cohort to the PsA Cohort 2a All Tofa 5 mg BID group and the RA P2P3 Tofa 5 mg BID group.

Table 78. Incidence Rates (Number of Patients with Event per 100 PYs) of SAEs and Adverse Events of Special Interest in Patients Treated with Tofacitinib 5 mg IR BID in AS (Randomised Phase 2 and 3 Studies), PsA (Randomised Phase 3 Studies) and RA (Randomised Phase 2 and 3 Studies) Programmes (While on Treatment Estimand)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Souce: Module 5.3.5.3 SCS Tables C2.6.1.1-E, C2.5.1.2.1-E, C2.5.2.2.1-E, C2.5.4.2.1-E, C2.5.10.2.1-E, C2.5.11.2.1-E, C2.3.3.3.1-E. C2.3.3.3.2-E, C2.3.13.6-E C2.5.1.2.1.1-E: PsA IR Module 5.3.5.3 PsA Cobont 2a Tabkes 00118.C2a 2.19.1, 295a.1.2a., C2a.10.2.1. C2a.2.1.1, C2a.2.2.1. C2a.2 5.1, C2a.3.11.1, C2a.2.8.1, C2a.2.10.1. C2a.10.1.2.3: RA IR Moduke 53.5.3 RA P2P3 Tables 1571.2.1,1571.10.1.1.1. 1571.8.1.1.1, 1571.11.1.1.1,1571.5.1.1.1, 1571.6.1.1.1, 1571.7.1.1,1571.9.1.1.1,1571.9.1.2.1. 1571.12.1.1

a. Includes the data from subjects who were randomised to tofacitinib 5 mg IR BID and the tofacitinib-treated period for the subjects who were randomised to the placebo → tofhcilinib S mg IR BID

b. Includes the data from subjects who were randomised to tofacitinib 5 mg IR BID

c.N value for MACE is 2401

d. Adjudieated events in all studies.

e. Opportunisthie infections exclude Tuberculosis.

g. VTE ineludes DVT and/or PE.

f. Adjudicated events in AS studies only.

h. Thrombosis includes DVT, PE and/or ATE

i. Adjudiealed events by a Pfizer Intemal Review Committee.

j. The numerator counts all the events occurred either on- or off-treatment, while PY (the denominator) is ealeulated to subject's Treatment Policy Risk Period in AS and subject's last dose + 28 days in RA

Exposure is the sum of treatment exposures of all the subjects in the group. Risk period is to subject's last dose + 28 days or to the end of the cohort. Events are counted within the risk period. PY (in patient-year) is the sum of the times to the first event for subjects with event or to the end of the risk period for subjects without event and is the denominator for the incidence rate calculation.

AS All Tofa Cohort All Tofa 5 mg BID group includes completed randomised Phase 2 Study A3921119 and Phase 3 Study A3921120.

Incidence rale is a naive estimate without adjusting for study. Exact Poisson (adjusted for PY) 95% CI is provided for the Incidence nate.

PsA Cohort 2a All Tofa 5 mg BID group inchudes completed randomised Phase 3 Shudies A3921091 and A3921125.

RA Cohort P2P3 Tofa 5 mg BID group includes completed randomised Phase 2 and 3 Shudies A392-1019, 1025, 1032, 1035, 1039, 1040, 1044 (2 years), 1045, 1046, 1064, 1068, 1069 (2 years), 1073, 1129, 1187 and 1237.

Table 79 summarises the incidence rate (While on Treatment Estimand) per 100 PY (with 95% CIs) for the AEs of special interest in All Tofa doses comparing the AS All Tofa group in the All Tofa Cohort to the PsA Cohort 3 All Tofa group and the RA P123LTE All Tofa group.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: Module 5.3.53 SCS Tables C2.3.3.3.2-E, C2.6.1.1-E, C2.5.1.2.1-E, C2.5.2.2.1-E, C2.5.4.2.1-E, C2.5.10.2.1-E, C2.5.11.2.1-E, C2.3.3.3.1-E, C2.3.1.3.6-E; PsA.IR Module 5.3.5 3 PsA Cobot 3 Tables 00118.C3.10.1.2.3. 0011$.C3.10 2.1.a, 00118.C3.10.2.1, 00118.C3.2.10.1, 00118.C3 2.8.1, 0011$.C3.2.19.1, 0011$.C3.2.5.1, 00118.C3.2.1.1, 00118.C3.3.13.3, 00118.C3.2.2.1: RA IR Modulke 5.3.5.3 RA P123LTE Tables 1571.6.2.1.1, 1571.5.2.1.1, 1582.1.1.1, 1582.3.1.1, 1582.2.1.1, 1582.11.1.1. 1582.4.1.1, 1582.10.4, 1571.10.2.1.1, 1571.11.2.1.1, 1571.12.2.1.

a. Adjudicated events in all studies.

b. Opportunistic infections exclude Tuberculosis.

C. Adjudicated events in AS studies only.

d. VTE inchudes DVT and/or PE

e. Thrombosis inchudes DVT, PE and/or ATE.

f.Adjudicated events by a PfizerIntemal Review Comumillee.

g. The mumerator counts all the events occured either on- or off-treatment, while PY (the denominator) is calculated to subject's Treatment Poliey Risk Period in AS, subject's last dose in PsA and subject's lhast dose + 28 days in RA.

Exposure is the sum of treatment exposures of all the subjects. Risk period is to subject's last dose + 28 days or to the end of the cohort except for all-cause mortality (all event last dose algorithm) noted above. Events are counted within the risk period.

PY (in patient-year) is the sum of the times to the first event for subjects with event or to the end of the risk period for subjects without event and is the denominator for the incidence rate caleulation.

Incidence rate Was a naive estimate without adjusting for study. Exact Poisson (adjusted for PY) 95% CI is provided for the incidence rate.

PsA Cohort 3 All Tofa group includes completed randomised Phase 3 Shudies A3921091, A3921125 and LTE Study A3921092.

AS All Tofa Cohort All Tofa group includes completed randomised Phase 2 Study A3921119 and Phase 3 Study A3921120.

- RA Cohort RA P123LTE Al1 Tofa group includes completed randomised Phase 2. 3 and LTE Studies A392-1019, 1024 (LTE). 1025, 1032, 1035, 1039, 1040, 1041 (LTE).

1044 (2 years). 1045, 1046, 1064, 1068, 1069 (2 years), 1073. 1109, 1129, 1130, 1152. 1187, 1192, 1215, and 1237.

Overall, in the AS placebo-controlled cohort (with exposure up to 16 weeks, thus short-term), the proportion of subject with AEs was similar or slightly higher in tofacitinib than in placebo: 101 (54.6%) vs 92 (49.2%). However, when the AS All Tofa cohort is considered (with longer duration of exposure), a higher incidence of AEs is found. In particular, subjects with AEs were 201 (63.6%) in tofacitinib 5 mg BID vs 251 (59.8%) in All tofacitinib (for a rough comparison, the number in the short-term placebo arm was 92, 49.2%).

Subjects with dose reduced or temporary discontinuation due to adverse events were 30 (9.5%) in tofacitinib 5 mg BID vs 32 (7.6%) in All tofacitinib (for a rough comparison, the number in the short-term placebo arm was 6, 3.2%).

Among the most common AEs , those with more marked difference vs placebo are reported (during the 16 weeks of the placebo-controlled period): infections and infestations were 114 (36.1%) in tofacitinib 5mg BID vs 135 (32.1%) in All tofacitinib vs 43 (23.0%) in placebo. Investigations AEs were reported in 53 (16.8%) in tofacitinib 5 mg BID vs 59 (14.0%) in all tofacitinib cohort vs 8 (4.3%) in the placebo. Most of these investigation AE cases were related to increased liver transaminases. The type of observed AEs is in line with the safety profile of tofacitinib kwon so far.

<div style=\"page-break-after: always\"></div>

In the placebo-controlled cohort (with a limited exposure up to 16 weeks), more AEs considered related to the IMP, were moderate in intensity in the tofacitinib arm compared to the placebo (8/185, 4% vs 3/187, 1%).

Due to the limited number of patients studied (185 in tofacitinib 5mg BID) and the short duration of the placebo-controlled period (up to 16 weeks), it is very difficult to evaluate the observed difference in the incidence of AEs; furthermore, many AEs that are typically associated to tofacitinib treatment (such as herpes zoster), are not observed in the placebo-controlled period.

Acute renal failure was observed in more cases in tofacitinib than in placebo, 5 (2.70%) vs 2 (1.07%). Increased creatinine is currently reported at the 4.8 tabular listing of ADRs and it is also observed in this submission (see below at lab findings). Even if the absolute numbers are small, the MAH was asked to elaborate more on the risk of acute renal failure (e.g. possible unbalanced risk factors, medication use, etc). With the exception of 1 participant with an AE coded to as 'serum creatinine increased', all events listed under the SMQ of 'acute renal failure' were coded as 'protein urine present'. In most of the cases the severity of the alteration was classified as 'trace' or '+1', only one patient had '+2' as severity of the finding and none had '+3' or '+4'. Moreover, all participants with AEs of protein urine present had creatinine levels within normal limits (WNL) at all visits. Therefore, it seems that the severity of the AEs observed was mild on average. The issues was solved.

Hepatic AEs (including: Hepatic Steatosis, Transaminase Elevations) were overall observed more frequently in tofacitinib than in placebo, 10 (5.40%) vs 2 (1.07%) (manually calculated adding the two PTs above) and this is consistent with the known impact of tofacitinib on liver enzymes.

There was a case of serious infection in the tofacitinib 5mg during the placebo-controlled period (meningitis aseptic) not considered as an opportunistic infection (and thus considered not related to the immunosuppressant effects of tofacitinib).

Haematological alterations were few in absolute numbers and difficult to assess.

In the AS program were not observed cases of: Malignancies, NMSC, CV events of MACE or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis. To interpret correctly these data, it must be taken into account the small number of patients and the limited exposure.

When the incidence rate for AEs of special interest in patients treated with tofacitinib 5 mg IR BID in the AS development program is compared to those observed in the PsA and RA programs, the incidences in the AS are lower, this is most probably due to the low exposure in the AS program compared to the other two conditions. The same is observed when the comparison is among the All tofacitinib cohort, that is among patients who received any tofacitinib dosage (and not only the 5 mg BID); in this case an exception is only observed for herpes zoster incidence that is higher in AS patients, incidence per 100 PY (95% CI) 2.68 (1.08, 5.53), compared to PsA, 1.76 (1.23, 2.44), but lower compared to RA, 3.58 (3.34, 3.84).

## Serious adverse event/deaths/other significant events

## Deaths

No deaths were reported in the AS clinical programme.

## SAEs

The proportion of patients reporting SAEs for each treatment group and the associated incidence rates (While on Treatment Estimand) are as follows:

<div style=\"page-break-after: always\"></div>

- -Tofa 5 mg BID group: 3 (1.62%) patients representing an incidence rate of 5.28 patients with events per 100 PY.
- -Placebo group: 2 (1.07%) patients representing an incidence rate of 3.56 patients with events per 100 PY. There was an additional patient who experienced 3 SAEs (Foetal death, Vaginal haemorrhage, and Uterine spasm) outside the 28-Day While on Treatment Risk Period; these events were not included in the incidence rate calculation.

SAEs in the Placebo-controlled Cohort are reported in Table 80

Table 80. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for Adverse Events                                                  | Tofa 5 mg BID (N=185)   | Placebo (N=187) n (%)   |
|--------------------------------------------------------------------------------------------------|-------------------------|-------------------------|
| Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term | n (%)                   |                         |
| EAR AND LABYRINTH DISORDERS                                                                      | 1 (0.5)                 | 1 (0.5)                 |
| Hypoacusis                                                                                       | 1 (0.5)                 | 0                       |
| Vertigo                                                                                          | 0                       | 1 (0.5)                 |
| EYE DISORDERS                                                                                    | 1 (0.5)                 | 0                       |
| Iridocyclitis                                                                                    | 1 (0.5)                 | 0                       |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                             | 1 (0.5)                 | 1 (0.5)                 |
| Condition aggravated                                                                             | 1 (0.5)                 | 1 (0.5)                 |
| INFECTIONS AND INFESTATIONS                                                                      | 1 (0.5)                 | 0                       |
| Meningitis aseptic                                                                               | 1 (0.5)                 | 0                       |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                                    | 0                       | 1 (0.5)                 |
| Thoracic vertebral fracture                                                                      | 0                       | 1 (0.5)                 |
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS                                                   | 0                       | 1 (0.5)                 |
| Foetal death                                                                                     | 0                       | 1 (0.5)                 |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS                                                         | 0                       | 1 (0.5)                 |
| Uterine spasm                                                                                    | 0                       | 1 (0.5)                 |
| Vaginal haemorrhage                                                                              | 0                       | 1 (0.5)                 |
| Total preferred term events (b)                                                                  | 4                       | 6                       |
| Total Number of Cases (c)                                                                        | 3                       | 4                       |
| Total Number of Subjects with Serious Adverse Events (d)                                         | 3                       | 3                       |
| Total Number of Subjects with Serious Adverse Events (e): 6                                      |                         |                         |

(a) SAEs are counted at MedDRA preferred term/analysis group with each individual SAE counted only once per subject per analysis group.

(b) Total number of events per subject per analysis group. (c) Number of cases that started in the analysis group.

(d) Total number of subjects having an event that started in the analysis group. (e) Overall count of subjects that had a Serious adverse Event in any analysis group.

A case is a single event or a series of related events not separated in time occurring in a single subject.

Source of Analysis Group is OC(Oracle Clinical). Source of SAE is SDW(Safety Data Warehouse).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v.23.0J coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adsaec Table Generation: 11NOV2020 (20:46)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adsae\\_s001

Table C1.3.3.2-E is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

SAEs reported in the All Tofa Cohort are summarised in Table 81.

Table 81. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for Adverse Events                                                  | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   |
|--------------------------------------------------------------------------------------------------|-----------------------------|--------------------|
| Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term | n (%)                       | n (%)              |
| EAR AND LABYRINTH DISORDERS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Hypoacusis                                                                                       | 1 (0.3)                     | 1 (0.2)            |
| EYE DISORDERS                                                                                    | 1 (0.3)                     | 1 (0.2)            |
| Iridocyclitis                                                                                    | 1 (0.3)                     | 1 (0.2)            |
| GASTROINTESTINAL DISORDERS                                                                       | 1 (0.3)                     | 1 (0.2)            |
| Abdominal adhesions                                                                              | 1 (0.3)                     | 1 (0.2)            |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                             | 1 (0.3)                     | 1 (0.2)            |
| Condition aggravated                                                                             | 1 (0.3)                     | 1 (0.2)            |
| HEPATOBILIARY DISORDERS                                                                          | 1 (0.3)                     | 1 (0.2)            |
| Hyperplastic cholecystopathy                                                                     | 1 (0.3)                     | 1 (0.2)            |
| INFECTIONS AND INFESTATIONS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Meningitis aseptic                                                                               | 1 (0.3)                     | 1 (0.2)            |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                                    | 1 (0.3)                     | 2 (0.5)            |
| Rib fracture                                                                                     | 1 (0.3)                     | 1 (0.2)            |
| Tendon injury                                                                                    | 0                           | 1 (0.2)            |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                                                  | 1 (0.3)                     | 1 (0.2)            |
| Spinal osteoarthritis                                                                            | 1 (0.3)                     | 1 (0.2)            |
| NERVOUS SYSTEM DISORDERS                                                                         | 1 (0.3)                     | 1 (0.2)            |
| Migraine                                                                                         | 1 (0.3)                     | 1 (0.2)            |
| RENAL AND URINARY DISORDERS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Ureterolithiasis                                                                                 | 1 (0.3)                     | 1 (0.2)            |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                  | 1 (0.3)                     | 1 (0.2)            |
| Pneumothorax                                                                                     | 1 (0.3)                     | 1 (0.2)            |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                           | 1 (0.3)                     | 1 (0.2)            |
| Subcutaneous emphysema                                                                           | 1 (0.3)                     | 1 (0.2)            |
| Total preferred term events (b)                                                                  | 12                          | 13                 |
| Total Number of Cases (c)                                                                        | 9                           | 10                 |
| Total Number of Subjects with Serious Adverse Events (d)                                         | 9                           | 10                 |
| Total Number of Subjects with Serious Adverse Events (e): 10                                     |                             |                    |

<div style=\"page-break-after: always\"></div>

## Table 81. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS All Tofa Cohort

## Number of Subjects Evaluable for Adverse Events

All Tofa 5 mg

BID

(N=316)

All Tofa

(N=420)

Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term

n (%)

n (%)

(a) SAEs are counted at MedDRA preferred term/analysis group with each individual SAE counted only once per subject per analysis group.

- (b) Total number of events per subject per analysis group. (c) Number of cases that started in the analysis group.

(d) Total number of subjects having an event that started in the analysis group.

(e) Overall count of subjects that had a Serious adverse Event in any analysis group.

A case is a single event or a series of related events not separated in time occurring in a single subject.

Source of Analysis Group is OC(Oracle Clinical). Source of SAE is SDW(Safety Data Warehouse). Included Protocols:

A3921119, A3921120 (Final Data).

MedDRA v.23.0J coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adsaec Table Generation: 11NOV2020 (22:32)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adsae\\_s001

Table C2.3.3.2-E is for Pfizer internal use.

The proportion of patients reporting SAEs for the All Tofa 5 mg BID group and the associated incidence rate (While on Treatment Estimand) are: All Tofa 5 mg BID group: 8 (2.53%) patients representing an incidence rate of 3.49 (95% CI: 1.51, 6.87) patients with events per 100 PY.

Severity of SAEs is shown in Table 82

## Table 82. Incidence and Severity od Treatment-Emergent Adverse Events

Table C2.3.1.3.3.2-E

TofacitinibSunmaryof ClinicalSafety(AnkylosingSpondylitis)

Page1 of 1

Incidence and Severity of Treatiment-Emergent AdverseEventsin&gt;=2%of Subjects in AnyAnalysis GroupbySystemOrgan Class andPreferred Term (TreatmentRelated)-TreatmentPolicyEstimand,ASAllTofaCohort

<!-- image -->

| Number of Subjects Evaluable for AEs                           | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa (N=420)   | AllTofa (N=420)   | AllTofa (N=420)   | AllTofa (N=420)   | AllTofa (N=420)   |
|----------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a)                                                    | Mild                    | Mod.                    | Sev.                    | Total                   | Mild              | Mod. Sev.         | Total             |                   |                   |
| Number (%) of Subjects: by SYSTEM ORGAN CLASS andPreferredTerm | (%)                     | (%)                     | (%)                     | (%)                     | (%)               | (%) (%)           | (%)               |                   |                   |
| GASTROINTESTINALDISORDERS                                      | 12 ( 3.8)               | 1 ( 0.3)                | 0                       | 13 ( 4.1)               | 19 ( 4.5)         | 3 ( 0.7) 0        | 22 (5.2)          |                   |                   |
| HEPATOBILIARYDISORDERS                                         | 6 ( 1.9)                | 1 ( 0.3)                | 0                       | 7 (2.2)                 | 1.9)              | 1( 0.2) 0         | 9( 2.1)           |                   |                   |
| INFECTIONSANDINFESTATIONS                                      | 28 ( 8.9)               | 8( 2.5)                 | 0                       | 36 ( 11.4)              | 35 ( 8.3)         | 11 ( 2.6) 0       | 46 ( 11.0)        |                   |                   |
| Upper respiratory tract infection                              | 13 ( 4.1)               | 1 ( 0.3)                | 0                       | 14 (4.4)                | 16 ( 3.8)         | 1( 0.2) 0         | 17 ( 4.0)         |                   |                   |
| INVESTIGATIONS                                                 | 31( 9.8)                | 3( 0.9)                 | 1( 0.3)                 | 35 ( 11.1)              | 34 ( 8.1)         | 4 ( 1.0) 1 (0.2)  | 39 ( 9.3)         |                   |                   |
| Protein urine present                                          | 7( 2.2)                 | 0                       | 0                       | 7 ( 2.2)                | 7(                | 0 0               | 7( 1.7)           |                   |                   |
| Weight increased                                               | 7( 2.2)                 | 0                       | 0                       | 7( 2.2)                 | 1.7) 7( 1.7)      | 0 0               | 7( 1.7)           |                   |                   |
| NERVOUSSYSTEMDISORDERS                                         | 6 ( 1.9)                | 2 ( 0.6)                | 0                       | 8( 2.5)                 | 9( 2.1)           | 2 ( 0.5) 0        | 11 ( 2.6)         |                   |                   |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS                   | 8 (2.5)                 | 1( 0.3)                 | 0                       | 9 (2.8)                 | 9 ( 2.1)          | 1 (0.2) 0         | 10 （ 2.4)         |                   |                   |

2.1

R

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurrence is counted. Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

ject's

TEAE in A39211i9 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

Maximumseverity at any dictionarylevelis calculated afterthereportsubset criteriais applied.

TEAEinA3921120isdefinedasthoseon-treatmenteventswhichstartduringtheeffectivedurationoftreatment.

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Each SOC row counts allthe events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column).

PFIZERCONFIDENTIAL

(Final Data: 10Sep2020)

SourceData:adaeTableGeneration: 21NOV2020 (07:57)

Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s040\\_1

RA Cohort RAP123LTE A11Tofa group includes completed randomisedPhase 2,3 and LTE Studies A392-1019,1024 (LTE),1025,1032,1035,1039,1040,1041(LTE), 1044 (2 years), 1045, 1046, 1064, 1068, 1069 (2 years), 1073, 1109, 1129, 1130, 1152, 1187, 1192, 1215, and 1237.

event he

<div style=\"page-break-after: always\"></div>

Regarding the SAEs , incidence rate was 5.28/100 PY in the tofacitinib 5mg BID in the placebo-controlled cohort, vs 3.56/100 PY of the placebo arm; the total number of cases were (tofacitinib 5 mg vs placebo) 3 vs 2. In All tofacitinib doses the incidence rate was 3.49/100 PY, that is similar to the placebo arm of the controlled cohort (but with different length of exposure); the total number of cases in the All tofacitinib cohort were (tofacitinib 5 mg BID vs All tofacitinib doses) 9 vs 10. However, it is important to keep in mind the limited number of subjects studied. Since the small numbers, it is difficult to identify the most common SAEs, because virtually all the observed SAEs occurred each in a single subject. Most of the SAEs were mild in severity in both 5mg and all dosses for tofacitinib during the 48-week period of the study.

In the placebo group a patient experienced 'foetal death'. Since 'pregnancy' was an exclusion criterion, the MAH clarified that the patient's pregnancy was a result of a contraceptive failure (condom and spermicide) but she was negative at the start of the study.

The MAH provided data of comparison between patients treated with tofacitinib in the AS program vs those in the RA/PsA programs for SAEs and AEs of Special Interest. Basically, except for herpes zoster in patients taking tofacitinib 5mg BID, all the SAEs and other AEs of special interest were apparently less frequent in the AS program compared to the RA and PsA programs. This was most probably due to the very low exposure in the AS program (PYR=232.98 for tofacitinib all doses) compared to PsA in which exposure was about 10 times higher (2037.97) and RA in which it was 100 times higher (23496.73).

## Laboratory findings

The pooled safety population has been used to evaluate changes from baseline in laboratory parameters of AS patients. For the Placebo-controlled Cohort, data for both A3921119 and A3921120 were pooled through Week 16. For the A3921119 study, the last dose of study medication was at the Week 12 visit. The Week 16 visit was a follow up visit 4 weeks after the last dose of study medication and was also included in the pooled safety population datasets.

Incidence of laboratory abnormalities are shown in Table 83 , without regard to baseline abnormality for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

Table 83 . Tofacitinib Summary of Clinical Safety (AS)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Laboratory Abnormalities: Number of SubjectsEvaluablefor LaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Laboratory Abnormalities: Number of SubjectsEvaluablefor LaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Laboratory Abnormalities: Number of SubjectsEvaluablefor LaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Tofa 5 mg BID 184 76 (41.3%)   | Tofa 5 mg BID 184 76 (41.3%)   | Placebo 184 89 (48.4%)   | Placebo 184 89 (48.4%)   |
|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
| Group                                                                                                                                     | Parameter(Units)                                                                                                                          | Primary Criteria                                                                                                                          | N                              | n (%)                          | N                        | n (%)                    |
|                                                                                                                                           | LDL Cholesterol (mg/dL)                                                                                                                   | >1.2x ULN                                                                                                                                 | 181                            | 4 ( 2.2)                       | 184                      | 3 ( 1.6)                 |
|                                                                                                                                           | Tniglycerides (mg/dL)                                                                                                                     | >1.3xULN                                                                                                                                  | 184                            | 7 (3.8)                        | 184                      | 3 ( 1.6)                 |
|                                                                                                                                           | Sodium (mEq/L)                                                                                                                            | <0.95xLLN                                                                                                                                 | 184                            | 0                              | 184                      | 1( 0.5)                  |
|                                                                                                                                           | Potassium (mEq/L)                                                                                                                         | >1.1x ULN                                                                                                                                 | 184                            | 2 ( 1.1)                       | 184                      | 0                        |
|                                                                                                                                           | Glucose (mg/dL)                                                                                                                           | >1.5xULN                                                                                                                                  | 184                            | 6 ( 3.3)                       | 184                      | 4 ( 2.2)                 |
|                                                                                                                                           | Creatine Kinase (U/L)                                                                                                                     | >2.0xULN                                                                                                                                  | 184                            | 8 (4.3)                        | 184                      | 9 ( 4.9)                 |
|                                                                                                                                           | Cholesterol (mg/dL)                                                                                                                       | >1.3xULN                                                                                                                                  | 184                            | 0                              | 184                      | 1(C 0.5)                 |
| URINALYSIS                                                                                                                                | Specific Gravity (Scalar)                                                                                                                 | >1.035                                                                                                                                    | 183                            | 2 ( 1.1)                       | 183                      | 6 (3.3)                  |
|                                                                                                                                           | pH (Scalar)                                                                                                                               | >8                                                                                                                                        | 183                            | 1 ( 0.5)                       | 183                      | 0                        |
|                                                                                                                                           | URINE Glucose                                                                                                                             | >=1                                                                                                                                       | 183                            | 2 ( 1.1)                       | 183                      | 1 ( 0.5)                 |
|                                                                                                                                           | Ketones                                                                                                                                   | >=1                                                                                                                                       | 183                            | 5 ( 2.7)                       | 183                      | 7 ( 3.8)                 |
|                                                                                                                                           | URINE Protein                                                                                                                             | >=1                                                                                                                                       | 183                            | 3 ( 1.6)                       | 183                      | 0                        |
|                                                                                                                                           | URINE Hemoglobin                                                                                                                          | >=l                                                                                                                                       | 183                            | 27 ( 14.8)                     | 183                      | 35 ( 19.1)               |
|                                                                                                                                           | URINE Erythrocytes (HPF)                                                                                                                  | >=20                                                                                                                                      | 72                             | 2 ( 2.8)                       | 73                       | 5 ( 6.8)                 |

<!-- image -->

| Laboratory Abnormalities: Nuumber ofSubjectsEvaluableforLaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Laboratory Abnormalities: Nuumber ofSubjectsEvaluableforLaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Laboratory Abnormalities: Nuumber ofSubjectsEvaluableforLaboratoryAbnormalities: Number (%) of Subjects with Laboratory Abnormalities:   | Tofa 5 mg BID 184 76 (41.3%)   | Tofa 5 mg BID 184 76 (41.3%)   | Placebo 184 89 (48.4%)   | Placebo 184 89 (48.4%)   |
|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
| Group                                                                                                                                    | Parameter (Units)                                                                                                                        | Primary Criteria                                                                                                                         | N                              | n (%)                          | N                        | n (%)                    |
|                                                                                                                                          | URINE Leukocytes (HPF)                                                                                                                   | >=20                                                                                                                                     | 74                             | 4 ( 5.4)                       | 79                       | 3 (3.8)                  |
|                                                                                                                                          | Hyaline Casts (/LPF)                                                                                                                     | [≤                                                                                                                                       | 4                              | 3 ( 75.0)                      | 8                        | 6 ( 75.0)                |

NOTE: N = total number of subjects in the Safety Analysis Set with at least one observation of the given laboratory test while on study treatment or during lag time. n = number of subjects with a laboratory abnormality meeting specified criteria while on study treatment or during lag time. Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects. Included Protocols: A3921119, A3921120 (Final Data).

Patients who had abnormalities for selected laboratory evaluations of interest for tofacitinib were required to  promptly  retest  a  laboratory  parameter  or  discontinue  study  medication  due  to  the  laboratory abnormalities. The number of patients who met the criteria for retesting a laboratory parameter of interest, or had to discontinue study medication due to laboratory abnormalities are presented in Table 84 for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

Table 84. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Laboratory Values Meeting Protocol Criteria for Monitoring and Discontinuation of Study Drug - Treatment Policy Estimand, AS Placebo-Controlled Cohort

|                                                                                                                       | Tofa5mg BID (N=185) n(9)   | Placebo (N-187) n(9)   |
|-----------------------------------------------------------------------------------------------------------------------|----------------------------|------------------------|
| Catepory.Monitoring Criteria                                                                                          |                            |                        |
| Met any monitoring cniteria                                                                                           | 4(2.2)                     | 9(4.8)                 |
| Any single hemoglobin drops>2g/dLbelowbaseline                                                                        | 0                          | 4(2.1)                 |
| Absolute neutrophil count <1.2x10*+9/L                                                                                | 1 (0.5)                    | 0                      |
| Absolute lymphocyte count <0.5x 10++g/L                                                                               | 1 (0.5)                    | 0                      |
|                                                                                                                       | 0                          | 1 (0.5)                |
| Serum creatinine increase >50% or increase >0.5 mg/dL over the average of screening and baseline values               | 0                          | 1(0.5)                 |
| Any creatinekinase (CK)>SxULN                                                                                         | 2(1.1)                     | 3(1.6)                 |
| Category.Discontinuation Cnitenia                                                                                     |                            |                        |
| Met any discontinuation cnteria                                                                                       | 1 (0.5)                    | 1(0.5)                 |
| Two sequential absolute neutrophil counts<1.0 x 1o**9/L                                                               | 0                          | 0                      |
| Two sequential absolute lymphocyte counts<5oo lymphocytes/mm**3                                                       | 0                          | 0                      |
| Two sequential hemoglobin <8.0 g/dL or decreases of >30% from baseline value                                          | 0                          | 0                      |
| Two sequential platelet counts <75x 10**9/L                                                                           | 0                          | 0                      |
| Two sequential AST orALT elevations>=3xULNwith at least one total bilirubin>= 2xULN                                   | 0                          | 0                      |
| Two sequential AST or ALT elevations >=3x ULN accompanied by hepatic injury (eg. new onset elevated PT/INR)           | 0                          | 0                      |
| Two sequential ASTorALTelevations>SxULN                                                                               | 1(0.5)                     | 0                      |
| Two sequential serum creatinine increase >5o% and increase >0.5mg/dLover the average of screening and baseline values | 0                          | 0                      |
| Two sequential creatine kinase (CK)elevations >1Ox ULN                                                                | 0                          | 0                      |
| A confirmed positive urine prepnancy test in a woman of childbearing potential                                        | 0                          | 1(0.5)                 |

A subject may have met multiple criteria. Each subject is counted only once for each row.

Baseline is defined as last non-missing assessment prior to first dose of investigational product (including Placebo).

N:Number of subjects included in the Safety Analysis Set,n (%): Number of subjects who meet the critenia (Percentages are based on N)

Inclnded Prolocols:A3921119,A3921120 (Final Data)

PFIZER CONFIDENTIAL SourceData:adIbTable Generation:11NOV2020(0S:37)

(FinalData:10Sep2020)Output File:/unblind 1120/A392 SCSPCEU/adlb s401

Table C1.3.4.4-E is forPfizer intermal use.

## Hemoglobin

Tofacitinib  is  associated  with  increased  incidence  of  anaemia.  Therefore,  patient  selection  based  on threshold Hb values was an exclusion criteria. Patients were required to have Hb levels ≥ 10 g/dL at the study enrollment visit to enroll in the AS studies.

Hb changes over time are presented for the Placebo-controlled Cohort in Figure 31 and All Tofa Cohort in Figure 32 . There were no patient discontinuations due to decreases in Hb.

Figure 31. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Hemoglobin (g/dL) - AS Placebo-controlled Cohort

<div style=\"page-break-after: always\"></div>

## Neutrophils

Tofacitinib has been associated with an increased incidence of neutropenia, therefore patient selection based on threshold ANC values was an exclusion criteria. The mean (± SE) Change from Baseline in Absolute Neutrophil Count is reported in Figure 33.

<!-- image -->

Source:Module 5.3.5.3 SCS Figure C1.3.4.3.4.4-E

Figure 32. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Hemoglobin (g/dL) - AS All Tofa Cohort

<!-- image -->

Source: Module 5.3.5.3 SCS Figure C2.3.4.3.4.4-E

<div style=\"page-break-after: always\"></div>

Figure 33. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Absolute Neutrophil Count (10 3 /mm 3 ) - AS Placebo-controlled Cohort

<!-- image -->

Source: Module 5.3.5.3 SCS Figure C1.3.4.3.4.4-E

## Platelets

Patient selection based on threshold platelet counts was implemented as exclusion criteria in clinical trials. To enrol in the AS programme, patients were required to have a platelet count ≥100,000 platelets/mm3 at the study enrolment visit. Platelet count changes over time are presented for the Placebo-controlled ( Figure 34) and All Tofa Cohort ( Figure 35). In the Placebo-controlled Cohort, there was a mean decrease from baseline  to  Week  4  for  the  Tofacitinib  5  mg  IR  BID  group.  Platelet  counts  decreased  around  40,000 averagely from baseline during the first 4 weeks. Afterwards, the platelet counts increased slightly until 16 weeks but remained averagely 30,000 under the baseline average count. Platelet change in the placebo arm was not considerable and remained almost unchanged compared to the baseline. In the placebocontrolled phase, there were no patients that had to discontinue because of 2 sequential platelet counts &lt;75 x 10**9/L.

The mean platelet counts were lower in the Tofacitinib 5 mg IR BID group compared to the Placebo group up to Week 16. The mean and median platelet counts remained within the normal range for all visits.

<div style=\"page-break-after: always\"></div>

Figure  34. Tofacitinib  Summary  of  Clinical  Safety  -  Mean  (±  SE)  Change  from  Baseline  in  Platelets (10 3 /mm 3 ) - AS Placebo-controlled Cohort

<!-- image -->

Source: Module 5.3.5.3 SCS Figure C1.3.4.3.4.4-E

Platelet counts decreased during the first 4 ( Table 85) weeks of tofacitinib treatment significantly (mean of approximately -45,000 in tofacitinib 5mg BID group).  After 4 th  week the platelet counts increased slightly but still remained significantly lower than the baseline (mean decrease of -30,000 until week 48).

Figure  35 Tofacitinib  Summary  of  Clinical  Safety-Mean  (±SE)  Change  from  Baseline  in  Platelets (103/mm3)-AS All Tofa Cohort

Table 85 show a comparison of platelet counts in AS vs RA/PsA clinical programs.

<!-- image -->

Table 85. Platelet Count (10 3 /mm 3 ) by Visit for AS Placebo-controlled Cohort versus RA and PsA - 3-month data

|       |                    | AS Placebo-controlled cohort   | RA All Phase 3 Tofa 5 mg BID   | PsA Cohort 1   |
|-------|--------------------|--------------------------------|--------------------------------|----------------|
| Visit | Summary Statistics |                                |                                |                |

<div style=\"page-break-after: always\"></div>

|          |                                | Tofa 5 mg BID           | Placebo                 | Tofa 5 mg BID       | Placebo              | Tofa 5 mg BID           | Placebo                 |
|----------|--------------------------------|-------------------------|-------------------------|---------------------|----------------------|-------------------------|-------------------------|
| Baseline | N1                             | 185                     | 187                     | 1183                | 666                  | 238                     | 236                     |
|          | Mean (SD)                      | 296.60 (81.705)         | 307.26 (84.463)         | 328.21 (95.81)      | 325.16 (93.87)       | 280.24 (86.30)          | 283.99 (88.04)          |
|          | Median (min, max)              | 285.00 (138.00, 666.00) | 298.00 (156.00, 593.00) | 314.0 (81.0, 849.0) | 311.0 (38.0, 833.0)  | 271.00 (153.00, 703.00) | 268.50 (125.00, 703.00) |
| Week 4   | N1                             | 183                     | 179                     | 1150                | 630                  | 233                     | 226                     |
|          | Mean (SD)                      | 251.04 (61.375)         | 304.13 (82.488)         | 295.57 (82.28)      | 327.23 (97.47)       | 257.67 (72.07)          | 280.24 (81.70)          |
|          | Median (min, max)              | 247.00 (109.00, 412.00) | 294.00 (151.00, 584.00) | 286.0 (67.0,746.0)  | 309.0 (125.0, 834.0) | 248.00 (117.00, 540.00) | 274.00 (105.00, 678.00) |
|          | Mean Change from Baseline (SD) | -45.03 (54.579)         | -2.78 (44.965)          | -33.08 (58.40)      | -0.26 (51.43)        | -22.79 (51.11)          | -1.70 (47.19)           |
| Week 8   | N1                             | 52                      | 51                      | -                   | -                    | 227                     | 222                     |
|          | Mean (SD)                      | 260.27 (62.552)         | 291.25 (74.371)         | -                   | -                    | 262.87 (67.36)          | 275.50 (78.16)          |
|          | Median (min, max)              | 250.00 (165.00, 452.00) | 279.00 (160.00, 537.00) | -                   | -                    | 257.00 (138.00, 547.00) | 265.00 (94.00, 594.00)  |
|          | Mean Change from Baseline (SD) | -34.04 (54.349)         | -3.57 (36.120)          | -                   | -                    | -17.90 (52.83)          | -5.44 (49.79)           |
| Week 12  | N1                             | 178                     | 168                     | 1105                | 606                  | 225                     | 216                     |
|          | Mean (SD)                      | 264.25 (57.953)         | 304.09 (82.642)         | 298.42 (82.69)      | 326.22 (97.79)       | 264.97 (73.14)          | 276.53 (90.24)          |
|          | Median (min, max)              | 261.50 (119.00, 418.00) | 293.00 (86.00, 548.00)  | 289.0 (48.0,833.0)  | 312.0 (112.0, 833.0) | 259.00 (108.00, 647.00) | 262.00 (76.00, 759.00)  |
|          | Mean Change from Baseline (SD) | -31.92 (56.558)         | 0.08 (48.507)           | -29.17 (65.69)      | 0.52 (60.12)         | -16.23 (53.19)          | -4.19 (54.04)           |
| Week     | N1                             | 179                     | 175                     | -                   | -                    | 237                     | 234                     |
| 16*      | Mean (SD)                      | 270.58 (61.094)         | 304.48 (89.657)         | -                   | -                    | 264.57 (73.25)          | 278.32 (92.01)          |
|          | Median (min, max)              | 274.00 (124.00, 440.00) | 293.00 (160.00, 604.00) | -                   | -                    | 259.00 (108.00, 647.00) | 262.50 (76.00, 759.00)  |
|          | Mean Change from Baseline (SD) | -26.98 (61.020)         | -3.10 (56.815)          | -                   | -                    | -15.52 (52.95)          | -4.91 (56.60)           |

Source: S0113 Module 5.3.5.3 SCS Tables C1.3.4.3.4.1-E and C1.3.4.3.4.3-E; S0000 Module 5.3.5.3 All Phase 3 Tables 14.2.2 and 14.2.3; S0014 Module 5.3.5.3 PsA Cohort 1 Tables C1.6.1.1 and C1.6.1.2

Abbreviation: AS = ankylosing spondylitis; BID = twice a day; max = maximum; min = minimum; N1= number of participants; PsA = psoriatic arthritis; RA= rheumatoid arthritis; SD = standard deviation; Tofa = tofacitinib.

Baseline is the latest pre-study treatment (Tofacitinib or placebo) dose measurement.

<div style=\"page-break-after: always\"></div>

Includes subjects with a Baseline measurement and at least one post Baseline measurement.

AS Placebo-Controlled Cohort: Includes Protocols A3921119 and A3921120.

RA All Phase 3:  Includes Protocols A3921032, A3921044(1 year), A3921045, A3921046 and A3921064.

PsA Cohort 1: Includes Protocols A3921091 and A3921125.

*PsA Cohort 1 last observation

Table 86. Platelet Count (10 3 /mm 3 ) by Visit in AS for All Tofa Cohort versus RA and PsA 1-year data

|          |                    | AS All Tofa Cohort All Tofa 5 mg BID   | RA All Phase 3 Tofa 5 mg BID   | PsA All PsA Average Tofa 5 mg BID   |
|----------|--------------------|----------------------------------------|--------------------------------|-------------------------------------|
| Visit    | Summary Statistics |                                        |                                |                                     |
| Baseline | N1                 | 316                                    | 1183                           | 445                                 |
| Baseline | Mean (SD)          | 302.26 (84.419)                        | 328.21 (95.81)                 | 274.48 (80.18)                      |
| Baseline | Median (Min, Max)  | 292.50 (138.00, 666.00)                | 314.0 (81.0, 849.0)            | 262.00 (76.0, 703.0)                |
| Week 4   | N1                 | 185                                    | 1150                           | 442                                 |
| Week 4   | Mean (SD)          | 251.87 (61.586)                        | 295.57 (82.28)                 | 254.46 (69.27)                      |
| Week 4   | Median (Min, Max)  | 247.00 (109.00, 412.00)                | 286.0 (67.0,746.0)             | 245.50 (105.0, 658.0)               |
| Week 4   | Mean Change from   | -45.50 (54.922)                        | -33.08 (58.40)                 | -20.08 (53.22)                      |
| Week 8   | N1                 | 181                                    | -                              | -                                   |
| Week 8   | Mean (SD)          | 281.24 (75.193)                        | -                              | -                                   |
| Week 8   | Median (Min, Max)  | 268.00 (121.00, 556.00)                | -                              | -                                   |
| Week 8   | Mean Change from   | -24.41 (55.588)                        | -                              | -                                   |
| Week 12  | N1                 | 178                                    | 1105                           | 437                                 |
| Week 12  | Mean (SD)          | 264.25 (57.953)                        | 298.42 (82.69)                 | 264.90 (70.14)                      |
| Week 12  | Median (Min, Max)  | 261.50 (119.00, 418.00)                | 289.0 (48.0,833.0)             | 259.00 (108.0, 647.0)               |
| Week 12  | Mean Change from   | -31.92 (56.558)                        | -29.17 (65.69)                 | -10.04 (55.12)                      |
| Week 16  | N1                 | 305                                    | -                              | -                                   |
| Week 16  | Mean (SD)          | 274.40 (65.597)                        | -                              | -                                   |
| Week 16  | Median (Min, Max)  | 276.00 (124.00, 612.00)                | -                              | -                                   |
| Week 16  | Mean Change from   | -27.90 (63.231)                        | -                              | -                                   |
| Week 24  | N1                 | 256                                    | 1252                           | 412                                 |
| Week 24  | Mean (SD)          | 278.95 (72.070)                        | 294.05 (84.79)                 | 263.04 (64.91)                      |
| Week 24  | Median (Min, Max)  | 270.00 (122.00, 577.00)                | 287.0 (95.0, 694.0)            | 254.00 (105.0, 514.0)               |
| Week 24  | Mean Change from   | -24.97 (57.480)                        | -36.12 (67.57)                 | -12.28 (58.56)                      |
| Week 32  | N1                 | 247                                    | -                              | -                                   |
| Week 32  | Mean (SD)          | 278.57 (74.249)                        | -                              | -                                   |
| Week 32  | Median (Min, Max)  | 271.00 (118.00, 552.00)                | -                              | -                                   |
| Week 32  | Mean Change from   | -26.81 (58.408)                        | -                              | -                                   |
| Week 36  | N1                 | -                                      | 871                            | 396                                 |
| Week 36  | Mean (SD)          | -                                      | 282.57 (81.88)                 | 262.64 (68.38)                      |

<div style=\"page-break-after: always\"></div>

|         | Median (Min, Max)   | -                       | 275.0 (88.0, 694.0)   | 251.50 (119.0, 602.0)   |
|---------|---------------------|-------------------------|-----------------------|-------------------------|
|         | Mean Change from    | -                       | -41.39 (67.81)        | -12.32 (62.11)          |
| Week 40 | N1                  | 214                     | -                     | -                       |
| Week 40 | Mean (SD)           | 282.83 (76.655)         | -                     | -                       |
| Week 40 | Median (Min, Max)   | 270.50 (115.00, 569.00) | -                     | -                       |
| Week 40 | Mean Change from    | -22.06 (63.704)         | -                     | -                       |
| Week 48 | N1                  | 124                     | -                     | -                       |
| Week 48 | Mean (SD)           | 264.94 (58.191)         | -                     | -                       |
| Week 48 | Median (Min, Max)   | 257.50 (117.00, 459.00) | -                     | -                       |
| Week 48 | Mean Change from    | -32.13 (55.047)         | -                     | -                       |
| Week 52 | N1                  | -                       | 820                   | 383                     |
| Week 52 | Mean (SD)           | -                       | 288.42 (80.06)        | 262.52 (67.87)          |
| Week 52 | Median (Min, Max)   | -                       | 282.0 (98.0, 910.0)   | 253.00 (107.0, 583.0)   |
| Week 52 | Mean Change from    | -                       | -35.38 (64.14)        | -13.34 (62.53)          |

Source:  S0113 Module 5.3.5.3 SCS Tables C2.3.4.3.4.1-E and C2.3.4.3.4.3-E; S0000 Module 5.3.5.3 All Phase 3 Table 14.2.2 and 14.2.3; S0014 Module 5.3.5.3 PsA Cohort 3 Tables 00118.C3.6.1.1 and 00118.C3.6.1.2

Abbreviation: AS = ankylosing spondylitis; BID = twice a day; max = maximum; min = minimum; N1= number of participants; PsA = psoriatic arthritis; RA= rheumatoid arthritis; SD = standard deviation; Tofa = tofacitinib.

Baseline is the latest pre-Tofacitinib dose measurement.

Includes subjects with a Baseline measurement and at least one post Baseline measurement.

AS All Tofa Cohort: Includes Protocols A3921119 and A3921120.

RA All Phase 3:  Includes Protocols A3921032, A3921044(1 year), A3921045, A3921046 and A3921064.

PsA Average Tofa 5 mg : Subjects with an average total daily dose of &lt;15 mg from Day 1 on Tofa. Includes Protocols A3921091,

## Liver Parameters

Tofacitinib has been associated with increases in liver test values compared to placebo. Most of these abnormalities have occurred in studies with background DMARD (primarily MTX) therapy.

Changes in AST in the placebo-controlled period are shown in Figure 36.

Figure 36. Tofacitinib Summary of Clinical Safety-Mean (±SE) Change from Baseline in AST (U/L) - AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.4.3.1.4-E

<!-- image -->

<div style=\"page-break-after: always\"></div>

The change of AST (U/L) levels at 16 week from baseline was: mean (SD) 2.94 (11.588) in tofacitinib 5 mg vs  0.18 (6.903) in placebo.

Changes in ALT in the placebo-controlled period are shown in Figure 37.

Figure 37. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in ALT (U/L) - AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.4.3.1.4-E

<!-- image -->

The change of AST (U/L) levels at 16 week from baseline was: mean (SD) 4.62 (20.662) in tofacitinib 5 mg vs  0.44 (10.134) in placebo.

An  analysis  of  the  proportion  of  patients  who  experienced  confirmed  liver  test  values  (2  consecutive elevations) at multiples of the ULN is presented for the Placebo-controlled Cohort is shown in Table 87.

<div style=\"page-break-after: always\"></div>

Table 87. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Number (%) of Subjects With Confirmed Liver Test Values as Multiples of Upper Limit of Normal (Without Regard to Baseline Abnormality)

- Treatment Policy Estimand, AS Placebo-Controlled Cohort

|                 | Tofa5mgBID (N=184) n (%)   | Placebo (N=184) n (%)   |
|-----------------|----------------------------|-------------------------|
| ALT             |                            |                         |
| =2xULN          | 4 (2.2)                    | 1 (0.5)                 |
| >-3xULN         | 1 (0.5)                    | 0                       |
| =5xULN          | 1 (0.5)                    | 0                       |
| =10xULN         | 0                          | 0                       |
| AST             |                            |                         |
| =2xULN          | 3 (1.6)                    | 0                       |
| =3xULN          | 1 (0.5)                    | 0                       |
| =5xULN          | 0                          | 0                       |
| 2=10xULN        | 0                          | 0                       |
| Total Bilinubin |                            |                         |
| -2xULN          | 0                          | 0                       |
| =3xULN          | 0                          | 0                       |

Confimed=at least 2 consecutive measurements with the subject.

N: Number of subjects who have a post-baseline observation for AST, ALT or total bilinubin; n (%): Number of subiects with the events (percentage based on N)

Inchuded Protocols: A3921119, A3921120 (Final Data).

PFIZER CONFIDENTIAL Source Data: adlb Table Generation: 09NOV2020 (21:09)

(Final Data: 10Sep2020) Output File: unblind 1120/A392 SCSPC EU/adlb s003 4

Table C1.3.4.3.4.8-E is for Pfizer intemal use.

## Renal Function Testing

Studies in RA patients treated with tofacitinib have demonstrated small mean increases in serum creatinine, which remained within the normal reference range ( Figure 38 ). The mean change from baseline for creatinine is shown in the following figure for the Placebo-controlled Cohort.

Figure 38. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Creatinine (mg/dL) - AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.4.3.2.4-E

<!-- image -->

<div style=\"page-break-after: always\"></div>

The changes of serum creatine at week 16 from baseline was: Mean (SD) 0.04 (0.100) in tofacitinib 5 mg vs 0.02 (0.095) in placebo.

## Lipid Parameters

Treatment with tofacitinib has been associated with dose-dependent increases in lipid parameters including total  cholesterol,  LDL  cholesterol  and  HDL  cholesterol.  Maximum effects have generally been observed within 6 weeks.

The mean change from baseline for cholesterol is shown in Figure 39 for the Placebo-controlled Cohort.

Figure  39. Tofacitinib  Summary  of  Clinical  Safety  -  Mean  (±  SE)  Percent  Change  from  Baseline  in Cholesterol (mg/dL) - AS Placebo-controlled Cohort

Module5.3.5.3SCSFigure C1.3.4.3.3.4-E

<!-- image -->

The changes from baseline for cholesterol were: mean (SD) 8.60 (15.164) in tofacitinib 5 mg vs 1.69 (13.083) in placebo.

The mean changes from baseline for HDL cholesterol are shown in Figure 40 for the Placebo-controlled Cohort.

Figure 40 . Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in HDL Cholesterol (mg/dL) - AS Placebo-controlled Cohort

Module5.3.5.3SCSFigure C1.3.4.3.3.4-E

<!-- image -->

The changes at week 16 from baseline for HDL (mg/dL) cholesterol were: mean (SD) 5.04 (19.951) in tofacitinib 5 mg vs -0.49 (16.540) in placebo.

<div style=\"page-break-after: always\"></div>

The mean changes from baseline for LDL cholesterol are shown in Figure 41 for the Placebo-controlled Cohort.

Figure 41 . Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in LDL Cholesterol (mg/dL) - AS Placebo-controlled Cohort

Module5.3.5.3SCSFigureC1.3.4.3.3.4-E

<!-- image -->

The changes at week 16 from baseline for LDL (mg/dL) cholesterol were: mean (SD) 10.37 (21.387) in tofacitinib 5 mg vs 4.46 (23.451) in placebo.

The mean changes from baseline for Triglycerides are shown in Figure 42 . for the Placebo-controlled Cohort.

Figure 42 . Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in Triglycerides (mg/dL) - AS Placebo-controlled Cohort

Module5.3.5.3SCSFigure C1.3.4.3.3.4-E

<!-- image -->

The changes at week 16 from baseline for Triglycerides (mg/dL) were: mean (SD) 14.58 (39.489) in tofacitinib 5 mg vs 10.62 (74.379) in placebo.

<div style=\"page-break-after: always\"></div>

## Blood pressure

Changes at week 16 from baseline for systolic blood pressure (mmHg) were, mean (SD): -0.1 (10.91) in tofacitinib 5 mg vs -0.2 (10.73) in placebo.

Changes at week 48 from baseline for systolic blood pressure (mmHg) were, mean (SD): -0.4 (11.20) in tofacitinib 5 mg BID and All tofa doses.

Changes at week 16 from baseline for diastolic blood pressure (mmHg) were, mean (SD): -0.1 (7.05) in tofacitinib 5 mg vs -0.5 (8.73) in placebo.

Table 87 shows the categorization of changes in blood pressure parameters

Table 87. Tofacitinib Summary of Clinical Safety (AS) - Categorization of Vital Signs Data

TableC2.3.5.2-E TofacitinibSummaryofClinicalSafety(AnkylosingSpondylitis)

CategorizationofVitalSignsData-TreatmentPolicyEstimand,ASAllTofaCohort

|                                     |                     | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa (N=420)   | AllTofa (N=420)   | AllTofa (N=420)   |
|-------------------------------------|---------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|
| Parameter(units)                    | Criteria            | N1                      | n (%)                   | n (%)                   | N1                | n (%)             | n (%)             |
| SITTINGSYSTOLICBLOODPRESSURE(MMHG)  | Value<90mmHg        | 314                     | 1(                      | 0.3)                    | 415               | 1(                | 0.2)              |
| SITTINGSYSTOLICBLOODPRESSURE(MMHG)  | Chg>=30mmHgincrease | 314                     | 11（                     | 3.5)                    | 415               | 12（               | 2.9)              |
| SITTINGSYSTOLICBLOODPRESSURE(MMHG)  | Chg>=30mmHgdecrease | 314                     |                         | 8 (2.5)                 | 415               | 11                | 2.7)              |
| SITTINGDIASTOLICBLOODPRESSURE(MMHG) | Value<50mmHg        | 314                     | 0                       |                         | 415               |                   | 2(0.5)            |
| SITTINGDIASTOLICBLOODPRESSURE(MMHG) | Chg>=20mmHgincrease | 314                     |                         | 16 (5.1)                | 415               | 19                | 4.6)              |
| SITTINGDIASTOLICBLOODPRESSURE(MMHG) | Chg>=20mmHgdecrease | 314                     |                         | 16 (5.1)                | 415               | 23(               | 5.5)              |
| SITTINGPULSERATE(BPM)               | Value<40bpm         | 314                     | 0                       |                         | 415               | 0                 |                   |
| SITTINGPULSERATE(BPM)               | Value>120bpm        | 314                     |                         | 1(0.3)                  | 415               | 1(                | 0.2)              |

## Body weight

Changes at week 16 from baseline for weight (kg) were, mean (SD): 1.8 (4.96) in tofacitinib 5 mg vs 0.5 (2.93) in placebo (see Figure 43 ).

Figure 43. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline Weight (Kg) - AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3SCSFigure C1.3.5.1.3-E

The changes of the weight from baseline among the All tofacitinib patients is shown in Figure 44.

<div style=\"page-break-after: always\"></div>

Figure 44. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Weight (Kg) AS All Tofa Cohort

<!-- image -->

Module5.3.5.3SCSFigureC2.3.5.1.3-E

At 48 weeks the change from baseline of the weight (kg) was, mean (SD) 2.2 (4.59) in the tofacitinib cohort in both arms (tofacitinib 5 mg and all tofacitinib doses).

Table 88 shows the shift in BMI categories.

Table 88 Shift Table of BMI Categories Relative to Baseline by Visit (Safety Analysis Set) (Final Analysis) - A3921120

|         |                                      | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        |
|---------|--------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|         |                                      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) |
| Visit   | BMI Catego ry at Baselin e (kg/m 2 ) | N                                 | N1                                | <25 n (%)                         | ≥25 to < 35 n (%)                 | ≥35 n (%)                         | N                                      | N1                                     | <25 (%)                                | ≥25 to < 35 n (%)                      | ≥35 n (%)                              |
| Week 16 | <25                                  | 50                                | 50                                | 46 (92.0)                         | 4 (8.0)                           | 0                                 | 59                                     | 58                                     | 52 (89.7)                              | 6 (10.3)                               | 0                                      |
|         | ≥25 to < 35                          | 74                                | 73                                | 2 (2.7)                           | 67 (91.8)                         | 4 (5.5)                           | 69                                     | 68                                     | 3 (4.4)                                | 65 (95.6)                              | 0                                      |
|         | ≥35                                  | 8                                 | 8                                 | 0                                 | 0                                 | 8 (100.0)                         | 8                                      | 7                                      | 0                                      | 0                                      | 7 (100.0)                              |
| Week 48 | <25                                  | 50                                | 49                                | 42 (85.7)                         | 7 (14.3)                          | 0                                 | 59                                     | 54                                     | 46 (85.2)                              | 8 (14.8)                               | 0                                      |
|         | ≥25 to < 35                          | 74                                | 68                                | 1 (1.5)                           | 64 (94.1)                         | 3 (4.4)                           | 69                                     | 66                                     | 1 (1.5)                                | 63 (95.5)                              | 2 (3.0)                                |
|         | ≥35                                  | 8                                 | 7                                 | 0                                 | 0                                 | 7 (100.0)                         | 8                                      | 5                                      | 0                                      | 0                                      | 5 (100.0)                              |

Source: S0113 Module 5.3.5.1 A3921120 Table 420a.1.4

Abbreviations: BID= twice a day; BMI= body mass index; N = number of subjects in the Safety Analysis Set; N1 = number of subjects with observations at baseline and at post-baseline visits.

Baseline was defined as last non-missing assessment on or before day 1 and prior to first dose of investigational product. One subject in tofacitinib 5 mg BID has missing baseline BMI.

Percentages of BMI categories at post-baseline visit is calculated using N1 as denominator, conditioned on BMI category at baseline.

BMI at Week 16 and Week 48 are calculated using Height at Screening and Weight at Week 16 and Week 48 respectively.

<div style=\"page-break-after: always\"></div>

## ECG

Table 89 shows the ECG parameters categorization for the placebo-controlled cohort.

Table 89. Tofacitinib Summary of Clinical Safety (AS) - Categorization of ECG Data

TableC1.3.6.2-E TofacitinibSummaryofClinicalSafety(AnkylosingSpondylitis)

CategorizationofECGData-TreatmentPolicyEstimand,ASPlacebo-ControlledCohort

<!-- image -->

|                                             |                | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Placebo (N=187)   | Placebo (N=187)   |
|---------------------------------------------|----------------|----------------------|----------------------|-------------------|-------------------|
| Parameter(units)                            | Criteria       | N1                   | n (%)                | N1                | n (%)             |
| PRINTERVAL,SINGLEBEAT(MSEC)                 | Value>=300     | 183                  | 0                    | 180               | 0                 |
|                                             | %Chg>=25/50%   | 183                  | 2（ 1.1)              | 180               | 1（ 0.6)           |
| QRSDURATION,SINGLEBEAT(MSEC)                | Value>=140     | 183                  | 1( 0.5)              | 180               | 2( 1.1)           |
|                                             | %Chg>=50%      | 183                  | 0                    | 180               | 1( 0.6)           |
| QTINTERVAL,SINGLEBEAT(MSEC)                 | Value>=500     | 183                  | 1 0.5)               | 180               | 0                 |
| QTCBINTERVAL,SINGLEBEAT(MSEC)450<=Value<480 |                | 183                  | 4（ 2.2)              | 180               | 10 (5.6)          |
|                                             | 480<=Value<500 | 183                  | 0                    | 180               | 2（ 1.1)           |
|                                             | Value>=500     | 183                  | 1（ 0.5)              | 180               | 0                 |
|                                             | 30<=Chg<60     | 183                  | 11 6.0)              | 180               | 10 (5.6)          |
|                                             | Chg>=60        | 183                  | 0.5)                 | 180               | 0                 |
| QTCFINTERVAL,SINGLEBEAT(MSEC)               | 450<=Value<480 | 183                  | 4（ 2.2)              | 180               | 6 (3.3)           |
|                                             | 480<=Value<500 | 183                  | 0                    | 180               | 0                 |
|                                             | Value>=500     | 183                  | 1( 0.5)              | 180               | 0                 |
|                                             | 30<=Chg<60     | 183                  | 7( 3.8)              | 180               | 6(3.3)            |
|                                             | Chg>=60        | 183                  | 1( 0.5)              | 180               | 0                 |

In the comparison between tofacitinib 5 mg BID and placebo (with exposure up to 16 weeks) there seem to be no particular signals of safety issues from laboratory findings, except for a slight higher proportion of subjects that had increased liver transaminases in tofacitinib compared to placebo. In particular, subjects with AST &gt;3.0x ULN were 4 (2.2%) in tofacitinib vs 1 (0.5%) in placebo; ALT &gt;3.0x ULN were 5 (2.7%) vs 1 (0.5%). Also Triglycerides (mg/dL) &gt;1.3x ULN were increased in 7 (3.8%) patients taking tofacitinib vs 3 (1.6%) in placebo. This confirms the known increase in the liver function tests.

No reduction in haemoglobin levels was observed in the AS program, despite the tendency of tofacitinib to induce anemia. Again, the plausible explanation is the limited exposure.

During the placebo-controlled period, a slight decrease in the neutrophil count was observed in the tofacitinib 5 mg BID compared to placebo. The reduction occurred already after few weeks of treatment. At week 16 (last visit of the placebo-controlled period), Neutrophils (10^3/mm^3) were: mean (SD) 4.66 (1.673) in tofacitinib 5mg vs 4.97 (1.831) in placebo.

There was a slight reduction in platelets count at week 16 in tofacitinib 5 mg vs placebo, mean (SD) (10^3/mm^3): 270.58 (61.094) vs  304.48 (89.657). However, the values remained in the normal range for all the visits.

Lipids were influenced by tofacitinib treatment, in particular a mild increase in total cholesterol, LDL, HDL and triglycerides was observed.

No clinically significant changes were observed in blood pressure during the up to 16 weeks of the placebo-controlled period in patients taking tofacitinib, and also at the end of the 48 weeks in the uncontrolled period.

An increase in weight was observed among tofacitinib patients: at week 16 the change from baseline was (kg) mean (SD): 1.8 (4.96) in tofacitinib 5mg vs 0.5 (2.93) in placebo. In the All tofacitinib cohort the increase was 2.2 (4.59) at 48 weeks in both arms (tofacitinib 5mg and All tofacitinib doses). The MAH has specified that the overall magnitude of the weight increase in the AS clinical program was considered

<div style=\"page-break-after: always\"></div>

to be mild in severity, with a mean increase of 2.2 kg at Week 48 in the All Tofa Cohort.  Similar increases were observed in the rheumatoid arthritis (RA) and psoriatic arthritis (PsA) clinical programs.

The percentage of participants that switched from the &lt;25 kg/m2 category to ≥25 - &lt;35 kg/m2 category was 14.3% and from the ≥25 to &lt;35 kg/m2 category to ≥35 kg/m2 category was 4.4% for the tofacitinib 5 mg BID treatment group at Week 48.

Since weight increase is already present in the tabular list at the 4.8 of the SmPC, this is considered sufficient in relation to the magnitude of observed effect.

No alterations in the ECG parameters were observed during the placebo-controlled phase.

## Safety in special populations

## Age

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs by Age Group for the AS All Tofa Cohort are presented in Table 90.

Table 90. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Age Group - While on Treatment Estimand, AS All Tofa Cohort

| Events Category                    | Age (Years)   | Analysis Group             | N       | (%) uI                    | nl(%)           | PY            | IR (95%C1)per 100 PY                                      |
|------------------------------------|---------------|----------------------------|---------|---------------------------|-----------------|---------------|-----------------------------------------------------------|
| TEAEs                              | <65           | All Tofa 5 mg BD All Tofa  | 309 407 | 193 ( 62.46) 241 ( 59.21) | 3 (0.97)        | 122.63 142.60 | 157.39 (135.97, 181.23) 169.01 (148.34, 191.75)           |
|                                    | >=65          | All Tofa 5 mg BID All Tofa | 7 13    | 5 (71.43) 7(53.85)        | 3 (0.74) 0 0    | 3.43 4.87     | 145.98 (47.40, 340.68) 143.88 (57.85, 296.45)             |
| SAEs                               | <65           | All Tofa 5 mg BD All Tofa  | 309 407 | 8 (2.59) 8 (1.97)         | 1(0.32) 1(0.25) | 223.73 253.30 | 3.58 (1.54, 7.05) 3.16 (1.36, 6.22)                       |
|                                    | >=65          | All Tofa 5 mg BD All Tofa  | 7 13    | 0 1(7.69)                 | 0 0             | 5.66 7.35     | 0.00 (0.00, 65.18) 13.61 (0.34, 75.82)                    |
| Severe AEs                         | <65           | All Tofa 5 mg BD All Tofa  | 309 407 | 7(2.27) 8 (1.97)          | 0 0             | 223.86 253.30 | 3.13 (1.26, 6.44) 3.16 (1.36, 6.22)                       |
|                                    | >=65          | All Tofa 5 mg BD All Tofa  | 7 13    | 0 0                       | 0 0             | 5.66 7.56     | 0.00 (0.00, 65.18) 0.00 (0.00,48.80)                      |
| Discontinuation of study           | <65           | All Tofa 5 mg BID          | 309     | 9 (2.91) 14 (3.44)        | 5 (1.62)        | 225.69        | 3.99 (1.82, 7.57)                                         |
|                                    | >=65          | All Tofa 5 mg BD All Tofa  | 7 13    | 1(14.29) 1(7.69)          | 0 0             | 5.66 7.56     |                                                           |
| Discontinuation of study treatment | <65           | All Tofa                   | 407     | 24 (7.77)                 | 6 (1.47)        | 255.26        | 5.48 (3.00, 9.20) 17.67 (0.45, 98.45) 13.23 (0.33, 73.71) |
|                                    | >=65          | All Tofa 5 mg BD All Tofa  | 309 407 | 30 (7.37)                 | 0 0             | 224.03 253.46 | 10.71 (6.86, 15.94) 11.84 (7.99,16.90)                    |
|                                    |               | AllTofa5mgBD               | 7       | 1 (14.29)                 | 0               | 5.66          | 17.68 (0.45, 98.50)                                       |
| Discontinuation due to AEs         |               |                            |         |                           |                 |               |                                                           |
|                                    |               | All Tofa                   | 13      | 1 (7.69)                  | 0               | 7.56          | 13.23 (0.34, 73.73)                                       |
|                                    |               | All Tofa 5 mg BD           |         |                           | 0               |               |                                                           |
|                                    |               | All Tofa                   |         |                           | 0               |               |                                                           |
|                                    | <65           |                            | 309     | 10 (3.24)                 |                 | 224.86        | 4.45 (2.13, 8.18)                                         |
|                                    |               |                            | 407     | 11 (2.70)                 |                 | 254.43        | 4.32 (2.16, 7.74)                                         |

<div style=\"page-break-after: always\"></div>

| Events Category                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Age (Years)                                                                   | Analsis Group                                                                                    | N                         | n(%)                                | nl(%)                 | PY                                         | IR(95C1）per100PY                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------|-------------------------------------|-----------------------|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| TEAEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 65                                                                            | All Tofa 5 mg BID AllTofa                                                                        | 309 407                   | 193 (62.46) 241(59.21)              | 3(0.97) 3(0.74)       | 122.63 142.60                              | 157.39 (135.97, 18123) 169.01 (148.34,191.75)                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 59                                                                            | All Tofa5mgBD All Tofa                                                                           | 7                         | 5(71.43) 7(53.85)                   | 0 0                   | 3.43 4.87                                  | 145.98 (47.40,340.68) 143.88 (57.85, 296.45)                                                                                   |
| SAEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                               | All Tofa5mgBD                                                                                    | 13 309                    | 8(2.59)                             | 1(0.32)               | 223.73                                     | 3.58 (1.54, 7.05)                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 65                                                                            | All Tofa                                                                                         | 407 7                     | 8(1.97) 0                           | 1(0.25) 0 0           | 253.30 5.66                                | 3.16 (1.36,6.22) 0.00 (0.00,65.18)                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 65                                                                            | AllTof5mg BD All Tofa                                                                            |                           | 1(7.69) 7(2.27) 8(1.97) 0           | 0 0 0 0               | 7.35                                       | 13.61 (0.34, 75.82)                                                                                                            |
| Severe AEs Discontination of study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | =65 59= 65 S9=                                                                | All Tofa 5 mg BD All Tofa All Tofa 5 mg BID All Tofa All Tof 5 mg BID All Tofa All Tofa 5 mg BID | 13 309 407 7 13 309 407 7 | 0 9(2.91) 14(3.44) 1(14.29) 1(7.69) | 5(1.62) 6(1.47) 0 0   | 223.86 253.30 5.66 7.56 225.69 255.26 5.66 | 3.13 (1.26, 6.44) 3.16 (1.36, 6.22) 0.00 (0.00,65.18) 0.00 (0.00,48.80) 3.99 (1.82, 7.57) 5.48 (3.00, 9.20) 17.67 (0.45,98.45) |
| Discontimation of study treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 65 >=65                                                                       | All Tofa All Tofa 5 mg BID All Tofa All Tofa 5 mz BID                                            | 13 309 407 7              | 24 (7.77) 30(7.37) 1(14.29)         | 0 0 0                 | 7.56 224.03 253.46 5.66                    | 13.23 (0.33, 73.71) 10.71 (6.86, 15.94) 11.84 (7.99, 16.90) 17.68 (0.45,98.50)                                                 |
| Discontinuation due to AEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 65 >=65                                                                       | AllTob All Tof 5 mg BD All Tofa                                                                  | 13 309 407                | 1(7.69) 10(3.24) 11(2.70)           | 0 0 0                 | 7.56 224.86 254.43                         | 13.23 (0.34, 73.73) 4.45 (2.13,8.18) 4.32 (2.16, 7.74)                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                               | All Tofa 5 mg BID All Tofa                                                                       | 7                         | 1(14.29) 1 (7.69)                   | 0 0                   | 5.66 7.56                                  | 17.68 (0.45,98.50) 13.23 (0.34, 73.73)                                                                                         |
| All Infections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                               |                                                                                                  | 309                       | 108 (34.95)                         |                       | 170.95                                     | 63.18 (51.82, 76.27)                                                                                                           |
| Serious Infections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 65 65                                                                         | All Tofa 5 mg BID All Tofa All Tofa 5 mg BID All Tofa                                            | 407 7 13                  | 129 (31.70) 3(42.86) 3 (23.08)      | 3 (0.97) 3 (0.74) 0 0 | 196.48 4.55                                | 65.66 (54.82, 78.01) 65.89 (13.59, 192.56) 46.49 (9.59, 135.86)                                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 65                                                                            | All Tofa                                                                                         | 60E 7                     | 1(0.32) 1 (0.25) 0                  | 0 0 0                 | 6.45 225.62 255.19 5.66                    | 0.44 (0.01,2.47) 0.39 (0.01,2.18) 0.00 (0.00, 65.18)                                                                           |
| Herpes Zoster                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | =65                                                                           | All Tofa 5 mg BID All Tofa 5 mg BID All Tofa                                                     | 407 13                    | 0 5 (1.62)                          | 0                     | 7.56                                       | 0.00 (0.00,48.80)                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 65 >=65                                                                       | All Tofa 5 mg BID All Tofa                                                                       | 600                       | 7(1.72) 0                           | 0 0                   |                                            | 2.23 (0.72,5.21) 2.76 (1.11.5.69)                                                                                              |
| 28-Day (While on Treatment) Risk Peniod is defined as the smallest of [time (in days) to last dose + 28 days]. [time to discontimwation from study]. [time to last observation].and [time to death] Under While on Treatment Estimand, PY (denominator for IR) is the sum of the times to the first event for subjects with an event or the risk peniods for subjects without an event within the 28-Day (While on Treatment) Risk Period N: Number of subjects included in the Safery Analysis Set; n: Nunber of subjects with an event within the 28-Day (While on Treatment) Risk Period; nl: Number of subjects with an event beyond the 28-Day (While on Treatment) Risk Period which are not inchaded in the IR estimation Incidence proportions PYs and IRs are estimated based on n under this estinand opgopgepopsoe tsexop refers to the date of first dose of tofacitinib treatment. Discontinmation due to AEs is a mixture of discontimuation of study (in stady A3921119) and | discontinuation of shudy treatment (in shudy A3921120) due to adverse events. | All Tofa 5 mg BID All Tofa                                                                       | 407 7                     | 0                                   | 0 0                   | 224.08 EEESC 5.66 7.56                     | 0.00 (0.00,65.18) 0.00 (0.00,48.80)                                                                                            |

## Gender

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs SAEs, and discontinuations due to AEs by Gender for the AS All Tofa Cohort are presented Table 91.

<div style=\"page-break-after: always\"></div>

Table 91. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Gender - While on Treatment Estimand, AS All Tofa Cohort.

<!-- image -->

## Race

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs SAEs, and discontinuations due to AEs by race for the AS All Tofa Cohort presented in Table 92.

<div style=\"page-break-after: always\"></div>

Table 92. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Race - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

| Events Category                    | Rate   | Analbsis Group                            | N     | n(96)                   | nl(%)           | PY            | IR (959h CI) per 100 PY                                                 |
|------------------------------------|--------|-------------------------------------------|-------|-------------------------|-----------------|---------------|-------------------------------------------------------------------------|
|                                    |        | All Tofh                                  | 1     |                         |                 | 1.00          | 0.00 (0.00, 369.14)                                                     |
| Diseontinvation of shudy treatment | White  | All Tof 5 mg BID                          | 252   | 19 ( 7.54)              |                 | 183.16        | 10.37 (6.25,16.20)                                                      |
|                                    |        | All Tofa                                  | 334   | 25 ( 7.49)              | 0               | 207.51        | 12.05 (7.80, 17.78)                                                     |
|                                    | Asian  | All Tofa 5 mg BID                         | 63    | 6(9.52)                 | 0               | 45.53         | 13.18 (4.84,28.68)                                                      |
|                                    |        | All Tofa                                  | 85    | 6 ( 7.06)               | 0               | 52.51         | 11.43 (4.19, 24.87)                                                     |
|                                    | Other  | All Tofa 5 mg BID                         | 1     | 0                       | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
|                                    |        | All Tofh                                  | 1     | 0                       | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
| Discontinuation due to AEs         | White  | All Tofn 5 mg BID                         | 252   | 10 ( 3.97)              | 0               | 183.50        | 5.45 (2.61, 10.02)                                                      |
|                                    |        | All Tofa                                  | 334   | 11 ( 3.29)              | 0               | 207.99        | 5.29 (2.64.9.46)                                                        |
|                                    | Asinn  | All Tofn 5 mg BID                         | 63    | 1 (1.59)                | 0               | 46.02         | 2.17 (0.06, 12.11)                                                      |
|                                    |        | All Tofa                                  | 85    | 1 (1.1$)                | 0               | 53.00         |                                                                         |
|                                    | Other  | All Tofn 5 mg BID                         | 1     | 0                       | 0               | 1.00          | 1.89 (0.05, 10.51) 0.00 (0.00, 369.14)                                  |
|                                    |        | All Tofa                                  | 1     | 0 93 (27.84)            | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
| All Infections                     | White  | All Tofa 5 mg BID                         | 252   | 78 (30.95)              | 3 (1.19)        | 144.98        | 53.80 (42.53,67.14)                                                     |
|                                    | Atian  | All Tofa                                  | 334   |                         | 3 (0.90)        | 166.80        | 55.76 (45.00, 68.30)                                                    |
|                                    | Other  | All Tofa 5 mg BID                         | 63    | 33 ( 52.38)             | 0               | 29.52         | 111.78 (76.94, 156.98)                                                  |
|                                    |        | All Tofh All Tofn 5 mg BID                | 85 1  | 39 ( 45.88) 0           | 0               | 35.13 1.00    | 111.01 (78.94, 151.75) 0.00 (0.00, 369.14)                              |
|                                    | White  | All Tofn 5 mg BID                         | 252   | 1(0.40)                 | 0               |               | 0.54 (0.01,3.03)                                                        |
|                                    |        | All Tofa                                  | 334   | 1 ( 0.30)               | 0               | 208.67        |                                                                         |
|                                    |        | All Tofa 5 mg BID                         |       |                         |                 | 184.18        | 0.00 (0.00,8.00)                                                        |
| Serious Infections                 |        |                                           | 63    | 0                       | 0               | 46.09         | 0.48 (0.01, 2.67)                                                       |
|                                    | Asian  |                                           |       |                         |                 |               |                                                                         |
|                                    |        | All Tofa                                  | S8    | 0                       | 0               | 53.08         | 0.00 (0.00,6.95)                                                        |
|                                    | Other  | All Tofa 5 mg BID                         | 1     |                         | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
|                                    |        | All Tofa                                  | 1     | 0 0                     | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
| TEAEs                              | White  | All To 5 mg BID All Tofa                  | 252   | 149 (59.13) 183 (54.79) | 3(1.19) 3(0.90) | 126.79        | 136.90 (115.80, 160.73) 144.33 (124.18, 166.82) 302.22 (223.58, 399.55) |
|                                    | Asian  | All Tofa 5 mg BID All Tofa                | 63    | 49 (77.78)              | 0               | 16.21         | 330.47 (255.05, 421.22)                                                 |
|                                    |        | All To 5mgBID                             | 85    | 65(76.47) 0             | 0 0             | 19.67 1.00    |                                                                         |
| SAEs                               |        | All Tofa                                  | 1 1   | 0                       | 0               | 1.00          | 0.00 (0.00,369.14) 0.00 (0.00, 369.14)                                  |
|                                    |        | All Tof5mgBID All Toa 5 mg BID            | 252   | 6(2.38) 7(2.10)         | 0 0             | 182.74        | 3.28 (1.20.7.15)                                                        |
|                                    | Asian  | All Tofa                                  | 334 9 | 2(3.17)                 | 1(1.59)         | 207.02 19'54  | 3.38(1.36.6.97) 4.38 (0.53, 15.83)                                      |
|                                    | Other  | All Tofa 5mg BID                          | 1     | 0                       |                 |               | 3.80 (0.46,13.73)                                                       |
|                                    |        | All Tofa                                  | 85    | 2(235)                  | 1(1.18)         | 52.62         |                                                                         |
|                                    |        | All TofaSmg BID                           | 1     | 0                       | 0 0             | 1.00          | 0.00 (0.00,369.14)                                                      |
|                                    | White  | All Tofa                                  |       |                         | 0               | 1.00          | 0.00 (0.00, 369.14)                                                     |
| Severe AEs                         | Asian  | All Tofa All Tof 5 mg BID                 | E9    | 7(2.78) 8(2.40)         | 0 0             | 182.43 206.78 | 3.84 (1.54,7.91)                                                        |
|                                    |        | All Tofa                                  | 252   | 0 0                     | 0               | 46.09 53.08   | 3.87 (1.67,7.62) 0.00 (0.00,8.00)                                       |
|                                    |        |                                           | 85 1  | 0                       | 0               | 1.00          | 0.00 (0.00,6.95)                                                        |
|                                    |        | All Tofa                                  | 1     | 0                       | 0               | 1.00          |                                                                         |
|                                    |        | All Tofa5mBID                             |       |                         |                 |               | 0.00 (0.00, 369.14)                                                     |
| Discontinmation of study           | White  |                                           | 252   |                         |                 | 184.26        | 0.00 (0.00, 369.14) 4.34 (1.87,8.55)                                    |
|                                    | Asian  | All Tofa 5 mg BID All Tofa All To 5mg BID | 9 85  | 8(3.17)                 | 3(1.19)         | 208.74 46.09  | 6.23 (3.32, 10.65) 3.77 (0.46, 13.61)                                   |
|                                    | Other  | All Tofa 5 mg BID                         | 1     | 13 (3.89) 2(3.17)       | 4(1.20) 2(3.17) | 1.00          | 4.34 (0.53, 15.67)                                                      |
|                                    |        | All Tofa                                  |       | 2(235)                  | 2(2.35)         | 53.08         |                                                                         |
|                                    |        |                                           |       | 0                       | 0               |               | 0.00 (0.00, 369.14)                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Geographical region

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs SAEs, and discontinuations due to AEs by geographic region for the AS All Tofa Cohort are presented in Table 93.

Table 93. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Geographic Region - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

<div style=\"page-break-after: always\"></div>

| All Infections     | North America(USand Canada)All Tofa5mgBID       |                   |   38 | 19 (50.00)   | 0        | 16.78   | 113.23 (68.17, 176.82)   |
|--------------------|-------------------------------------------------|-------------------|------|--------------|----------|---------|--------------------------|
|                    |                                                 | All Tofa          |   51 | 20 (39.22)   | 0        | 20.07   | 99.65 (60.87,153.89)     |
|                    | European Union                                  | All Tofa 5 mg BID |  136 | 43 (31.62)   | 0        | 74.92   | 57.40 (41.54, 77.31)     |
|                    |                                                 | All Tofa          |  200 | 57(28.50)    | 0        | 91.89   | 62.03 (46.98,80.37)      |
|                    | Asia                                            | All Tofa 5 mg BID |   61 | 31 (50.82)   | 0        | 28.44   | 109.02 (74.07, 154.74)   |
|                    |                                                 | AllTofa           |   83 | 37(44.58)    | 0        | 34.05   | 108.68 (76.52.149.80)    |
|                    | Rest of Werld                                   | All Tofa 5 mg BID |   81 | 18 (22.22)   | 3(3.70)  | 55.37   | 32.51 (19.27, 51.38)     |
|                    |                                                 | All Tofa          |   86 | 18 (20.93)   | 3 (3.49) | 56.92   | 31.62 (18.74, 49.98)     |
| Senious Infections | North America (US and Canada) All Tofa 5 mg BID |                   |   38 | 0            | 0        | 24.47   | 0.00 (0.00,15.07)        |
|                    |                                                 | AllTofa           |   51 | 0            | 0        | 28.05   | 0.00 (0.00,13.15)        |
|                    | Euwopean Union                                  | All Tofa 5 mg BID |  136 | 0            | 0        | 97.00   | 0.00 (0.00.3.80)         |
|                    |                                                 | All Tofa          |  200 | 0            | 0        | 116.36  | 0.00 (0.00,3.17)         |
|                    | Asia                                            | All Tofa 5 mg BID |   61 | 0            | 0        | 44.05   | 0.00 (0.00,8.37)         |
|                    |                                                 | AllTofa           |   83 | 0            | 0        | 51.04   | 0.00 (0.00,7.23)         |
|                    | Rest of World                                   | All Tofa 5 mg BID |   81 | 1(1.23)      | 0        | 65.74   | 1.52 (0.04,8.47)         |
|                    |                                                 | All Tofa          |   86 | 1(1.16)      | 0        | 67.30   | 1.49 (0.04,8.28)         |
| Herpes Zoster      | North Amenica (US and Canada) All Tofa 5mg BID  |                   |   38 | 2(5.26)      | 0        |         | 8.50 (1.03,30.71)        |
|                    |                                                 | AllTofa           |   51 | 2(3.92)      | 0        | 27.11   | 7.38 (0.89,26.65)        |
|                    | European Union                                  | All Tofa 5 mg BID |  136 | 3 (2.21)     | 0        | 96      | 3.11 (0.64,9.10)         |
|                    |                                                 | AllTofa           |  200 | 4(2.00)      | 0        | 115.61  | 3.46 (0.94,8.86)         |
|                    | Asia                                            | All Tofa5mg BID   |   61 | 0            | 0        | 44.05   | 0.00(0.00.8.37)          |
|                    |                                                 | AllTofa           |   83 | 1(1.20)      | 0        | 50.80   | 1.97 (0.05,10.97)        |
|                    | Rest of World                                   | All Tofa 5 mg BID |   81 | 0            | 0        | 65.82   | 0.00 (0.00,5.60)         |
|                    |                                                 | All Tofa          |   86 | 0            | 0        | 67.37   | 0.00 (0.00,5.48)         |

| Events Category                 | Geographic Region                               | Analysis Group    |   N | n (%)      | nl(%)    |     PY | IR (95% CI) per 100 PY   |
|---------------------------------|-------------------------------------------------|-------------------|-----|------------|----------|--------|--------------------------|
|                                 |                                                 | All Tofa          |  86 | 4 (4.65)   | 0        |  67.05 | 5.97 (1.63, 15.27)       |
| Discontinuationof study         | North America (US and Canada) All Tofa 5 mg BID |                   |  38 | 4 (10.53)  | 1(2.63)  |  24.47 | 16.34 (4.45, 41.85)      |
|                                 |                                                 | All Tofa          |  51 | 5 (9.80)   | 2 (3.92) |  28.05 | 17.82 (5.79, 41.60)      |
|                                 | European Union                                  | All Tofa 5 mg BID | 136 | 2 (1.47)   | 2 (1.47) |  97    | 2.06 (0.25, 7.45)        |
|                                 |                                                 | All Tofa          | 200 | 6 (3.00)   | 2 (1.00) | 116.36 | 5.16 (1.89, 11.22)       |
|                                 | Asia                                            | All Tofa 5 mg BID |  61 | 2 (3.28)   | 2 (3.28) |  44.05 | 4.54 (0.55, 16.40)       |
|                                 |                                                 | All Tofa          |  83 | 2 (2.41)   | 2 (2.41) |  51.04 | 3.92 (0.47,14.16)        |
|                                 | Rest of World                                   | AllTofa5mgBID     |  81 | 2 (2.47)   | 0        |  65.82 | 3.04 (0.37, 10.98)       |
|                                 |                                                 | All Tofa          |  86 | 2(2.33)    | 0        |  67.37 | 2.97 (0.36, 10.72)       |
| Discontinuationofstudytreatment | North America(US and Canada)All Tofa 5mgBID     |                   |  38 | 8 (21.05)  | 0        |  24.07 | 33.23 (14.35, 65.49)     |
|                                 |                                                 | All Tofa          |  51 | 10 (19.61) | 0        |  27.52 | 36.34 (17.43, 66.83)     |
|                                 | European Union                                  | All Tofa5mgBID    | 136 | 6 (4.41)   | 0        |  96.59 | 6.21 (2.28, 13.52)       |
|                                 |                                                 | All Tofa          | 200 | 10 (5.00)  | 0        | 115.93 | 8.63 (4.14, 15.86)       |
|                                 | Asia                                            | All Tofa 5 mg BID |  61 | 6 (9.84)   | 0        |  43.49 | 13.80 (5.06, 30.03)      |
|                                 |                                                 | All Tofa          |  83 | 6(7.23)    | 0        |  50.47 | 11.89 (4.36, 25.87)      |
|                                 | Rest of World                                   | All Tofa5 mg BID  |  81 | 5(6.17)    | 0        |  65.54 | 7.63 (2.48, 17.80)       |
|                                 |                                                 | All Tofa          |  86 | 5 (5.81)   | 0        |  67.09 | 7.45 (2.42, 17.39)       |
| Discontinuationdue toAEs        | North America (US and Canada) All Tofa 5 mg BID |                   |  38 | 3 (7.89)   | 0        |  24.29 | 12.35 (2.55, 36.10)      |
|                                 |                                                 | All Tofa          |  51 | 3 (5.88)   | 0        |  27.87 | 10.77 (2.22, 31.46)      |
|                                 | European Union                                  | All Tofa 5 mg BID | 136 | 4 (2.94)   | 0        |  96.66 | 4.14 (1.13, 10.60)       |
|                                 |                                                 | All Tofa          | 200 | 5 (2.50)   | 0        | 116.02 | 4.31 (1.40, 10.06)       |
|                                 | Asia                                            | All Tofa 5 mg BID |  61 | 1 (1.64)   | 0        |  43.98 | 2.27 (0.06, 12.67)       |
|                                 |                                                 | All Tofa          |  83 | 1 (1.20)   | 0        |  50.96 | 1.96 (0.05, 10.93)       |
|                                 | Rest ofWorld                                    | All Tofa 5 mg BID |  81 | 3 (3.70)   | 0        |  65.59 | 4.57 (0.94, 13.37)       |
|                                 |                                                 | All Tofa          |  86 | 3 (3.49)   | 0        |  67.14 | 4.47 (0.92, 13.06)       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Concomitant and Prior Medications for AS

The impact of prior bDMARD medication use and csDMARD use at baseline on safety was assessed in the overall pooled safety population. In both Study A3921119 and Study A3921120, patients were prohibited from receiving bDMARDs during the study. In A3921119, patients with prior use of bDMARDs were excluded. In  Study  A3921120,  patients  with  prior  use  of  bDMARDS  were  permitted to  be  enrolled;  however, approximately 80% were required to be bDMARD naïve. Patients were stratified by prior treatment history: (1) bDMARD-naive (approximately 80%) and (2) Tumor Necrosis Factor inhibitor-inadequate responder or bDMARD use (without inadequate response) (approximately 20%).

The majority of patients with AS in the clinical programme were naive to bDMARDs, with 81.6% in the All Tofa 5 mg BID group in the All Tofa Cohort having no previous experience with bDMARDs.

The incidence and proportions and incidence rates for general events and infections by prior treatment history are presented in Table 94.

Table  94. Tofacitinib  Summary  of  Clinical  Safety  (Ankylosing  Spondylitis)  Incidence  Proportions  and Incidence  Rates  for  General  Events  and  Infections  by  Prior  Treatment  History  -  While  on  Treatment Estimand, AS All Tofa Cohort

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Concomitant csDMARDs

The majority (71.8%) of patients in the AS clinical programme were not taking concomitant csDMARDs (Day 1). The incidence and proportions and incidence rates for general events and infections by Day 1 concomitant csDMARD use are presented in Table 95.

Table 95. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Day 1 Concomitant csDMARD Use - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

| Events Category                   | Day 1 Concomitant csDMARD Use   | Analysis Group                             | N          | (e6)u                            | nl(%)                   | PY                 | IR (95% CI) per 100 PY                                                |
|-----------------------------------|---------------------------------|--------------------------------------------|------------|----------------------------------|-------------------------|--------------------|-----------------------------------------------------------------------|
| TEAEs                             | Yes No                          | All Tofa 5 mg BID AllTofa All Tofa 5 mgBID | $9 128 227 | 52(58.43) 74(57.81) 146 ( 64.32) | 1(1.12) 1(0.78) 2(0.88) | 35.84 43.59 1206   | 145.11 (108.37,190.29) 169.76 (133.29,213.11) 161.84 (136.65, 190.32) |
| SAEs                              |                                 | All Toa 5mg BID All Tofa                   | 89 128     | 1(1.12) 2(1.56)                  | 1(1.12) 1(0.78)         | 62.81 74.70        | 1.59 (0.04, 8.87) 2.68 (0.32,9.67)                                    |
| Severe AEs                        | Yes                             | All Tofa 5 mg BID AllTofa                  | $9 128     | 2(229) 2(1.56)                   | 0 0                     | 62.02 74.12        | 3.22 (0.39,11.65) 2.70 (0.33.9.75)                                    |
|                                   | No                              | All Tofa 5 mg BID AllTofa                  | 227 292    |                                  | 0 0                     | 167.50 186.74      | 2.99 (0.97,6.97) 3.21 (1.18, 6.99)                                    |
| Discontinnation of study          | Yes No                          | All Tofa 5 mg BID AllTofa All Tofa 5mgBID  | 68 128 227 | (stt)t 3(2.34) (25)s             | 1(1.12) 1(0.78) 4(1.76) | 62.89 74.98 168.47 | 3.18 (0.39, 11.49) 4.00 (0.83, 11.69) 4.75 (2.05.9.36)                |
|                                   | Yes                             | All Tofa All Tofa 5 mg BID                 | 292 $9     | 12(4.11) 5(5.62)                 | 5 (1.71) 0              | 187.84 62.56       | 6.39 (3.30, 11.16) 7.99 (2.59, 18.65)                                 |
| Discontinnation ofstudy treatment |                                 | All Tofa                                   | 128 227    | (69+）9                           | 0                       | 74.65              | 8.04 (2.95,17.49)                                                     |
|                                   | No                              | All Tofa 5mg BID All Tofa                  | 292        | 20(8.81) 25(8.56)                | 0 0                     | 167.13 186.37      | 11.97 (7.31.18.48) 13.41 (8.68, 19.80)                                |
| Discontinmaticn doe toAEs         | Yes                             | AllTofa5mgBID                              | 89         | 2(229)                           | 0                       | 62.$1              | 3.18 (0.39,11.50)                                                     |

<!-- image -->

Effects by age are very difficult to estimate since the limited number of subjects &gt;65 years (n=13) vs &lt;65 years (n=407) and thus no conclusions can be drawn.

As to the gender , in almost all the categories for the general events, and also for herpes zoster, female patients had higher incidence rates compared to male. However, the cohort was unbalanced since there were 594 males and 142 females. Therefore, firm conclusions are difficult to be drawn.

Regarding the race most patients in the tofacitinib 5 mg BID group were White (n=252) and few were Asian (n=63). In general, Asian patients in the tofacitinib 5 mg group experienced more AEs, n=49 (77.78%), IR per 100PY (95% CI): 302.22 (223.58, 399.55) compared to White, n=149 (59.13%), IR per 100PY (95% CI): 136.90 (115.80, 160.73), and experienced more Infections, Asian: n=33 (52.38%), IR per 100PY (95% CI): 111.78 (76.94, 156.98) vs White: n=78 (30.95%), IR per 100PY (95% CI):

<div style=\"page-break-after: always\"></div>

53.80 (42.53, 67.14). A similar trend was observed for the All tofacitinib doses. However, again the limited number of Asian patients makes difficult to draw any firm conclusion.

Some differences were observed in the distribution of AEs by geographical region. However, the number of patients for each regions does not allow a fully reliable evaluation. Overall, general events for European region were in line, or less frequent, than for the other regions, and data about Asia confirm the increased AEs incidence rate for Asian sub-population.

When analysed by previous treatment , patients were divided in two categories: bDMARD-naive (approximately 80%) and TNF inhibitor-inadequate responder or bDMARD use (without inadequate response) (approximately 20%). Therefore, the number of subjects with previous bDMARD use was small (n=58, all treated with tofacitinib 5 mg BID) compared to those bDMARD-naïve (n=362 with all tofacitinib doses). Overall, a consistent increase in general events (such as AEs, SAEs, discontinuations, etc) and infections was observed in patients with previous treatment with TNFi or bDMARD compared to those bDMARD-naïve. AEs were n=42 (72.41%), IR per 100 PY (95% CI): 201.32 (145.09, 272.12) in previous treated vs n=156 (60.47%), IR per 100 PY (95% CI): 148.31 (125.95, 173.49) in naïve patients. The highest difference was observed for Discontinuation of study treatment, which involved n=13 (22.41%) subjects, IR per 100 PY (95% CI):  30.02 (15.98, 51.33) in previous treated, vs n=12 (4.65%), IR per 100 PY (95% CI): 6.44 (3.33, 11.25) in naïve patients. The number of patients in the previous treated group is small and thus any conclusion is difficult, but such results could be expected, since it is biologically plausible that patients already exposed to previous treatments develop more AEs when subsequently treated with tofacitinib.

When analysed by concomitant csDMARD therapy, a trend of higher incidence was observed in many categories of general events in patients not taking concomitant csDMARD compared to those taking csDMARD (TEAEs 64.3% vs 58.4%, SAEs 3.1% vs 1.1%, Discontinuation of study treatment 8.8% vs 5.6%, Discontinuation due to AEs 4.0% vs 2.3%, All Infections 37.0% vs 30.3%; in tofacitinib 5 mg BID of the All tofacitinib odes cohort). Again the number of patients enrolled in the two groups was not high, 227 vs 89 in the 'not taking concomitant csDMARD' vs 'taking concomitant csDMARD' respectively, and was unbalanced with a very small group of patients taking concomitant csDMARD. Therefore, any difference observed is difficult to evaluate. Furthermore, there doesn't seem to be a biological rationale, since the contrary was expected.

## Discontinuation due to adverse events

AEs leading to discontinuation of study drug in the Placebo-controlled Cohort, described in the next table, were infrequent in both treatment groups (&lt;3%). The proportion of patients reporting discontinuations of study drug due to AEs for each treatment group and the associated incidence rates (While on Treatment Estimand) are as follows ( Table 96 ):

- Tofa 5 mg BID group: 4 (2.16%) patients representing an incidence rate of 7.04 patients with events per 100 PY.
- Placebo group: 4 (2.14%) patients representing an incidence rate of 7.10 patients with events per 100 PY.

<div style=\"page-break-after: always\"></div>

Table 96. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                             | Tofa 5 mg BID (N=185)   | Placebo (N=187)   |
|------------------------------------------------------------------|-------------------------|-------------------|
| Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | n (%)                   | n (%)             |
| With Any Adverse Event                                           | 4 (2.2)                 | 4 (2.1)           |
| EAR AND LABYRINTH DISORDERS                                      | 1 (0.5)                 | 0                 |
| Hypoacusis                                                       | 1 (0.5)                 | 0                 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS             | 1 (0.5)                 | 0                 |
| Peripheral swelling                                              | 1 (0.5)                 | 0                 |
| HEPATOBILIARY DISORDERS                                          | 0                       | 1 (0.5)           |
| Hypertransaminasaemia                                            | 0                       | 1 (0.5)           |
| INFECTIONS AND INFESTATIONS                                      | 1 (0.5)                 | 0                 |
| Meningitis                                                       | 1 (0.5)                 | 0                 |
| INVESTIGATIONS                                                   | 1 (0.5)                 | 0                 |
| Alanine aminotransferase increased                               | 1 (0.5)                 | 0                 |
| Aspartate aminotransferase increased                             | 1 (0.5)                 | 0                 |
| Gamma-glutamyltransferase increased                              | 1 (0.5)                 | 0                 |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                  | 0                       | 1 (0.5)           |
| Spinal pain                                                      | 0                       | 1 (0.5)           |
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS                   | 0                       | 1 (0.5)           |
| Pregnancy                                                        | 0                       | 1 (0.5)           |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                           | 0                       | 1 (0.5)           |
| Psoriasis                                                        | 0                       | 1 (0.5)           |

Subjects are only counted once per treatment per event.

Totals for the No. of Subjects at a higher level are not necessarily the sum of those at the lower levels since a subject may report two or more different adverse events within the higher level category. The table is based on the data from OC AE only.

N: Number of subjects included in the Safety Analysis Set. n (%): Number of subjects with the event (Percentages are based on N). Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 10NOV2020 (03:04)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s181\\_1

Table C1.3.1.1-E is for Pfizer internal use.

AEs leading to discontinuation of study drug in the All Tofa Cohort are described in Table 97 . In the All Tofa Cohort, the proportion of patients who discontinued study drug due to AEs for the All Tofa 5 mg BID group and the associated incidence rate (While on Treatment Estimand), which was similar to the All Tofa group is presented below:

- All Tofa 5 mg BID group: 11 (3.48%) patients representing an incidence rate of 4.77 (95% CI: 2.38, 8.54) patients with events per 100 PY.

<div style=\"page-break-after: always\"></div>

Table 97. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                 | All Tofa (N=316)   | All Tofa (N=316)   | 5 mg BID   | All Tofa (N=316)   | All (N=420)   | All (N=420)   | Tofa       | All (N=420)   |
|------------------------------------------------------|--------------------|--------------------|------------|--------------------|---------------|---------------|------------|---------------|
| Severity(a) Number (%) of Subjects: by ORGAN CLASS   | Mild n (%)         | Mod. n (%)         | Sev. n (%) | Total n (%)        | Mild n (%)    | Mod. n (%)    | Sev. n (%) | Total n (%)   |
| SYSTEM and Preferred Term With Any Adverse Event     | 1 (0.3)            | 9 (2.8)            | 1 (0.3)    | 11 (3.5)           | 1 (0.2)       | 10 (2.4)      | 1 (0.2)    | 12 (2.9)      |
| CARDIAC DISORDERS                                    | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Tachycardia                                          | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| EAR AND LABYRINTH DISORDERS                          | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Hypoacusis                                           | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| GASTROINTESTINAL DISORDERS                           | 1 (0.3)            | 1 (0.3)            | 0          | 2 (0.6)            | 1 (0.2)       | 1 (0.2)       | 0          | 2 (0.5)       |
| Abdominal adhesions                                  | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Abdominal pain                                       | 1 (0.3)            | 0                  | 0          | 1 (0.3)            | 1 (0.2)       | 0             | 0          | 1 (0.2)       |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Peripheral swelling                                  | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| HEPATOBILIARY DISORDERS                              | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Hepatic function abnormal                            | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| INFECTIONS AND INFESTATIONS                          | 0                  | 3 (0.9)            | 0          | 3 (0.9)            | 0             | 4 (1.0)       | 0          | 4 (1.0)       |
| Herpes zoster                                        | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 2 (0.5)       | 0          | 2 (0.5)       |
| Meningitis                                           | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Pharyngitis streptococcal                            | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| INVESTIGATIONS                                       | 0                  | 1 (0.3)            | 1 (0.3)    | 2 (0.6)            | 0             | 1 (0.2)       | 1 (0.2)    | 2 (0.5)       |
| Alanine aminotransferase increased                   | 0                  | 1 (0.3)            | 1 (0.3)    | 2 (0.6)            | 0             | 1 (0.2)       | 1 (0.2)    | 2 (0.5)       |
| Aspartate aminotransferase increased                 | 0                  | 1 (0.3)            | 1 (0.3)    | 2 (0.6)            | 0             | 1 (0.2)       | 1 (0.2)    | 2 (0.5)       |
| Blood alkaline phosphatase increased                 | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Gamma-glutamyltransferase increased                  | 0                  | 1 (0.3)            | 1 (0.3)    | 2 (0.6)            | 0             | 1 (0.2)       | 1 (0.2)    | 2 (0.5)       |
| NERVOUS SYSTEM DISORDERS                             | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Dizziness                                            | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| VASCULAR DISORDERS                                   | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Hypertension                                         | 0                  | 1 (0.3)            | 0          | 1 (0.3)            | 0             | 1 (0.2)       | 0          | 1 (0.2)       |
| Total preferred term events                          | 1                  | 14                 | 3          | 18                 | 1             | 15            | 3          | 19            |

<div style=\"page-break-after: always\"></div>

Table 97. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Severity(a)                            | Mild                        | Mod.                        | Sev.                        | Total                       | Mild               | Mod.               | Sev.               | Total              |
| Number (%) of Subjects: by             | n (%)                       | n (%)                       | n (%)                       | n (%)                       | n (%)              | n (%)              | n (%)              | n (%)              |

(a) If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is counted. Subjects are counted only once per treatment per  event.  For  the  TESS  algorithm  any  missing  severities  have  been  imputed  as  severe  unless  the  subject  experienced  another occurrence of the same event in a given treatment for which severity was

recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n: Number of subjects with the events (Percentages are based on N). Included Protocols: A3921119, A3921120 (Final Data). The table is based on the data from OC AE only.

MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 10NOV2020 (07:26)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s040\\_tof

Table C2.1.1.3.3-E is for Pfizer internal use.

The incidence rate of AEs leading to drug discontinuation was similar between tofacitinib 5mg BID and placebo, during the placebo-controlled periods (which was up to 16 weeks): 7.04/100 PY in tofacitinib vs 7.10/100 PY in placebo. The number of subjects with any AE leading to discontinuation was 4 (2.2%) in tofacitinib 5mg BID vs 4 (2.1%) in placebo (placebo-controlled cohort) and there was no single AE that was more common than others (due to the limited exposure). In the tofacitinib 5mg BID of the All tofa cohort (up to 48 weeks), the incidence rate was 4.77/100 PY. In this cohort, the number of subjects with any AE leading to discontinuation was 11 (3.5%) in the tofacitinib 5mg BID and 12 (2.9%) in All tofacitinib.

## Post marketing experience

In the EU, Xeljanz was granted a marketing authorisation on 21 March 2017, for the treatment of RA. In June 2018, it was approved for treatment of psoriatic arthritis (PsA), and in July 2018, it was also approved for the treatment of ulcerative colitis (UC).

The MAH monitors post-marketing data across the different approved indications (RA, PsA, and UC), which reflects the safety profile of tofacitinib since marketing approval. The updated post-marketing surveillance data and US Corrona RA Registry Study A3921205 subset analysis, provided in this SCS, supplements the clinical data and provides evidence of the long-term safety of tofacitinib 5 mg IR BID in the real-world setting. An additional 4 EU based ongoing registries (ARTIS, RABBIT, BIOBADASER and BSRBR) in RA patients are monitored and provide further evidence of the long-term safety of tofacitinib 5 mg IR BID in the real-world setting.

<div style=\"page-break-after: always\"></div>

The MAH has provided a literature search of published clinical trials and observational studies to identify relevant safety data relating to AEs of special interest in patients treated with biologic DMARDs for AS. Incidence rates from external published clinical trials and observational studies were compared to rates from the tofacitinib AS programme.

## Post-authorisation study A3921133

Post-authorisation study A3921133 has been designed to evaluate the safety of tofacitinib 5 mg BID and tofacitinib 10 mg BID compared to a tumour necrosis factor inhibitor (etanercept or adalimumab) in patients with RA. The available data shows that tofacitinib increases the risk of venous thromboembolism (DVT and pulmonary embolism (PE)) in patients with RA and PsA, especially in patients treated with tofacitinib 10 mg BID, and patients with risk factors for venous thromboembolism, as well as risk factors for cardiovascular events. On 12 February 2019 the MAH informed EMA that an increased risk of PE and overall mortality had been reported in Study A3921133. In this clinical trial, the overall incidence of PE was 5.96-fold higher in tofacitinib 10 mg twice daily arm of the study compared with the TNF inhibitor arm, and approximately 3-fold higher than tofacitinib in other studies across the tofacitinib development programme.

On 12 February 2019, the MAH informed EMA that an increased risk of pulmonary embolism (PE) and overall mortality had been reported in Study A3921133. In this clinical trial, the overall incidence of PE was 5.96-fold higher in tofacitinib 10 mg twice daily arm of the study compared with the TNF inhibitor arm, and approximately 3-fold higher than tofacitinib in other studies across the tofacitinib development programme. The data safety monitoring board (DSMB) recommended to modify Study A3921133 to discontinue treatment with tofacitinib 10 mg BID. Of note, the FDA subjected the continuation of the trial to the condition that subjects assigned to the 10 mg BID dose were switched to the lower 5 mg BID dose.

## Post-Marketing Surveillance Reports

The RMP (Module 5.3.6 RMP Report) includes the current post-marketing data (data cut off 05 Nov 2019). Information from the post-marketing setting is also included in the PSUR submitted to the EMEA at 1-year intervals (Module 5.3.6 November 2020 PSUR). Findings from post-marketing data have been consistent with the safety profile for tofacitinib.

## US Corrona RA Registry Study A3921205 Safety Data

The US Corrona RA Registry Study A3921205, a non-interventional post-authorisation safety study (PASS), was completed in March 2020 using a 31 Jan 2019 data cut. The aim was to describe the rates of safety events in tofacitinib initiators compared with bDMARD initiators in real-world clinical use using data from the Corrona RA registry. This study of the safety of tofacitinib in exposed RA patients was based on data collected within the US Corrona RA Registry. The report of Corrona RA registry has not been found in the dossier.

## Safety from the ARTIS real-world dataset

The ARTIS register study (A3921391) comprised a cohort of 10,603 Swedish patients who were comparable to patients in the Phase 3 AS clinical trial programme (A3921120). The crude incidence rates for safety events in the ARTIS database for AS patients overall and for all bDMARD initiators (bDMARD experienced or bDMARD naïve as of the index date 01 Jul 2006) are presented in Table 98.

Table 98. Crude Incidence Rates (per 100 PYs) of Safety Events Among Ankylosing Spondylitis Patients in the ARTIS Register, With Censoring at 48 Weeks

<div style=\"page-break-after: always\"></div>

|                      | OverallAS (N=10603)   | OverallAS (N=10603)   | OverallAS (N=10603)   | bDMARD-naiveb (N=9756)   | bDMARD-naiveb (N=9756)   | bDMARD-naiveb (N=9756)   | bDMARD-experienced (N=3463)   | bDMARD-experienced (N=3463)   | bDMARD-experienced (N=3463)   |
|----------------------|-----------------------|-----------------------|-----------------------|--------------------------|--------------------------|--------------------------|-------------------------------|-------------------------------|-------------------------------|
|                      | NE                    | PYs                   | CIR                   | NE                       | PYs                      | CIR                      | NE                            | PYs                           | CIR                           |
| Seriousinfectionsd   | 217                   | 6755                  | 3.21 (2.80,3.65)      | 201                      | 6009                     | 3.34 (2.90,3.82)         | 34                            | 2271                          | 1.50 (1.04, 2.04)             |
| IO                   | 3                     | 6755                  | 0.04 (0.01,0.11)      | 3                        | 6009                     | 0.05 (0.01,0.12)         | 1                             | 2271                          | 0.04 (0.00,0.16)              |
| TBf                  | 1                     | 6755                  | 0.01 (0.00,0.05)      | 1                        | 6009                     | 0.02 (0.00,0.06)         | 0                             | 2271                          | 0.00 (0.00,0.00)              |
| Pneumoniaf           | 84                    | 6755                  | 1.24 (0.99, 1.52)     | 78                       | 6009                     | 1.30 (1.03,1.60)         | 7                             | 2271                          | 0.31 (0.12,0.58)              |
| Hospitalised HZf     | 0                     | 6755                  | 0.00 (0.00,0.00)      | 0                        | 6009                     | 0.00 (0.00,0.00)         | 0                             | 2271                          | 0.00 (0.00,0.00)              |
| Allmalignanciesg     | 45                    | 6587                  | 0.68 (0.50,0.90)      | 44                       | 5924                     | 0.74 (0.54,0.98)         | 10                            | 2025                          | 0.49 (0.24, 0.84)             |
| NMSCh                | 19                    | 6582                  | 0.29 (0.17, 0.43)     | 18                       | 5919                     | 0.30 (0.18,0.46)         | 3                             | 2024                          | 0.15 (0.03,0.36)              |
| MACEi                | 211                   | 6726                  | 3.14 (2.73,3.57)      | 205                      | 5982                     | 3.43 (2.97, 3.91)        | 11                            | 2270                          | 0.48 (0.24,0.81)              |
| DVTi                 | 15                    | 6747                  | 0.22 (0.12, 0.35)     | 15                       | 6002                     | 0.25 (0.14,0.39)         | 1                             | 2270                          | 0.04 (0.00,0.16)              |
| Hospitalised PEk     | 26                    | 6747                  | 0.39 (0.25,0.55)      | 24                       | 6003                     | 0.40 (0.26, 0.57)        | 1                             | 2270                          | 0.04 (0.00,0.16)              |
| VTE1                 | 39                    | 6740                  | 0.58 (0.41, 0.77)     | 37                       | 5996                     | 0.62 (0.43,0.83)         | 2                             | 2269                          | 0.09 (0.01,0.25)              |
| ATEm                 | 2                     | 6755                  | 0.03 (0.00,0.08)      | 2                        | 6009                     | 0.03 (0.00,0.09)         | 0                             | 2271                          | 0.00 (0.00,0.00)              |
| Hypertensionn        | 56                    | 6734                  | 0.83 (0.63,1.06)      | 53                       | 5990                     | 0.88 (0.66,1.14)         | 5                             | 2269                          | 0.22 (0.07, 0.45)             |
| GI perforationsn     | 5                     | 6753                  | 0.07 (0.02,0.15)      | 5                        | 6009                     | 0.08 (0.03,0.17)         | 1                             | 2270                          | 0.04 (0.00,0.16)              |
| ILD°                 | 0                     | 6755                  | 0.00 (0.00,0.00)      | 0                        | 6009                     | 0.00 (0.00,0.00)         | 0                             | 2271                          | 0.00 (0.00,0.00)              |
| All-cause mortalitvo | 54                    | 6755                  | 0.80 (0.60.1.03)      | 54                       | 6009                     | 0.90 (0.68.1.15)         | 3                             | 2271                          | 0.13 (0.03.0.32)              |

Incidence rates for all events, except hospitalized HZ and ILD, were higher among bDMARD-naïve compared with the bDMARD-experienced group.

Safety 'Trial-Like Subcohort' from the US Truven MarketScan Analysis

The Truven MarketScan study consisted of 2 patient cohorts. Cohort A comprised adults (≥18 years of age) with active AS within the United States Truven MarketScan database between 01 Jan 2010 and 31 Dec 2017. Cohort B was a subset of Cohort A, but more closely reflected patients within Study A3921120 via the application of trial-like exclusion criteria. A total of 5,196 AS patients were identified with 6,506 eligible biologic treatment episodes in Cohort A; 2,253 patients with 2,662 treatment episodes included in the Cohort B analysis. AEs of special interest in \"Trial-like' Sub-Cohort (Cohort B) is presented in tables 99, 100, 101, 102 and 103, 104 .

Table 99 \"Trial-like' Sub-Cohort (Cohort B) -Serious Infections

|            | Time    | AllbDMARD initiators (N=2,253)   | AllbDMARD initiators (N=2,253)            | bDMARDnaive initiators (N=1,362)   | bDMARDnaive initiators (N=1,362)          | bDMARDexperienced initiators (N=891)   | bDMARDexperienced initiators (N=891)      |
|------------|---------|----------------------------------|-------------------------------------------|------------------------------------|-------------------------------------------|----------------------------------------|-------------------------------------------|
|            |         | n                                | Weighted IncidenceRate (95% CI) per 100PY | n                                  | Weighted IncidenceRate (95% CI) per 100PY | n                                      | Weighted IncidenceRate (95% CI) per 100PY |
| Serious    | 16weeks | 24                               | 3.24                                      | 10                                 | 2.12                                      | 14                                     | 5.03                                      |
| Infectiona |         |                                  | (2.00, 4.98)                              |                                    | (0.94,4.10)                               |                                        | (2.58, 8.82)                              |
|            | 48weeks | 47                               | 3.59                                      | 25                                 | 2.78                                      | 22                                     | 5.16                                      |
|            |         |                                  | (2.57,4.87)                               |                                    | (1.76,4.18)                               |                                        | (3.08, 8.10)                              |

Table 100 'Trial-like' Sub-Cohort (Cohort B) -Other Infections

Table 101 'Trial-like' Sub-Cohort (Cohort B) -Malignancies

|    | Time    | AllbDMARDinitiators (N=2,253)   |
|----|---------|---------------------------------|
| 01 | 16weeks | 0.24 (0.03, 0.91)               |
|    | 48weeks | 0.17 (0.03, 0.51)               |
| HZ | 16weeks | 0.53 (0.17, 1.26)               |
|    | 48weeks | 0.74 (0.37,1.34)                |

<div style=\"page-break-after: always\"></div>

|                                       | Time     |   n | AllbDMARDinitiators (N=2,253) Weighted Incidence Rate (95% CI) per100PY   |
|---------------------------------------|----------|-----|---------------------------------------------------------------------------|
| Malignancies excluding NMSC           | 16 weeks |   0 | 0.00 (0.00, 0.57)                                                         |
|                                       | 48 weeks |   3 | 0.15 (0.03,0.43)                                                          |
| Lymphoma                              | 16weeks  |   0 | 0.00 (0.00, 0.57)                                                         |
|                                       | 48 weeks |   1 | 0.05 (0.00, 0.30)                                                         |
| NMSC                                  | 16weeks  |   3 | 0.32 (0.06, 0.95)                                                         |
|                                       | 48weeks  |   6 | 0.29 (0.10, 0.64)                                                         |
| Breast Cancer (females only; N=874)   | 16 weeks |   0 | 0.00 (0.00,1.49)                                                          |
|                                       | 48weeks  |   1 | 0.04 (0.00, 2.79)                                                         |
| Prostate Cancer (males only; N=1.379) | 16 weeks |   0 | 0.00 (0.00, 0.93)                                                         |
|                                       | 48weeks  |   1 | 0.05 (0.00, 0.45)                                                         |

## Table 102 'Trial-like' Sub-Cohort (Cohort B) -Cardiovascular Events

|            | Time     | (N=2,253) n   | AllbDMARDinitiators Weighted Incidence Rate (95% CI) per100PY   |
|------------|----------|---------------|-----------------------------------------------------------------|
| MI         | 16 weeks | 1             | 0.14 (0.00, 0.78)                                               |
| Stroke     | 16weeks  | 2             | 0.23 (0.03,0.86)                                                |
|            | 48weeks  | 4 3           | 0.23 (0.06,0.58)                                                |
| MIorStroke | 16weeks  |               | 0.37 (0.07, 1.11)                                               |
|            | 48weeks  | 8             | 0.51 (0.21, 1.04)                                               |
| MACE       | 16weeks  | 5             | 0.60 (0.19, 1.43)                                               |
|            | 48weeks  | 10            | 0.61 (0.28, 1.16)                                               |

## Table 103 'Trial-like' Sub-Cohort (Cohort B) -Thromboembolic Events

|     | Time     | AllbDMARDinitiators (N=2,253) WeightedIncidenceRate(95% CIper100 PY   |
|-----|----------|-----------------------------------------------------------------------|
| DVT | 16weeks  | 0.80 (0.20, 2.15)                                                     |
|     | 48weeks  | 0.39 (0.11, 0.96)                                                     |
| PE  | 16 weeks | 0.23 (0.01, 1.29)                                                     |
|     | 48weeks  | 0.22 (0.03, 0.80)                                                     |
| VTE | 16weeks  | 1.04 (0.32, 2.49)                                                     |
|     | 48weeks  | 0.62 (0.23,1.33)                                                      |

## Table 104'Trial-like' Sub-Cohort (Cohort B) -ILD

|     | Time    | AllbDMARDinitiators   |
|-----|---------|-----------------------|
| ILD | 16weeks | 0.00 (0.00,0.57)      |
|     | 48weeks | 0.10 (0.01,0.37)      |

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

Known Safety Profile Tofacitinib, in the already approved indications, has shown a safety profile mainly characterised by the following: serious venous thromboembolism (VTE) events including pulmonary embolism (PE), some of which fatal, and deep vein thrombosis (DVT); serious and sometimes fatal infections; viral reactivation and cases of herpes virus reactivation; lymphomas have been observed; non-melanoma skin cancers (NMSC) have been reported; gastrointestinal perforation.

Moreover, on 18 January 2021 the MAH informed the EMA about an Emerging Safety Issue (ESI) notification for tofacitinib pertaining to two signals identified from review of the final study data for coprimary endpoints in Study A3921133, specifically including the increased incidence of adjudicated MACE and adjudicated malignancies (excluding NMSC). Interim results of the study have been assessed as part of a signal procedure (EPITT ref. No. 19382). Consequently, sections 4.4, 4.8 and 5.1 of the SmPC and correspondent sections of the Package Leaflet were updated to appropriately reflect the information. The RMP was also updated with additional risk minimisation measures and a DHPC for tofacitinib was also endorsed. The final study report of Study A3921133 is currently under evaluation (EMEA/H/C/004212/II/0044) and the assessment will follow.

Source of data Two studies are included in the present analysis: 1) one completed Phase 2, 12-week long randomised double-blind, placebo-controlled, dose-ranging Study A3921119 in patients with AS. Tofacitinib IR was evaluated at doses of 2, 5 and 10 mg BID; 2) one completed pivotal Study A3921120, 48-week long phase 3, randomised, double-blind, placebo-controlled (first 16 weeks) study of the efficacy and safety of tofacitinib in patients with active AS. Tofacitinib IR was evaluated at a dose of 5 mg BID.

The integrated analysis of safety included pooling of the two studies to assess: 1) short-term (0-16 weeks) safety of tofacitinib 5 mg IR BID in comparison to placebo in the combined trials (the 'Placebocontrolled Cohort'); 2) longer-term (0-48 weeks) safety of tofacitinib in the combined trials' (the 'All Tofa Cohort'). The All Tofa Cohort has 2 analysis groups: All Tofa 5 mg BID (tofacitinib 5 mg IR BID in the combined trials) and All Tofa (tofacitinib 2 mg, 5 mg, and 10 mg BID in the combined trials).

Exposure 253 patients were exposed to tofacitinib 5 mg BID (the intended dosage for the current application) for at least 6 months (patients-year (PY)=194), and 108 patients for at least 1 year (PY=100). There were 108 patients with AS with an exposure longer than 12 months.  The number of patients exposed to a long-term treatment (e.g., 12 months) is limited, considering that the sought indication is a chronic disease requiring long-term therapy and also considering some safety concerns of the drug emerging with long term use. In accordance with EMA guidelines, which consider appropriate to have data from periods longer than 12-month in this specific context, the MAH was asked to update the safety data and analysis for those subjects who experienced an exposure longer than 1 year. However, the MAH responded that during the AS program, no additional risks specific to AS emerged, and that the overall safety profile, including long-term safety, of the AS population is consistent with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Since RA and PsA are also chronic diseases requiring long-term therapy, the MAH, thus, considers the longterm safety data (≥1 year) for tofacitinib gathered from RA and PsA patients to be applicable to the AS population. Therefore, the MAH does not foresee to conduct a specific study to gather long-term data in the AS population. This is acceptable.

Adverse events Overall, in the AS placebo-controlled cohort (short-term exposure, up to 16 weeks), the proportion of subject with AEs was slightly higher in tofacitinib than in placebo (54.6% vs 49.2%).

The most frequently reported TEAEs in the tofacitinib arm of the Placebo-controlled Cohort were within the Infections and infestations (27.6%), Gastrointestinal disorders (13%), Musculoskeletal and connective tissue disorders SOCs (8.1%), and ALT/AST increase (3.2% and 2.2%). This was slightly lower in the placebo arm (23%, 15%, 11.2%, 0.5% and 0%, respectively). Similarly, the most frequently reported

<div style=\"page-break-after: always\"></div>

TEAEs in the All Tofa Cohort were within the Infections and infestations (32.1%), Gastrointestinal disorders (16.2%), Musculoskeletal and connective tissue disorders (10.5%) SOCs.

However, when the All Tofa cohort is considered, a higher incidence of AEs is found (as expected since the longer exposure): subjects with AEs were 63.6% in tofacitinib 5 mg BID.

Due to the limited number of patients studied in the placebo-controlled trial (185 in tofacitinib 5mg BID) and the short duration of the placebo-controlled period (up to 16 weeks), it is very difficult to evaluate the observed difference in the incidence of AEs; furthermore, many AEs that are typically associated to tofacitinib treatment (such as herpes zoster), are not observed in the placebo-controlled period.

For the following AEs Hazard Ratios are higher in tofacitinib arm versus placebo: acute renal failure (HR=2.57), hypertension (2.05), weight increase (2), hyperlipidaemia (2.01) and transaminase elevations (4.03). Hypertension, weight increase, hyperlipidaemia and transaminase elevation are mentioned in SmPC 4.8. Seven cases of HZ (all non-serious) were reported in the AS clinical programme. The incidence rate per 100 PY was higher than in the PsA dataset and comparable to RA dataset (2.7, 1.7 and 3.6, respectively). Herpes zoster is already reported as a common AE in table 6 of current 4.8.

Acute renal failure was observed in more cases in tofacitinib than in placebo, 5 (2.70%) vs 2 (1.07%). It was 3.8% in All Tofa cohort, all treated with tofacitinib 5mg BID. Almost all the events listed under the SMQ of 'acute renal failure' were coded as 'protein urine present'. In most of the cases the severity of the alteration was classified as 'trace' or '+1', only one patient had '+2' as severity of the finding and none had '+3' or '+4'. Moreover, all participants with AEs of 'protein urine present' had creatinine levels within normal limits at all visits. Therefore, it seems that the severity of the AEs observed was mild on average. The risk of creatinine increase is already recognized at the 4.8 tabular listing of ADR in the SmPC.

Hepatic AEs (including: Hepatic Steatosis, Transaminase Elevations) were overall observed more frequently in tofacitinib than in placebo (5.40% vs 1.07%) and this is consistent with the known impact of tofacitinib on liver safety.

In the AS program were not observed cases of: Malignancies, NMSC, CV events of MACE or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis. To interpret correctly these data, it must be taken into account the small number of patients and the limited exposure.

When the incidence rate for AEs of special interest in patients treated with tofacitinib in the AS development program is compared to those observed in the PsA and RA programs, the incidences in the AS are lower, this is almost certainly due to the low exposure in the AS program compared to the other two conditions. An exception is observed for herpes zoster incidence that is higher in AS patients (2.68/100 PY) compared to PsA (1.76/100 PY) but lower compared to RA (3.58/100 PY).

When compared to the RA/PsA programs, except for herpes zoster in patients taking tofacitinib 5mg BID, all the SAEs were apparently less frequent in the AS program. This was most probably due to the very low exposure in the AS program (PYR=232.98 for tofacitinib all doses) compared to PsA in which exposure was about 10 times higher (2037.97) and RA in which it was 100 times higher (23496.73).

SAEs and deaths No deaths were reported in the AS clinical program. Incidence rate of SAEs (per 100 PY) was slightly higher in tofacitinib 5 mg than in placebo (5.28 vs 3.56) but the total number of cases was small (3 vs 2). In All tofacitinib doses the incidence rate was 3.49, that is similar to the placebo arm of the controlled cohort. There were 13 SAEs in 10 patients occurred under all tofa cohort (n=1 for each PT): Hypoacusis, Iridocyclitis, Abdominal adhesions, Condition aggravated, Hyperplastic cholecystopathy, Meningitis aseptic, Rib fracture, Tendon injury, Spinal osteoarthritis, Migraine, Ureterolithiasis, Pneumothorax and Subcutaneous emphysema. The rate of SAEs is comparable in the tofacitinib arm as compared to placebo.Since the small numbers, it is difficult to identify the most common SAEs, because

<div style=\"page-break-after: always\"></div>

virtually all the observed SAEs occurred each in a single subject. Most of the SAEs were mild in severity and many were managed by drug withdrawal.

## Laboratory findings

Inclusion criteria for AS tr ials only allowed patients with a platelet count ≥100,000 platelets/mm 3 . Platelet counts showed a mean decrease of almost -30,000/mm 3  after 48 weeks in the All Tofa cohort. In the AS clinical program, a decrease in mean platelet counts was observed from baseline to Week 4 in the Tofacitinib 5 mg IR twice a day (BID) group: platelets decreased of about 30.000/mm 3  at Week 16, wehereas in the placebo group there was no substantial change compared to baseline (up to week 16). Furthermore, the reduction observed in the tofacitinib group persisted with the same magnitude (i.e., at least 30.000/mm 3 ) through week 48. From the data provided, a reduction in platelet count is also observed in RA and PsA patients, and the magnitude of this reduction is somehow comparable to what observed in SA. The lowest platelet count for an individual participant was 109,000 cells/mm 3  and was mild in severity No participants had platelet counts meeting the criteria of moderate or severe laboratory abnormalities. Therefore, the data presented by the MAH indicates that the risk of platelet reduction is not specific to AS but it seems to be present in the other indications, too. The SmPC section 4.8. has been modified to reflect the fact that patients enrolled in the clinical program were required to have a platelet count &gt;100,000 /mm 3 .

AST, ALT and bilirubin increased in tofacitinib arm but were steady in the placebo arm (AST &gt;3.0x ULN: 2.2% vs 0.5%; ALT &gt;3.0x ULN: 2.7% vs 0.5%). This is mentioned adequately in 4.4 and 4.8 of the proposed SmPC.

Subjects with increased Triglycerides were also higher in tofacitinib than in placebo (&gt;1.3x ULN: 3.8% vs 1.6%). In general, the whole lipid profile was influenced by tofacitinib, with mild increase in total cholesterol, LDL, HDL and triglycerides; these AEs are already acknowledged in the SmPC.

Other laboratory result changes were comparable between tofacitinib arm and placebo arm in placebocontrolled cohort.

Vital signs No clinically significant changes were observed in blood pressure during the 16 weeks of the placebo-controlled period in patients taking tofacitinib or at the end of the 48 weeks (in the uncontrolled period); no alterations in the ECG parameters were found.

An increase in weight was observed among tofacitinib patients compared to placebo groups at 16 weeks (mean change from baseline: 1.8 vs 0.5 kg). In the All tofacitinib cohort at 48 weeks the increase was 2.2 kg (tofacitinib users). The percentage of participants that switched from the &lt;25 kg/m2 category to ≥25 - &lt;35 kg/m2 category was 14.3% and from the ≥25 -&lt;35 kg/m2 category to ≥35 kg/m2 category was 4.4% for the tofacitinib 5 mg BID treatment group at Week 48. Weight increase is already present in the AEs tabular list at the 4.8 of the SmPC.

Special populations Effects by age are very difficult to estimate since the limited number of subjects (exposed to all tofacitinib doses) &gt;65 years (n=13) vs &lt;65 years (n=407) and thus no conclusions can be drawn). Data from the RA indication has shown a higher risk for serious infections in patients older than 65 years. This is reflected in the SmPC (4.4).

As to the gender, in almost all the categories of general events (and also for herpes zoster) female patients had higher incidence rates compared to male. However, the cohort was unbalanced since there were 594 males and 142 females.

Regarding the race most patients in the tofacitinib 5 mg BID group were White (n=252) and few were Asian (n=63). In general, more Asian patients in the tofacitinib 5 mg group experienced AEs (77.78%)

<div style=\"page-break-after: always\"></div>

compared to White (59.13%); more Asian subjects experienced Infections (52.38%) than White patients (30.95%). This is reflected in the SmPC, section 4.4.

Limited data regarding treatment with tofacitinib during pregnancy is available. No additional concerns are raised from AS pivotal trials.

## Concomitant medication

Recommendations regarding DDIs are extrapolated from RA and PsA studies. No additional DDI studies have been conducted for the AS indication. This is considered acceptable, because, considering the underlying pathophysiology of RA, PsA and AS (all auto-immune diseases) and treatment options, no additional interaction issues are expected for the AS indication.

Most patients (80%) were bDMARD-naïve, and only few (20%, n=58) had used TNF inhibitor or bDMARD (20%, n=58) prior to the start of the study. Overall, a consistent increase in general events (such as AEs, SAEs, discontinuations, etc) and infections was observed in patients with previous treatment with TNFi or bDMARD compared to those bDMARD-naïve: AEs were 72.41% vs 60.47%. The highest difference was observed for 'Discontinuation of study treatment', which involved 22.41% vs 4.65% of patients. The number of patients in the 'previously treated' group is small and thus any conclusion is difficult, but such results could be expected, since it is biologically plausible that patients already exposed to previous treatments develop more AEs when subsequently treated with tofacitinib.

## Discontinuation due to AEs

The rate of discontinuation due to AEs was low (n=11, 3.48%) in tofacitinib 5mg BID arms. The most frequent SOC reported for discontinuation belongs to infections (n=3, 0.9%). Infection is a known risk of JAK-inhibitors and is adequately discussed in proposed text of tofacitinib SmPC section 4.4. No new concerns are raised due to discontinuation after infection.

## Post-marketing experience

US Corrona RA Registry Study A3921205 report has not been provided in the submitted dossier. However, the results of this study are assessed separately by PRAC (EMEA/H/C/004214/II/0023). Indirect comparison between the ARTIS register safety results and the All Tofa AS cohort shows a higher incidence rate for HZ (0 vs 2.8, respectively) in treatment with tofacitinib. The weighted incidence rate for HZ is also higher in All Tofa AS cohort compared to this rate in the Truven analysis (2.8 and 0.74, respectively). Therefore, it can be concluded that the risk of HZ is higher if patients with AS would be treated with tofacitinib compared to bDMARDs or general AS population. This is reflected in SmPC, 4.4 and 4.8 (see assessor's discussion on 'adverse events of special interest').

A higher incidence of venous thromboembolism has been observed in post-marketing RA study A3921133 compared to AS pivotal trials. Considering short follow up in AS pivotal trials, VTE events remain a concern for AS indication. This is reflected adequately in the RMP.

## 2.5.2. Conclusions on clinical safety

In conclusion, patient's exposure in the sought indication is limited. However, from the data available do not emerge new important signals of safety, and tofacitinib is already used in similar conditions (RA and PsA). The MAH considers that the safety profile of tofacitinib in the intended population can be extrapolated from the long-term safety data available for the RA and PsA population and does not plan to conduct any other clinical trial to gather these data from the AS population. This is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version 17.1 with this application. The (main) proposed RMP changes include information for the new therapeutic indication ankylosing spondylitis (AS). This includes information regarding:

- The epidemiology of AS (Part II, Module SI)
- AS clinical trial exposure and description of AS clinical dataset (Part II, Module SIII)
- AS inclusion criteria and AS exposure of special populations from the AS development programme (Part II, Module SIV)
- A summary of the AS clinical datasets presented for the safety concerns, as well as inclusion of AS clinical data for all safety concerns (Part II, Module SVII)

In addition, the MAH included some changes regarding updated post-authorisation exposure (Part II Module SV, and Module SVII), a clarification regarding the age of juvenile rats and juvenile monkeys under juvenile toxicity (Part II, Module SII), and explanatory notes regarding studies in the pharmacovigilance plan (Part III, Part V, Part VI).

The CHMP endorsed the Risk Management Plan version 17.1 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                         |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Venous thromboembolic events (DVT/PE)                                                                                              |
| Important identified risks   | Serious and other important infections                                                                                             |
| Important identified risks   | HZ reactivation                                                                                                                    |
| Important identified risks   | Decrease in neutrophil counts and neutropenia                                                                                      |
| Important identified risks   | Decrease in lymphocyte counts and lymphopenia                                                                                      |
| Important identified risks   | Decrease in Hgb levels and anaemia                                                                                                 |
| Important identified risks   | Lipid elevations and hyperlipidaemia                                                                                               |
| Important identified risks   | NMSC                                                                                                                               |
| Important identified risks   | Transaminase elevation and potential for DILI                                                                                      |
| Important potential risks    | Malignancy                                                                                                                         |
| Important potential risks    | Cardiovascular risk                                                                                                                |
| Important potential risks    | GI perforation                                                                                                                     |
| Important potential risks    | ILD                                                                                                                                |
| Important potential risks    | PML                                                                                                                                |
| Important potential risks    | All-cause mortality                                                                                                                |
| Important potential risks    | Increased immunosuppression when used in combination with biologics and immunosuppressants including B-lymphocyte depleting agents |
| Important potential risks    | Increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients                               |
| Important potential risks    | Primary viral infection following live vaccination                                                                                 |
| Important potential risks    | Increased exposure to tofacitinib when co-administered with CYP3A4 and CYP2C19 inhibitors                                          |
| Important potential risks    | Off-label use including in children with JIA or IBD a                                                                              |
| Important potential risks    | Higher incidence and severity of AEs in the elderly                                                                                |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                             |
|------------------------------|------------------------------------------------------------------------|
| Missing information b        | Effects on pregnancy and the foetus                                    |
| Missing information b        | Use in breastfeeding                                                   |
| Missing information b        | Effect on vaccination efficacy and the use of live/attenuated vaccines |
| Missing information b        | Use in patients with mild, moderate, or severe hepatic impairment      |
| Missing information b        | Use in patients with moderate or severe renal impairment               |
| Missing information b        | Use in patients with evidence of hepatitis B or hepatitis C infection  |
| Missing information b        | Use in patients with elevated transaminases                            |
| Missing information b        | Use in patients with malignancy                                        |

a In the previously submitted RMP version 12.2 for pcJIA, this safety concern was proposed to be removed as an important potential risk.

b In the previously submitted RMP version 12.2 for pcJIA, 'Long-term safety in pcJIA patients' was added as a missing information. AE = adverse event; CYP = cytochrome P450; DILI = drug-induced liver injury; DVT = deep vein thrombosis; GI = gastrointestinal; Hgb = haemoglobin; HZ = herpes zoster; IBD = inflammatory bowel disease; ILD = interstitial lung disease; JIA = juvenile idiopathic arthritis; MTX = methotrexate; NMSC = non-melanoma skin cancer; pcJIA = polyarticular course juvenile idiopathic arthritis; PE = pulmonary embolism; PML = progressive multifocal leukoencephalopathy; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RMP = risk management plan

## Pharmacovigilance plan

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                                           | Safety Concerns Addressed                                                                                                                                                                                                                                                                              | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                      | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                             | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                                            | None                                                                                                                                                                                                                                                                                                   | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                      | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                             | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                                            | None                                                                                                                                                                                                                                                                                                   | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                          | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Study A3921133: Phase 3B/4 randomised safety endpoint study of 2 doses of tofacitinib in comparison to a TNF inhibitor in subjects with RA On-going                                                                        | To continue to evaluate the 2 safety concerns that have a long latency period (ie, adjudicated MACE and adjudicated malignancies excluding NMSC of tofacitinib in patients with RA                                                              | - adjudicated MACEs (suspected PE cases are being adjudicated as part of the secondary endpoint of CV events other than adjudicated MACE - adjudicated malignancies excluding NMSC - adjudicated opportunistic OI events including TB - adjudicated hepatic events - all-cause mortality (adjudicated) | Study start Study finish Final report                                                                                                                                                                                      | 14/03/2014 05/10/2020 31/10/2021                                                                                                                                                                                           |
| Biospecimen Testing Study (Study Number Pending) On-going                                                                                                                                                                  | To explore potential biomarkers from the A3921133 study to a) assess the biological basis for the observed excess risk of VTE in subjects receiving tofacitinib (10 mg BID) and/or b) to identify patients at higher risk for PE or VTE events. | - venous thromboembolism                                                                                                                                                                                                                                                                               | Study start Study finish Final report                                                                                                                                                                                      | 30/09/2019 31/03/2020 30/09/2020 (please note this study has completed and included in the previous EU RMP version 14.1, which is currently under PRAC review)                                                             |
| Prescribers' survey A3921334 (RA, PsA, UC) Planned                                                                                                                                                                         | An EU-based survey for prescribers of tofacitinib for RA, PsA, and UC. (aRMM effectiveness assessment)                                                                                                                                          | - venous thromboembolism (DVT/PE) - serious and other important infections - HZ reactivation - malignancies - NMSC                                                                                                                                                                                     | Study start Study finish Final report                                                                                                                                                                                      | 31/01/2021 31/07/2021 30/06/2022                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                            | Summary of Objectives                                                                                   | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Milestones                            | Due Dates                        |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|----------------------------------|
| Drug utilisation study A3921321 Planned | An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) | impairment - the extent to which patient screening and laboratory monitoring recommendations and recommendations regarding limitations of use, including off label use of 10 mg BID among RA and PsA patients, minimisation of use of 10 mg BID maintenance therapy among UC patients at high risk for venous thromboembolism and among UC patients without high risk for venous thromboembolism who have not been treated with alternative treatment options (and concurrent conditions, such as pregnancy, hepatic impairment, or concomitant use of bDMARDs) are followed - off label use | Study start Study finish Final report | 31/12/2019 30/06/2022 30/06/2023 |

<div style=\"page-break-after: always\"></div>

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study                                                                                                                                           | Summary of Objectives                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                    | Milestones                            | Due Dates                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Status A US-based drug utilisation study using either electronic health care records (EHR) or administrative claims database (A3921348) Planned | To assess prescription trends over time, as well as evaluate compliance with RMMs                             | - Extent to which patient screening and laboratory monitoring recommendations and recommendations regarding limitations of use, including avoidance of 10 mg maintenance therapy among UC patients at high risk for venous thromboembolism (and concurrent conditions, such as pregnancy, hepatic impairment, or concomitant use of biologics) are followed - off-label use. | Study start Study finish Final report | 30/06/2020 30/06/2025 30/06/2026 (please note this study has merged into study A3921347 and addressed in EU RMP version 16.1, currently under PRAC review) |
| Prospective, non- interventional active surveillance study embedded within the ARTIS registry (A3921314) On-going                               | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting | - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - CV risk a - GI perforation - PML - all-cause mortality - increased risk of AEs in patients treated with tofacitinib in combination use of MTX - higher incidence and severity of AEs in elderly patients (≥65 years)                                                          | Study start Study finish Final report | 30/09/2018 30/09/2025 30/09/2026                                                                                                                           |
| Prospective, non- interventional active surveillance study embedded within the BSRBR registry (A3921312) On-going                               | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting | including infections - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - CV risk a - GI perforation - PML - all-cause mortality - increased risk of AEs in patients treated with tofacitinib in combination use of MTX - higher incidence and severity of AEs in elderly patients (≥65 years) including infections                | Study start Study finish Final report | 30/09/2018 30/09/2025 30/09/2026                                                                                                                           |
| Prospective, non- interventional active surveillance study embedded within the RABBIT registry (A3921317) On-going                              | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting | - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - CV risk a - GI perforation - PML - all-cause mortality                                                                                                                                                                                                                        | Study start Study finish Final report | 30/09/2018 30/09/2025 30/09/2026                                                                                                                           |

<div style=\"page-break-after: always\"></div>

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                     | Milestones                            | Due Dates                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prospective, non- interventional active surveillance study embedded within the BIOBADASER registry (A3921316) On-going        | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting                                                                                                                                                                                                              | including infections - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - CV risk a - GI perforation - PML - all-cause mortality - increased risk of AEs in patients treated with tofacitinib in combination use of MTX - higher incidence and severity of AEs in elderly patients (≥65 years) including infections | Study start Study finish Final report | 30/09/2018 30/09/2025 30/09/2026                                                                                                                                  |
| Prospective, non- interventional active surveillance pregnancy study embedded within the US OTIS registry (A3921203) On-going | To estimate the risk of birth defects and other adverse pregnancy outcomes occurring in offspring of patients exposed to tofacitinib during pregnancy, and to detect any increase in the prevalence or pattern of these outcomes among exposed pregnancies as compared with internally generated disease- matched and non- | - birth defects and other adverse pregnancy outcomes                                                                                                                                                                                                                                                                                                          | Study start Study finish Final report | RA: 30/04/2014 PsA: 30/06/2019 UC: 30/06/2019 AS: TBD RA: 30/09/2023 PsA: 30/09/2023 UC: 30/09/2023 AS: TBD RA: 30/09/2024 PsA: 30/09/2024 UC: 30/09/2024 AS: TBD |

<div style=\"page-break-after: always\"></div>

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study                                                                                                                           | Summary of Objectives                                                                                          | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                       | Milestones                               | Due Dates                        |
|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|----------------------------------|
| Status Prospective, non- interventional active surveillance studies embedded within the Corrona registry (A3921329 UC) On-going | To provide additional longitudinal safety data regarding the use of tofacitinib in the US for UC patients.     | - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - malignancies - NMSC - MACE - PML - GI perforation - all-cause mortality - higher incidence and severity of AEs in elderly patients ( ≥ 65 years) including infections- safety outcomes with 10 mg BID dose during maintenance (in a separate sub-analysis)           | UC Study start Study finish Final report | 30/06/2019 30/06/2027 31/12/2027 |
| Prospective, non- interventional active surveillance study (SWIBREG) A3921344 Planned                                           | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting. | - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - MACE - GI perforation - PML - all-cause mortality - higher incidence and severity of adverse events in elderly patients ( ≥ 65 years) including infections- safety outcomes with 10 mg BID dose during maintenance (in a separate sub- analysis) | Study start Study finish Final report    | 30/06/2020 31/10/2025 31/10/2026 |
| Prospective, non- interventional active surveillance study (UR-CARE) A3921352 Planned                                           | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting. | - venous thromboembolism (DVT/PE) - serious infections - HZ reactivation - NMSC - malignancy - MACE - GI perforation - PML - all-cause mortality - higher incidence and severity of adverse events in elderly patients ( ≥ 65 years) including infections                                                                                       | Study start Study finish Final report    | 30/06/2020 31/10/2025 30/09/2026 |

<div style=\"page-break-after: always\"></div>

## Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                    | Summary of Objectives                                                                                                                                                                                        | Safety Concerns Addressed                                                                                                                                                                                                                                  | Milestones                            | Due Dates                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prospective, non- interventional active surveillance study examining tofacitinib safety in UC A3921347 On-going | To quantify the incidence of key safety events of interest in moderate-to- severe UC patients treated with tofacitinib and other systemic therapies in the clinical practice (real world) setting            | - venous thromboembolism (DVT/PE) - mortality b - malignancies - opportunistic and serious infections - HZ - major adverse cardiovascular endpoints - GI perforation- safety outcomes with 10 mg BID dose during maintenance (in a separate sub- analysis) | Study start Study finish Final report | 30/06/2020 30/06/2025 30/06/2026 (please note study A3921348 has been merged into A3921347 and milestones updated, which are included in EU RMP version 16.1, currently under PRAC review) |
| Shingrix study Planned                                                                                          | To determine the immune response from the new non- live zoster vaccine (Shingrix; Recombinant, adjuvanted zoster vaccine) vs placebo vaccine in UC and RA patients on background tofacitinib or TNF blocker. | - primary viral infection following live vaccination                                                                                                                                                                                                       | Study start Study finish Final report | TBD TBD TBD                                                                                                                                                                                |

a. Specifically, MACE

b. Due to limitations related to the claims database, only in-hospital mortality can be assessed Please note, for Study A3921133, on 19 February 2019, the 10 mg dose was discontinued. AE = Adverse Event; ARTIS = Anti-rheumatic Therapies In Sweden; BIOBADASER = Registro Español De Acontecimientos Adversos De Terapias Biológicas En Enfermedades Reumáticas; BSRBR = British Society For Rheumatology Biologics Register; CV = cardiovascular; DLP = data lock point; ENEIDA = Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales; EU = European Union; GI = gastrointestinal; MACE = major adverse cardiac event; MTX = methotrexate; NMSC = non-melanoma Skin Cancer; OI = opportunistic infection; OTIS = Organisation Of Teratology Information Specialists; PML = progressive multifocal leukoencephalopathy; PRAC = Pharmacovigilance Risk Assessment Committee; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RABBIT = Rheumatoide Arthritis-Beobachtung Der Biologika-Therapie; RMM = risk minimisation measure; SWIBREG = Swedish National Quality Registry for Inflammatory Bowel Disease, TB = tuberculosis; TBD = to be determined; TNF = tumour necrosis factor; UC = ulcerative colitis; US = United States

## Risk minimisation measures

No new routine risk minimisation measures have been proposed by the applicant.

| Safety Concern             | Risk Minimisation Measures   | Pharmacovigilance Activities   |
|----------------------------|------------------------------|--------------------------------|
| Important Identified Risks | Important Identified Risks   | Important Identified Risks     |

<div style=\"page-break-after: always\"></div>

| Safety Concern                         | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Venous thromboembolic events (DVT/PE)  | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) •A3921348: A US-based drug utilisation study using electronic health care records (aRMM effectiveness assessment): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review. •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. •A3921347: Prospective non- interventional active surveillance study in the US (UC): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review. •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •Biospecimen Testing Study (Study Number Pending): please note this study has completed and included in the previous EU RMP version 14.1, |
| Serious and other important infections | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.3 Contraindications SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties                                                                                                                                                                                             | which is currently under PRAC review. Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure).                                                                                                              | focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Prospective, non-interventional active surveillance study using 2 European UC registries (Swedish National Quality Registry for Inflammatory Bowel Disease [SWIBREG] - A3921344, and the United Registries for Clinical Assessment and Research [UR-CARE] - A3921352), over 5 years. •A3921347: Prospective non- interventional active surveillance study in the US (UC): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review. |
| HZ reactivation  | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. •A3921347: Prospective non- interventional active surveillance study in the US (UC): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review.                                                                       |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                    |
|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Decrease in neutrophil counts and neutropenia | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists,                       | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |
| Decrease in lymphocyte counts and lymphopenia | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists,                       | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |
| Decrease in Hgb levels and anaemia            | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |
| Lipid elevations and hyperlipidaemia          | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers                                                                                                               | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |
| NMSC                                          | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects                                                                                                                                                                                                                                                | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None                                               |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                  | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure).                                                                                                                                    | •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. |
| Transaminase elevation and potential for DILI   | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor.                                                                                                                                                                                                                                                                                                                                                                                              |
| Prescriber Brochure). Important Potential Risks | Prescriber Brochure). Important Potential Risks                                                                                                                                                                                                                                                                                             | Prescriber Brochure). Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Malignancy                                      | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure).                                                       | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years.                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Safety Concern      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                                                                                                                                                                                                         | •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. •A3921347: Prospective non- interventional active surveillance study in the US (UC): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Cardiovascular risk | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: None proposed                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. •A3921347: Prospective non- interventional active surveillance study in the US (UC): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review. |
| GI perforation      | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Safety Concern      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ILD                 | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PML                 | Routine risk minimisation measures: Not applicable Additional risk minimisation measures: None proposed                                                                                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years. |
| All-cause mortality | Routine risk minimisation measures: SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: None proposed                                                                                                                                                                                    | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                                                      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                     |                                                                                                                                                                                                                                                                                                                              | •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over 5 years •A3921133: A large, post-approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921347 (UC): Prospective non- interventional active surveillance study in the US (in-hospital mortality): please note A3921348 was merged into A3921347 in the EU RMP version 16.1, which is currently under PRAC review. |
| Increased immunosuppression when used in combination with biologics and immunosuppressants including B- lymphocyte depleting agents | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) Routine pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients                                | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure).                       | beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                            | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary viral infection following live vaccination                                        | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists,                                                                                                    | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Shingrix study                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Increased exposure to tofacitinib when co-administered with CYP3A4 and CYP2C19 inhibitors | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.5 Interaction with other medicinal products and other forms of interaction Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Off-label use including children with JIA or IBD                                          | Prescriber Brochure). Routine risk minimisation measures: SmPC Section 4.1 Therapeutic indication SmPC Section 4.2 Posology and method of administration Additional risk minimisation measures: None proposed                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Protocol A3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment)                                                                                                                                                                                                                                                                                                                                                                                                               |
| Higher incidence and severity of AEs in the elderly                                       | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Prescriber Brochure).                   | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •Prospective, non-interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR-CARE [A3921352]) over t 5 years. |
| Missing Information                                                                       | Missing Information                                                                                                                                                                                                                                                                                                                                                | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                         | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effects on pregnancy and the foetus                                    | Routine risk minimisation measures: SmPC Section 4.3 Contraindications SmPC Section 4.6 Fertility, pregnancy, and lactation Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure).        | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Monitoring via an established pregnancy registry (US OTIS). •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) |
| Use in breastfeeding                                                   | Routine risk minimisation measures: SmPC Section 4.3 Contraindications SmPC Section 4.6 Fertility, pregnancy, and lactation Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure).        | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                 |
| Effect on vaccination efficacy and the use of live/attenuated vaccines | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure).                                           | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                 |
| Use in patients with mild, moderate, or severe hepatic impairment      | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.3 Contraindications SmPC Section 5.2 Pharmacokinetic properties Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU- based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) Routine pharmacovigilance activities                         |
| Use in patients with moderate or severe renal impairment               | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 5.2 Pharmacokinetic properties                                                                                                                                                                                                                            | beyond adverse reaction reporting and signal detection: None                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                              | Risk Minimisation Measures                                                                                                                         | Pharmacovigilance Activities                                                                                                                    |
|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                             | Additional risk minimisation measures: None proposed                                                                                               | None                                                                                                                                            |
| Use in patients with evidence of hepatitis B or C infection | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: None proposed | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |
| Use in patients with malignancy                             | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: None proposed | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None |

AE = adverse event; ARTIS = Anti-rheumatic Therapies In Sweden; BIOBADASER = Registro Español De Acontecimientos Adversos De Terapias Biológicas En Enfermedades Reumáticas; BSRBR = British Society For Rheumatology Biologics Register; DILI = drug-induced liver injury; DVT = deep vein thrombosis; EU = European Union; GI = gastrointestinal; Hgb = haemoglobin; HZ = herpes zoster; IBD = inflammatory bowel disease; ILD = interstitial lung disease; JIA = juvenile idiopathic arthritis; MACE = major adverse cardiac event; MTX = methotrexate; NMSC = non-melanoma skin cancer; OI = opportunistic infection; PASS = post-authorisation safety study; PE = pulmonary embolism; PML = progressive multifocal leukoencephalopathy; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RABBIT = Rheumatoide Arthritis-Beobachtung Der Biologika-Therapie; RMM = risk minimisation measure; SmPC = Summary of Product Characteristics; SWIBREG = Swedish National Quality Registry for Inflammatory Bowel Disease, TNF = tumour necrosis factor; UC = ulcerative colitis

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Xeljanz 5mg/10 mg/ 11 mg PR. The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

AS is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine and is part of the family of related SpA disorders, which also includes PsA. AS or radiographic axial SpA is defined by the presence of definitive radiographic sacroiliitis based upon 1984 Modified New York classification criteria. AS causes chronic inflammation at the insertion of ligaments and tendons in the

<div style=\"page-break-after: always\"></div>

axial skeleton (entheses) and may progress from inflammation in the sacroiliac joints to sacroiliac and spine ankylosis over time. AS is also associated with peripheral arthritis, and enthesitis, and extraarticular manifestations such as anterior uveitis, psoriasis, and IBD. Osteoporosis is a common AS comorbidity. AS is often present for many years before it is diagnosed and typically presents in people between 20 and 40 years of age, with a higher prevalence in males, leading to back pain, stiffness, fatigue, progressive disability and adverse effects on health.

Overall, the pathogenesis of AS is not well characterised but seems to include both genetic and environmental components, which combine to elicit a chronic inflammatory response involving the innate and adaptive immune systems. A genetic link was noted. 90 - 95% of white Western European people with AS are positive for the HLA-B27 allele, and risk increases with HLA-B27-positive relatives. -related quality of life. Confirmation that TNFaplha (secreted by Th1 and T CD8+ cells) and IL-17 (secreted by Th17 and T CD8+ cells) contribute to the pathogenesis of AS has been provided by the efficacy of interventions such as TNFi and anti-IL-17 mAb. These biologic therapies directly inhibit the effect of 1 cytokine pathway. Tofacitinib, a small molecule inhibitor of JAK, interferes directly (eg, IL-23) or indirectly (eg, TNFalpha, IL-17) with the signalling of multiple AS-associated cytokines.

## 3.1.2. Available therapies and unmet medical need

Based on the current evidence and the considerations of ASAS and EULAR, NSAIDs and TNFi remain the primary classes of medications for the treatment of axial SpA (including AS). Sulfasalazine is considered only for the treatment of peripheral arthritis. IL-17i are recommended for patients with active disease in whom TNFi are contraindicated, and in primary nonresponders to TNFi. The use of IL-17i should be avoided in patients with active IBD, as TNFi monoclonal antibodies are better options. Moreover, recently, also another JAK inhibitor has been authorized in EU for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Treatments are available to control and delay the progression of symptoms of AS. However, additional therapy options are still needed as up to 50% of patients with AS continue to have active disease despite treatment with NSAIDsor biological agents.

The use of NSAIDs is limited by gastrointestinal and other adverse events. Other effective agents for the treatment of active AS are bDMARDs, which require parenteral administration and may be limited by loss of efficacy, often due to immunogenicity.

As a number of genes and cytokines have been implicated in the pathogenesis of AS, it is likely that the etiology of AS is complex and has a plethora of underlying contributory factors. This implies that additional treatment options with mechanisms of action distinct from those currently available, are needed as options for different AS patients.

In summary, despite the advances that have been made in the last decade in the treatment of AS, a significant number of patients with AS still have active disease and remain refractory to currently available pharmacotherapies. Unmet medical need therefore remains for a new effective oral DMARD with a new MOA that provides a favourable benefit-risk profile and broadens the treatment options for adult patients with AS to achieve and sustain clinical benefit.

## 3.1.3. Main clinical studies

With this submission, the MAH seeks a new indication for Tofacitinib for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. The recommended dose of tofacitinib is 5 mg administered twice daily.

<div style=\"page-break-after: always\"></div>

In support of the sought indication, the MAH is providing:

i) supportive data from Study A3921119 a phase 2, multicenter, randomised, double-blind, placebocontrolled dose ranging, parallel group efficacy and safety study designed to characterise the dose response of tofacitinib 2 mg BID, 5 mg BID and 10 mg BID in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs;

ii) confirmatory evidence from one pivotal study A3921120, a phase 3, randomized, double-blind, placebo-controlled, parallel group comparing tofacitinib 5mg dosed twice daily to placebo in subjects with active AS, who had experienced an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, or TNFi-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]). The study design included a 16-week double-blind treatment period, a 32-week open-label treatment period (all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48) and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

The study included subjects with active AS defined as: Modified New York Criteria for Ankylosing Spondylitis (1984), BASDAI score of ≥ 4 and back pain score (BASDAI Question 2) of ≥ 4 at both screening and baseline and that have had an inadequate response to at least 2 different NSAIDs. Additionally, bDMARD naïve, TNFi-IR, or bDMARD (non-IR) exposed were enrolled in this study. The proportion of bDMARD-naïve and TNFi-IR or bDMARD use (non-IR i.e., discontinued the bDMARD due to other reasons than lack of efficacy or intolerance) was of approximately 80%/20%.

Randomization was stratified by prior treatment history: (1) bDMARD-naive and (2) TNFi-IR or bDMARD use (non-IR).

Overall inclusion and exclusion criteria were adequate for selecting an active AS population and also for taking into account the safety profile of the drug. Moreover, criteria for defining previous or concomitant allowed, or prohibited therapies and stable doses are considered acceptable.

## 3.2. Favourable effects

Tofacitinib dose selected for the phase 3 pivotal A3921120 study comes from the phase 2 study.

Primary endpoint: a statistically significant higher proportion of patients in the tofacitinib 5 mg BID group reached ASAS20 at week 16 in comparison to the placebo group with a treatment difference of 27.08 (95% CI: 15.89, 38.28), which is in line with the 20% difference expected in the sample size calculation. Moreover, the primary analysis is supported by results from all the pre-specified supportive analyses.

The key secondary endpoint ASAS40 was also met from a statistical perspective with a higher response rate of subjects in tofacitinib 5 mg BID group (40.6%) compared to placebo group (12.5%) at week 16.

The effect size of ASAS40 being very similar to that observed for ASAS20 and of clinical relevance.

Consistent results are shown by subgroup analyses. For both ASAS20 and ASAS40 a better response rate between study drug and placebo is reported in bDMARDs naïve compared to TNF-IR subjects or bDMARD [Non-IR].

The individual components of the ASAS responses (type I controlled) and ASAS 5/6 (not controlled) results were consistent with those of the primary and key secondary endpoint.

Numerous secondary endpoints controlled for multiplicity have been selected for assessing tofacitinib efficacy on different disease domains and this is supported, however limitations are foreseen.

Results from primary and key secondary endpoint were supported by an important secondary (type I controlled) endpoint ASDAS (CRP) which is a validated and accepted method to assess disease activity

<div style=\"page-break-after: always\"></div>

and physical function considered a very important disease activity. The LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the PLB arm at week 16, delta of -0-98) showing a clinically relevant difference. At week 48 improvement of ASDAS(CRP) from baseline is still seen.

Other endpoint has been provided as secondary but not controlled for type I error supporting tofacitinib effect across important clinical measures i.e.: ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3), ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16; a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoints measuring improvement. Measure of partial remission was also supportive [i.e., ASDAS partial remission: a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001]

Supportive results were obtained from different Quality of Life endpoints (i.e., ASQoL).

Measures of spinal mobility, i.e., Linear BASMI (BASMI lin) composite score change at week 16, is a relevant efficacy parameter in axial SpA. Results were not robust as those evaluating tofacitinib efficacy on sign and symptoms/inflammation of the disease showing a change at week 16 (of -0.63 versus -0.11 for Tofa and PLB, respectively; similar change (-0.6-0.7) at week 48) statistically significant but not clinically relevant.

Results from Study A3921119 were supportive of the phase 3 study with regard to different endpoints mainly pertaining to disease activity and physical functions, health related outcomes.

According to a systematic review and meta-analysis of placebo-controlled trials of EMA-approved biological DMARDs, including ASAS20/40 at week 12-16, in patients with AS with or without previous experience with biological DMARDs: ASAS40 responses for tofacitinib 5 mg BID across Studies A3921119 and A3921120, were similar compared with adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab and secukinumab.

## 3.3. Uncertainties and limitations about favourable effects

Dose selection comes from the phase 2 study A3921119 (2 mg, 5 mg and 10 mg doses) in order to derive the optimal dose for the phase 3 study A3921120. The relationship between tofacitinib exposure (Cavg) and clinical response was not adequately captured by the E-R model. The MAH clarified that the ASAS20 and ASAS40 response rates shown in the VPC plots as ' observed ' are observed proportions for each stratified group.

Although the design of the phase 3 pivotal Study A3921120 could be acceptable, the lack of an active comparator arm hampers assessing the relative B/R balance. As an alternative, the Applicant has performed a meta-analysis of approved treatments and included the results of the tofacitinib trials (dosefinding and pivotal study) as supportive data. Accordingly, the treatment effects of tofacitinib 5 mg BID versus placebo were within the range of EMA approved treatments, which indirectly supports the clinical relevance of treatment effects. Moreover, no information was provided on evaluation of dose reduction/stop and/or increased dose interval for subjects obtaining resolution of inflammation to avoid unnecessary toxicity.

The choice of the primary endpoint (ASAS20 response at week 16) is not in line with the current EMA Guideline indicating that ASAS40 response is preferred primary endpoint since is more stringent. However, the clinical development program plans for the treatment of AS generally reflects the CHMP Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1).

<div style=\"page-break-after: always\"></div>

Efficacy of tofacitinib 5 mg BID was maintained up to week 48 in the patients on tofacitinib, while patients switching from placebo to tofacitinib at week 16 'catched up' and approached the effect of the group already on tofacitinib from baseline. It is remarkable that the group originally on placebo did not completely reach the effect of the group remaining on tofacitinib in ASAS response and secondary outcomes. However, as this is a randomised trial, as baseline variables were on average similar between the two treatment groups, and attrition was low, it is not expected that this observation can be meaningfully explained (not pursued). It also is possible that the open-label phase may have contributed to the observation of an increase in efficacy from week 16 to week 48, which however cannot be fully evaluated due to a lack of blinding and lack of comparator (not pursued).

In the subgroup of AS patients with a body weight &gt;100 kg, the estimate of the treatment effect in ASAS40 was -13% in favour of placebo. This was not seen in the subgroup analysis of body weight and ASAS20, and bodyweight does not appear to influence exposure up to 140 kg (SmPC section 5.2). According to the MAH the trend of ASAS40 at Week 16 in the Study A3921120 participants with a body weight &gt;100 kg could be explained by the small sample size. Moreover, no major differences in tofacitinib exposure over the range of body weights studied were reported and no clinically significant decrease in efficacy of tofacitinib has been observed in &gt;100 kg RA patients. Therefore, all together these observations do not allow to draw firm conclusion on a lower efficacy in patients with &gt;100 kg body weight.

Although consistent results were shown by subgroup analyses for both ASAS20 and ASAS40 response rates, these were higher in the subgroups of subjects identified by very high disease activity or in those with higher baseline hsCRP (&gt;2.87 mg/L) suggesting that tofacitinib could perform better in this target population however numbers are limited.

A minority of patients had extra-articular manifestations at baseline to perform a subgroup analysis. In view of the potential differences in response in this subgroup of subject's uncertainty remains on it. In order to get reassurance on the efficacy of tofacitinib in subjects with peripheral arthritis a separate analysis for ASAS20, ASAS40, delta ASDAS(CRP) has been required for this subgroup.

Among secondary endpoint, no endpoint that could monitor structural changes, has been included thus no data could be derived on this disease domain.

Measures of low disease activity or partial remission were also supportive of a better effect of tofacitinib but were assessed only as part of secondary not controlled endpoints and showed very/limited effect size when inactive disease/partial remission was the goal therefore these could not be regarded as conclusive. Some questionnaire used to evaluate Quality of Life endpoints is not disease specific and broadly used thus results could be seen only as indicative.

## 3.4. Unfavourable effects

The safety profile of tofacitinib is mainly characterised by different types of AEs, included venous thromboembolism and pulmonary embolism, serious infections, cases of non-melanoma skin cancers (NMSC), gastrointestinal perforation. Moreover, a recent Emerging Safety Issue (ESI) has been notified pertaining cardiovascular events (MACE) and malignancies.

The proportion of subject with AEs (exposure up to 16 weeks) was slightly higher in tofacitinib than in placebo (54.6% vs 49.2%). However, when the All Tofa cohort is considered (longer exposure), a higher incidence of AEs is found: subjects with AEs were 63.6% in tofacitinib 5 mg BID.

The most frequently reported TEAEs in the tofacitinib arm of the Placebo-controlled Cohort were within the Infections and infestations (27.6%), Gastrointestinal disorders (13%), Musculoskeletal and connective tissue disorders SOCs (8.1%), and ALT/AST increase (3.2% and 2.2%). The most frequently reported

<div style=\"page-break-after: always\"></div>

TEAEs in the All Tofa Cohort were within the Infections and infestations (32.1%), Gastrointestinal disorders (16.2%), Musculoskeletal and connective tissue disorders (10.5%) SOCs.

Among the most common AEs, those more common in tofacitinib 5 mg BID, and with the highest differences vs placebo, were 'infections and infestations' (36.1% vs 23.0%) and 'investigations' AEs (16.8% vs 4.3%). Most of these investigation AEs were related to increased liver transaminases.

Acute renal failure was observed in more patients treated with tofacitinib than with placebo, 5 (2.70%) vs 2 (1.07%). The small number does not allow drawing any conclusion on this point, but most of the events were mild and creatine increase is already listed as AE in the SmPC.

Hepatic AEs were overall observed more frequently in tofacitinib than in placebo (5.40% vs 1.07%). Consistently with this, a higher proportion of subjects had increased liver transaminases in tofacitinib compared to placebo (AST &gt;3.0x ULN: 2.2% vs 0.5%; ALT &gt;3.0x ULN: 2.7% vs 0.5%).

Seven cases of HZ (all non-serious) were reported in the AS clinical programme. The incidence rate per 100 PY was higher than the incidence rate in the PsA dataset and comparable to the RA dataset (2.7, 1.7 and 3.6, respectively).

SAEs (per 100 PY) were higher in tofacitinib 5 mg than in placebo (5.28 vs 3.56) but occurred in a minority of subjects. Most SAEs were considered mild in severity, only one subject experienced a severe SAE in both tofacitinib 5 mg and tofacitinib all doses' groups during the 48 weeks period.

The number of patients needing 'dose reduced or temporary discontinuation' was 9.5% vs 3.2% in tofacitinib 5   mmmg BID versus placebo.

The whole lipid profile was influenced by tofacitinib, with mild increase in total cholesterol, LDL, HDL and triglycerides; an increase in weight was observed among tofacitinib patients compared to placebo groups at 16 weeks (mean change from baseline, kg: 1.8 vs 0.5; in the All tofacitinib cohort at 48 weeks the increase was 2.2 kg) both potentially negatively impacting the CV risk of these patients.

ALT and bilirubin increased in the tofacitinib arm but were steady in the placebo arm.

Incidence rates for TEAEs, discontinuation of study treatment, discontinuations due to AEs, all infections and HZ were generally higher for females compared to males and for patients &gt;= 65 years old compared to younger patients.

A worst safety profile was observed in patients with previous treatment with TNFi or bDMARD compared to those bDMARD-naïve: AEs were 72.41% vs 60.47%. The highest difference was observed for 'Discontinuation of study treatment', which involved 22.41% vs 4.65% of patients.

## 3.5. Uncertainties and limitations about unfavourable effects

The limited exposure in the sought indication could not be sufficient to unveil possible adverse effects that could be specific to AS. The placebo-controlled period was limited to 16 weeks; due to this fact, and also to the limited number of patients studied, it is very difficult to evaluate the observed difference in the incidence of AEs; furthermore, many AEs that are typically associated to tofacitinib treatment (such as herpes zoster), are not observed in the placebo-controlled period.

Inclusion criteria for AS trials only allowed inclusion of patients with a platelet count ≥ 100,000 platelets/mm3. It is not clear whether patients with lower platelet counts should safely be allowed to be treated with tofacitinib, as a general decrease in platelet count has been observed over time, not only in the AS program but also in the other approved indications (RA and PsA). Platelet counts showed a mean decrease of almost 30,000/mm3 after 48 weeks in the All Tofa cohort. However, only one patient had an

<div style=\"page-break-after: always\"></div>

AE of thromocitopenya (considered as mild). The SmPC has been modified to reflect the fact that patients enrolled in the clinical program were required to have a platelet count &gt;100,000 /mm3.

Although the incidence rate for most AEs of special interest observed in the AS development program is lower compared to that observed in the PsA and RA programs and cases of AEs that are known components of  the  safety  profile  of  tofacitinib  in  the  other  indications:  Malignancies,  NMSC,  CV  events  of  MACE  or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis could noy be excluded that these findings should be ascribed to the limited exposure.

Considering that the sought indication is a chronic disease requiring long-term therapy and also considering some safety concerns of the drug emerging with long-term use, an update of safety data and analyses coming from AS subjects exposed more than 1 year was deemed important to provide reassurance on this key uncertainty. However, the MAH considers the long-term safety profile of tofacitinib in the AS population as similar to what observed for RA and PsA patients and, thus, the MAH does not plan to conduct further studies to gather long-term safety data from the AS population. This is considered acceptable by the CHMP. Effects by age are very difficult to estimate since the limited number of subjects &gt;65 years (n=13) vs &lt;65 years (n=407).

Overall, female patients had higher incidence rates of AEs compared to male, but the cohort was unbalanced since there were 594 males and 142 females.

Most patients in the tofacitinib 5 mg BID group were White and few were Asian (n=63). Higher incidence of AEs (including infections) was observed in Asian patients.

A higher incidence of venous thromboembolism has been observed in post-marketing RA study A3921133 compared to AS pivotal trials. Considering short follow up in AS pivotal trials, VTE events remain a concern for AS indication also.

## 3.6. Effects Table

Table 1. Effects Table for tofacitinib in the AS indication

| Effect                       | Short description                              | Unit               | Tofacitini b 5mg BID   | Placeb o           | Uncertainties / Strength of evidence    | References         |
|------------------------------|------------------------------------------------|--------------------|------------------------|--------------------|-----------------------------------------|--------------------|
| Favourable Effects           | Favourable Effects                             | Favourable Effects | Favourable Effects     | Favourable Effects | Favourable Effects                      | Favourable Effects |
| ASAS20 Wk 16                 | %patients achieving ASAS20 response at Week 16 | %                  | 56.39%                 | 29.41%             | Difference in response 27.08 (p<0.0001) | Study A3921120     |
| ASAS40 Wk 16                 | %patients achieving ASAS40 response at Week 16 | %                  | 40.60%                 | 12.50%             | Difference in response 28.17 (p<0.0001) | Study A3921120     |
| ASDAS- CRP change at week 16 | Change from baseline in ASDAS-CRP at week 16   |                    | -1.36                  | -0.39              | p<0.0001 for comparison vs placebo      | Study A3921120     |
| ASQoL change at week 16      | Change from baseline in ASQoL units            |                    | -4.03                  | -2.01              | p<0.001 for comparison vs placebo       | Study A3921120     |
| SF-36 v2 PCS change          | Change from baseline in SF- 36v2 PCS           |                    | 6.69                   | 3.14               | p<0.0001 for comparison vs placebo      | Study A3921120     |

<div style=\"page-break-after: always\"></div>

| Effect                        | Short description                                      | Unit   | Tofacitini b 5mg BID   | Placeb o   | Uncertainties / Strength of evidence   | References                    |
|-------------------------------|--------------------------------------------------------|--------|------------------------|------------|----------------------------------------|-------------------------------|
| at week 16                    |                                                        |        |                        |            |                                        |                               |
| BASMI lin change at week 16   | Change from baseline in BASMIlin units                 |        | -0.63                  | -0.11      | p<0.0001 for comparison vs placebo     | Study A3921120                |
| FACIT-F change at week 16     | Change from baseline in FACIT-F                        |        | 6.54                   | 3.12       | p<0.001 for comparison vs placebo      | Study A3921120                |
| Unfavourable Effects          | Unfavourable Effects                                   |        |                        |            |                                        |                               |
| %of n with AE                 | proportion of subject with AEs                         | %      | 54.6                   | 49.2       |                                        | Studies A3921120/ 119         |
| infectio ns and infestati ons | proportion of subject with infections and infestations | %      | 36.1                   | 23         |                                        | Studies Studies A3921120/ 119 |
| investig ation                | proportion of subject with investigation AEs           | %      | 16.8                   | 4.3        |                                        | Studies A3921120/ 119         |
| Hepatic AEs                   | proportion of subject with hepatic AEs                 | %      | 5.40                   | 1.07       |                                        | Studies A3921120/ 119         |
| SAEs                          | proportion of subject with SAEs                        | %      | 5.28                   | 3.56       |                                        | Studies A3921120/ 119         |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

A clinically relevant effect as measured by ASAS20/ASA40 has been demonstrated for tofacitinib 5 mg BD in the target population of adult patients with AS who have responded inadequately to conventional therapy.  Most of the secondary endpoints measuring mainly signs and symptoms, inflammation and QoL endpoints provide supportive results. For other disease domains such as spinal mobility and enthesitis only limited or only a trend in effect was seen.

Infections were the only reported AE of Special Interest in the AS studies; 7 cases of HZ (all non-serious) were reported. Platelet decrease has been observed during the AS trials (mean change from baseline until 48 weeks of -30,000). There are concerns regarding the risk of bleeding for patients with low platelet counts (&lt;100,000/mm3), since a reduction in platelets is observed with tofacitinib also in the other indications.

In general, from the available safety data no new important safety concerns emerge, the safety profile seems overlapping with what already known from other approved indications. However, patient's exposure is limited, and the sought indication is a chronic disease, requiring long-term therapy. The MAH considers the long-term safety profile of tofacitinib in the AS population as similar to what observed for

<div style=\"page-break-after: always\"></div>

RA and PsA patients and, thus, the MAH does not plan to conduct further studies to gather long-term safety data from the AS population. This is considered acceptable by the CHMP.

## 3.7.2. Balance of benefits and risks

The benefits of using tofacitinib for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy are considered to outweigh the risks.

## 3.8. Conclusions

The overall B/R of Xeljanz is positive in the following indication:

Ankylosing spondylitis

Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy for XELJANZ film-coated tablets; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 17.1 of the RMP has been accepted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being

<div style=\"page-break-after: always\"></div>

received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Xeljanz-H-C-4214-II-35

## Attachments

1. SmPC, Package Leaflet (changes highlighted) as a relevant example with changes highlighted as adopted by the CHMP on 14 October 2021.